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Zusammenfassung 
Krebs ist eine chronische Erkrankung, bei der Körperzellen durch Mutationen entarten, 
unkontrolliert wachsen und unter bestimmten Voraussetzungen gesundes Gewebe 
infiltrieren. Heutzutage zählt Krebs als zweithäufigste Todesursache der westlichen Welt zu 
den wichtigsten epidemiologischen Krankheitsbildern unserer Gesellschaft. Neben 
klassischen Behandlungsmethoden wie Resektion des Tumorgewebes, Chemo- oder auch 
Immuntherapie ist die Entwicklung neuer Therapieoptionen von großer Bedeutung. Eine 
mögliche neue therapeutische Alternative ist der Einsatz kleiner, nicht kodierender, 
regulatorischer RNAs wie z.B. miRNAs. MiRNAs sind an der Regulation wesentlicher 
biologischer Prozesse wie Entwicklung, Differenzierung oder Proliferation beteiligt, indem sie 
die Genexpression über den Mechanismus der RNA-Interferenz beeinflussen. Seit ihrer 
Entdeckung bestätigte sich die Annahme, dass miRNAs sowohl tumorsuppressive als auch 
onkogene Funktionen ausüben, weshalb sie sich nicht nur als diagnostische oder 
prognostische Biomarker des Krebsgewebes eignen, sondern auch als Therapeutika selbst 
eingesetzt werden könnten. In einer miRNA-Substitutionstherapie wird der Verlust oder die 
Herunterregulierung einer miRNA mit tumorsuppressiver Wirkung durch externe Zugabe 
ausgeglichen. Eine Antisense-Therapie vermittelt hingegen eine Inhibition onkogener 
miRNAs durch komplementäre Oligonukleotide. Eine sichere und effiziente Aufnahme der 
RNA-Moleküle zum Wirkort muss in beiden Ansätzen sichergestellt werden. Zurzeit ist die 
Entwicklung effizienter Delivery-Systeme der limitierende Faktor für miRNA-basierte 
Therapieansätze. 
In dieser Arbeit wurde zunächst das Proto-Onkogen PIM1 bezüglich einer möglichen 
RNAi-basierten Antikrebstherapie untersucht. Eine Überexpression der PIM1 Kinase wird in 
zahlreichen soliden Tumoren oder malignen Entartungen des hämatopoetischen Systems 
beobachtet und ist in der Regel mit einem schwerwiegenden Krankheitsverlauf assoziiert. 
In vitro-Studien an humanen Leukämie- und Kolonkarzinom-Zelllinien konnten erstmalig 
zeigen, dass die zelluläre PIM1 Proteinexpression durch eine miRNA mit tumorsuppressiver 
Wirkung, nämlich miR-33a, spezifisch herunterreguliert wird, woraus zusätzlich ein 
proliferationsinhibierender Effekt resultiert. Ein erfolgreiches Delivery von nanopartikulären 
Vesikeln aus miR-33a Oligonukleotiden und einem nicht toxischen, verzweigtkettigen 
Polyethylenimin (PEI F25 LMW) führte in Maus-Tumor-Modellen zu einem antitumorigenen 
Effekt, der durch eine Reduktion des Tumorvolumens gezeigt werden konnte. Diese 
in vitro- und in vivo-Studien weisen das Proto-Onkogen PIM1 erstmalig als 
erfolgversprechendes Zielobjekt für eine miRNA-vermittelte Substitutionstherapie aus. 
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Der Fokus des zweiten Projektes lag auf der Entwicklung neuartiger LNA-basierter miRNA 
Inhibitoren, im Weiteren LNA-Antiseeds genannt, bestehend aus einzelsträngigen 
Oligonukleotiden mit sog. Locked Nucleic Acid (LNA)-Modifikationen und einem natürlich 
vorkommenden Phosphodiester-Nukleotidrückgrat. Im Allgemeinen erhöht ein LNA-Design 
sowohl die Resistenz der Oligonukleotide gegenüber einem Abbau durch zelluläre 
Nukleasen als auch ihre Affinität zur Ziel-miRNA, wobei durch komplementäre Bindung an 
onkogene miRNAs deren zelluläre Funktionen ausgeschaltet werden. Bereits die 
Verwendung geringer Konzentrationen an LNA-Antiseeds zeigte in humanen Krebs-Zelllinien 
eine nahezu vollständige Inhibition onkogener miRNAs der miR-106b Familie, die durch eine 
Steigerung der endogenen Derepression des Tumorsuppressors P21 gezeigt wurde. Eine 
erfolgreiche Verpackung der neuartigen LNA-basierten miRNA Inhibitoren mit dem 
verzweigtkettigen Polyethylenimin PEI F25 LMW sowie die funktionelle Aufnahme der 
gebildeten Nanopartikel in humane Krebszelllinien konnte in weiteren in vitro-Experimenten 
gezeigt werden. Der Einsatz von PEI F25 LMW komplexierten LNA-Antiseed 
miRNA-Inhibitoren könnte nun auch in Xenograft-Tumor-Modellen der Maus als ein 
erfolgversprechender Ansatz einer Antisense-Therapie getestet werden. 
Im dritten Themenkomplex dieser Arbeit wurde die transkriptionelle Regulation des 
onkogenen miRNA Clusters miR-17-92 untersucht. Eine Überexpression dieses Clusters ist 
mit gesteigerter Proliferation, Angiogenese und verminderter Apoptose assoziiert und wird in 
zahlreichen hämatopoetischen und soliden Tumoren beobachtet. Die Transkription von 
miR-17-92 wird dabei maßgeblich durch das Onkogen MYC reguliert. In vitro-Experimente in 
humanen Krebs-Zelllinien zeigten, dass auch der miR-17-92 Cluster zu jenen 20 % aller 
MYC regulierten Gene gehört, dessen Transkription durch einen Synergismus zwischen 
MYC und PIM1 gesteuert wird. Weitere Untersuchungen hinsichtlich der transkriptionellen 
Regulation von miRNA Promotoren könnten zukünftig dazu beitragen, die Zusammenhänge 
zwischen miRNA-Expression und der Entstehung von Krebs näher zu charakterisieren. 
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Abstract 
Cancer is a chronic disease caused by a degeneration of somatic cells due to mutations. In 
general cells grow erratic and under certain conditions this leads to an infiltration of even 
healthy tissues. To date cancer is the second most common cause of death in the Western 
world and belongs to one of the most important epidemiological diseases of our society. 
Besides traditional methods in cancer treatment such as resection of tumor tissue, chemo- or 
immunotherapy, the development of novel therapeutic strategies is of the highest 
importance. One therapeutic option would include the use of small non-coding regulatory 
RNAs such as miRNAs. MiRNAs are involved in the regulation of crucial biological processes 
such as development, differentiation or proliferation due to the control of the cell’s gene 
expression via RNA interference. Since the discovery of miRNAs, evidence has emerged 
that they can exert either tumor-suppressive or oncogenic functions. Thus miRNAs are not 
only applied as diagnostic or prognostic biomarkers of cancerous tissues, but can also 
function as therapeutics. In miRNA replacement therapy a loss or downregulation of a 
tumor-suppressive miRNA is adjusted with addition of this single miRNA. On the contrary an 
antisense therapy approach mediates the inhibition of oncogenic miRNAs by antisense 
oligonucleotides. Safe and efficient delivery of the oligonucleotides has to be guaranteed for 
both approaches. Currently the development of such efficient delivery systems is the critical 
and limiting factor upon miRNA-based therapy designs. 
In this thesis the proto-oncogene PIM1 was considered regarding a putative RNA-based 
anti-cancer strategy. Overexpression of PIM1 kinase usually is associated with severe forms 
of cancers with bad prognosis in several solid tumors or malign degenerations of the 
hematopoietic system. In vitro studies revealed a specific reduction of PIM1 protein levels in 
human leukemia and colon carcinoma cell lines due to a miRNA with tumor-suppressive 
potential, namely miR-33a. Additionally this decrease in PIM1 resulted in an inhibition of 
proliferation. Successful delivery with nanoparticle complexes composed of miR-33a 
oligonucleotides and a non-toxic branched polyethylenimine (PEI F25 LMW) showed an 
anti-tumor effect in mouse colon carcinoma models that was obtained through a reduction in 
tumor size. These in vitro and in vivo studies provide evidence for the first time that the 
proto-oncogene PIM1 is a promising target for miRNA replacement therapy. 
The second project dealt with the development of novel LNA-based miRNA inhibitors, termed 
LNA antiseeds, composed of single-stranded RNA oligonucleotides with locked nucleic acid 
(LNA) modifications and a natural phosphodiester backbone. In general an LNA design 
enhances the resistance of oligonucleotides against cellular degradation by nucleases. 
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Furthermore affinity of the molecule to the miRNA of interest is increased. Cellular functions 
of the targeted oncogenic miRNAs are silenced due to complementary binding to the 
inhibitor. A use of minor amounts of LNA antiseeds already revealed an almost complete 
inhibition of miRNAs of the miR-106b family in human cancer cell lines which was connected 
to an endogenous derepression of the tumor suppressor P21. Successful complex formation 
of the novel LNA antiseeds with the branched polyethylenimine PEI F25 LMW has been 
proven. Furthermore in vitro experiments confirmed a functional delivery of the resulting 
nanoparticles into human cancer cell lines. Application of PEI F25 LMW complexed 
LNA antiseed miRNA inhibitors could now be tested as a promising antisense therapy 
approach in xenograft tumor mouse models. 
The third topic addressed the transcriptional regulation of the oncogenic miRNA cluster 
miR-17-92. Overexpression of this miRNA cluster is associated with enhanced proliferation, 
sustained angiogenesis and reduced apoptosis in several hematopoietic malignancies and 
solid tumors. Transcription of human miR-17-92 is significantly regulated by the oncogene 
MYC. In vitro experiments in human cancer cell lines confirmed that miR-17-92 belongs to 
one of those 20 % of MYC regulated genes which transcription is controlled by a synergism 
of MYC and PIM1. Further investigations regarding transcriptional control of miRNA 
promoters could provide profound evidences for a better understanding of a connection 
between miRNA expression levels and the development of cancer.  
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1 Introduction 
1.1 Cancer 
Cancer is defined as a chronic disease (1) and includes more than 100 distinct types and 
subtypes of malignancies found within different organs (2). In general cancer is known as a 
malignant neoplasm which develops as a clone from one single cell of origin (3) after one or 
more oncogenic events have occurred (Figure 1).  
 
Figure 1: Formation 
of a malignant 
neoplasm. A 
malignant neoplasm 
generates after several 
oncogenic events have 
occurred (following 
Visvader, 2011 (4)). 
 
Since the ancient Egyptian time period, malignant diseases have awoken the interests of 
scientists; in particular to clarify their origins and to understand more about molecular 
mechanisms, prevention, etiology, pathogenesis and treatment of cancer (5). The treatment 
of tumors was described in ancient Egyptian and Greek literature and the histological 
diagnosis of cancer in an Egyptian mummy (6) provided evidence that this disease is not 
only a current problem. Thus to treat cancer it is important to understand the underlying 
molecular mechanisms in order to predict how a neoplasm will evolve. Then we maybe will 
have the ability to interfere with and disrupt the clonal evolution of a neoplasm to prevent 
cancer formation. Even if initiation of a neoplasm cannot be prevented, early detection and 
correct diagnosis of malignant cancer will probably lead to increased cure rates (7). 
Therefore it is necessary to classify tumors and differentiate between benign and malignant 
instances. Whereas benign tumors are not cancerous and do not spread out in the body, 
malignant neoplasms are characterized by their ability to invade nearby tissues and organs, 
also known as metastasis (8), (9). In general tumors are classified in various categories 
depending on the cell type or tissue they evolve from. For instance a carcinoma is defined as 
a tumor beginning in any internal organ, leukemia is a cancer that arises from hematopoietic 
cells and a lymphoma or myeloma derives from cells of the immune system (9). In Germany 
approximately 470,000 new cases of cancer were estimated in 2008 by the Robert Koch 
Institute (10). The causes of cancer are multiple and can be assigned to environmental 
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factors like diet or smoking, reproductive and sexual behavior, geophysical factors, 
occupational exposures, medicine and/or infections (11), (12). 
1.1.1 Carcinogenesis 
In literature carcinogenesis is described as the formation and development of cancer. It is 
characterized by a progression of changes on genetic and cellular levels. Reprogramming of 
a cell leads to uncontrolled cell division, thus forming a malignant neoplasm. The cause of 
cancer development is diverse and only in a few cases is it caused by one single factor (2). 
In general, 3-12 (or even more) physiological relevant mutations are required to form a 
malignant neoplasm (13) (Figure 1). The accumulation of mutations during a cell’s lifetime is 
called somatic evolution (3), (7). At the cellular level, a selection benefit exists for increased 
cell proliferation and survival for those cells harboring a competitive advantage in at least one 
of six essential alterations: (i) self-sufficiency in proliferative signals, (ii) insensitivity to growth 
suppressors, (iii) tissue invasion and metastasis, (iv) limitless replicative potential, (v) 
sustained angiogenesis and (vi) the evasion of programmed cell death (2) (Figure 2).  
 
 
Figure 2: Selection benefit of 
cancer cells. Most cancers 
have acquired a selection 
benefit during their 
development mediated through 
one of those six mechanistic 
strategies (following Hanahan & 
Weinberg, 2011 (1)). 
 
 
 
All of the aforementioned biological properties are additionally accelerated by genomic 
instability (2). Capabilities such as proliferation and immortality that allow cancer cells to 
survive are complemented by the inflammatory state of the cell, autophagy, necrosis or the 
reprogramming of the cell’s energy metabolism (1). Furthermore the growth advantage and 
increased survival of the tumor is a consequence of chromosomal rearrangements, 
mutations and gene amplifications caused by the inactivation of tumor suppressor genes (14) 
or the activation of oncogenes (15). A tumor suppressor gene, a so-called anti-oncogene, is 
a gene that encodes for a protein which blocks the development of cancer in the cell e.g. by 
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the regulation and/or control of cell division or by initiation of apoptosis (16). In contrast an 
oncogene is a gene that has the potential to cause cancer and evolves by e.g. the mutation 
or overexpression of a proto-oncogene, and thus becomes activated (17). In general 
oncogenes can be subdivided into six major groups: (i) chromatin remodelers, (ii) 
transcription factors, (iii) growth factors, (iv) growth factor receptors, (v) signal transducers 
and (vi) apoptosis regulators (15). Likewise, small non-coding RNAs (ncRNAs), in particular 
the class of microRNAs (miRNAs), are associated with tumor development (18). It has been 
reported that even half of all annotated miRNAs map within fragile chromosomal regions that 
can be linked to human cancer (19). 
1.1.2 Treatment of cancer 
Due to the fact that cancer is the second most common cause of death (5) in the Western 
world, treatment of malignant neoplasms is of the highest importance. Although crude cancer 
surgery took place in the ancient Egypt (5), the establishment of radiation by Emil Grubbe in 
1957 (20), followed by subsequent research, means that nowadays treatments are much 
more focused on individual patients (21). New healing procedures, earlier diagnosis of 
cancer and ‘personalized’ therapy are the first steps of translating cancer research into 
targeted therapeutics (22). Such molecular techniques (23) include the development of small 
molecules, peptide mimetics, monoclonal antibodies (mABs) and antisense oligonucleotides 
(24). Several mABs and small molecule compounds have now been approved for cancer 
therapy (24). In general mABs show significant promise due to their low toxicity profiles in 
clinical studies (25). Moreover they are well-tolerated compared with conventional 
chemotherapeutic agents (25). Since miRNA expression profiles are used to classify tumors 
(26) based on the tissue type and/or stage of disease (27), (18) one promising therapeutic 
strategy is miRNA-based therapy (18) which has been successfully established using in vivo 
animal models thus far (28) and already has been tested in clinical trials (29). 
1.2 RNA interference and miRNAs 
1.2.1 Discovery of miRNAs 
RNA interference (RNAi), a form of post-transcriptional gene silencing (30), was first 
described in 1998 by Fire and Mello (31) in the worm C. elegans. RNAi, which is thought to 
be the oldest and most ubiquitous cellular antiviral defense system, is a biological process in 
which small non-coding double-stranded RNA molecules interfere with messenger RNAs 
(mRNAs) to inhibit gene expression (32). Before the discovery of RNAi, the gene lin-4 was 
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found in 1993 by Ambros and Lee in C. elegans (33). Cel-lin-4 codes for two small transcripts 
of ~61 and 22 nt which show complementarity to a sequence located in the 3’-UTR of 
Cel-lin-14 (33). Later on the Cel-lethal-7 (Cel-let-7) gene was described. It encodes a 21 nt 
long RNA transcript that has been shown to regulate the expression of several genes which 
are involved in the timing of developmental transition in C. elegans (34). These findings 
preceded a new class of small non-coding regulatory RNAs being described - microRNAs 
(miRNAs) (35), (36), (37). To date more than 15,000 miRNA gene loci are annotated and 
expressed in over 140 different species and organisms (38). In mammals ~2000 miRNAs 
(38) represent about 1 % of the human genome (39). MiRNAs are able to target dozens or 
even hundreds of different mRNAs to regulate and fine-tune the cellular expression of about 
50 % of all protein-coding genes (40). This regulation takes place in almost all biological 
processes and is important for genome functions such as chromosome segregation, 
transcription, RNA stability, RNA processing, and translation (41). Furthermore, miRNAs play 
crucial roles in cellular processes; they are involved in development, proliferation, 
differentiation, the stress response and apoptosis (39). 
1.2.2 Genomics, biogenesis and mechanism of miRNAs 
In general miRNAs are encoded in the genome and can be subdivided into intergenic, 
intronic or exonic genomic organized miRNAs (42) (Figure 3). Intergenic miRNAs are found 
in genomic regions which are not part of known functional transcription units (TUs). They are 
generally monocistronic or polycistronic and have their own promoter and/or other regulatory 
elements (43) and a primary miRNA (pri-miRNA) transcript length of several kb (44). About 
50 % of all known miRNA genes are encoded within TUs (45) (either protein-coding or 
non-coding (35)), and are termed intronic miRNAs. Intronic miRNAs themselves can be 
transcribed either by the host gene promoter or an own promoter element as single or 
clustered pri-miRNA transcripts (46). In some special cases, a whole intron acts as a 
pri-miRNA transcript and therefore is called mirtron. This pri-miRNA is recognized and 
processed by the splicing machinery (47). Exonic located miRNAs are very rare and overlap 
with exons of ncRNAs (42). The transcription of miRNA genes is a complex process that until 
now has been only poorly understood (48). 
The biogenesis and generation of mature miRNAs can be divided into several processing 
steps (Figure 3).  
  Introduction    
5 
 
 
Figure 3: Biogenesis of miRNAs. (i) Transcription of exonic, intergenic or intronic miRNA 
genes is followed by (iia) nuclear processing of the pri-miRNA transcript by the 
microprocessor complex (DROSHA/DGCR8) generating the pre-miRNA. (i) Transcription of 
a mirtron is performed by the spliceosome generating a pre-miRNA transcript. (iib) The 
pre-miRNA is actively exported into the cytoplasm by Exportin-5 using RAN-GTP. (iic) In the 
cytoplasm the pre-miRNA is processed by the RNase III enzyme DICER1 into the 
double-stranded miRNA/miRNA*. (iii) Passenger strand degradation follows the 
incorporation of the miRNA/miRNA* duplex into the miRISC complex. (iv) After target 
recognition of the miRNA binding site in the 3’-UTR of an mRNA, translational repression 
and/or mRNA cleavage occurs mediated by proteins of the AGO family. 
 
Firstly, (i) transcription of the miRNA gene has to occur followed by (ii) several maturation 
steps, then (iii) the RNA-induced silencing complex (RISC) assembly has to form (49) before 
finally (iv) mRNA cleavage or translational repression can take place. (i) Transcription of 
partially long pri-miRNA transcripts (49) is dependent on RNA polymerase II (POLR2) based 
on the findings that these primary transcripts contain cap-structures as well as poly(A) tails 
(48) which are classical signals for POLR2 transcription maturation. (ii) The first maturation 
step in human miRNA processing is initiated by the microprocessor complex (50) composed 
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of the nuclear RNase III enzyme DROSHA (51) associated with 
DiGeorge syndrome chromosomal region 8 (DGCR8) protein (52). In this step the longer 
primary transcript is cleaved into an approximately 70 nt long precursor miRNA (pre-miRNA) 
(43) which folds into a defined stem-loop structure (35) harboring a 5’-phosphate and a 2 nt 
overhang on the 3’-OH terminus (53). The pre-miRNA afterwards is exported from the 
nucleus into the cytoplasm. This active transport process is mediated by the export receptor 
XPO5 termed Exportin-5 using RAN-GTP (54), (55) and is triggered by the matured 
stem-loop structure (56). The second end of the precursor miRNA is processed in the 
cytoplasm by the RNase III endonuclease Dcr-1 homolog (Drosophila) (DICER1) (57), (58), 
(51) generating again a 5’-phosphate and a 2 nt overhang on the 3’-OH terminus on the 
opposite site (49) of the miRNA. Thus a short (approximately 22 nt long) duplex termed 
miRNA/miRNA* is formed (37). (iii) The RISC assembly follows DROSHA cleavage, 
nucleocytoplasmic export and cytoplasmic DICER1 cleavage. Several proteins of the 
argonaute family (argonaute RISC catalytic component 1-4, AGO 1-4) are part of this 
miRNA-induced silencing complex (miRISC) including its catalytic core (59), (60), (61). The 
strand of the miRNA duplex with its 5’-end less tightly paired (62) (and thus shows higher 
thermodynamic instability) enters the miRISC complex and generates the mature and 
functional miRNA (63), (64), (59). The miRNA* strand of the matured duplex is degraded 
(65). Subsequently the miRISC complex leads to post-transcriptional gene silencing via 
target recognition of mRNAs in the cytoplasm. Post-transcriptional gene silencing can 
happen by two different mechanisms depending on the identity of the target: (i) mRNA 
cleavage or (ii) translational repression (49). (i) Cleavage of an mRNA occurs if the miRNA 
has sufficient complementarity to the mRNA. The cleavage site appears between the 
nucleotides pairing to residues 10 and 11 of the miRNA (59). (ii) After the discovery of 
miRNAs it was proposed that miRNAs modulate post-transcriptional gene expression via 
translational repression (66). The most efficient translational inhibition is provided by a 
cooperative mechanism (67) and specific target selection of miRNAs (68). The ability to 
translationally repress a target mRNA mostly depends on perfect Watson-Crick base pairing 
of the miRNA’s seed region (69), mainly the first 8 nt on the 5’-end of the mature miRNA. In 
some cases additional pairing of the 3’-end of the miRNA is needed (69). It was recently 
discovered that miRNAs can also target other genomic regions such as 5’-UTRs (70), coding 
regions (71) or promoter elements (72) after their import into the nucleus (73). All findings 
implicate the important regulatory mechanisms of this class of small non-coding RNAs and 
demonstrate the enormous ability of these post-transcriptional gene regulators to intervene in 
the pathogenesis of human cancers (74) by targeting either tumor suppressor genes or 
oncogenes. 
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1.2.3 MiRNAs associated with cancer 
Since the discovery of miRNAs, evidence has emerged that miRNAs can function as tumor 
suppressors or as oncogenes, by blocking or activating the cell’s malignant potential 
respectively, and are therefore referred to as oncomiRs (19), (74). Their role in cancer 
development is based on three important observations (75). Firstly, they are involved in cell 
proliferation and apoptosis (33) and can affect all other stated hallmarks of cancer such as 
tissue invasion or metastasis (74). Secondly, miRNAs are frequently located at fragile 
regions of chromosomes (76). Thirdly, miRNA expression is deregulated in several malignant 
tumors (77). 
In 2002 it was reported for the first time that miRNAs are deregulated and as a result are 
involved in the development of human cancer (78). A deletion of a 30 kb region on 
chromosome 13q14, encoding the miRNA genes of miR-15a and miR-16-1, or a down 
regulation of these miRNAs is associated with B-cell chronic lymphocytic leukemia (B-CLL) 
(79). Additionally it has been found that those two miRNAs act as tumor suppressors and 
induce apoptosis by targeting the oncogene B-cell lymphoma 2 (BCL2) (80). Ongoing studies 
and miRNA profilings of human cancers have revealed cell type and tissue specific 
signatures of miRNAs (39). MiRNAs, which had overall higher expression levels, were 
identified as oncogenic miRNAs that generally repress tumor suppressor genes. As an 
example, miR-155 overexpressed in B-cell lymphomas (81) has been reported to target the 
suppressor of cytokine signaling (SOCS) proteins (82). Another miRNA, oncogenic miR-21, 
is overexpressed in breast cancer (83) and targets several tumor suppressor genes like 
phosphatase and tensin homolog (PTEN) (84), BCL2 (85) and tissue growth factor beta 
(TGFB) (86) mediating cell survival, proliferation and differentiation of cells. Further important 
oncogenic miRNAs are encoded in the miR-17-92 polycistron (87) and are described to be 
involved in several cellular processes such as proliferation or angiogenesis (88). Several 
miRNAs are transcriptionally induced by tumor suppressors or oncogenes (78). The 
tumor protein 53 (TP53) induces the transcription of the miR-34 family in response to DNA 
damage (89), (90) and v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) 
protein, a classical oncogene, transcriptionally activates the expression of the oncogenic 
miRNAs miR-17-92 (91) or represses the transcription of tumor-suppressive miRNAs like 
let-7 (92). An increased risk of cancer formation is also associated with mutations and/or 
single nucleotide polymorphisms (SNPs) in miRNA binding sites of oncogenes such as the 
Kirsten rat sarcoma viral oncogene homolog (KRAS) protein (93) regulated by miRNA let-7. 
These multiple functions of miRNAs in carcinogenesis implicate that miRNAs are 
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considerably beneficial as diagnostic and prognostic biomarkers to differentiate between 
malignant and benign forms of tumors (77), (94), (95). 
1.3 MiRNAs as cancer therapeutics 
In the last decade two major findings have established the use of miRNAs as an anti-cancer 
therapy: (i) miRNA expression differs in cancerous and normal tissues (79), (96), (81), (97) 
and (ii) a change in the cancer’s phenotype can be caused by targeting miRNA expression 
(98), (99), (100). As previously mentioned miRNAs are involved in the post-transcriptional 
gene regulation of several genes being part of a large cellular regulatory network (100). Thus 
an enormous advantage of miRNA-based therapeutic strategies in the cancer treatment is 
the ability of miRNAs to target multiple genes which are connected to distinct biological 
cellular processes in different molecular pathways such as normal or malignant homeostasis 
(89), (101). A modification of the miRNA expression levels in cancer tissues to restore 
normal homeostasis is possible because miRNAs show key functions in the coordination of 
the whole cancer network (100). To address the pharmacological modulation of 
cancer-associated miRNAs there are two possible strategies available: (i) use of drugs that 
allow the modulation of miRNA expression e.g. blocking their processing in the cellular 
system (102), or (ii) a direct regulation of miRNA expression levels by either the substitution 
of less expressed tumor suppressor miRNAs (called miRNA replacement) (103), (28) or the 
inhibition of oncogenic miRNAs by antisense oligonucleotides (104). 
1.3.1 Strategies to restore tumor-suppressive miRNAs 
Restoring a lost or downregulated tumor-suppressive miRNA, which targets an oncogene, 
can be modulated by miRNA replacement therapy. An enhanced expression of the miRNA 
can either be mediated by (i) virus-associated vector systems or (ii) the introduction of 
synthetic oligonucleotides, termed miRNA mimics. (i) In the case of using vector systems the 
miRNA gene of interest is packed in the virus and expressed after transduction into cells or 
tissues. Viral vector-based systems, including adenovirus-associated (AAV) or 
lentivirus-associated vectors (LAV), have a high transduction efficiency of target cells, but 
there might be a residual risk of viral infections for treated patients (105). In 2009 it was 
shown that an AAV-mediated delivery successfully increased the expression of 
tumor-suppressive miR-26a in a murine liver cancer model and suppressed tumorigenesis 
without measurable toxicity (106). (ii) MiRNA mimics are usually double-stranded molecules. 
The guide strand is identical to the selected miRNA of interest whereas the passenger strand 
is chemically modified at the 5’- and 3’-termini to avoid loading into the miRISC complex 
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(105). For delivery of miRNA mimics, they have to be formulated for their uptake into cellular 
systems. Recently restoring of several downregulated tumor-suppressive miRNAs has been 
successfully tested to reduce tumor growth in mouse cancer models (28), (107). 
The advantage of miRNA replacement therapy is that a restored miRNA has the same 
sequence as the deleted or downregulated miRNA of interest, and thus is expected to target 
the identical set of mRNAs (108). As a consequence, miRNA replacement therapy offers the 
possibility of recovering those cellular programs which are active in normal cells. Cellular 
pathways that are necessary for the generation of a malignant tumor are switched by 
re-introduction of tumor-suppressive miRNA mimics (108), hopefully without any side effects. 
MiRNA replacement has emerged as a promising therapy in the treatment of cancer, 
particularly because of an overall lower expression of miRNAs in tumor versus normal 
tissues (77). 
1.3.2 Strategies to inhibit oncogenic miRNAs  
Effective inhibition of oncogenic miRNAs can be achieved using anti-miRNAs in the 
treatment of cancer. In general those anti-miRNAs are single-stranded antisense 
oligonucleotides, termed antimiRs, which are complementary to the miRNA of interest. 
AntimiRs are used to sequester oncogenic cellular miRNAs leading to their functional 
inhibition (109). However the ability of the miRNA to repress endogenous target mRNAs of 
e.g. tumor suppressors is prevented by several cellular mechanisms (105). To reach the best 
possible resistance against cellular nucleases and to increase the binding affinity to the 
miRNA, the antisense oligonucleotides have to be chemically modified including 
modifications in (i) the internucleotide linkages and/or (ii) the sugar (109). (i) In 
phosphorothioate modified oligonucleotides a sulfur atom replaces one of the non-bridging 
oxygen atoms in the phosphate group of the backbone linkage; this modification leads to 
improved nuclease stability as well as an increased binding to plasma proteins (110). (ii) The 
most commonly used modifications in antimiR design are several variations in the 2’-sugar 
position (Figure 4). 
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Figure 4: Modifications of antimiRs. Schematic overview of antisense 
oligonucleotide modifications including a 2’-O-methyl (2’-O-Me), a 
2’-O-methoxyethyl (2’-O-MOE), a 2’-fluoro (2’-F), a locked nucleic acid (LNA) 
or a morpholino modification. 
 
The first sequence-specific inhibition of let-7 miRNA function was demonstrated using a 
2’-O-methyl (2’-O-Me) modified antisense oligonucleotide (111). To date several other 
modifications have been described such as 2’-O-methoxyethyl (2’-O-MOE), 2’-fluoro (2’-F) or 
locked nucleic acid (LNA), a class of bicyclic RNA analogues (112). In LNA the ribose is 
locked in a C3’-endo conformation by introduction of a methylene bridge between the 
2’-oxygen and the 4’-carbon of the sugar. This modification results in an increased affinity 
towards the complementary miRNA of 2 to 8 °C per introduced LNA modification (113), 
(114), (115). Morpholino oligomers are another modification. In these uncharged molecules 
the ribose moiety is exchanged for a six-membered morpholino ring (116). This antimiR 
design has been successfully tested in zebrafish models to target pri-miRNAs and miRNAs. 
In this study, morpholino-modified antisense oligonucleotides acted sequence-specific and 
non-toxic (117). Beneath an increase of target affinity, all antimiRs with variations in the 
ribose moiety show nuclease resistance and delayed degradation in the cellular system 
(109). Presently, approaches to block and inhibit oncogenic miRNAs with antimiRs of 
different designs hold a lot of promise as anti-cancer drugs. Further establishment of 
anti-miRNA treatments may open new ways in combination therapies to modulate or even 
cure cancer. 
1.3.3 Delivery and perspective of miRNA-based therapeutics 
For the establishment of (i) miRNA replacement therapies or (ii) antimiR strategies to inhibit 
miRNAs, the delivery of the oligonucleotides into cells, tissues and/or organs is the major 
bottleneck. A safe and efficient delivery of these molecules is the critical factor upon 
development of miRNA-based therapeutics. (i) In case of miRNA replacement therapy either 
viral vector-based systems (107) or formulated, double-stranded miRNA mimics (28) shall 
gain the loss of the respective miRNA (Figure 5). To date several studies have implicated the 
promising possibility of miRNA replacement therapy in the treatment of cancer. Several 
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downregulated tumor-suppressive miRNAs have been successfully re-introduced into cells 
and/or tissues to decrease tumor growth in mouse models. MiRNA replacements of the 
let-7 miRNA (118) or miR-34 (119) have been described to act as cancer therapeutics in 
murine lung cancers; the systemic delivery of miR-16 inhibits the growth of metastatic 
prostate tumors (120) and miRNA replacement therapy of miR-145 and miR-33a mimics are 
efficacious in a model of colon carcinoma (28). An optimized formulation for efficient and safe 
in vivo delivery of miRNA mimics in mouse cancer models has been shown for intravenous 
(121), intratumoral (28), intraperitoneal (28) and intranasal (107) application so far (105). The 
delivery of miRNAs has been done by using liposome nanoparticles (122), atelocollagen 
(120) or polyethyleneimine (28) implicating a formulated antimiR delivery. (ii) To date several 
antimiR designs (Figure 5) have been established either in vitro or in vivo (123). In 2005 a 
novel class of antisense oligonucleotides, termed antagomiRs, was described (124). These 
antagomiRs are 3’-cholesterol-conjugated single-stranded 2’-O-Me oligonucleotides 
complementary to the miRNA of interest. Pharmacological inhibition was shown for e.g. 
miR-16 or miR-122. Furthermore the cholesterol conjugation was found to improve cellular 
uptake of these molecules in vivo (124). Another in vivo delivery approach has been 
described for unconjugated, phosphorothioate modified antisense oligonucleotides (125), 
(126) targeting oncogenic and liver-specific miR-122. Either longer oligonucleotides which 
are comprised of DNA and LNA modifications (125) or short 8-mer tiny LNAs (126) exhibit 
good tissue uptake and good pharmacokinetic properties in vivo (105). A recent in vitro study 
also described polyethyleneimine formulated 14-meric LNA antiseeds as promising miRNA 
inhibitors (104). This approach enables the possibility to target even whole miRNA families 
characterized by the same nucleotides in the seed region of the miRNA (104).  
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Figure 5: Design of miRNA-based therapeutics. MiRNA-based 
therapies can be divided into miRNA replacement therapy to 
restore a loss of a miRNA mediated by viral vector based 
systems or formulated miRNA mimics (black arrows) or an 
antimiR design such as antagomiRs, formulated or unformulated 
antimiRs (red line) to inhibit cellular functions of oncogenic 
miRNAs. 
 
The development of novel anti-cancer therapeutics holds great promise and the first 
miRNA-based therapeutic has reached clinical trials (105). This therapeutic is an 
LNA-phosphorothioate-modified miRNA inhibitor against miR-122, termed miravirsen (29). 
MiR-122 is specifically expressed in the human liver and plays a role in the modulation of 
cholesterol homeostasis (127). Besides it facilitates RNA replication of the hepatitis C virus 
(HCV) following infection of humans (128). In 2012 miravirsen was tested in HCV-infected 
human patients for the first time. Its application is well-tolerated and shows long-lasting 
suppression of viremia (29). The design and development of miRNA-based therapeutics is 
opening up new possibilities for the treatment of cancer and may become a powerful 
therapeutic strategy in combination therapies if standard treatment approaches are 
unsuccessful due to chemo-resistance, metastasis and/or recurrence of the tumor (129).  
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1.4 Analyzed oncogenes 
1.4.1 The human PIM1 kinase 
The PIM1 gene was identified in 1984 as a proto-oncogene in several mouse tumor models. 
In murine leukemia virus (MuLV)-induced lymphomas, transcriptional activation of the 
PIM1 gene was associated with a proviral insertion into a quite small chromosomal region 
(130) within the PIM1 domain. In general the PIM kinases (PIM1, PIM2 and PIM3 (131), 
(132)) belong to a family of constitutively active serine/threonine kinases with several cellular 
targets (133). They are naturally expressed in several tissues such as bone marrow, thymus, 
spleen, prostate or hippocampus (134) being involved in e.g. T-cell activation (135) or fetal 
hematopoiesis (136). They play crucial roles in the process of malignant transformation even 
in human cancer (137) because they are associated with proliferation, differentiation, 
apoptosis and tumorigenesis (138). Overexpression of PIM kinases is correlated with a very 
poor prognosis in a wide range of hematopoietic malignancies such as mantle cell lymphoma 
or non-Hodgkin’s lymphoma and solid cancers such as prostate cancer (139), (140). To 
study the physiological effects of PIM kinases, PIM knockout mice have been generated. It 
was shown that PIM1 deficient mice grow almost normally, but show a specific defect in 
interleukin (IL)-3 and -7-dependent growth of pre-B-cells and mast cells (141), (142). Triple 
knockout mice, with PIM1, PIM2 and PIM3 deficiencies, are viable and fertile, but have 
obviously manifested a phenotype showing reduction of body size and moderate defects in 
growth factor signaling and T-cell proliferation (132). In humans the PIM1 gene is located on 
chromosome 6p21.1-p21.31, a region of approximately 5 kb harboring six exons and five 
introns. The mRNA transcript (NM_002648) has a length of 2684 bp (137) and produces two 
proteins of 34 and 44 kDa due to an alternative translation initiation at an upstream 
CUG codon (143) (Figure 6a). PIM1 expression is tightly controlled by (i) transcriptional, 
(ii) post-transcriptional, (iii) translational and (iv) post-translational regulation (138) (Figure 
6b). Transcriptional activation of the PIM1 gene is dependent on several growth factors, 
hormones or cytokines such as GM-CSF, prolactin and IL-3, -5, -7 or -12 that activate the 
signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) (137), (138). 
(ii) Post-transcriptional regulation of PIM1 is associated with miRNA binding. It has been 
reported that miR-1 (144), miR-33a (103) and miR-328 (145) target the 3’-UTR of 
PIM1 mRNA and modulate and/or decrease protein expression. (iii) Translation of the 
PIM1 mRNA is shown to be cap-dependent (146) because of long GC-rich destabilizing 
regions in the 5’-UTR of PIM1 mRNA. Furthermore it was reported that translation is 
regulated by the eukaryotic translation initiation factor 4E (EIF4E) binding to an EIF4E 
sensitivity element in the PIM1 3’-UTR which mediates nuclear export and enhances 
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translation (147). (iv) The first evidence that the PIM1 protein is post-translationally regulated 
arose from variable turnover rates of the different protein isoforms (34 and 44 kDa isoform) 
showing half-lives of approximately 1 h and 10 min, respectively (138). PIM1 is able to 
activate itself by autophosphorylation on serine 8 and 190 (S8, S190) residues (137). The 
kinase is stabilized by heat shock protein 90 (HSP 90) (148); a decrease of PIM1 protein 
levels is catalyzed by the protein phosphatase 2A (PP2A) (149), followed by ubiquitination 
and degradation of PIM1 in the proteasome. Many phosphorylation targets of PIM1 have 
biological functions associated with cell cycle progression and apoptosis (137) such as the 
cyclin-dependent kinase inhibitors CDKN1A (in the following termed P21) (150) and 
CDKN1B (P27) (151), the cell division cycle 25A (CDC25A) (152) and C (CDC25C) (153) 
proteins or the pro-apoptotic protein BCL-2 associated agonist of cell death (BAD) (154). 
Another phosphorylation target of PIM1 is the chromobox homolog 3 (CBX3) protein, also 
referred to as heterochromatin protein 1 gamma homolog (Drosophila) (HP1G) which is 
associated with transcriptional repression via chromatin silencing (155) or gene activation 
being localized with elongating POLR2 (156). Furthermore PIM1 phosphorylation mediates 
stabilization of the oncogene MYC and thereby enhances transcriptional activity (157). A 
strong synergism of MYC and PIM1 has been established in tumorigenesis of transgene 
mice (158). MYC was shown to recruit PIM1 to MYC/MYC-associated factor X (MAX) 
complexes which are associated with enhancer box elements (E-boxes) in enhancer 
segments of euchromatin regions, followed by PIM1 mediated phosphorylation on 
histone 3 serine 10 (H3S10) residues to induce gene expression (159).  
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Figure 6: Regulatory network of PIM1. (a) PIM1 gene, transcript and proteins. The 
human PIM1 gene is located on chromosome 6 and encodes six exons (dark blue 
boxes) with large 5’- and 3’-UTRs containing GC-rich regions (light blue area). The two 
protein isoforms are synthesized using alternative translation initiation sites (solid and 
dashed arrows); additional codons are present at the 5’-end of the mRNA (light blue 
box). PIM proteins have different molecular masses and their kinase domain is indicated 
by a white box (following Nawijn, Alendar & Berns, 2011 (133)). (b) Involvement of PIM1 
in signal transduction pathways. The expression of PIM1 is directly regulated by 
STAT3/5 induced by growth factors hormones or cytokines (light yellow ovals). 
Post-transcriptional regulation of PIM1 mRNA is mediated by miRNAs or EIF4E (light 
green ovals). HSP90 and PP2A post-translationally modify PIM1 protein levels (green 
ovals). Several phosphorylation targets of PIM1 (yellow P) are indicated (violet ovals) 
which are involved in various cellular signaling pathways (following Bachmann & Möröy, 
2005 (137)). 
 
PIM kinases are promising targets for pharmacological inhibition (133) because they control 
several important signaling pathways in cellular processes. If these processes such as 
apoptosis, hypoxia or cell cycle control are deregulated, a malignant transformation is 
promoted (160). To date several small-molecule PIM kinase inhibitors (161), (162), (163) 
have been designed. All of them are ATP-competitive binders within the catalytic 
ATP-binding domain of the kinase and prevent PIM-dependent phosphorylation of the 
cellular targets (160). Another promising targeting strategy is RNAi to post-transcriptionally 
downregulate PIM1 protein levels. So far a PIM1-specific siRNA and one miRNA, namely 
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miR-33a, have been successfully used to target PIM1 in a colon carcinoma xenograft mouse 
model (28) to inhibit tumor growth. 
1.4.2 The human miRNA cluster miR-17-92 
The human miRNA cluster miR-17-92 is one of the best characterized polycistronic miRNA 
clusters. Known as oncomiR-1, the cluster encodes six miRNAs, namely miR-17, miR-18a, 
miR-19a, miR-20a, miR-19b-1 and miR-92-1 (164), deriving from a long primary transcript 
(87). In mammals two highly conserved paralogs have been identified: the miR-106a-363 
and the miR-106b-25 clusters (164). The miRNAs of these three clusters can be categorized 
into four different miRNA families: (i) the miR-17 family which comprises miR-17, miR-20a/b, 
miR-93 and miR-106a/b, (ii) the miR-18 family with miR-18a/b, (iii) the miR-19 family which 
consists of miR-19a and miR-19b-1 and -2 and (iv) the miR-92 family consisting of miR-25, 
miR-92a-1 and -2 and miR-363 (88). The human miR-17-92 cluster can be found at 
chromosome 13q31.3 (NG_032702.1) and was identified in 2004 as a novel gene, named 
chromosome 13 open reading frame 25 (C13orf25) (Figure 7a) which was amplified in 
hematopoietic malignancies (96) and solid tumors (165). The genomic locus consists of four 
exons and three introns from which a 5058 bp long non-protein coding RNA transcript 
(AB176708.1) is generated (96). The coding sequence of miR-17-92 is located in intron 3 
with a primary transcript of about 1 kb in length (164). The sequence upstream of the 
cluster’s coding sequence can be subdivided into AT- and GC-rich parts. The host gene 
promoter is controlled by the E2F transcription factor 1-3 (E2F1-3) with E2F3 being the main 
E2F variant associated with the host gene promoter (166). The core promoter region is found 
in exon 1 in the GC-rich part about 3.4 kb apart from the miR-17-92 coding sequence, where 
a consensus initiator sequence is located downstream of a non-consensus TATA-box (167), 
(166). However, in line with the findings that almost a third of intronic miRNAs show 
transcriptional activity, which is independent of a host gene promoter (168), O’Donnell et al. 
found highly conserved enhancer box elements (E-boxes) close to the AT-rich sequence 
region (91). Additionally at this chromosomal region an intronic TSS was predicted to be 
localized approximately 200 bp downstream of E-box 3 (169). These E-box elements are 
consensus sequences recognized by the transcriptional activator MYC (91). The results 
suggest that transcriptional activity of the miR-17-92 cluster may be generated by two 
independent TSSs (91), (169). 
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Figure 7: Regulatory network of the human miR-17-92 cluster. (a) Genomic organization of human miR-17-92 
on C13orf25. The locus consists of four exons (orange boxes) and the sequence upstream of the cluster can be 
subdivided in an AT-rich and GC-rich part; the host gene promoter controlled by E2F3 (167) (light green box) is 
located at the beginning of the GC-rich part, while the functional MYC site E3 (91), (169) (green oval) is close to 
the intronic AT-rich region. Two transcription start sites (TSS) are indicated (black and dashed arrow) (b) 
Pleiotropic functions of miR-17-92 achieved by repressing specific targets (light yellow ovals). Transcription of 
miR-17-92 may be generated by MYC and/or E2F1/2/3 (green and light green boxes) which trans-activate each 
other. Depending on the physiological context and cell type, miR-17-92 can promote proliferation, increase 
angiogenesis and inhibit apoptosis (following Olive, Jiang & He, 2010 (88)). 
 
The oncogenic activity of the miR-17-92 cluster was first seen in an in vivo mouse 
B-cell lymphoma model in which the cluster cooperated with the oncogene MYC (87) and 
accelerated tumorigenesis (Figure 7b). MiR-19 was identified as the key oncogenic miRNA of 
the cluster targeting the tumor suppressor protein PTEN (170), (171), thus mediating 
repression of apoptosis and promoting tumorigenesis of MYC induced lymphomas. To date 
overexpression of the miR-17-92 cluster has been intensely investigated in human cell 
culture and several animal models to elucidate its pleiotropic functions during normal 
development and/or malignant transformation (88). Thus the pleiotropic functions implicate 
that the role of miR-17-92 is manifold and arise from post-transcriptional regulation of several 
targets which are part of different physiological contexts, placing miR-17-92 in between a 
complex regulatory signaling network (Figure 7b). One important auto-regulatory feedback 
loop has been reported between E2F factors, MYC and miR-17-92 expression. In this 
network, the miRNAs miR-17 and miR-20a target the pro-apoptotic protein E2F1 and 
maintain a homeostasis towards proliferative signals (167). Other targets of miR-17-92 are 
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the pro-apoptotic protein BCL2-like 11 apoptosis facilitator (BCL2L11) and the tumor 
suppressor PTEN or the cyclin-dependent kinase inhibitor P21. Repression of these specific 
targets promotes proliferation and shows less activation-induced cell death in transgenic 
mice (172), (173), (174). The angiogenic activity of the miR-17-92 cluster is mediated by 
miR-18 and miR-19 which repress the thrombospondin 1 (TSP1) protein and the 
connective tissue growth factor (CTGF) (175). However, understanding the functions of 
miR-17-92 may help to explore the role of miRNAs in the network of cancer and offers the 
possibility to investigate clinical applications of anti-miRNA treatments. 
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1.5 Goal of the project 
MiRNAs play crucial roles in important cellular processes such as development, proliferation, 
differentiation, the stress response and apoptosis (39). They can be used either as 
diagnostic and prognostic biomarkers (77) or as novel anti-cancer strategies to treat 
malignant forms of tumors (100). 
 
Figure 8: Goal of the 
project. (1) The 
proto-oncogene PIM1 as 
a target of miR-33a 
in vitro and in vivo. (2) 
Establishment of novel 
miRNA inhibitors, called 
LNA antiseeds, to 
scrutinize inhibition of 
oncogenic miRNAs of 
the miR-17-92 cluster on 
the tumor suppressor 
P21. (3) Investigation of 
the transcriptional 
regulation of the human 
miR-17-92 cluster by 
E2F3 and MYC 
considering a putative 
MYC/PIM1 synergism. 
 
In the first project, the proto-oncogene PIM1 was established as target for miRNAs. PIM1 
was chosen because the constitutively active serine/threonine kinase PIM1 is overexpressed 
in different cancer types and as a consequence leads to severe forms of cancer associated 
with poor prognosis (133). The proto-oncogene PIM1 has been described as an important 
cellular target for cancer therapies and to date there has been extensive research into 
designing novel and specific inhibitors against PIM kinases. To selectively reduce cellular 
levels of PIM1 protein in vitro and in vivo, one focus of the project was to use RNAi to target 
PIM1 (Figure 8, 1) which can be mediated either by small interfering RNA (siRNA) or 
miR-33a. On condition that PIM1 is a target of miR-33a in vitro in different cell lines, this 
tumor-suppressive acting miRNA should be established in miRNA replacement therapy in 
subcutaneous colon carcinoma mouse models. Delivery of miR-33a would be mediated by a 
branched cationic polyethylenimine (PEI F25 LMW) which in previous studies has been used 
as powerful delivery agent for siRNAs (176). 
A second project was to develop novel miRNA inhibitors for the use in miRNA-based 
therapies (Figure 8, 2). Because overexpression of oncogenic miRNAs is associated with the 
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development of cancer due to a reprogramming of the cell’s homeostasis, we designed small 
LNA-modified oligonucleotides harboring a natural phosphodiester backbone, termed 
LNA antiseeds, to block and inhibit oncogenic miRNAs. Delivery of these molecules should 
be performed with this polyethylenimine PEI F25 LMW and thus complex formation and 
delivery of the nanoparticles has to be established in vitro, initially. 
The third project involved the investigation of the transcriptional regulation of the human 
miRNA cluster miR-17-92 (Figure 8, 3). MiR-17-92 is one of the best characterized 
polycistronic miRNA clusters in humans associated with oncogenic activity. Unfortunately 
little is known about its transcriptional regulation. The cluster is placed between a complex 
regulatory network of the oncogene MYC and E2F transcription factors (91), (167). Thus 
deletion analyses of the AT-rich promoter region should reveal MYC dependence on 
transcriptional activation. Furthermore colocalization of the proto-oncogene PIM1 and its 
phosphorylation target HP1G were investigated. Analysis of the pri-mir-17-92 expression 
levels after RNAi-mediated silencing of MYC, E2F3 and PIM1 proteins should provide 
presumption that transcriptional regulation of the miR-17-92 cluster partially is 
PIM1-dependent. 
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2 Materials and Methods 
2.1 Buffers, Media and Solutions 
Individual conditions for buffers, media and solutions which were used throughout the 
complete laboratory work are figured out in the single chapters to facilitate their correlation to 
the different disciplines. All buffers were generated with double-distilled water (ddH2O) and 
sterile filtered if not indicated otherwise. In case of preparing large amounts of media or 
solutions they were formulated with demineralized water and autoclaved 121 °C for 20 min 
using 1 bar pressure. 
2.2 Oligonucleotides 
2.2.1 DNA oligonucleotides 
All DNA primers used throughout this thesis were purchased from Metabion (Martinsried, 
Germany) and ordered as 100 µM stock solutions. For longer time storage the primers were 
kept at 4 °C in a refrigerator. All DNA primers were used for PCR reactions and designed 
using the software tool Oligo Analyzer 3.1 (Integrated DNA Technologies, Munich, 
Germany). 
2.2.1.1 Primers for cloning 
Primers that were needed for cloning experiments are listed in Appendix J. They were 
phosphorylated before usage (2.15.2) or were designed carrying the respective palindromic 
sequence for a restriction endonuclease (2.15.4). Primers that were used for mutagenesis 
PCR (2.15.8.2) have a much longer nucleotide sequence harboring point mutations in the 
middle of the primer sequence. 
2.2.1.2 Primers for DNA sequencing 
To verify DNA sequences of generated plasmid constructs Sanger sequencing was 
performed at eurofins mwgΙoperon (2.15.10) using primer sequences listed in Appendix K. 
2.2.1.3 Primers for RNA analyses 
Quantitative PCR reactions (2.15.8.3) of human mRNA or non-coding RNA levels were done 
using primer sequences listed in Table 1. 
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Table 1: Primers for RNA analyses. 
RNA transcript 
Name of 
DNA primer 
Sequence 5’  3’ 
Product 
length [bp] 
hsa 5S rRNA 
qPCR 5S rRNA fwd 5‘- TCT CGT CTG ATC TCG GAA GC 
88 
qPCR 5S rRNA rev 5‘- AGC CTA CAG CAC CCG GTA TT 
hsa ß-Actin 
qPCR Actin fwd 5'- CCA ACC GCG AGA AGA TGA 
97 
qPCR Actin rev 5'- CCA GAG GCG TAC AGG GAT AG 
hsa MYC 
qPCR MYC fwd 5‘- CCT TGC AGC TGC TTA GAC 
116 
qPCR MYC rev 5’- GAG TCG TAG TCG AGG TCA T 
hsa E2F3 
qPCR E2F3 fwd 5’- GAG ACT GAA ACA CAC AGT CC 
98 
qPCR E2F3 rev 5’- CCT GAG TTG GTT GAA GCC 
hsa PIM1 
qPCR PIM1 fwd 5'- ATC AGG GGC CAG GTT TTC T 
73 
qPCR PIM1 rev 5'- GGG CCA AGC ACC ATC TAA T 
hsa pri-mir-17-92 
qPCR pri-17-92 fwd 5’- CAT CTA CTG CCC TAA GTG CTC CTT 
68 
qPCR pri-17-92 rev 5’- GCT TGG CTT GAA TTA TTG GAT GA 
 
2.2.1.4 Primers for cDNA generation of miRNAs 
To generate cDNA (2.15.7) of human miRNAs specific stem-loop miRNA primers were 
designed according to Chen et al. (178). A list of all used primers is depicted in Table 2. The 
6/7 nt indicated by lower case letters are reverse complementary to the 3’-end of the miRNAs 
listed in Appendix L. 
Table 2: Primers for cDNA generation of miRNAs. 
MiRNA 
Name of 
DNA primer 
Sequence 5’  3’ 
hsa-miR-15a loop miR-15a RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACc aca aac 
hsa-miR-16-1 loop miR-16-1 RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACc gcc aat 
hsa-miR-17/20a loop miR-17/20a RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACc tac ctg 
hsa-miR-24-1 loop miR-24-1 RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACc tgt tc 
hsa-miR-26a loop miR-26a RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACa gcc tat 
hsa-miR-33a loop miR-33a RT 
5'- TGG ATA TCC ACA CCA GGG TCC GAG GTA TTC GGT 
GTG GAT ATC CAt gca atg 
hsa-miR-33b loop miR-33b RT 
5’- GUC GUA UGG UCA CGA GGG UCC GAG GUA UUC 
CGU GAC CAU ACG ACg caa ug 
hsa-miR-144 loop miR-144 RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACa gta cat 
hsa-miR-374a loop miR-374a RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACc act tat 
has-miR-423 loop miR-423 RT 
5'- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACa aag tct 
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2.2.1.5 Primers for qPCR of miRNAs 
Quantitative PCR reactions (2.15.8.3) were conducted to determine human miRNA levels in 
several cell lines. The primers are based on the human miRNA sequences which are listed in 
Appendix L. To obtain roughly the same melting temperature of the individual primers in 
subsequent qPCR reactions, a 5’-overhang was designed that is indicated by lower case 
letters in Table 3. 
Table 3: Primers for qPCR of miRNAs. 
MiRNA Name of DNA primer Sequence 5’  3’ 
Product 
length [bp] 
hsa-miR-15a miR-15a QT forward 5'- cgc gcT AGC AGC ACA TAA TG 61 
hsa-miR-16-1 miR-16-1 QT forward 5'- cgc gcT AGC AGC ACG TAA AT 61 
hsa-miR-17 miR-17 QT forward 5'- cgc gcC AAA GTG CTT ACA GTG 62 
hsa-miR-20a miR-20a QT forward 5'- gcc gcg cTA AAG TGC TTA TAG TG 64 
hsa-miR-24-1 miR-24-1 QT forward 5'- cgc gcT GGCTCA GTT CAG CAG 62 
hsa-miR-26a miR-26a-1 QT forward 5'- cgc gcT TCA AGT AAT CCA GG 61 
hsa-miR-33a miR-33a QT forward 5'- cgc gcG TGC ATT GTA GTT G 60 
hsa-miR-33b miR-33b QT forward 5’- cgc gcG TGC ATT GCT GTT G 60 
hsa-miR-144 miR-144 QT forward 5'- gcg cgc gcT ACA GTA TAG ATG 62 
hsa-miR-374a miR-374a QT forward 5'- gcc gcg cTT ATA ATA CAA CCT G 63 
has-miR-423 miR-423 QT forward 5'- cTG AGG GGC AGA GAG CG 58 
 reverse primer miR-33a 5'- CAC CAG GGT CCG AGG T - 
 reverse primer miR-33b 5‘- CAC GAG GGT CCG AGG TA - 
 uni reverse primer QT 5'- GTG CAG GGT CCG AGG T - 
 
2.2.2 RNA oligonucleotides 
RNA oligonucleotides used in this thesis were purchased from different companies as 
indicated in the following chapters. They were ordered lyophilized and diluted in 
double-distilled water if not indicated otherwise. For long time storage RNA oligonucleotides 
were kept at -20 to -80 °C. 
2.2.2.1 SiRNAs 
Used siRNAs were purchased from Metabion (Martinsried, Germany), Ambion® Life 
Technologies (Darmstadt, Germany) or Dharmacon Thermo Fisher Scienific (Lafayette, CO, 
USA) and listed in Table 4. All siRNA oligonucleotides were designed as double-stranded 
DICER1 processing products (sense and antisense orientation) with an overhang of two 
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deoxythymidines (dT) positioned on their 3’-end. The sense strand is specific and fully 
complementary (location either in the coding sequence or the 3’-UTR) to the human mRNA 
of interest. 
Table 4: SiRNAs. 
MRNA of 
interest 
Name of siRNA Sequence 5’  3’ 
VR1 mRNA VR1 siRNA (179) 
sense 5'- GCG CAU CUU CUA CUU CAA CdTdT 
antisense 5'- GUU GAA GUA GAA GAU GCG CdTdT 
PIM1 mRNA 
PIM1 siRNA 
(1130) 
sense 5'- GAU AUG GUG UGU GGA GAU AdTdT 
antisense 5'- UAU CUC CAC ACA CCA UAU CdTdT 
PIM1 siRNA 
(1491) 
sense 5'- GGA ACA ACA UUU ACA ACU CdTdT 
antisense 5'- GAG UUG UAA AUG UUG UUC CdTdT 
siRNA 33a 
sense 5'- AAA AUG CAC AAA CAA UGC AdTdT 
antisense 5'- UGC AUU GUU UGU GCA UUU UdTdT 
luc mRNA siRNA luc 
sense 5'- CUU ACG CUG AGU ACU UCG AdTdT 
antisense 5'- UCG AAG UAC UCA GCG UAA GdTdT 
MYC mRNA siRNA MYC 
sense 5'- CAG GAA CUA UGA CCU CGA CUA dTdT 
antisense 5’- UAG UCG AGG UCA UAG UUC CUG dTdT 
E2F3 mRNA siRNA E2F3 
sense 5’- ACA GCA AUC UUC CUU AAU AdTdT 
antisense 5’- UAU UAA GGA AGA UUG CUG UdTdT 
 
SiRNAs were ordered lyophilized and were diluted in siRNA buffer (30 mM HEPES KOH 
pH 7.4, 100 mM KCl, 2 mM Mg2Cl, 50 mM NH4Ac) to reach concentrations up to 2 µg/µL. 
After determination of siRNA concentration (2.14.1) they were prepared for long time storage 
at -80 °C.  
2.2.2.2 MiRNA Mimics 
Modified miRNA mimics, called miRIDIAN miRNA mimics, were purchased from Dharmacon 
Thermo Fisher Scientific (Lafayette, CO, USA). MiRIDIAN miRNA mimics are intended to 
mimic native miRNAs and are generated as double-stranded RNA molecules which are 
chemically enhanced with a proprietary design. Their sequences are based on the human 
endogenous, mature miRNAs listed in the miRBase Sequence Database 16.0 (180). All 
miRNAs were dissolved in ddH20 and prepared for storage at -80 °C. Used miRNAs are 
listed below (Table 5): 
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Table 5: MiRNA mimics. 
MiRNA of 
interest 
Order Number Sequence 5’  3’ 
hsa-miR-33a (C-300509-07) 5'- GUG CAU UGU AGU UGC AUU GCA 
hsa-miR-33b (C-300958-03) 5'- GUG CAU UGC UGU UGC AUU GC 
hsa-miR-15a (C-300482-03) 5'- UAG CAG CAC AUA AUG GUU UGU G 
hsa-miR-16-1 (C-300483-03) 5'- UAG CAG CAC GUA AAU AUU GGC G 
Negative  
control mimic #1 
(CN-001000-01) no sequence available 
hsa-miR-33a - 
leader 5'- GUG CAU UGU AGU UGC AUU GCA 
passenger 5’- TGC AAT GCA ACT ACA ATG CAC 
hsa-miR-33b - 
leader 5'- GUG CAU UGC UGU UGC AUU GC 
passenger 5'- CAG UGC CUC GGC AGU GCA GCC C 
 
In case of hsa-miR-33a and -33b the DICER1 processing product of pre-miR-33a and 
pre-miR-33b as published in the miRBase Sequence Database 14.0 (2.18.6) was additionally 
purchased by eurofins mwg|operon (Table 5), but lacking the 5’-terminal phosphate. The 
leader and passenger strand were dissolved in siRNA annealing buffer (30 mM HEPES KOH 
pH 7.4, 100 mM KCl, 2 mM Mg2Cl, 50 mM NH4Ac) respectively. After measuring RNA 
concentration (2.14.1) equimolar amounts of each strand were mixed and heated to 95 °C. 
Annealing of both strands was done for 1 h at 37 °C to receive the double-stranded DICER1 
processed miRNA product. 
2.2.2.3 MiRNA hairpin inhibitors 
MiRNA hairpin inhibitors, called miRIDIAN hairpin inhibitors, were purchased from 
Dharmacon Thermo Scientific (Lafayette, CO, USA). MiRIDIAN hairpin inhibitors are 
chemically enhanced RNA molecules that are designed to inhibit endogenous miRNA 
functions. Thus their purpose is to discover and investigate natural functions of miRNAs 
(181). Their sequences are based on the human endogenous mature miRNAs listed in the 
miRBase Sequence Database 16.0 (180). All miRIDIAN hairpin inhibitors were dissolved in 
double-distilled water and prepared for long-term storage at -80 °C. Used 
miRIDIAN hairpin inhibitors are depicted in Table 6: 
Table 6: MiRIDIAN hairpin inhibitors. 
MiRNA of 
interest 
Order number Sequence 5’  3’ 
hsa-let-7a (IH-300473-07) 5'- UGA GGU AGU AGG UUG UAU AGU U 
hsa-miR-17 (IH-300485-06) 5'- CAA AGU GCU UAC AGU GCA GGU AG 
hsa-miR-20a (IH-300491-05) 5'- UAA AGU GCU UAU AGU GCA GGU AG 
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2.2.3 LNA-based oligonucleotides 
As a second class of miRNA inhibitors RNA oligonucleotides containing an LNA (Locked 
Nucleic Acid) modification were designed. This modification mimics an RNA structure 
because it contains an O2’-C4’-methylene-linked bicyclic ribose unit which locks its 
conformation in the C3’-endo conformation and thus increases the stability of this 
oligonucleotide (113), (114). The LNA based oligonucleotides were purchased from 
RiboTask (Odense, Denmark). They were ordered as lyophilized dry powder, dissolved in 
double-distilled water and stored at -20 °C.  
2.2.3.1 LNA miRNA inhibitors 
All LNA-modified oligonucleotides showed fully complementarity to the human miRNAs of 
interest to gain miRNA inhibition. The ordered LNA oligonucleotides (Table 7) harbor a 
natural phosphodiester (PO) backbone with one exception containing a modified 
phosphorothioate (PS) backbone. They have introduced the LNA modification at some or all 
positions of the oligonucleotide, except for isolated 2’-oxymethyl pyrimidine residues, marked 
as [mU] and [mC] (Table 7), that are introduced to lower self-pairing of the individual 
oligonucleotides.  
Table 7: LNA miRNA inhibitors. 
MiRNA of 
interest 
Name of 
LNA oligonucleotide 
Sequence 5’  3’ 
hsa-miR-17-5p 
hsa-miR-20a 
LNA (PS) miR-17/20a 5'- GCA CT[mU] TG 
hsa-miR-17-5p LNA miR-17 5'- CTG TAA GCA CT[mU] TG 
hsa-miR-20a LNA miR-20a 5'- CTA TAA GCA [mC]T[mU] TA 
hsa-let-7a LNA let-7a (8-mer) 5'- CTA CCT CA 
hsa-let-7a LNA let-7a (10-mer) 5'- TAC TAC CTC A 
hsa-let-7a LNA let-7a (12-mer) 5'- CCT ACT ACC TCA 
hsa-let-7a LNA let-7a (14-mer) 5'- AAC CTA CTA CCT CA 
- LNA anti-RNase P (182) 5'-CAA GCA GCC UAC CC 
 
2.3 Antibodies 
All primary and secondary antibodies were used for Western Blot experiments (2.9.2) or 
chromatin immunoprecipitation assays (2.15.11) and are listed below (Table 8, Table 9). 
They were purchased from Santa Cruz Biotechnology (Heidelberg, Germany) expect for the 
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ABCA1 antibody which was ordered from Abcam (Cambridge, UK) and the Phospho HP1G 
antibody that was purchased from Cell Signaling (Danvers, MA, USA). 
Table 8: Primary antibodies. 
Name of primary 
antibody 
Order 
number 
Isotype specificity 
Dilution 
for WB 
ChIP 
assay 
AbcA1 (AB.H10) ab-18180 mouse monoclonal IgG1 1:1,000 - 
ß-Actin (C4) sc-47778 mouse monoclonal IgG1 
1:1,000; 
1:5,000; 
1:10,000 
- 
Cdk6 (C-21) sc-177 rabbit polyclonal IgG 1:2,000 - 
c-Myc (9E10) sc-40 mouse monoclonal IgG1 - 1 µg 
p21 (F-5) sc-6246 mouse monoclonal IgG2b 1:200 - 
p53 (DO-1) sc-126 mouse monoclonal IgG2a 1:1,000 - 
Phospho HP1G (Ser83) 2600S rabbit polyclonal IgG1 - 1 µg 
Pim-1 (12H8) sc-13513 mouse monoclonal IgG1 1:500 1 µg 
 
Table 9: Secondary antibodies. 
Name of secondary 
antibody 
Order 
number 
Isotype specificity 
Dilution 
for WB 
ChIP 
assay 
Goat anti-mouse IgG-HRP sc-2005 IgG1, IgG2a, IgG2b, IgG3, IgG4 1:5,000 1 µg 
Goat anti-rabbit IgG-HRP sc-2004 IgG1, IgG2a, IgG2b, IgG3, IgG4 1:5,000 - 
 
2.4 Size markers 
For size detection of proteins, DNA or RNA molecules several size markers were used which 
are listed in Table 10. All ladders were applied according to the manufacturer’s protocols 
respectively. 
Table 10: Size markers. 
Name of ladder Company Type Size range Purpose 
PageRuler Plus 
Prestained Protein Ladder 
Thermo Fisher Scientific protein 10-250 kDa WB analyses 
2-Log DNA Ladder New England Biolabs
®
 DNA 0.1-10.0 kb Cloning 
10 bp DNA Ladder Invitrogen
®
 DNA 10-330 bp qPCR analyses 
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2.5 Bacterial cell culture 
Microbial cell culture is a standard method in molecular biology. It was used for cloning 
experiments to multiply bacteria containing different plasmids of interest. All media, buffer, 
flasks or pipets needed for bacterial cell culture were autoclaved for 20 min at 121 °C and 
1 bar pressure. 
2.5.1 Bacterial strains 
For all cloning experiments the bacterial strain E. coli DH5α (genotype: supE44 hsdR17 
recA1 endA1 gyrA96 thi-1 relA1, (183)) was used. This strain has an ampicillin resistance 
gene to select clones after transformation of plasmids. 
2.5.2 Bacterial growth on agar plates 
To grow bacterial cells on agar plates, LB medium (Lysogeny Broth, (184); 5 g/L yeast 
extract, 10 g/L peptone, 10 g/L NaCl) was supplemented with agar (15 g/L). The agar plates 
were stored at 4 °C for up to one month. To amplify E. coli DH5α strains, ampicillin was 
added into the agar culture medium with a final concentration of 100 µg/mL and E. coli 
strains of interest were spread out on agar plates. After overnight incubation at 37 °C one 
single colony was used to inoculate liquid bacterial growth medium.  
2.5.3 Bacterial cell culture in liquid medium 
E. coli DH5α strains were cultivated in LB medium (5 g/L yeast extract, 10 g/L peptone, 
10 g/L NaCl) supplemented with 100 µg/mL ampicillin at 37 °C from 8 h till overnight. For 
long time storage of designed constructs and strains, the cultures were diluted 1:1 with sterile 
98 % glycerol, frozen with liquid nitrogen and stored at -80 °C. In general grown bacterial cell 
cultures were used for plasmid preparation (2.15.1). 
2.5.4 Preparation of chemically competent E. coli DH5α cells 
To prepare chemically competent E. coli DH5α cells, 150 mL of LB medium were 
pre-warmed and inoculated with 3 mL of an overnight culture. Cells were grown at 37 °C and 
shaken at 200 rpm in an incubator (GFL 3033) till an optical density OD576 of 0.6 was 
reached. After pelleting the cells at 5000 rpm and 4 °C for 7 min, cells were carefully 
resuspended in 15 mL of pre-cooled TFB-1 solution (10 mM MOPS pH 7.0, 10 mM RbCl) 
and were pelleted again. Afterwards cell pellet was resuspended in 6 mL of pre-cooled 
TFB-3 solution (100 mM MOPS pH 6.5, 50 mM CaCl2, 10 mM KCl, 15 % glycerin) and 50 µL 
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aliquots were frozen in liquid nitrogen before chemically competent E. coli DH5α cells were 
stored at -80 °C.  
2.5.5 Transformation of bacterial cells 
Transformation of bacterial cells was discovered in 1928 by the bacteriologist Griffith (185) 
and is a standard laboratory procedure in molecular biology. Transformation allows uptake, 
incorporation and expression of genetic material e.g. plasmid DNA into bacterial cells. First of 
all chemically competent E. coli DH5α cells were thawed on ice. After addition of negatively 
charged plasmid DNA (up to 1 µg, 2.15.1) or ligation reaction (up to 20 µL, 0), cells were 
incubated on ice for 30 min. DNA uptake occurred after pre-cooled cells were heat-shocked 
at 42 °C for 45 sec. After incubation of the mixture on ice for 2 min, 300 µL of pre-warmed LB 
medium without antibiotic was added. Cells were shaken at 600 g and 37 °C for 30-60 min. 
Subsequently the transformation reaction was spread out onto agar plates and incubated as 
described above (2.5.2). 
2.6 Eukaryotic cell culture 
In mammalian cell culture immortalized cell lines of interest can be subcultured under sterile 
conditions in a laminar air flow (Thermo Scientific, Schwerte, Germany) and cultivated in a 
humidified atmosphere (NuAire, Plymouth, USA) at 37 °C and 5 % CO2. Cell lines derive 
from isolated tumors of different organs or tissues. Cultivation of these cells depends on their 
method to grow. Suspension cell lines are easily passaged with a small amount of culture 
diluted with media, whereas adherent cell cultures have to be detached before only a small 
proportion can be seeded into new culture flasks. To allow optimal growth conditions, media 
for cultivation of eukaryotic cells have to be supplemented with several nutrients including 
Fetal Calf Serum (FCS). 
2.6.1 Eukaryotic cell culture of suspension cell lines 
2.6.1.1 K562 
The chronic myelogenous leukemia cell line K562 was derived from the pleural effusion of a 
53-year old female with terminal blast crises by Lozzio and Lozzio (186). This cell line grows 
in suspension and is cultured in RPMI 1640 (Roswell Park Memorial Institute) medium 
containing 10 % FCS. In general cells were subcultured every 2-3 days with a cell density of 
0.25-1 * 106 cells/mL and were incubated in a humidified atmosphere (37 °C, 5 % CO2).  
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2.6.2 Eukaryotic cell culture of adherent cell lines 
2.6.2.1 HeLa 
The adherent cell line HeLa was established in 1951 as the first immortal cell line and 
derived from cervical cancer cells of a 51-year-old female named Henrietta Lacks (187). 
Cells were cultivated in a humidified atmosphere (37 °C, 5 % CO2) in IMDM medium 
(Iscove’s Modified Dulbecco Medium) supplemented with 10 % FCS. HeLa cells were 
subcultured twice a week by rinsing the medium, washing cells with PBS and detaching 
adherent cells with 2 mL of trypsin/EDTA solution (0,25 % (w/v) trypsin, 0,53 mM EDTA). The 
cell suspension was filled up with 8 mL of IMDM medium and cells were seeded in a 
subculture ratio of 1:10 or 1:20 in fresh culture vessels. 
2.6.2.2 LS174T 
LS174T cells were received as a trypsinized variant of the colorectal adenocarcinoma cell 
line LS180 which derived from a 58-year-old female patient (188). Multiplication of the cells 
was done according to the procedure for HeLa cells, but LS174T cells were seeded into 
culture flasks in a ratio of 1:5. 
2.6.2.3 Skov-3 
The ovarian carcinoma cell line Skov-3 was isolated from a 64-year-old Caucasian female 
(189). Cells were cultured in the same manner as described aforementioned. A ratio of 1:3 to 
1:5 was used for subcultures. 
2.6.2.4 HCT 116 
HCT 116 cells, generated from an adult male gender, derive from a colorectal carcinoma cell 
line growing as adherent cells. Cells were subcultured as described above and were seeded 
in a ratio of 1:5 to 1:8 twice a week. 
2.7 Experimental working with animals 
For this thesis subcutaneous colon carcinoma xenograft mouse experiments were performed 
to establish the first miRNA replacement therapy (28) based on the cationic polyethylenimine 
PEI F25 LMW. All studies including keeping, treatment and therapy establishment of mice 
were done in the working group of Prof. Dr. Achim Aigner.  
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2.7.1 Athymic nude mice 
Athymic nude mice (Hsd:Athymic Nude-Foxn1nu, 6-8 weeks old) were obtained from Harlan 
Winkelmann (Borchen, Germany) and were kept in tight stages at 23 °C in a humidified 
atmosphere with standard rodent chow, water available ad libitum and a 12 hour light/dark 
cycle. Animal studies were done according to the national regulations and were approved by 
the Regierungspräsidum Gießen (Germany).  
2.7.2 Subcutaneous xenograft colon carcinoma tumor models 
To generate subcutaneous xenograft mouse models, a total of 1.5 * 106 LS174T or HCT116 
cells in a total volume of 150 µL PBS were s.c.-injected into both flanks of the mice. After 
establishment of solid tumors and randomizing animals in specific treatment groups, the 
treatment with PEI/miRNA or PEI/siRNA complexes was done according to the information 
given at Ibrahim et al. (28). Tumor volumes were monitored during the experiment that was 
finished by scarification of the mice. Afterwards tumor tissues were prepared for selected 
analyses.  
2.7.3 MiRNA tissue uptake in vivo 
Radioactive determination of miRNA tissue distribution was done with [32P]-end labeled 
miRNAs. In mice, subcutaneous tumors were initiated until a size of approximately 8 mm in 
diameter was reached (2.7.2). PEI F25 LMW complex formation was performed using 
[32P]-end labeled miRNAs of interest (2.8.2.2). Complexes were introduced into the mice via 
i.p.- or i.v.-injection and 4 h later they were sacrificed. To quantitate tissue distribution of the 
miRNAs, total RNA was isolated from different tissues (more information available at Ibrahim 
et al. (28)).  
2.8 Transfection of mammalian cell lines 
Transfection of mammalian cell lines is a process to introduce nucleic acids such as DNA or 
RNA molecules into cells. In general the term transfection is used for non-viral targeting of 
eukaryotic cells where transient pores in the cell membrane allow uptake of the material. This 
transient pores can be generated by using several techniques. For electroporation the cells 
are exposed to a short single electric impulse which transiently increases the permeability of 
the cell membrane. A very efficient transfection method is liposome delivery via cationic 
polymers such as polyethylenimine. The polycation interacts with the negatively charged 
nucleic acids and thus forms liposomes which are taken up via endocytosis. 
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2.8.1 Transfection procedure of suspension cell lines 
For transfection of the suspension cell line K562 with plasmid DNA, siRNA, miRNA mimics or 
LNA-modified antisense oligonucleotides cells were harvested for 5 min at 390 g. Afterwards 
cells were washed twice with 10 mL of RPMI 1640 without FCS. 2 * 106 cells, in a total 
volume of 100 µL medium, were electroporated in a 4 mm cuvette with a single pulse for 
10 ms at 330 V using a Bio-Rad Gene Pulser Xcell (Bio-Rad, Munich, Germany). Per 1 * 106 
cells 5 µg of plasmid DNA or 1 µg of siRNA, miRNA mimic or LNA-modified 
antisense oligonucleotide was used. After electroporation cells were seeded into 12-well cell 
culture plates containing 1.5 mL RPMI 1640 supplemented with 10 % FCS. Cells were 
incubated for up to 120 h in a humidified atmosphere (37 °C, 5 % CO2). Subsequently cells 
were prepared either for Western Blot analysis, WST-1 assay, luciferase assay or total RNA 
extraction (2.9.2, 2.10.2, 2.9.5, 2.16.2). 
2.8.2 Transfection procedure of adherent cell lines 
Transfection of adherent cell lines was done by liposome delivery using either 
LipofectamineTM 2000 (Life Technologies Invitrogen, Darmstadt, Germany) or the cationic 
polymer PolyEthyleneImine F25 Low Molecular Weight (PEI F25 LMW; Sigma Aldrich, 
Taufkirchen, Germany) prepared and purified as described at Werth et al. (190). 
2.8.2.1 Transfection with LipofectamineTM 2000 
The adherent cell lines HeLa, LS174T and Skov-3 were transfected with 
LipofectamineTM 2000 (Life Technologies Invitrogen, Darmstadt, Germany) according to the 
manufacturer’s protocol. 
8 * 104 HeLa cells were seeded in a 24-well plate the day before transfection. Transfection 
procedure was proceeded in 400 µL IMDM medium without FCS. 0.5 µg of individual 
pGL3 reporter construct was diluted in 50 µL of Optimem I (Life Technologies Invitrogen, 
Darmstadt, Germany) and for co-transfection mixed with the respective amount of 
LNA antiseed, LNA control, siRNA, miRNA mimic or miRNA control. 1.5 µL of 
LipofectamineTM 2000 were used per transfection and diluted in 50 µL of Optimem I. After 
incubation at room temperature for 5 min both components were mixed and incubated 
another 15 min. Afterwards complexes were added to the media. The medium was aspirated 
4-6 h later and exchanged by IMDM supplemented with 10 % FCS. 24-96 h after transfection 
cells were prepared for luciferase reporter assays, total RNA extractions, WST-1 assays or 
Western Blotting experiments (2.9.5, 2.16.2, 2.10.2, 2.9.2). 
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To transfect LS174T cells, 0.5 * 106 cells were seeded in a 12-well plate one day prior 
treatment. 40 pmol PIM1-specific siRNA, miRNA mimics or controls were used and mixed 
with 2 µL of Lipofectamine™ 2000 according to the manufacturer’s protocol. Cells were 
incubated 24-96 h in a humidified atmosphere.  
For transfection of Skov-3 cells 1 * 105 cells were seeded into a 12-well plate. The day of 
co-transfection 2 µL of Lipofectamine™ 2000 were mixed with 25 ng of the PIM1 cDNA 
clones (2.13.1) and 20 pmol PIM1-specific siRNA or miRNA mimic according to the 
manufacturer’s protocol. After incubation for 48 h in a humidified atmosphere cells were 
prepared for Western Blotting experiments (2.9.2). 
2.8.2.2 Transfection with PEI F25 LMW 
For complexation of miRNA inhibitors with PEI F25 LMW HeLa cells were pre-transfected 
with pGL3 control reporter vector DNA using LipofectamineTM 2000 as described above. After 
6 h the medium was replaced by IMDM containing 10 % FCS and PEI complexes were 
added. For PEI F25 LMW complexation indicated amounts of siRNA, LNA antiseeds or 
miRIDIAN hairpin inhibitors were diluted in 50 µL complexation buffer (150 mM NaCl, 10 mM 
HEPES pH 7.4) and equilibrated for 5 min at room temperature (RT). In general a 
PEI/oligonucleotide mass ratio of 2.5:1 or 5:1 was obtained. A ratio of 5:1 resulted in a 
N/P ratio of 33 which had been determined as optimal for siRNA complexation (190), (176). 
The N/P ratio is based on a ratio of PEI Nitrogen per nucleic acid Phosphate. After 
equilibration of PEI F25 LMW in 50 µL complexation buffer the oligonucleotide and the PEI 
solution were mixed and briefly vortexed. An incubation step at room temperature for 
30-60 min followed to allow the complexes to form. PEI F25 LMW complexes were added to 
the cells. 48 h later cells were lyzed and prepared for reporter assay measurements (2.9.5), 
determination of PEI F25 LMW complexation efficacy (2.10.2) or atomic force microscopy 
(2.17).  
2.9 Protein techniques 
2.9.1 SDS PAGE 
SDS PAGE (SodiumDodecylSulfate PolyAcrylamide Gel Electrophoresis) is a method to 
separate denatured proteins according to their electrophoretic mobility. SDS functions as 
detergent and binds to amino acids of linearized proteins what results in a negative charge of 
the protein samples. The disc electrophoresis evolved by Ornstein and Davis (191) resulted 
in an improvement concerning the sharpness of separated proteins caused by a pH shift in 
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the stacking and separating buffer conditions. To prepare 15 % SDS gels the components 
depicted in Table 11 were mixed and polymerized between two glass plates. 
Table 11: Composition of 15 % SDS PAGE gels. 
Ingredient Separating gel Stacking gel 
4x separating gel buffer 
(1.5 M Tris-HCl pH 8.8, 0.6 % SDS) 
4 mL - 
4x stacking gel buffer 
(0.5 M Tris-HCl pH 6.8, 0.6 % SDS) 
- 1,8 mL 
acrylamide/bisacrylamide 
(30 % solution) 
8 mL 1 mL 
APS (10 % solution) 160 µL 75 µL 
TEMED 16 µL 7,5 µL 
ddH20 ad 16 mL ad 7,5 mL 
 
SDS PAGE was performed subsequent to fixation of the gel matrix. Protein samples of 
interest were resuspended in 100-200 µL of lysis buffer (125 mM Tris-HCl pH 6.8, 4 % SDS, 
1.4 M 2-mercaptoethanol, 0.05 % bromophenol blue) and heated to 95 °C for 5 min. 
Electrophoresis was performed in a Bio-Rad Mini-PROTEAN® 3 cell mini gel system 
(Bio-Rad, Munich, Germany) in 1x running buffer (192 mM glycine, 25 mM Tris-HCl, 0.01 % 
SDS) for 1 h at 180 V.  
2.9.2 Western Blot 
The Western Blot method was devised in 1979 (192) to transfer separated proteins onto a 
solid carrier like a PVDF (PolyVinyliDine Fluoride) membrane following polyacrylamide gel 
electrophoresis. Immobilized proteins can be probed with specific antibodies and visualized 
by chemo-luminescence or colorimetric techniques. After finishing SDS PAGE (2.9.1) the 
polyacrylamide gel was incubated in transfer buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 
10 % methanol) for 30 min to fix the proteins in the gel matrix. Proteins were transferred onto 
an ImmobilonTM-P PVDF membrane (Millipore, MA, USA). The membrane was activated in 
methanol for 2 min before incubating for 15 min in transfer buffer. Similarly, the blotting paper 
was soaked in transfer buffer. Protein transfer was done in a 
Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad, Munich, Germany) for 30 min at 10 V. 
Afterwards the membrane was incubated for 2 h in 5 % milk powder in TBST (10 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 0.1 % Tween 20) before overnight incubation with the 
primary antibody started. After three washing steps in TBST the incubation with an individual 
secondary antibody followed for 1 h. The primary and secondary antibodies which were used 
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for Western Blot experiments are depicted in Table 8 and Table 9. After a final washing step 
blots were incubated with Amersham ECLTM or ECLplusTM Western Blotting Detection 
Reagents according to the manufacturer’s protocol. For detection of chemo-luminescence 
Kodak® BioMaxTM light films, Kodak® GBX Developer and Replenisher and GBX Fixer and 
Replenisher were used. The exposure time differed between 1 to 15 min depending on the 
protein that was detected. To visualize the internal loading control, the blots were treated 
with stripping buffer (62.5 mM Tris-HCl pH 6.7, 100 mM 2-mercaptoethanol, 2 % SDS) for 
30 min at 50 °C in a hybridization oven (Biometra, Goettingen, Germany), were blocked 
again for 1 h in milk powder (5 % solution in TBST) and afterwards were incubated with the 
ß-Actin antibody.  
2.9.3 ELISA 
Enzyme Linked Immunosorbent Assay (ELISA) is a powerful analytical biochemistry assay. 
This technique can be used for diagnostic differentiation of protein levels in treated versus 
untreated tumor tissues. For this thesis the group of Prof. Dr. Achim Aigner performed a 
PIM1-specific ELISA to analyze xenograft colon carcinoma tumor samples in mice which 
were treated with PIM1-specific siRNA or a miR-33a-mimic. Furthermore ELISA experiments 
were conducted to detect changes in TNFα and LPS levels monitoring unspecific effects of 
PEI/miRNA or PEI/siRNA treatment (for detailed information see (28)). After coating the 
antibody onto a 96-well plate overnight the supernatant of a tumor sample lysate was added 
to the plate the next morning. Several washing steps followed, before the specific detection 
antibody was applied to each single well. Detection was performed using a HRP-coated 
secondary antibody which was able to turn the offered substrate into a colored product. 
Subsequently the rising amounts of colored product were detected in a FLUOstar OPTIMA 
micro plate reader (BMG Labtech, NYC, USA).  
2.9.4 Liver enzyme activity assays 
To determine non-specific and/or toxic effects of PEI/miRNA complexes in mouse 
experiments, changes in the activity of the liver enzymes aspartate aminotransferase (AST, 
SGOT) and alanine aminotransferase (ALT, SGPT) were determined using an enzyme assay 
kit obtained from DiaSys Diagnostic Systems (Holzheim, Germany). Evaluation of the assay 
was done 60 min after four consecutive i.p.-injection-treatments. Enzyme activity assays 
were performed in Prof. Dr. Achim Aigner group; further information can be found at Ibrahim 
et al. (28).  
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2.9.5 Luciferase reporter assay 
48 h after incubation of K562 or HeLa cells with the respective pGL3 luciferase reporter 
plasmids and/or siRNAs, miRNA mimics or LNA-modified antisense oligonucleotides, 
luciferase reporter assays were performed using the Promega Luciferase Assay System 
(Promega, Mannheim, Germany). K562 were centrifuged (5 min, 390 g, RT), washed with 
500 µL of PBS and pelleted before lyzing with 200 µL of 1.2x reporter lysis buffer (Promega, 
Mannheim, Germany). The media of HeLa cells or other adherent growing cells was 
aspirated and cells were lyzed in 100 µL of 1.2x reporter lysis buffer after a previous washing 
step with PBS. Cells were incubated in reporter lysis buffer for 1 h at room temperature, 
while shaking at 1,800 rpm. Next assay measurement was performed in a white 96-well 
plate. 10 µL of cell lysate were mixed with 10 µL of luciferase substrate. Luminescence was 
measured immediately in a Safire2TM micro plate reader (Tecan, Crailsheim, Germany). 
Custom settings for measurement were defined as ‘Luminescence’ for measurement mode, 
’10 msec’ were set as integration time with a shake duration of ‘3 sec’ and as plate definition 
‘GRE96fw.pdf’ was chosen. 
2.10 Cell cycle analyses 
The cell cycle, also termed cell-division cycle, leads to division and replication of a mother 
cell into two daughter cells. In mammalian cells this can be departed into four phases 
including two periods, interphase and cell division. Thus the interphase is consisting of 
G- and S-phase, in which cells first increase in size, then DNA synthesis starts, replication 
occurs and afterwards cell division into two daughter cells can take place in mitosis phase. 
Mitosis itself is divided in prophase, prometaphase, metaphase, anaphase and telophase. 
The regulation of the cell cycle is strongly controlled in mammalian cellular systems and is 
used as a checkpoint for proliferation of cells in tumor studies. Anti-cancer treatments can 
store the cell cycle at one distinct point or can delay the proliferation of cells. This has to be 
considered using several different experimental methods. 
2.10.1 Cell cycle analyses using nocodazole 
For cell cycle analyses the chemical nocodazole was used. This anti-neoplastic agent affects 
the cytoskeleton and synchronizes cells by blocking a formation of metaphase spindles after 
entry into mitosis. Nocodazole was used for cell cycle analyses in K562 and LS174T cells. In 
case of K562 cells nocodazole was added 24 h after transfection of siRNAs or miRNAs 
(2.8.1, 2.8.2). LS174T cells were treated 48 h after transfection. Nocodazole was applied to 
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the medium at a final concentration of 100 ng/mL. A 16 h (LS174T) to 24 h (K562) incubation 
step followed in a humidified atmosphere at 37 °C, before cells were washed with PBS and 
fresh medium was added to release cells from the mitotic block. Cells were cultivated for 
another 48 h before harvesting. Then fixation of the cells was performed to do FACS analysis 
(2.12).  
2.10.2 WST-1 assay 
Before usage of modified RNA oligonucleotides as therapeutic agents it is important to 
question whether these molecules cause a growth delay, have cytotoxic effects or influence 
cell viability. Thus cell viability of different mammalian cells can be determined with the water 
soluble tetrazolium salt WST-1 (Roche Applied Science, Mannheim, Germany). During the 
assay the tetrazolium salt is cleaved to a dark red formazan dye by cellular mitochondrial 
dehydrogenases that are present in viable cells. Absorbance directly correlates with the 
amount of viable and metabolically active cells in the culture. The assay was performed in a 
micro titer plate as indicated in the protocol of the manufacturer. Cells of interest (e.g. 
0.5 * 104 HeLa cells) were seeded one day prior to transfection. The day of transfection cells 
were treated with RNA oligonucleotide complexes of interest (2.8.2). 48 h after transfection a 
WST-1 proliferation assay was done using 10 µL of water soluble tetrazolium salt which was 
directly given to the cultured cells. Measurement of resulting formazan dye was performed 
after a 2 h incubation step at 37 °C in a humidified atmosphere in a Safire2TM 
micro plate reader (Tecan, Crailsheim, Germany). Absorbance was determined at 450 nm 
choosing a reference wavelength of 650 nm. Cell viability was calculated using a background 
control as reference. 
2.10.3 Cell counting method 
To determine the increase of the total number of viable cells in suspension cell lines, it is 
more likely to use cell counting. The enzymatic catalytic reaction of the formazan dye used in 
the WST-1 assay is possible, but uniform colorization of the product is limited. Thus cell 
counting was performed to consider antiproliferative effects on growth of the suspension cell 
line K562 after siRNA, miRNA mimic or LNA antiseed treatment. Cells were cultivated two 
days prior to transfection or treatment in the indicated medium (2.8.1) containing only 2 % 
FCS to slow down the cell cycle due to serum starvation. The day the experiment was 
started, cells were counted and 1 * 106 cells were seeded into a 12-well plate containing 
1.5 mL of RPMI 1640 supplemented with 2 % FCS. Every 24 h cells were counted with a 
hemocytometer (Marienfeld, Lauda-Königshofen, Germany) and the medium was exchanged 
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by pelleting the cells at 2050 rpm for 5 min if necessary. By analyzing the total number of 
cells, cell proliferation of untreated versus treated cells was compared.  
2.11 Apoptosis assays 
Apoptosis is the process of programmed cell death which occurs in multicellular organisms. 
Characteristic changes in e.g. the morphology of cells include cell shrinking, nuclear or 
chromosomal DNA fragmentation as well as chromatin condensation. These biochemical 
events afterwards lead to cell death. The principle of apoptosis was first described in 1842 by 
the German scientist Carl Vogt and later studied and further described by a number of 
scientists (193). The process of apoptosis can be controlled by either extracellular (e.g. 
toxins, cytokines) or intracellular (e.g. glucocorticoids, hypoxia) signals and to date can be 
detected via multiple assay systems. 
2.11.1 Cell death detection assay 
Induction of apoptosis after PIM1-specific siRNA or miR-33a treatment (2.8.1) was 
determined in a cell death detection assay. For K562 cells the Cell Death Detection ELISA 
(Roche Applied Biosciences, Mannheim, Germany) was used according to the 
manufacturer’s protocol. Microtiter plates were pre-coated with an anti-histone antibody 
(clone H 11-4) and were incubated with lyzed cells. Addition of an anti-DNA antibody 
(clone MCA-33) was followed by an incubation step for 90 min. For detection of mono- and 
oligo-nucleosomes 2,2’-Azinobis-3-ethylBenzThiazolin-6-Sulfonic acid (ABTS) substrate 
solution was applied. This substrate is cleaved by peroxidases which are bound to the 
immune-complexes. The resulting ABTS-radical can be photometrically determined. 
Absorbance was measured with a Safire2™ micro plate reader at 405 nm (Tecan, 
Crailsheim, Germany). 
2.11.2 Caspase assay 
To determine the apoptosis rate in LS174T cells, the Caspase-Glo® 3/7 Assay (Promega, 
Mannheim, Germany) was used according to the manufacturer’s protocol. The assay 
provides a proluminescent caspase-3/-7 substrate which is cleaved to release aminoluciferin. 
Thereafter this cleaved product is used by luciferase for the production of light that in the 
following can be detected. Briefly 1 * 103 cells per well were seeded in 96-well plates and 
transfected with PIM1-specific siRNA or miRNA (2.8.2). After 120 h the 
caspase Glo® 3/7 substrate was prepared in serum-free medium and 100 µL were added to 
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the cells prior to incubation for 1 h at room temperature. For the detection of caspase activity 
luminescence was measured using a FLUOstar OPTIMA micro plate reader (BMG Labtech, 
NYC, USA). 
2.12 FACS 
A powerful biophysical technique to allow cell counting, sorting or protein engineering is flow 
cytometry. A specialized type is Fluorescence-Activated Cell Sorting (FACS) which sorts a 
heterogeneous mixture of biological cells. Cells are illuminated with a single light impulse and 
a number of detectors evaluate combination of scattered and fluorescent light. By this one 
single cell at a time is sorted based upon its specific fluorescence or light pattern. 
2.12.1 Cell sorting via propidium iodide staining 
One defined viability assay is performed by measuring cell membranes integrity. This can be 
done via a staining with the fluorescent dye propidium iodide which is an intercalating agent. 
Propidium iodide is impermeable for cell membranes of viable cells and thus colours only 
DNA fragments of dead cells. For FACS analysis K562 and LS174T cells were harvested 
after synchronizing their cell cycle with nocodazole (2.10.1), were fixed in 70 % ethanol in 
PBS and incubated for 1 h on ice. After incubation with 50 µg/mL RNase A (Thermo Fisher 
Scientific, Schwerte, Germany) at 37 °C for 30 min, cells were stained with 50 µg/mL 
propidium iodide solution. Afterwards FACS analyses were done using a 
BD FACSCalibur™ system (Becton-Dickinson, Heidelberg, Germany). These analyses were 
performed with the help of the working group of Prof. Dr. Achim Aigner. 
2.13 Plasmid construction 
In general plasmids are DNA molecules that are independent of genomic DNA. Plasmid DNA 
mainly is circular and differs in size. In case of genetic engineering plasmids are called 
vectors and are a powerful tool in molecular biology to amplify DNA or proteins of interest. All 
vectors used in this thesis are designed to allow amplification in eukaryotic cells.  
2.13.1 Full-length PIM1 cDNA clone 
To obtain ectopic PIM1 expression in PIM1 negative mammalian cell lines, a full-length 
PIM1 cDNA clone (Cat. No.: SC110975, Accession No.: NM_002648.2 hsa PIM1 oncogene, 
vector pCMV6-XL4; vector sequence imprinted in Appendix P) was purchased from OriGene 
(Rockville, MD, USA). The eukaryotic vector has a size of 4.7 kb plus 2.6 kb 
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PIM1 cDNA insert. Ectopic PIM1 expression in human cell lines is driven via a strong CMV 
promoter. The PIM1 cDNA clone was introduced into chemically competent E. coli DH5α 
cells for further multiplication (2.5.3). To analyze specific miR-33a targeting of PIM1 mRNA, 
several PIM1 cDNA clone mutants were generated. 
 
Figure 9: pCMV6-XL4 PIM1 
cDNA. Schematic overview 
of the PIM1 cDNA clone; the 
PIM1 cDNA (yellow arrow) is 
cloned behind a CMV 
promoter. 
 
 
 
 
2.13.1.1 ∆ 3’-UTR PIM1 cDNA clone 
To generate the Δ 3’-UTR PIM1 cDNA clone, the PIM1 full-length cDNA clone was digested 
with the fast digest enzyme HindIII (Thermo Fisher Scientific, Schwerte, Germany). The two 
HindIII restriction sites are positioned ~50 bp downstream of the PIM1 stop codon and 
~400 bp upstream of the poly(A) tail (positions 1424 and 2311 in sequence NM_002648.3). 
After removal of the ~0.9 kb HindIII-fragment the vector was re-ligated and transformed into 
chemically competent E. coli DH5α cells (2.5.3). The Δ 3’-UTR PIM1 cDNA clone lacks about 
two thirds of the 3’-UTR of PIM1 which includes also the miR-33a target site. Thus this 
cDNA clone is important in studying the functions of miR-33a. 
2.13.1.2 PIM1 cDNA clone harboring a mutated miR-33a target site 
The PIM1 cDNA clone harboring a mutated miR-33a target site was derived from the 
cDNA clone lacking large parts of the PIM1 3’-UTR (2.13.1.1) and an already existing 
pGL3 control reporter construct harboring the 3’-UTR of PIM1 with a site mutated version of 
the miR-33a target site (2.13.3.2). Therefore both vector constructs were digested with the 
restriction endonuclease HindIII (Thermo Fisher Scientific, Schwerte, Germany) to generate 
for the one hand the fragment of the PIM1 cDNA clone lacking large parts of the 
PIM1 3’-UTR and on the other hand the HindIII-generated 3’-UTR insert containing the 
mutated miR-33a target site. After separation of the fragments by agarose gel 
electrophoresis (2.14.2.1) and cleaning up fragmented plasmid DNA (2.15.9), a re-ligation 
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step was applied, followed by its transformation into E. coli DH5α cells (2.15.5, 2.5.3). 
Correct insertion of the HindIII-cleaved fragments was verified via DNA sequencing 
(2.15.10).  
2.13.2 pGL3 control reporter vector 
In this thesis the commercially available pGL3 control reporter plasmid (Promega, 
Mannheim, Germany; vector sequence imprinted in Appendix Q; Figure 10a) was used for 
promoter studies and analyses of miRNA target sites via luciferase assays. This reporter 
vector consists of a luciferase gene strongly expressed by a SV40 promoter. For 
investigation of putative promoter constructs the SV40 promoter was exchanged by the 
promoter sequence of interest (Figure 10b). To determine miRNA-specific targeting of a 
protein of interest, its 3’-UTR was cloned behind the luciferase gene (Figure 10c). 
 
 
Figure 10: pGL3 control reporter vector and its derivatives. (a) Schematic overview of the 
pGL3 control reporter vector. (b) Schematic overview of the C13orf25 promoter constructs; the individual 
sequence of the promoter construct (yellow arrow) is cloned in front of the luciferase coding region. (c) 
Schematic overview of the 3’-UTR constructs; the 3’-UTR of the protein of interest (yellow arrow) is cloned 
behind the luciferase coding region. 
 
2.13.3 Cloning of different pGL3 reporter vector constructs 
In the following chapters all pGL3 reporter vector constructs are described which were used 
in this thesis. Cloning experiments were done by several researchers and also depicted in 
detail elsewhere.  
  Materials and Methods   
42 
 
2.13.3.1 pGL3 control PIM1 3’-UTR reporter construct 
In the 3’-UTR of human PIM1 one miR-33a target site is located. To determine specific 
effects of a miR-33a mimic on PIM1 mRNA, its 3’-UTR was cloned into the 
pGL3 control reporter vector. Human PIM1 3’-UTR was amplified from genomic DNA of the 
erythroleukemia cell line K562 using the primers listed in Appendix J. Afterwards the 
PIM1 3’-UTR was cloned into the unique XbaI site of the pGL3 control reporter vector located 
directly behind the luciferase gene. A transformation step into E. coli DH5α cells followed 
(2.5.5). Correct insertion of the PIM1 3’-UTR was validated via restriction digest of the 
plasmid and DNA sequencing (2.15.4, 2.15.10). The generated reporter construct was 
performed by Robert Prinz (194). 
2.13.3.2 pGL3 control PIM1 3’-UTR mutated miR-33a target site reporter 
construct 
To eliminate the miR-33a target site in the pGL3 control PIM1 3’-UTR vector, a mutagenesis 
PCR according to Brennecke et al. (195) was performed using primers listed in Appendix J. 
DNA sequencing (2.15.10) verified correctness of introduced mutations. This reporter 
construct was cloned by Robert Prinz (194). 
2.13.3.3 pGL3 control hsa-let-7a target site reporter constructs 
To introduce a hsa-let-7a site behind the luciferase coding sequence of the 
pGL3 control reporter vector, two complementary DNA oligonucleotides (Appendix J) 
encoding the let-7a target sequence (MIMAT0000062) (2.18.6) were annealed in annealing 
buffer (30 mM HEPES KOH pH 7.4, 100 mM KCl, 2 mM Mg2Cl, 50 mM NH4Ac) and cleaved 
with the restriction enzyme XbaI (2.15.4). Afterwards the DNA fragment was cloned into the 
unique XbaI site located immediately downstream of the luciferase gene of the linearized and 
dephosphorylated (2.15.2) pGL3 control reporter plasmid. Correct insertion of the 
double-stranded DNA oligonucleotide was identified through linearizing of recombinant 
plasmids via a unique BlpI site which was introduced with the annealed DNA insert. Cloning 
of the insert resulted in two opposite orientations that were identified by DNA sequencing 
(2.15.10). These clones, giving rise to RNA transcripts harboring a let-7a target site, were 
classified as ‘forward orientation’; those with the opposite insert orientation served as 
negative control reporter plasmids, termed as ‘inverted orientation’. Cloning studies were 
done by Robert Prinz (194). 
  Materials and Methods   
43 
 
2.13.3.4 pGL3 control P21 3’-UTR reporter construct 
The 3’-UTR of human P21 harbors two target sites for members of the human 
miR-106b family, namely miR-17-5p and miR-20a. To determine the effects of LNA antiseeds 
directed against mature miR-106b family members on P21 protein levels, its 3’-UTR was 
cloned into the pGL3 control reporter vector via the XbaI site. Initially the 3’-UTR was 
amplified from human genomic DNA of K562 cells using primers listed in Appendix J. 
Afterwards the amplicon was subcloned into a pCR™2.1-TOPO® vector 
(TOPO® TA Cloning® kit, Invitrogen, Karlsruhe, Germany) prior to insertion into the 
pGL3 control vector. Correct introduction of the insert was applied using restriction digest as 
well as DNA sequencing (2.15.4, 2.15.10). Creation of the construct was performed by 
Robert Prinz (194). 
2.13.3.5 pGL3 control P21 3’-UTR mutated miR-106b family target sites reporter 
construct 
Mutagenesis of the two miR-106b family target sites in the P21 3’-UTR was performed via 
mutagenesis PCR (2.15.8.2) of the pGL3 control P21 3’-UTR reporter vector. Primers were 
designed according to Brennecke et al. (195) and are listed in Appendix J. The generated 
amplicons were cloned into E. coli DH5α cells (2.5.5) and correct insertion of the mutations 
was verified via DNA sequencing (2.15.10). This construct was generated by Robert Prinz 
(194). 
2.13.3.6 pGL3 control C13orf25 promoter constructs 
To study the intronic AT-rich region preceding the miR-17-92 cluster, several 
C13orf25 promoter constructs were cloned. These constructs include individual segments 
which either start ~100 nt or ~200 nt upstream of the miR-17 coding sequence. Therefore the 
pGL3 control reporter plasmid was used and the strong SV40 promoter deleted via restriction 
digest with the two enzymes BglII and HindIII. At this position the favored 
C13orf25 segments were introduced harboring the respective restriction enzyme sites. 
Promoter fragments were initially amplified from human genomic K562 DNA using the 
primers listed in Appendix J. The amplicons were purified and digested with BglII and HindIII 
for re-introduction and ligation into the pGL3 control reporter vector (2.15.5). The vectors 
containing a 1.5 kb insert, a shortened insert of 625 bp or a 339 bp insert were generated by 
Robert Prinz (194). Similarly some promoter constructs were cloned by Dorothee Hartmann 
(196). One construct was designed containing 297 bp of C13orf25, a second one harbored 
only 197 bp. Additionally a 250 bp, a 190 bp and a 108 bp construct were cloned. One 
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construct comprised an inverted sequence of the 339 bp reporter construct and dealt as in 
internal control plasmid. All segments were cloned into E. coli DH5α cells (2.5.5) and were 
verified via DNA sequencing (2.15.10).  
2.14 General nucleic acid techniques 
Nucleic acid techniques can be used either for DNA or RNA oligonucleotides. DNA or RNA 
samples were stored at -20 °C for longer periods and dissolved in double-distilled water. 
2.14.1 Determination of nucleic acid concentration 
Nucleic acids are able to absorb light at a specific wavelength. The aromatic ring of each 
base can absorb light at the distinct wavelength of 260 nm. The nucleic acid concentration 
can be determined according to the law of Lambert-Beer (Equation 1) which relates the 
absorption of light to the properties of a material or solution that light has travelled through. 
The concentration of a sample can be determined if the absorbance is measured and the 
molar absorptivity as well as the path length of the cuvette are known. 
Equation 1: Law of Lambert-Beer. 
E = ε * c * l 
[E]: extinction 
[ε]: molar absorptivity (extinction coefficient) [1/(M * cm)] 
[c]: molar concentration [M] 
[l]: path length of the cuvette [cm] 
 
During the laboratory work the concentration of nucleic acids was determined using 
double-distilled water as solvent. For absorption of 1 at 260 nm (1 A260) and a cuvette path 
length of 1 cm following concentrations of nucleic acids can be assumed (Equation 2): 
Equation 2: Concentration of nucleic acids. 
1 A260 dsDNA → 50 µg/mL 
1 A260 ssDNA → 37 µg/mL 
1 A260 RNA → 40 µg/mL 
 
The purity of nucleic acids can be estimated by measuring the ratio of A260/A280. The aromatic 
amino acids of proteins have their absorbance maximum at 280 nm. If the nucleic acid 
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solution is not contaminated with proteins or phenol (2.16.3) its absorbance ratio will be in 
between of 1.8 to 2.0 (183). 
2.14.2 Nucleic acid gel electrophoresis 
In 1955 O. Smithies performed the separation of serum in a gel electrophoresis (197) via 
starch gels for the first time. This was the beginning of an enormous and powerful method to 
analyze macromolecules, in particular nucleic acids. This technique is used in molecular 
biology to separate DNA or RNA molecules depending on their length. Because DNA and/or 
RNA oligonucleotides naturally contain a phosphodiester backbone, these molecules are 
negatively charged. This charge is a direct proportion to the amount of phosphate groups in 
the nucleotide chain. Thus the length of the DNA or RNA of interest can be determined.  
2.14.2.1 Agarose gel electrophoresis 
Separation of nucleic acids in an agarose gel matrix was established in 1964 and initially 
described by Tsanev et al. (198). Negatively charged nucleic acids, commonly DNA 
fragments or RNA oligonucleotides with a size larger than 500 nt, are able to migrate in an 
electric field towards the anode. During the laboratory work of this thesis analyses of DNA 
vectors, PCR reactions and PEI complexes were performed using agarose gel 
electrophoresis. To prepare agarose gels, variable amounts of agarose (Table 12) were 
diluted in TBE buffer (89 mM Tris-HCl, 89 mM borate, 2 mM EDTA) according to the needed 
separation range.  
Table 12: Separation range of agarose gels. 
% Agarose (w/v) 
DNA fragment size 
(kb) 
0.5 1.0-30.0 
0.7 0.8-12.0 
1.0 0.5-7.0 
1.2 0.4-6.0 
1.5 0.2-3.0 
2.0 0.1-2.0 
 
The indicated amount of agarose was added into 1x TBE buffer and was dissolved by 
heating it up in the microwave. After cool down of the solution ethidium bromide was 
complemented with a final concentration of 250 ng/mL. The gel solution was tipped into an 
agarose gel slide and a comb was applied before gelation of the matrix. DNA samples were 
mixed with 5x DNA loading dye (100 mM Tris-HCl pH 7.5, 50 mM EDTA pH 8.0, 70 % 
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glycerin (v/v), 0.05 % bromophenol blue (w/v), 0.05 % xylene cyanol blue (w/v)) and then 
loaded onto the agarose gel. Gel electrophoresis was done using TBE as running buffer. In 
general electrophoresis was run for 1 h at 80 mA in a PerfectBlue gel system Mini S 
(PEQLAB Biotechnologie, Erlangen, Germany). PEI complexes were analyzed in 1 % 
agarose gels for 2 h at 50 mA, after being dissolved in 5x DNA loading dye. 
2.14.2.2 Polyacrylamide gel electrophoresis 
PolyAcrylamide Gel Electrophoresis (PAGE) was first described in 1967 (199). The usage of 
a polyacrylamid matrix has several advantages in comparison to agarose matrices. The gels 
are much thiner, are transparent and beyond more reliable in separating smaller DNA 
fragments or RNA oligonucleotides up to 300 nt. In consequence of a radical polymerisation 
reaction acrylamide and bisacrylamide are able to cross-link, forming a structured grid that 
harbors a defined pore size. Polyacrylamide gel electrophoresis can be performed either in 
native or denaturing method and size separation is dependent on the ratio of 
acrylamide/bisacrylamide in the matrix (Table 13). The migration speed of single-stranded 
DNA can be estimated using two dyes, BromoPhenol Blue (BPB) and Xylene Cyanol Blue 
(XCB), during gel electrophoresis.  
Table 13: Size fragmentation in PAGE. 
Ratio of 
polyacrylamide [%] 
BPB 
[nt] 
XCB 
[nt] 
8 19 70-80 
10 12 55 
 
Polyacrylamide gels were poured between two glass plates which were tightened with 
several clamps. A comb with the favored number of pockets was introduced between the 
plates before the gel solution was fixed. Hardening of the matrix took 30 min. The gel was 
placed in between an upper and lower chamber, the comb was removed and the pockets 
rinsed with TBE (89 mM Tris-HCl, 89 mM borate, 2 mM EDTA). PAGE was performed in self-
made equipment (University of Lübeck, Germany) using 8-30 mA for 30 min to several hours 
depending on the percentage, conditions and size of the prepared gel. During this thesis 
native polyacrylamide gel electrophoresis was needed to separate amplified products of 
quantitative PCR which have a product length smaller than 100 bp. For this purpose 
polyacrylamide gel solution (10 % acrylamide/bisacrylamide (48:2) in TBE) was prepared and 
0.01 volume of APS (dissolved as a 10 % solution) and 0.001 volume of TEMED were added 
to start radical polymerisation reaction. PCR samples were mixed with required amounts of 
5x DNA loading dye (2.15.8) and were loaded onto the gel. Native PAGE was started as 
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described above. After finishing electrophoresis DNA fragments were detected using 
ethidium bromide (2.14.3.1). Denaturing polyacrylamide gel electrophoresis was performed 
to separate RNA. The buffer contains urea to interact with the stacking bases and destroy 
hydrogen bonds. This leads to a destabilization of RNA secondary structures. Analyses of 
total RNA were performed on 8 % denaturing PAGE (8 % acrylamide/bisacrylamide (48:2), 
8 M urea in TBE). Commonly 0.5 to 1 µg of total RNA was used and mixed with 
2x denaturing loading buffer (66 % (v/v) formamide, 2.6 M urea, 0.02 % (w/v) bromophenol 
blue, 0.02 % (w/v) xylene cyanol blue in 2x TBE). Samples were heated up to 95 °C for 2 min 
and were kept on ice until loading on the gel matrix. Denaturing PAGE was done as indicated 
above. After finishing electrophoresis RNA was stained using ethidium bromide (2.14.3.1).  
2.14.3 Staining of nucleic acids 
After gel electrophoresis of nucleic acids these molecules can be visualized using several 
staining techniques. Most commonly separated DNA or RNA samples are detected with 
small compounds which enable intercalation of the compound between stacked bases of 
DNA or RNA molecules respectively. Subsequently these compounds can be exposed to 
ultraviolet light (UV light) to generate fluorescence or they are visible themselves.  
2.14.3.1 Ethidium bromide staining of nucleic acids 
Ethidium bromide is used to detect separated nucleic acids in molecular biology (200). This 
fluorescent dye intercalates into double-stranded DNA or partially double-stranded RNA. 
When it is exposed to UV light, it shows an orange fluorescence emitting light at a 
wavelength of 590 nm. Staining of agarose gels was done following gel electrophoresis, 
while ethidium bromide was already included in the gel matrix (2.14.2.1). In case of 
polyacrylamide gels (2.14.2.2) DNA or RNA samples were stained after electrophoresis was 
finished. Therefore the gel was incubated in an appropriate volume of water containing 
5 µg/mL ethidium bromide. After a 10 min shaking step at room temperature DNA or RNA 
bands can be detected and visualized using the gel documentation system Gerix 1000 
(biostep, Jahnsdorf, Germany). Agarose or polyacrylamide gels were digitalized and 
recorded onto an USB flash drive for documentation. 
2.14.3.2 Crystal violet staining of DNA 
Crystal violet is another dye to stain DNA in agarose gels. The triarylmethane dye can be 
used as a non-toxic intercalating agent. It is used for detection of nucleic acids which should 
not be exposed to UV light to avoid destruction of DNA helices, especially DNA needed for 
in vitro cloning experiments. For staining procedure (2.14.2.1) it is applied directly into the 
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agarose gel matrix in a concentration of 10 µg/mL diluted in TBE buffer (89 mM Tris-HCl, 
89 mM borate, 2 mM EDTA) and also the running buffer contains crystal violet in the 
indicated concentration. After finishing the agarose gel electrophoresis separated and dyed 
DNA bands were excised immediately with a sterile scalpel for further application. 
2.14.3.3 Silver staining of nucleic acids 
In 1973 Kerenyi and Gallyas first described the detection of proteins in gel matrices using 
silver ions (201). Nucleic acids are negatively charged. Positive silver ions can be chemically 
reduced to a silver coating at their surface and thus nucleic acids are stained. For silver 
staining nucleic acids were separated in agarose or polyacrylamide gels and fixed in the gel 
matrix using fixating solution (50 % MeOH (v/v), 12 % acetic acid (v/v)) for 15 min at room 
temperature on a shaker. Fixation step was repeated three times. Afterwards excessive 
amounts of acetic acid were washed out of the matrix with 30 % EtOH solution, again three 
times for 5 min at room temperature. Then the gel matrix was incubated for 45 sec in a 
freshly prepared coating solution (50 mL ddH20, 33 µL HCHO 35 %, 25 µL Na2S2O3 43 %) 
and washed three times for 1 min in double-distilled water. Silver incubation (2 g/L AgNO3 
supplemented with 660 µL HCHO 35 %) was performed for 20 min at room temperature 
using a shaker. Subsequently excess of silver ions was washed out with double-distilled 
water for 1 min. Reduction of silver ions was done using reduction solution (60 g/L Na2CO3, 
150 mL were supplemented with 75 µL of HCHO 35 % and 1.5 µL of Na2S2O3 43 %). When 
the expected bands had appeared, the gel was rinsed with water. Finally reduction was 
stopped using 7 % acetic acid. Gels were stored in 30 % EtOH solution and pictured using a 
Bio-Rad GS-800 Calibrated Densitometer (Munich, Germany). Pictures were digitalized onto 
an USB flash drive. 
2.14.3.4 SYBR® Gold staining of nucleic acids 
Detection of single- or double-stranded DNA or RNA oligonucleotides can be performed 
using SYBR® gold (Invitrogen™ Life Technologies, Darmstadt, Germany). This most 
sensitive fluorescent staining dye is an unsymmetrical cyanine dye that exhibits fluorescence 
increase upon binding to nucleic acids using standard ultraviolet transilluminators (202). The 
SYBR® Gold staining dye is provided as a 10.000-fold concentrate and was used for staining 
of DNA or RNA samples in agarose or polyacrylamide gel systems. The concentrated 
staining solution was diluted in TBE buffer (89 mM Tris-HCl, 89 mM borate, 2 mM EDTA) and 
protected from light. Gel matrices were incubated for 10-40 min at room temperature in a 
dish covered with an appropriate amount of solution. During this incubation step dishes were 
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kept in the dark or covered with aluminum foil. Afterwards 1x dilution was stored for up to one 
month at 4 °C and SYBR® gold stained nucleic acids were detected in UV light.  
2.14.3.5 Autoradiography 
Detection of nucleic acids is also possible using [32P]-labeled oligonucleotides. 
Autoradiography of the radioactive-labeled sample can be visualized in a phosphor-imaging 
analyzer after a separating process in an agarose or a polyacrylamide gel matrix has 
occurred. Therefore the gel matrix was wrapped into transparent foil and exposed to an 
imaging plate for time periods between 1 min to overnight depending on the amount of 
radioactive material. Afterwards the imaging plate was scanned using a 
Fuji FLA-3000 R Phosphorimager (Fujifilm, Düsseldorf, Germany). Quantification of the DNA 
or RNA samples was calculated using the software AIDA (Version 3.45). 
2.15 DNA techniques 
2.15.1 Plasmid preparation 
Plasmid preparation of overnight cultures (about 3-5 mL of culture medium) was performed 
using the GenejetTM Plasmid Miniprep Kit (Thermo Fisher Scientific, Schwerte, Germany) 
according to the manufacturer’s protocol. In case of preparing larger amounts of bacterial cell 
culture (200-500 mL of culture medium) plasmid DNA was cleaned up using the 
NucleoBond® PC 500 purification kit (Macherey-Nagel, Düren, Germany). Recovered 
plasmid DNA was diluted in double-distilled H2O before the resulting concentration was 
determined in a spectral photometer (Thermo Fisher Scientific, Schwerte, Germany). 
2.15.2 Phosphorylation of 5’-OH ends of DNA oligonucleotides 
Synthetic DNA primers have to be phosphorylated on the free 5’-OH end to enhance the 
efficiency of cloning experiments (2.13). For this purpose a recombinant T4 polynucleotide 
kinase from E. coli was obtained from Thermo Fisher Scientific (Schwerte, Germany). This 
enzyme is able to confer the gamma-phosphate of ATP to the free 5’-OH to phosphorylate 
the 5’-end of single-stranded DNA oligonucleotides. Reaction mixture was mixed as indicated 
at the manufacturer’s protocol and is shown in Table 14. 
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Table 14: Phosphorylation of DNA oligonucleotides. 
Ingredient Concentration Amount 
DNA oligonucleotide 100 µM 0.5 µL 
Reaction buffer A 10x 2 µL 
ATP 10 mM 2 µL 
T4 PNK 
(Thermo Fisher Scientific) 
10 U/µL 1 µL 
ddH20 - ad 20 µL 
Phosphorylation reaction: 37 °C for 30-60 min 
Inactivation: 75 °C for 10 min 
 
2.15.3 Removal of 5’-phosphate groups of plasmid DNA 
For cloning experiments using linearized vector DNA (2.15.4) the 5’-phosphate has to be 
removed to avoid re-circularization during the ligation reaction (2.15.5). This was done using 
the Thermo Scientific FastAP Thermosensitive Alkaline Phosphatase (Schwerte, Germany) 
according to the instructions given by the manufacturer (Table 15).  
Table 15: Dephosphorylation of DNA. 
Ingredient Concentration Amount 
Linearized vector DNA - 1 µg 
Reaction buffer for AP 10x 2 µL 
FastAP 
(Thermo Fisher Scientific) 
1 U/µL 1 µL 
ddH20 - ad 20 µL 
Dephosphorylation reaction: 37 °C for 10 min 
Inactivation: 75 °C for 5 min 
 
2.15.4 Restriction digest of DNA 
A restriction endonuclease is an enzyme that catalyzes endonucleolytic cleavage of 
double-stranded DNA at a specific recognition site, also termed restriction site. The 
recognition site is a specific sequence of 4-8 nucleotides which show a palindromic 
sequence arrangement. First discovered and isolated in the 1970s (203), (204), to date 
several hundreds of restriction enzymes are commercially available from different bacterial or 
archaeal organisms. They are grouped in four types, but for molecular cloning experiments, 
commonly type II restrictions endonucleases are used. To cleave a DNA sequence they do 
not require ATP. For them it is sufficient to use Mg2+ ions as a cofactor. Restriction 
endonucleases are able to generate either displaced ends on the 5’- and 3’-end (termed 
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sticky end generation) or cut DNA strands at the same position (termed blunt end 
generation). For analytical purposes and cloning experiments several restriction enzymes 
were used which are listed in Table 16. 
Table 16: Restriction enzymes. 
Restriction enzyme 
Recognition sequence 
5’  3’ 
FastDigest BglII 
(Thermo Fisher Scientific) 
5’- A↓GATCT 
FastDigest BlpI 
(Thermo Fisher Scientific) 
5’- GC↓TNAGC 
FastDigest HindIII 
(Thermo Fisher Scientific) 
5’- A↓AGCTT 
FastDigest XbaI 
(Thermo Fisher Scientific) 
5’- T↓CTAGA 
 
Restriction digestion reactions were performed according to the manufacturer’s instructions 
(Table 17). If possible FastDigest restriction enzymes (Thermo Fisher Scientific, Schwerte, 
Germany) were used. Digestion reactions were incubated for up to 30 min at 37 °C followed 
by a heating step to denature the enzyme. Samples were analyzed on an agarose gel 
(2.14.2.1) and stained with ethidium bromide. All digestion reactions needed for further 
cloning experiments were separated for preparative purposes and stained either with 
ethidium bromide or crystal violet (2.14.3.1, 2.14.3.2). After finishing gel electrophoresis DNA 
fragments were cut and cleaned up (2.15.9). 
Table 17: Restriction digest. 
Ingredient Concentration 
Amount 
Analytical 
digest 
Cloning 
DNA - 500 ng up to 5 µg 
Restriction buffer 10x 1 µL 5 µL 
FD restriction enzyme 
(Thermo Fisher Scientific) 
1 FDU 0.5 µL up to 5 µL 
ddH20 - ad 10 µL ad 50 µL 
Digestion: 5-30 min at 37 °C 
Heat inactivation: as indicated by the manufacturer 
 
2.15.5 Ligation of DNA fragments 
In molecular biology ligation of DNA fragments is an enzymatic linking of a 5’-phosphate and 
a 3’-hydroxyl termini of one or two DNA fragment(s) to form a new phosphodiester bond. This 
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reaction is catalyzed by the enzyme T4 DNA ligase (205). For cloning experiments either 
DNA vectors or amplified DNA of PCR reactions were digested with the favored restriction 
enzymes to generate a distinct 5’- or 3’-end. Afterwards two fragments having the same 
restricted ends, blunt ends or sticky ends, were incubated for up to 4 h at room temperature 
with T4 DNA ligase (Thermo Fisher Scientific, Schwerte, Germany) as shown in Table 18. 
The ligation reaction was used for transformation reactions into bacterial E. coli DH5α cells 
(2.5.3). 
Table 18: Ligation reaction.  
Ingredients Concentration Amount 
Plasmid DNA - 1-100 ng 
Insert DNA - 500 ng 
Reaction buffer 10x 2 µL 
T4 DNA ligase 
(Thermo Fisher Scientific) 
5 Weiss U/µL 2 µL 
ddH20 - ad 20 µL 
Ligation: 1-4 hours, RT 
 
2.15.6 Human genomic DNA preparation 
Human genomic DNA (gDNA) was prepared for cloning experiments of respective 
pGL3 control vector constructs. Therefore the human erythroleukemia cell line K562 was 
used. Preparation of human total DNA was done with the DNeasy® Blood & Tissue Kit 
(Quiagen, Hilden, Germany). 5 * 106 K562 cells were centrifuged and washed with PBS until 
the total DNA was prepared according to the manufacturer’s protocol using the 
‘Spin-Column Protocol’ for purification of total DNA from human cells. After elution of total 
DNA its concentration was determined in a spectral photometer (Thermo Fisher Scientific, 
Schwerte, Germany) and DNA was prepared for following PCR amplification reactions 
(2.15.8.1). The preparation of human genomic DNA was performed by Robert Prinz (194). 
2.15.7 Reverse transcription 
Reverse transcriptase (RT) is an RNA-dependent DNA polymerase which allows generation 
of complementary DNA (cDNA) from an RNA template. Reverse transcriptase is needed for 
the replication of retroviruses. In 1970 two independent researchers (206), (207) found this 
enzyme. Since this discovery the door was open to create single-stranded DNA from RNA 
templates to further study the transcriptome of different organisms. For this thesis cDNA was 
arisen from total RNA or RNA, which was enriched for RNA transcripts smaller than 200 nt. 
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Therefore the RevertAid H Minus reverse transcriptase (Thermo Fisher Scientific, Schwerte, 
Germany) was used. This transcriptase is a recombinant variant of the M-MuLV RT lacking 
the RNaseH activity to increase the yield of full-length cDNA. In general 250-1000 ng of RNA 
were transcribed using 5-10 pmol of a specific reverse primer or 100 pmol of random 
hexamer primer according to the manufacturer’s protocol (Table 19). In addition a negative 
control for each RNA sample in the absence of reverse transcriptase was produced to check 
for DNA contamination of the samples. 
Table 19: Reverse transcription. 
Ingredient Concentration Amount +RT Amount -RT 
RNA - 250-1000 ng 250-1000 ng 
Primer 
gene-specific 10 µM 0.5 µL 0.5 µL 
random hexamer 
(Thermo Fisher Scientific) 
100 µM 1 µL 1 µL 
ddH20 - ad 11 µL ad 12 µL 
Heating Step: 80 °C for 10 min 
place samples on ice 
RT buffer 
(Thermo Fisher Scientific) 
5x 4 µL 4 µL 
dNTPs 
10 mM  
(2.5 mM each) 
2 µL 2 µL 
ddH20 - 2 µL 2 µL 
RevertAid H Minus  
reverse transcriptase 
(Thermo Fisher Scientific) 
200 U/µL 1 µL - 
reverse transcription: 42 °C for 60 min 
inactivation of RT: 70 °C for 10 min 
 
In the following the samples were prepared for quantitative real-time PCR measurements 
(2.15.8.3). The cDNA sample was diluted 1:5 or 1:10 with double-distilled water depending 
on the number of RNA transcripts that should be detected. QPCR was performed either 
straight after cDNA synthesis or samples were stored at -20 °C until usage. 
2.15.8 PCR  
PCR (Polymerase Chain Reaction) has been developed in 1983 by Kary Mullis (208). It is a 
technique to amplify DNA in an exponential manner. Used as a common procedure in 
molecular biology e. g. for cloning experiments, to date it can also be used for quantifying 
multiplied DNA sequences. 
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2.15.8.1 Amplification of genomic DNA 
Purified human genomic DNA (gDNA) of K562 cells was used for amplification of the 
PIM1 3’-UTR, the P21 3’-UTR or the C13orf25 promoter region. The primers needed for 
amplification reaction of the respective constructs are depicted in Appendix J. The reaction 
set up was mixed (Table 20) and after multiplication of gDNA (Table 21) the products are 
used for cloning into the pGL3 control vector (194).  
Table 20: Reaction mixture gDNA. 
Ingredient Concentration Amount 
gDNA (K562) - 300 ng 
Taq buffer with KCl 10x 5 µL 
dNTP mix 2.5 mM each 1 µL 
Primer fwd 100 µM 0.5 µL 
Primer rev 100 µM 0.5 µL 
MgCl2 25 mM 2 µL 
Taq DNA polymerase 
 (Thermo Fisher Scientific) 
5 U/µL 0.5 µL 
ddH20 - ad 50 µL 
 
Table 21: Amplification gDNA. 
Step 
Temperature 
[°C] 
Time 
[sec] 
Repeat 
Denaturation 94 300 1 
Amplification 
cycle 
94 45 
30 56 60 
72 90 
Fill up cycle 72 420 1 
Cooling 10 ∞ - 
 
2.15.8.2 Mutagenesis PCR for cloning experiments 
To generate mutations into the seed region of miRNA target sequences in the 
pGL3 3’-UTR constructs mutagenesis PCR was performed. Therefore primers were 
designed according to Brennecke et al. (195) in case of mutating miRNA target sequences or 
by hand for all other introduced mutations. Nucleotides which should be exchanged in 
mutagenesis PCR were introduced in the forward primer sequence (Appendix J). Additionally 
a fully complementary reverse primer was designed (Appendix J). Mutations are positioned 
in the middle of the primer and flanked by approximately 10-15 nt on each site. As a template 
individual pGL3 control 3’-UTR or C13orf25 promoter constructs were used for PCR reaction 
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(Table 22). After a phosphorylation reaction of the two respective primers (2.15.2), the 
amplification of the template was performed as indicated in mutagenesis PCR reaction 
(Table 23). Amplification program is dependent on the length of the amplicon.  
Table 22: Reaction mixture mutagenesis PCR. 
Ingredient Concentration Amount 
Template - 100 ng | 1 ng 
Pfu buffer with MgSO4 10x 10 µL | 5 µL 
dNTP mix 2.5 mM each 1.6 µL | 1 µL 
Primer fwd, 
phosphorylated 
2.5 µM  2.5 µL | 4 µL 
Primer rev, 
phosphorylated 
2.5 µM 2.5 µL | 4 µL 
MgSO4 25 mM 12 µL | 5 µL  
Pfu DNA Polymerase 
(Thermo Fisher 
Scientific) 
2.5 U/µL 1 µL | 1 µL 
ddH2O - ad 100 µL | 50 µL 
 
Table 23: Amplification mutagenesis PCR. 
Step 
Temperature 
[°C] 
Time 
[sec] 
Repeat 
Denaturation 95 180-300 1 
Amplification cycle 
95 30-60 
15-30 50-60 40-90 
72 30-840 
Fill up cycle 72 600 1 
Cooling 8-10 ∞ - 
 
2.15.8.3 Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) is a technique to amplify DNA and simultaneously 
determine arising amounts of a target DNA or cDNA of interest. During this thesis several 
mRNAs or ncRNAs were analyzed using SYBR Green (Thermo Fisher Scientific, Schwerte, 
Germany). This DNA binding dye causes fluorescence upon interfering with the amplified 
dsDNA, but also including non-specific products. Increasing amounts of DNA lead to an 
increase of fluorescence which can be detected at each amplification cycle. Thus the amount 
of DNA can be measured. For quantification of miRNAs, generated miRNA-specific cDNA 
(2.15.7) was diluted and qPCR measurements performed using primers listed in Table 3. To 
determine human RNA levels of mRNAs or pri-mir-17-92, cDNA was diluted in the same 
manner and for quantification reactions primers depicted in Table 1 were used. Quantitative 
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PCR reactions were applied as described in Table 24 using freshly prepared or frozen cDNA 
samples. Amplification was done using either a LightCycler® 2.0 from Roche (Mannheim, 
Germany) or a MyiQ™5 Real-Time PCR Detection System (Bio-Rad, Munich, Germany) 
according to the instructions depicted in Table 25 and Table 26. Analyses of generated data 
was performed with the applied software iQ™5 (version 2.0) and 2-Cp, 2-ΔCp and 2-ΔΔCp values 
evaluated according to Schmittgen and Livak (209). 
Table 24: Quantitative real-time PCR. 
Ingredient Concentration Amount 
cDNA 
1:5 or 1:10 
dilution 
4 µL 
Absolute qPCR 
SYBR Green Mix 
(Thermo Fisher 
Scientific) 
2x 10 µL 
Primer fwd 5 µM 0.5 µL 
Primer rev 5 µM 0.5 µL 
ddH2O - 5 µL 
 
Table 25: Amplification qPCR of mRNAs. 
Step 
Temperature 
[°C] 
Time 
[sec] 
Repeat 
Initial 
Denaturation 
95 900 1 
Amplification 
cycle 
95 10 
55 55 10 
72 10 
Melting Curve 55  95 15 
1 °C per 
sec 
Cooling 40 30 - 
 
Table 26: Amplification qPCR of miRNAs. 
Step 
Temperature 
[°C] 
Time 
[sec] 
Repeat 
Initial 
Denaturation 
95 900 1 
Amplification 
cycle 
95 10 
55 60 20 
72 12 
Melting Curve 55  95 10 
1 °C per 
sec 
Cooling 40 10 - 
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2.15.9 Purification of PCR reactions 
Purification of PCR reactions was applied to remove remaining template DNA, primers 
and/or dNTPs which were used in the amplification reaction. This either can be performed 
after the amplification step of the PCR reaction (2.15.8) or can be done after separation of 
the amplified PCR product in an agarose gel (2.14.2.1). The Wizard® SV Gel and 
PCR Clean-Up System (Promega, Mannheim, Germany) was used for purification. In case of 
purifying the PCR reaction the whole volume of PCR mixture was incubated with the 
indicated amount of Membrane Binding Solution before binding to the silica membrane of the 
Wizard® SV Minicolumns. If the amplicon was initially separated in an agarose gel, the band 
of interest was excised and dissolved in Membrane Binding Solution according to the 
manufacturer’s protocol. In both cases DNA was eluted from the columns in a centrifugation 
step and used for further experiments. 
2.15.10 DNA sequencing 
DNA sequencing reactions were sent out and performed at eurofins mwg|operon (Ebersberg, 
Germany). Samples were prepared according to the company’s instructions. Purified plasmid 
DNA was diluted in double-distilled water to a volume of 15 µL possessing a concentration of 
about 50-100 ng/µL. In some cases a specific primer (2 pmol/µL in a minimum volume of 
15 µL) was sent out together with the sample (Appendix K). Several days later the 
sequencing analyses could be checked at the web page of eurofins (www.eurofinsdna.com) 
and data could be aligned to the vector sequence for validity and integrity.  
2.15.11 ChIP assay 
Chromatin ImmunoPrecipitation (ChIP) is a method to determine interactions between 
specific proteins and specific genomic regions such as promoter elements or DNA binding 
sites. Cross-linked ChIP (ChIPX) is mainly suited for mapping of the DNA target of 
chromatin-associated proteins. Thus proteins are reversibly cross-linked to their associated 
chromatin regions via formaldehyde or UV-light. These temporarily bonded DNA/protein 
complexes are shared and the protein of interest is selectively immunoprecipitated. After 
purification of the associated DNA fragments their sequences can be determined and be 
referred to the respective chromatin region. For this thesis, chromatin immunoprecipitation 
was performed according to a protocol from the Or Gozani lab 
(http://www.stanford.edu/group/gozani) at Stanford University with some modifications. 
2 * 107 K562 cells in 13 mL RPMI medium were cross-linked with 1 % formaldehyde for 
10 min at 37 °C. Reactions were stopped by adjusting to 0.125 M glycine and cells were 
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collected by centrifugation at 400 g for 5 min at room temperature. For cell lysis cells were 
resuspended in 750 µL RIPA-buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 % 
deoxycholate, 1 % NP-40, 0.1 % SDS, 0.2 mM PMSF) supplemented with the 
cOmplete Mini Protease Inhibitor Cocktail from Roche (Mannheim, Germany) according to 
the manufacturer’s instructions. Lyzed cells were sonicated in a Branson Sonifier 250 (duty 
cycle 50 %, output control 2, for 3.5 min on ice water) (Heinemann, Schwäbisch Gmünd, 
Germany) and centrifuged at maximum speed (13.000 rpm, 10 min at 4 °C). The supernatant 
was pre-cleared with 10 µL of blocked Staphylococcus aureus cells (PANSORBIN® Cells, 
Calbiochem/Merck, Darmstadt, Germany) for 15 min at 4 °C on a rotor wheel. After a second 
centrifugation step (13.0000 rpm, 5 min, RT), the supernatant was split into two samples 
(each ~350 µL, representing + and - specific antibody (AB)) which were adjusted to buffer D 
(16.7 mM Tris-HCl pH 8.1, 167 mM NaCl, 1.2 mM EDTA, 1.1 % Triton-X 100, 0.01 % SDS) 
and a total volume of 500 µL. 1 µg (1 to 5 µL) of the respective antibody was added to 
+ AB samples, whereas the same volume buffer D was added to - AB samples. At this point 
also the mock control was prepared, consisting of 500 µL buffer D. + AB, - AB and mock 
samples were then incubated for at least 3 h at 4 °C. The following antibodies were used: 
monoclonal anti-c-Myc (sc-40), anti-Pim-1 (sc-13513) and anti-phospho-HP1G (Ser83) 
antibody (2600S); Table 8). In the case of mouse monoclonal antibodies samples were 
additionally incubated for 1 h with a second monoclonal goat anti-mouse IgG antibody 
(sc-2005, Table 9). Immunoprecipitation was initiated by adding 10 µL of Pansorbin® cells to 
the + AB, - AB and mock samples, followed by incubation for 15 min at room temperature. 
Samples were centrifuged (13.0000 rpm, 3 min, RT); the supernatant of the - AB sample was 
saved, later serving as the input control. Pellets were washed twice with dialysis buffer 
(50 mM Tris-HCl pH 8.0, 2 mM EDTA) and four times with IP-wash buffer (100 mM Tris-HCl 
pH 9.0, 500 mM LiCl, 1 % NP40, 1 % deoxycholate). Antibody-bound material was eluted 
from Pansorbin® cells by adding 150 µL elution buffer (50 mM NaHCO3, 1 % SDS), vortexing 
and centrifugation (13.000 rpm, 3 min, RT). The supernatant was collected and the 
procedure was repeated. Reverse cross-linking and RNA digestion was performed in 280 µL 
buffer (0.3 M NaCl, and 1 µL RNaseA (10 mg/mL, Thermo Fisher Scientific, Schwerte, 
Germany)) for 5 h at 67 °C in a hybridization oven (Biometra, Goettingen, Germany). 
Chromatin was precipitated with 2.5 volumes of ethanol, followed by a ProteinaseK (Thermo 
Fisher Scientific, Schwerte, Germany) digest that was done according to the manufacturer’s 
protocol. DNA was purified by phenol/chloroform extraction (2.16.3) and ethanol precipitation 
in the presence of 0.3 M NaOAc pH 5.2. PCR amplification using Taq DNA polymerase and 
the co-immunoprecipitated DNA as template was done under the following conditions: 2 min 
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at 95 °C in the absence of enzyme, followed by 35 amplification cycles of 45 sec at 95 °C, 
45 sec at 60 °C, 45 sec at 72 °C using primers listed in Table 27.  
Table 27: Primers for ChIP assay. 
Name of 
Primer 
Sequence 5’  3’ 
Product 
length 
[bp] 
A1 forward 5’- AAA GGC AGG CTC GTC GTT G 
93 
A1 reverse 5’- CGG GAT AAA GAG TTG TTT CTC CAA 
A2 forward 5’- ACA TGG ACT AAA TTG CCT TTA AAT G 
367 
A2 reverse 5’- AAT CTT CAG TTT TAC AAG GTG ATG 
A3 forward 5’- ACT GCA GTG AAG GCA CTT GT 
167 
A3 reverse 5’- TGC CAG AAG GAG CAC TTA GG 
A4 forward 5’- CCA ATA ATT CAA GCC AAG CAA 
137 
A4 reverse 5’- AAA TAG CAG GCC ACC ATC AG 
A5 forward 5’- GCC CAA TCA AAC TGT CCT GT 
212 
A5 reverse 5’- CGG GAC AAG TGC AAT ACC AT 
 
2.16 RNA techniques 
2.16.1 RNA extraction for small RNAs of mammalian cell lines 
Characterization of small RNAs such as miRNAs has been raised in the last decades. 
Playing important roles in gene regulation and developmental processes, these small 
non-coding RNAs are of enormous interest in many research topics. For this thesis isolation 
of small RNA molecules was done using the mirVana™ miRNA Isolation Kit purchased from 
Ambion (Life Technologies, Darmstadt, Germany). All extractions were done according to the 
given manufacturer’s protocol. Small RNA isolation was performed with about 5 * 106 cells 
growing in suspension or under adherent conditions. After a washing step with PBS cells 
were lyzed in about 500 µL Lysis/Binding Solution supplemented in the Isolation Kit. An acid 
phenol/chloroform extraction followed which provides a robust purification to remove large 
amounts of DNA (210). Therefore one volume of Acid Phenol:Chloroform solution was 
added, the mixture vortexed and centrifuged. The upper aqueous phase was loaded onto a 
glass-fiber filter and after a centrifugation step, a second filter was included and enriched 
small RNAs were eluted in 10-20 µL ddH2O. Afterwards concentration of RNA was 
determined in a spectral photometer (Thermo Fisher Scientific, Schwerte, Germany) and 
small RNAs were used to generate cDNA for quantification of miRNA levels (2.15.7). 
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2.16.2 Total RNA extraction of mammalian cell lines 
Total RNA extraction of different mammalian cell lines was applied to quantitate the cellular 
activity at different time points or after different treatments of the cells. Thus different levels in 
gene expression and regulation can be determined. For this purpose total cellular RNA of 
mammalian cells was purified using a variation of the 
guanidinium thiocyanate-phenol-chloroform extraction method described in 1987 by Piotr 
Chomczynski and Nicoletta Sacchi (210). For purification about 5 * 106 cells were counted 
and washed with PBS. Afterwards they were lyzed by pipetting up and down in 750 µL of 
Tri-lysing buffer (0.8 M guanidinium thiocyanate, 0.4 M ammonium thiocyanate, 0.1 M 
sodium acetate pH 5.0, 5 % glycerin, 48 % aqua-phenol pH < 5.0). The solution was 
incubated for 5 min at room temperature and 200 µL of chloroform was added. A shaking 
step for 30 sec using a vortex mixer followed. Subsequently the solution was incubated for 
10 min at room temperature and organic and aqueous phase separated via a centrifugation 
step for 20 min at room temperature and 13.300 rpm. The upper aqueous phase was shaken 
out a second time with one volume of chloroform to enrich purity of RNA and to discard as 
much DNA and protein contamination as possible. After the solution was shaken out for 
15 sec using a vortex mixer the sample was separated again and spun down at 13.300 rpm 
for 5 min. In the following the aqueous phase was transferred into a new tube and total RNA 
precipitated with one to two volume(s) of isopropanol for 10-30 min at room temperature. 
Total RNA was pelleted via centrifugation at 13.300 rpm for 30 min at 4 °C and the pellet 
washed with 75 % ethanol. Finally RNA concentration was measured in a spectral 
photometer (Thermo Fisher Scientific, Schwerte, Germany) following either a DNaseI 
treatment (2.16.4) or total RNA was prepared for quantitative PCR measurements (2.15.8.3). 
2.16.3 Phenol/chloroform extraction of RNA 
DNaseI digested total RNA extracts (2.16.4) have to be purified via phenol/chloroform 
extraction to get rid of protein and salt impurity. Sample material after DNaseI digestion was 
formulated in a volume of 200 µL which is the minimum amount of starting volume. This 
solution was mixed with one volume of aqua-phenol pH < 5.0 for RNA preparation. The 
sample was shaken vigorously for 30-60 sec and then incubated for 5 min at room 
temperature. Subsequently the sample was centrifuged for 5 min at 13.000 rpm using a 
centrifuge and the upper aqueous phase transferred to a new tube. One volume of 
chloroform was added and again the sample was shaken for 15 sec using a vortex mixer. 
Another centrifugation step follows (5 min, 13.000 rpm, RT). Once again the upper aqueous 
phase was pipetted into a new tube. RNA was precipitated by adding 1-2.5 volume(s) of 
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isopropanol right after sodium acetate had been added to the sample to reach a final 
concentration of 0.3 M NaAc. Precipitation was performed for 10 min at room temperature 
and RNA pelleted for 30 min at 4 °C and 13.000 rpm. To free the RNA pellet of salt ions, a 
washing step with 75 % EtOH was included, followed by another centrifugation step. RNA 
pellet was dried for 5 min and dissolved in 10-20 µL of double-distilled water. RNA 
concentration was determined and calculated in a spectral photometer (Thermo Fisher 
Scientific, Schwerte, Germany). 
2.16.4 DNaseI digestion 
To get rid of any DNA contamination, extracted total RNA (2.16.2) was digested with DNaseI 
(Thermo Fisher Scientific, Schwerte, Germany). RNase-free DNaseI is able to digest 
single- and double-stranded DNA by hydrolyzing phosphodiester bonds. Enzymatic activity 
and thus cleavage efficiency is dependent on Ca2+ ions. For digestion of DNA in total RNA 
prepared samples 1 µg of RNA was mixed with 1 U DNaseI and incubated for 30 min at 
37 °C as described by the manufacturer’s protocol (Table 28). Afterwards DNaseI enzyme 
was heat deactivated and an additional DNaseI digestion step was included, followed by 
another phenol/chloroform extraction (2.16.3) to remove hydrolyzed DNA fragments, DNaseI 
enzyme and salt ions.  
Table 28: DNaseI digestion. 
Ingredient Concentration Amount 
RNA - 1 µg 
DNaseI buffer 10x 10 µL 
DNaseI, RNase-free 
(Thermo Fisher Scientific) 
50 U/µL 1 U 
ddH20 - ad 100 µL 
DNA digestion: 37 °C for 30 min 
Inactivation of DNaseI: 65 °C for 10 min 
DNaseI buffer 1x 25 µL 
DNaseI, RNase-free 
(Thermo Fisher Scientific) 
50 U/µL 1 U 
ddH20 - ad 250 µL 
DNA digestion: 37 °C for 30 min 
Phenol/chloroform extraction 
 
2.16.5 Radiolabeling of the 5’-end of RNA 
5’-end labeling of double-stranded siRNA or small single-stranded RNA oligonucleotides 
(Table 29) was performed using the T4 polynucleotide kinase (Thermo Fisher Scientific, 
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Schwerte, Germany) isolated from E. coli T4 bacteriophage. This enzyme catalyzes the 
transfer of a gamma-phosphate from [γ-32P]-ATP to the 5’-OH end of single- or 
double-stranded nucleic acids.  
Table 29: Oligonucleotides for 5’-end labeling. 
Name of oligonucleotide Sequence 5’  3’ 
VR1 siRNA (179) 
sense 5’- GCG CAU CUU CUA CUU CAA CdTdT 
antisense 5’- GUU GAA GUA GAA GAU GCG CdTdT 
pRNA 14-mer (211) 5’- GUU CGG UCA AAA CU 
pRNA 8-mer (212) 5’- GUU CGG UC 
 
The phosphorylation mixture was prepared as indicated in Table 30 using radiolabeled ATP 
purchased at Hartmann Analytic GmbH (Braunschweig, Germany). 
Table 30: Radiolabeling mixture. 
Ingredient Concentration Amount 
RNA oligonucleotide - 30 pmol 
Reaction buffer A  10x 2 µL 
[γ-
32
P]-ATP  3000 Ci/mmol 3 µL 
T4 PNK 
(Thermo Fisher Scientific) 
10 U/µL 1.5 µL 
ddH20 - ad 20 µL 
Phosphorylation reaction: 37 °C for 60 min 
Purification: illustra MicroSpin G-25 spin columns 
 
Afterwards the phosphorylation reaction was purified from unincorporated nucleotides using 
illustra MicroSpin G-25 spin columns (GE Healthcare Life Sciences, Freiburg, Germany) 
according to the manufacturer’s protocol. The radiolabeled RNA was eluted and the amount 
of radioactivity and the efficiency of labeling reaction were measured in a 
1900 CA TRI-CARB® Liquid Scintillation Analyzer (Perkin Elmer, MA, USA). Radiolabeled 
RNA oligonucleotides were used to perform radioactive studies on PEI complexes (2.8.2.2, 
2.16.6).  
2.16.6 Determination of PEI complex formation efficacy 
To determine the efficacy of PEI F25 LMW complex formation with nucleic acids or 
LNA antiseeds, a radioactive assay was employed as described previously (213). 500 ng of 
single-stranded RNA, 14- or 8-meric, or double-stranded siRNA were used, mixed with trace 
amounts (104 Cerenkov cpm) of 5’-[32P]-end labeled siRNA, RNA 14-mer or RNA 8-mer 
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(Table 29) respectively. Complex formation was performed with the indicated amounts of 
PEI F25 LMW (2.8.2.2). Samples were mixed with 5x DNA loading dye (10 mM Tris-HCl 
pH 7.6), 80 % glycerol, 0.03 % bromophenol blue, 0.03 % xylene cyanol blue) and analyzed 
in agarose gel electrophoresis (2.14.2.1). Complex formation was analyzed by 
autoradiography (2.14.3.5) of the agarose gel for 3 h using a 
Fuji FLA-3000 R Phosphorimager (Fujifilm, Germany). The ratio of free to partially and fully 
complexed RNA was calculated using AIDA software (Version 3.45). 
2.17 Atomic force microscopy 
Atomic Force Microscopy (AFM) is a high-resolution type of scanning probe microscopy first 
described in the 1980s by Binnig and Rohrer (214) as a technique to detect surfaces at an 
atomic level. The technique uses piezoelectric elements that are able to facilitate tiny and 
precise movements. This enables a very powerful and accurate measurement. 
PEI/LNA complexes were analyzed by atomic force microscopy and were done with the help 
of the working team of Prof. Dr. Bakowsky at the Institute of Pharmaceutical Technology and 
Biopharmaceutics, Philipps-Universität Marburg, Germany. Complexes were prepared 
(2.8.2.2) with 500 ng of LNA 14-mer 17-5p or LNA 8-mer (PS) and increasing amounts of 
PEI F25 LMW. Complexes were directly transferred onto a silicon chip by dipping the chip 
into the complex solution. AFM was performed on a vibration-damped NanoWizard (JPK 
instruments, Berlin, Germany) as described in detail elsewhere (215). Commercially 
available pyramidal Si3N4 tips (NSC16 AIBS, Micromasch, Estonia) mounted to a cantilever 
with a length of 230 µm. A resonance frequency of about 170 kHz and a nominal force 
constant of about 40 N/m were used. To avoid damage of the sample surface, 
measurements were performed in intermitted contact. The scan speed was proportional to 
the scan size and the scan frequency was between 0.5 and 1.5 Hz. Images were obtained by 
displaying the amplitude signal of the cantilever in the trace direction and the height signal in 
the retrace direction, both signals were simultaneously recorded. The complexes were 
visualized either in height or in amplitude mode (512 x 512 pixels). 
2.18 Bioinformatics and software tools 
In this chapter important bioinformatical methods and software tools are listed which were 
used throughout the complete work for this thesis. 
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2.18.1 GraFit™ 
The program GraFit™ (Version 5.0) is a data analysis software for Microsoft© Windows™ 
and was needed for creating scientific graphs depicted in most figures. GraFit™ is 
programed by Robin J. Leatherbarrow (216) for Erithacus Software Ltd. (Horley, U.K.) and 
provides the experimental scientist with a tool for visualization and analyses of existing data.  
2.18.2 CorelDRAW® Graphics Suite 
CorelDRAW® Graphics Suite is a graphic and image editing collection of the 
Corel™ Corporation (Ottawa, Canada). In 1989 version 1.2 was released for 
Microsoft© Windows™ computer systems and for this thesis version CorelDRAW® 
release 11.0 was used. The software is based on vector graphics construction and was 
applied for figure drawing.  
2.18.3 Statistical analyses 
2.18.3.1 R 
Since 1993 the open source programming language R is available to use it for statistical 
computing. This software was used to generate two-sided t-test analyses to identify 
significant data in between the obtained values.  
2.18.3.2 GraphPad Prism® 
Another software program used for statistical analyses was GraphPad Prism® (Version 4.0) 
available for Microsoft© Windows™. This tool was used by the group of Prof. Dr. Achim 
Aigner to calculate Student’s t-test, 1-way ANOVA/Tukey’s multiple comparison posttests 
and 2-way ANOVA/Bonferroni posttests. 
2.18.4 NCBI 
The National Center for Biotechnology Information (NCBI) was founded in 1988 through 
legislation and harbors relevant information to biotechnology such as an index of biomedical 
research articles in PubMed or PubMed Central, the genome sequencing data or the 
GenBank. All researchers working in the field of biotechnology or molecular biochemistry use 
the different information tools offered by the NCBI (http://www.ncbi.nlm.nih.gov/). Another 
important tool being part of the NCBI is the BLAST sequence alignment tool. Designed in 
1990 the Basic Local Alignment Search Tool (BLAST) (217) is a powerful program to search 
for local alignments in different organisms comparing protein or DNA sequences which are 
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part of the GenBank with those being experimentally validated. To date it is the most often 
used software tool worldwide analyzing biological data of sequenced material. 
2.18.5 TargetScan 
MiRNA target sites were predicted using the online software tool TargetScan Release 5.1 
(http://www.targetscan.org/vert_50/) which is provided by the 
Massachusetts Institute of Technology. The search page of TargetScan is available for 
searching target sites in mammals or mouse sequences, but is also at hand for worm, fly and 
fish based data search. Therefore the software is searching for the presence of conserved 
8- or 7-mer nucleotide sites which match the seed region of individual miRNAs (218). The 
program also includes the identification of seed sequences that have included mismatch 
positions, but only if this mismatches can be compensated by a conserved 3’-pairing of the 
miRNA (219). For searching in mammals the program ranks hits based on the predicted 
efficacy of targeting which is calculated by using the context score of the sites including 
site-type, 3’-pairing, local AU and position contribution (69). The software is permanently 
improved and now version 6.2 is available. 
2.18.6 MiRBase 
The bioinformatical software program miRBase is available as an archive of microRNA 
sequences and annotations (http://www.mirbase.org/). The biological database is hosted and 
maintained at the University of Manchester and had been set up by the microRNA registry of 
Sam Griffiths-Jones in 2004 (180). The miRBase registry provides the inclusion of novel 
miRNA genes and helps to assign names (220). MiRBase can be used to search for 
annotated miRNAs, while each entry represents a predicted hairpin of a miRNA transcript, 
giving information about the location and sequence of the mature miRNA. This software tool 
was used to search for mammalian miRNAs of interest e.g. to establish primer design for 
miRNA quantification. 
2.18.7 ClustalW and WebLogo 
The Clustal series is a software tool for doing multiple sequence alignments of three or more 
protein or DNA sequences (221). Started in 2003 ClustalW can be used to generate 
phylogenetic trees and is available at the webserver of the European Bioinformatics Institute 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). For the purpose needed in this thesis ClustalW 
was used to generate multiple sequence alignments of promoter regions or of selected 
3’-UTRs of different organisms to check sequence conservation of miRNA target sites. To 
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create a defined picture of conserved regions a WebLogo (222) was compiled. The 
WebLogo software is designed to make sequence logos as easy as possible. They are 
pictured as a graphical representation of amino acids or nucleic acids. In the WebLogo the 
stack of each symbol and its corresponding height is dependent on the conservation of the 
amino acid or nucleotide in the respective alignment.  
2.18.8 PromPredict 
To identify putative promoter sequence elements within the AT-rich region of C13orf25, the 
software tool PromPredict (http://nucleix.mbu.iisc.ernet.in/prompredict/prompredict.html) was 
used. This tool was designed in the Manju Bansal lab (223) to identify promoter regions in 
genomic DNA sequences based on differences in DNA stability between neighboring 
regions. 
2.18.9 Neural Network Promoter Prediction 
The Neural Network Promoter Prediction software tool is a program of the 
Berkeley Drosophila Genome Project (http://www.fruitfly.org/seq_tools/promoter.html). In 
2001 the software was generated by M.G. Reese (224). For this thesis the program was 
used for promoter predictions of the AT-rich region within C13orf25 and helps to find putative 
promoter elements. 
2.18.10 McPromoter 006 
McPromoter 006 is a statistical tool for the prediction of transcription start sites in eukaryotic 
DNA and was initially developed by Uwe Ohler (225) in 1999 
(http://tools.genome.duke.edu/generegulation/McPromoter/). The software tool was used to 
predict intronic promoter regions within C13orf25. 
2.18.11 Promoter 2.0 Prediction Server 
Promoter 2.0 predicts is a software tool to predict transcription start sites of vertebrates 
(http://www.cbs.dtu.dk/services/Promoter/) that was developed in 1998 by Steen Knudsen 
(226) and was used search for transcription start sites within C13orf25.  
2.18.12 CorePromoter 
CorePromoter is a prediction program for transcription start sites based on a Quadratic 
Discrimination Analysis of human core-promoters. The software tool was developed in 1998 
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by Michael Zhang (227) and the web-based software 
(http://rulai.cshl.org/tools/genefinder/CPROMOTER/human.htm) was used to search for 
promoter elements within the human C13orf25 AT-rich intronic region. 
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3 Results and Discussion 
The following section is a summary of the scientific publications resulting from my research 
work. The publications will be briefly resumed by topic in single chapters including a short 
discussion about the results obtained. Detailed information concerning the results, materials, 
and methods are given in the respective publications. 
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3.1 Project 1: The proto-oncogene PIM1 is a target of miR-33a in vitro and 
in vivo (publication I and II) 
Introduction 
The PIM1 kinase belongs to a family of constitutively active serine/threonine kinases (133) 
which fulfills important functions in cellular processes that are involved in malignant 
transformation of cells (137) and as a consequence PIM1 is classified as a proto-oncogene. 
Overexpression of this kinase is correlated with a poor prognosis in almost all hematopoietic 
malignancies and solid cancers (133), in our study represented by the chronic myelogenous 
leukemia cell line K562 and the colorectal adenocarcinoma cell line LS174T. PIM1 is a 
promising target for therapeutic strategies in the treatment of cancer (133) because a large 
number of PIM1 targets are involved in proliferation, differentiation and apoptosis to promote 
tumorigenesis (138). To date small molecular compounds which compete for ATP-binding 
have been designed to mediate post-translational regulation of the PIM1 kinase (160).  
In our study, we revealed to use RNAi-mediated protein knockdown of PIM1 through 
PIM1-specific siRNA and miRNA as a novel therapeutic approach for targeting PIM1 at the 
mRNA level. 
 
Results 
For this purpose, we initially performed in silico screenings using bioinformatical tools to 
search for putative miRNA binding sites within the PIM1 3’-UTR and indeed several of such 
sites could be identified for the binding of e.g. the miRNAs miR-15a, miR-16-1 and miR-33a. 
These three miRNAs have been further considered in the following in vitro experiments 
because (i) miR-15a and miR-16-1, which are characterized by the same seed sequence, 
are known as tumor suppressors via targeting of the anti-apoptotic B-cell lymphoma 2 
(BCL2) protein and thus inducing apoptosis (80) and (ii) the highest conservation within the 
putative miRNA binding sites in the PIM1 3’-UTR was shown for miR-33a including the seed 
region as well as nt 13-17 of the miRNA.  
Low expression levels of miR-33a in normal and cancer cell lines such as K562, LS174T, 
Skov-3, HEK293, HUH7 or HepG2 do not refer to a direct correlation between a 
tumor-suppressive function of endogenously expressed miR-33a in the regulation of PIM1 
mRNA. However the high conservation of the miR-33a binding site in the PIM1 3’-UTR and 
the overall low expression levels of this miRNA in the tested cancer cell lines suggested the 
possibility to reduce PIM1 levels in tumor cells by transfection of commercially available 
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miRNA mimics (Dharmacon/Thermo Fisher Scientific). Indeed the transfection of 
miR-33a mimics decreased PIM1 protein levels in the two tested cell lines K562 and LS174T 
about 40-60 %, whereas miR-15a and miR-16-1 miRNA mimics failed in the downregulation 
of PIM1 (Figure 11a).  
Another highly ranked putative target of miR-33a is the cell cycle regulator 
cyclin dependent kinase 6 (CDK6) harboring two conserved putative miR-33a binding sites 
within the PIM1 3’-UTR. CDK6 is associated with D-type cyclins and involved in cell cycle 
progression by regulating G1/S transition (228).  We asked if CDK6 is also regulated by 
miR-33a, but we could not validate CDK6 as a target of miR-33a in K562 cells (Figure 11b). 
In a mouse system, the tumor suppressor p53 (TP53) (229) was found to be a target of 
miR-33a. However we could not confirm this result in LS174T cells (Figure 11c). Another 
published target of miR-33a is the ATP-binding cassette transporter A1 (ABCA1) (230), 
(231). Reduction of ABCA1 protein levels could not be tested in the two cell lines due to an 
overall too low endogenous expression of ABCA1 protein. 
 
 
Figure 11: Human PIM1 is a 
target of miR-33a. (a) In K562 
cells PIM1 is downregulated by a 
miR-33a mimic, while miR-15a and 
miR-16-1 mimics as well as the 
control mimic have no measurable 
effects on PIM1 protein expression 
levels. ß-Actin serves as an 
internal loading control. (b) 
Knockdown efficacy of a 
miR-33a mimic after transfection 
into K562 cells. PIM1 expression 
levels are substantial decreased, 
whereas no effect was detected for 
the highly predicted target CDK6. 
ß-Actin serves as an internal 
loading control. (c) In LS174T cells 
knockdown efficacy of a 
miR-33a mimic was detected. A 
substantial decrease of protein 
expression was observed for PIM1. 
Although TP53 was reported to be 
a target of miR-33a in the mouse 
system (229), we were unable to 
detect a significant repression of 
human TP53. ß-Actin serves as an 
internal loading control. 
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The specificity of miR-33a binding to the 3’-UTR of PIM1 was shown (i) by luciferase reporter 
assays as well as (ii) ectopic PIM1 expression in PIM1 negative cells. (i) A reporter vector 
containing the PIM1 3’-UTR behind a firefly luciferase showed substantial downregulation of 
luciferase activity after co-transfection with a miR-33a mimic, whereas the repression effects 
were abrogated when using a seed-mutagenized variant of the reporter (Figure 12a). 
(ii) Ectopic PIM1 expression was performed in the ovarian carcinoma cell line Skov-3 to 
further substantiate that miR-33a specifically and directly represses PIM1 expression. In fact, 
Western Blot experiments confirmed downregulation of ectopic expressed PIM1 protein 
levels by miR-33a. A loss of responsiveness was seen either for a seed-mutagenized 
construct or a PIM1 cDNA clone lacking large parts of the PIM1 3’-UTR (Figure 12b). 
 
 
 
Figure 12: MiR-33a-specific regulation of PIM1 expression. (a) K562 cells were co-transfected 
with the control mimic or a miR-33a mimic and a reporter plasmid containing the PIM1 3’-UTR or a 
seed-mutagenized variant fused to the luciferase coding region respectively. Data represent mean 
values derived from at least three independent experiments (+/- S.E.M.). (b) Effects of the 
miR-33a mimic and a PIM1-specific siRNA on ectopic PIM1 expression were detected in Western 
Blot experiments. Therefore a full-length PIM1 cDNA clone, a miR-33a target site mutagenized 
variant (seed mut) or a vector lacking large parts of the 3’-UTR of PIM1 (Δ 3’-UTR) were 
co-transfected with a control siRNA (si con.), a PIM1-specific siRNA (si PIM1), a control mimic 
(c-mimic) or a miR-33a mimic into Skov-3 cells. ß-Actin serves as an internal loading control. 
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To further characterize the miR-33a-dependent downregulation of PIM1 protein levels, we 
compared the observed effect with a knockdown mediated by a PIM1-specific siRNA. 
Although the siRNA transfection resulted in an even more efficient knockdown of PIM1, the 
time-dependent decrease of protein levels of miR-33a and a PIM1-specific siRNA in K562 
cells were similar and still present after 96 h post-transfection (Figure 13).  
 
 
Figure 13: Long-term effects 
of PIM1 knockdown by the 
miR-33a mimic. Comparison of 
the PIM1 knockdown 
persistence for the miR-33a 
mimic versus the PIM1-specific 
siRNA detected 24, 72 and 96 h 
post-transfection. 
 
 
As it has been reported that PIM1 is involved in the regulation of cell proliferation in K562 
cells (157), we hypothesized that a negative effect on proliferation might be associated with 
the biological relevance of the observed miR-33a effects. Indeed an anti-proliferative effect 
could be verified in the two investigated cell lines K562 and LS174T either for a 
PIM1-specific siRNA or the miR-33a mimic (data not shown). 
 
So far we have established PIM1 as a target of miR-33a, thus opening up the possibility to 
further investigate the proto-oncogene PIM1 in an anti-cancer approach using the 
tumor-suppressive miR-33a for miRNA replacement therapy. For this reason we started 
formulation of miR-33a with the cationic branched polyethylenimine PEI F25 LMW which has 
been previously established as excellent in vivo delivery agent for siRNAs in mouse tumor 
models (176). To assess the therapeutic anti-tumor activity of miR-33a, a subcutaneous 
LS174T colon carcinoma xenograft mouse model was generated and treated by systemic 
injection of the PEI/miR-33a complexes. The systemic PEI/miR-33a replacement therapy 
resulted in a significant reduction in tumor growth of about 40 % (Figure 14a,c). Consistent 
with the inhibition of tumor growth, a reduction of PIM1 protein levels could be determined 
during the analysis of the tumors after termination of the experiment (Figure 14b). During the 
experimental period of PEI/miR-33a treatment no reduction in body weight of the mice was 
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detectable. Furthermore induction of immune responses, any hepatotoxicity or other 
unwanted side effects of miR-33a replacement therapy was not observed. 
 
 
Figure 14: Antitumor effects of systemic PEI/miR-33a treatment in LS174T tumor xenografts. (a) 
Inhibition of tumor growth of systemically injected PEI/miR-33a complexes compared with negative control 
treated mice. (b) Analysis of the tumor xenografts upon termination of the experiment reveals a reduction 
of PIM1 protein levels upon PEI/miR-33a treatment in comparison to a control treatment. (c) 
Representative examples of treated mice. 
 
Discussion 
In our study miR-33a has been established as a miRNA being implicated in tumor 
progression in vitro and in vivo. It was shown in luciferase reporter assays as well as in 
Western Blot experiments that the oncogenic kinase PIM1 is a specific target of 
tumor-suppressive miR-33a. Likewise transfection of miR-33a mimics decelerated 
proliferation and polyethylenimine-based miRNA replacement therapy successfully reduced 
tumor growth without unwanted side effects in a xenograft mouse model of colon cancer. 
Human miR-33a and related miR-33b are encoded in the intron of human 
sterol regulatory element binding protein 2 (SREBP2) on chromosome 22 and SREBP1 on 
chromosome 17 and are transcribed together with the host gene respectively. SREBPs are 
key regulators in lipid metabolism and homeostasis. Recently it was reported that both, 
miR-33a and miR-33b, are involved in the regulation of cholesterol biosynthesis and uptake, 
repressing proteins like ABCA1 (230), (231) which is involved in cholesterol efflux. 
Antagonism of miR-33a/b with antisense oligonucleotides has been shown to mediate 
reverse cholesterol transport and regression of atherosclerosis in mice (232). In non-human 
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primates a study was initiated to establish a therapeutic approach against dyslipidemia in 
cardiovascular disease risk. After inhibition of miR-33a/b with a 2’-F/MOE modified 
phosphorothioate antisense oligonucleotide, plasma high-density lipoprotein (HDL) levels of 
the monkeys were raised and very-low-density-lipoprotein (VLDL) triglycerides were lowered 
(233). However a long-term antimiR-33 study in high-fat, high-cholesterol-fed Ldlr-/- mice 
failed to prevent progression of atherosclerosis (234), maybe due to the absence of miR-33b 
in rodents. 
In our study we have demonstrated that PIM1 is a genuine target of miR-33a, although we 
have not yet identified the biological constellation(s) under which miR-33a levels are 
overexpressed to directly repress endogenous PIM1. Expression of miR-33a/b is generally 
low (230) either in normal or cancer tissues and is associated with SREBP transcription.  
Therefore a linkage between cholesterol homeostasis and cell proliferation seems to be the 
most obvious constellation to identify a natural context of miR-33a-dependent PIM1 
regulation. There are also other biological circumstances where PIM1 is upregulated. For 
example PIM1 has cardioprotective effects which are mediated through an overexpression in 
cardiac progenitor cells (235), (236). As another example PIM1 is induced during the 
development of monocytes to macrophages (own observations). However miR-33a has not 
been analyzed under these conditions. The tumor suppressor activity of miR-33a/b has also 
been shown for the regulation of the oncogene MYC (237). In medulloblastoma cells a 
statin-induced upregulation of miR-33b substantially decreased cellular MYC protein levels 
and for this reason presents a promising therapeutic option against cancers involving MYC 
overexpression (237). SREBP expression has also been implicated in the regulation of the 
cell cycle (238) and thus a connection between miR-33a and cell cycle progression has been 
reported in the liver cell line HUH7. In this context CDK6 and cyclin D1 (CCND1) have been 
established as targets of miR-33a reducing cell proliferation and arresting the cell cycle in 
G1 phase (239). 
Taken together, these findings emphasize an essential role of miR-33a in the cellular 
connection of several molecular pathways. In addition cell-type and tissue-specific regulatory 
pathways as well as expression levels of miR-33a seem to be crucial and regulation of 
miR-33a/b in therapeutic approaches has to be well-balanced. However our PEI/miR-33a 
replacement strategy showed antitumor effects in vivo and an accumulation of delivered 
miRNAs in tumor tissues has been shown (28). Ultimately personalized therapy and targeted 
delivery is preferable in order to reduce side effects and extensive research in this field 
should be promoted. 
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3.2 Project 2: Novel seed-directed LNA antimiRs as potent miRNA inhibitors 
in vitro (publication III) 
Introduction 
MiRNA expression differs in normal and cancer tissues (39) and overexpression of 
oncogenic miRNAs is often associated with malignant transformation and tumorigenesis 
(100). One important oncogenic miRNA cluster is the miR-17-92 cluster that can promote 
proliferation and is involved in the inhibition of apoptosis (88). MiRNAs of this cluster, miR-17 
and miR-20a, have been reported to post-transcriptionally control the cell cycle regulator P21 
(240), an important and well-characterized cyclin-dependent kinase inhibitor with tumor 
suppressor activity (241). The inhibition of oncogenic miRNAs to modulate oncogenic 
pathways is a promising therapeutic strategy in the prevention and treatment of cancer. 
AntimiR design is a challenging task because there are several chemical modifications 
available to enhance resistance against cellular nucleases and to increase the binding affinity 
to the target miRNA of interest (109). To date a safe and efficient delivery of antimiRs is still 
the main bottleneck. Successful in vivo delivery of antagomiRs (124) which are conjugated 
with cholesterol to improve their cellular uptake has been reported. Moreover tiny LNAs (126) 
which harbor a phosphorothioate (PS) backbone can also be delivered without any 
formulation in a mouse tumor model. A formulated delivery of unconjugated antimiRs has not 
been explored so far. 
In our study we scrutinized a novel class of potent miRNA inhibitors: single-stranded short 
LNA oligonucleotides harboring a natural phosphodiester backbone (PO), henceforth termed 
LNA antiseeds (PO). We tested length-dependent miRNA inhibition of several LNA antiseeds 
to explore even miRNA family targeting. Furthermore we established complex and 
nanoparticle formation of the LNA antiseeds with the cationic branched polyethylenimine 
PEI F25 LMW to enable the delivery into a broad spectrum of tissues and organs.  
 
Results 
As a first experimental approach we determined the minimum LNA antiseed (PO) length 
which is needed for the inhibition of miRNA function. Thus we investigated inhibitory effects 
of 8-, 10-, 12-, and 14-meric LNA antiseeds (PO) against miRNA let-7a. For this purpose we 
cloned a hsa-let-7a target sequence in the 3’-UTR of a luciferase reporter gene (Promega); 
as a control we replaced the sequence by an inverted hsa-let-7a target sequence. The 
inhibitory effect of miRNA let-7a in HeLa cells was shown by a derepression of the luciferase 
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activity. Only weak effects were obtained with the 8- or 10-meric LNA antiseeds (PO) (data 
not shown), whereas 12- and 14-meric LNA antiseeds (PO) efficiently derepressed the 
luciferase reporter even in low concentration ranges of 1-20 nM (Figure 15). As a negative 
control we used an unspecific and unrelated 14-mer LNA oligonucleotide directed against 
bacterial RNaseP (182). A commercially available antimiR against let-7a, designed as a 
miRNA hairpin inhibitor (181), served as in internal positive control for derepression of the 
reporter system (Figure 15). 
 
Figure 15: LNA antiseeds 
(PO) as miRNA inhibitors. 
Comparison of 12- and 
14-meric LNA antiseeds 
(PO) with a commercially 
available hairpin inhibitor 
(hp inhib.) targeting a 
hsa-let-7a luciferase 
reporter at the indicated 
concentrations. As a control 
an unrelated LNA 14-mer 
(LNA con.) was used. 
Values are derived from at 
least three independent 
experiments (+/- S.E.M.) 
after co-transfection into 
HeLa cells. 
 
 
In a second approach we determined derepression activity of LNA antiseeds (PO) by the 
investigation of an endogenously expressed target gene. Therefore derepression of basal 
protein levels of the tumor suppressor P21 was analyzed in the erythroleukemia cell line 
K562. This cell line expresses P21 mRNA, but protein levels are barely sufficient for the 
detection in Western Blot experiments. Recently it has been reported that P21 is 
post-transcriptionally regulated by miRNAs of the miR-106b family (240) e.g. miR-17 and 
miR-20a. We therefore hypothesized that miR-17 and miR-20a, which are overexpressed in 
K562 cells (103), repress endogenous P21 protein levels in the indicated cell line. To test 
this, 14-meric LNA antiseeds (PO) directed against the two miRNAs were transfected into 
K562 cells, and indeed caused substantial increase of P21 protein levels in comparison to an 
unrelated LNA control. The effect of raised P21 protein levels mediated by the 
LNA antiseeds (PO) was persistent and could still be detected 120 h after a single 
transfection of the LNA antiseeds (PO) (Figure 16a). The specificity of the observed 
LNA antiseed (PO) effect was analyzed with a luciferase reporter vector (Promega). For this 
purpose, the 3’-UTR of P21 and a seed-mutagenized variant were cloned behind the firefly 
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luciferase of the reporter vector. As a positive control, commercially available miRNA hairpin 
inhibitors (181) were compared with the LNA antiseeds (PO). At a concentration of 10 nM the 
derepression of luciferase activity was not as substantial as it was observed with the 
LNA antiseeds (PO) directed against miR-17 and miR-20a. Moreover the combination of 
equimolar concentrations of the hairpin inhibitors enhanced derepression of the reporter that 
was now comparable to the effect of the single LNA antiseeds (PO) (Figure 16b). These 
findings implied that LNA antiseeds (PO) are able to inhibit and block miRNAs of the same 
family, whereas miRNA inhibitors are more specific to a single miRNA. As a further positive 
control, we tested a tiny LNA directed against the seed region of miR-17/20a, and indeed 
found highly efficient derepression of the reporter system (Figure 16b), but also a slight 
increase in luciferase activity for the seed-mutagenized reporter construct (Figure 16c) 
implicating slight non-specific effects. 
 
 
 
Figure 16: Specific inhibitory effects of LNA antiseeds (PO) against the miR-106b family. (a) Duration of 
P21 derepression by LNA antiseeds (PO) versus hairpin inhibitors (hp inhib.). Expression of basal P21 protein 
levels were analyzed by Western Blot after transfection of the antimiRs into K562 cells. (b) Specific derepression 
activity of the indicated miRNA inhibitors after co-transfection with the P21 3’-UTR luciferase reporter into HeLa 
cells. Luciferase activity values are derived from at least three independent experiments (+/- S.E.M.). (c) Effects 
of the indicated miRNA inhibitors on luciferase expression using the seed-mutated version of the reporter in HeLa 
cells. Values are derived from at least three independent experiments (+/- S.E.M.). 
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As the delivery of antisense oligonucleotides is the major bottleneck for therapeutic 
applications, unconjugated LNA antiseeds with a PO backbone have to be formulated e.g. 
with polyethylenimine for the use in in vivo studies to enable uptake into cells and tissues. 
Previously we have established the use of the branched cationic polyethylenimine 
PEI F25 LMW for systemic delivery of siRNA (176) or for miRNA replacement therapy (28). 
To explore efficient LNA antiseed complex formation with PEI F25 LMW, we performed 
atomic force microscopy (AFM) to visualize the shaped nanoparticles. In fact formation of 
polymeric nanoparticles was observed upon mixing of PEI F25 LMW with an 
LNA antiseed (PO) (Figure 17a). After demonstrating the efficient formation of homogenous 
nanoparticles, we analyzed PEI/LNA let-7a (PO) complexes in the hsa-let-7a-specific 
luciferase reporter assay in HeLa cells. This PEI-based delivery strategy mediated 
substantial derepression of luciferase activity in vitro (Figure 17b), thus providing the basis 
for future research of LNA antiseeds also in mouse tumor models. 
 
 
Figure 17: Functional delivery 
of PEI/LNA antiseed (PO) 
nanoparticles. (a) Detection of 
PEI F25 LMW/LNA nanoparticles 
using atomic force microscopy. 
(b) In HeLa cells co-transfection 
of the hsa-let-7a luciferase 
reporter with PEI/LNA antiseed 
let-7a (PO) nanoparticles leads to 
derepression of luciferase 
activity. Values are derived from 
at least three independent 
experiments (+/- S.E.M.). 
 
 
 
Discussion 
The advantages of antimiR-based applications are (i) to analyze important cellular functions 
of miRNAs by blocking them and thereby preventing post-transcriptional regulation or (ii) to 
inhibit overexpressed and oncogenic miRNAs in several disease states. To date 
antimiR-based therapy has been successfully established in vitro and in vivo using several 
different modifications either in the backbone or the sugar positions of the oligonucleotides. 
One of the most important variations is the introduction of LNA sugar modifications, where 
the ribose is sterically stabilized and locked in the C3’-endo conformation. LNA modifications 
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enable an increase of target affinity by enhancing the melting temperature (Tm) of the 
oligonucleotide (115),(242). It has been reported that the dissociation constant of LNA/RNA 
hybrids, which can be determined as koff value, is dramatically reduced (243), and thus 
LNA oligonucleotides are very efficient and persistent in blocking RNA functionality. A better 
resistance against cellular nucleases has been shown that is further increased by the 
introduction of phosphorothioate linkages (105), (244). Despite this advantage, a 
phosphorothioate modified antisense oligonucleotide has some disadvantages such as a 
non-specific binding to cellular proteins associated with toxic side effects (245), (244). 
Preferentially oligonucleotides harboring a natural phosphodiester backbone should be used 
for systemic application because they show no toxicity or any side effects (28), (244). 
However antimiRs with a phosphorothioate backbone can be delivered unconjugated; 
nevertheless a formulation of the LNA antiseeds (PO) with the cationic branched 
polyethyleneimine PEI F25 LMW has many advantages. PEI polymers are able to (i) protect 
the incorporated nucleic acids against nucleases, (ii) mediate the cellular uptake and 
(iii) trigger the release of the oligonucleotides into the cytoplasm via a proton/sponge effect 
(246). Furthermore in miRNA replacement therapy the cationic branched PEI F25 LMW has 
proven a targeted delivery of the nucleic acids into tumor tissues causing neither toxicity nor 
an increase of hepatic enzymes or any immunostimulatory effects (28). Thus 
polyethyleneimine formulated miRNA-based LNA antiseed (PO) therapy is a promising 
option to inhibit oncogenic miRNAs and should be further investigated in in vivo tumor mouse 
models of different cancer types. 
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3.3 Project 3: Transcriptional regulation of the human miR-17-92 cluster         
(manuscript in preparation IV) 
Introduction 
The oncogenic miRNA cluster miR-17-92 is one of the best characterized human miRNA 
clusters and encodes six miRNAs, namely miR-17, miR-18a, miR-19a, miR-20a, miR-19b 
and miR-92a. Also referred to as oncomiR-1 or C13orf25, miR-17-92 is associated with 
hematopoietic malignancies and solid cancers (96). Overexpression of the cluster promotes 
proliferation, inhibits apoptosis and accelerates angiogenesis (88). Analyses to study 
transcriptional regulation of miRNAs or miRNA clusters are necessary and relevant to 
develop novel strategies aiming at cancer prevention. Unfortunately only few miRNA 
promoters have been identified or closer characterized to date (169). Transcription of the 
polycistronic miR-17-92 cluster has been shown to be in part controlled by an E2F-regulated 
host gene promoter with E2F3 being the main E2F variant associated with the host gene 
promoter (167), (166). Additionally transcription originates from an intronic AT-rich region 
directly upstream of the miRNA coding region (169) which had been determined by 
nucleosome mapping combined with chromatin signatures to identify transcriptionally active 
promoters (247), (248), (249). Cluster expression originating from the intronic AT-rich region 
is activated by the transcription factor MYC that binds to a conserved E-box element (E3) 
approximately 1.5 kb upstream of the miR-17-92 coding sequence (87), (91), (248). 
In our study we scrutinized promoter activity emanating from the intronic AT-rich region. ChIP 
experiments identified the proto-oncogene PIM1 and one of its phosphorylation targets 
HP1G (155) to be associated with the chromatin region comprising the functional 
MYC-binding site. SiRNA-mediated knockdown of PIM1 protein resulted in decreased levels 
of pri-mir-17-92 transcript levels. Both results provide evidence that the miR-17-92 cluster 
belongs to those 20 % of all MYC regulated genes that show a synergism with the oncogenic 
kinase PIM1 (159).  
 
Results 
As a first experimental approach we analyzed MYC-dependent transcriptional activation of 
the intronic AT-rich sequence. Therefore we cloned several pGL3 control luciferase reporter 
constructs (Promega) that were generated from the intronic AT-rich promoter region (Figure 
18a). After transfection into K562 and HeLa cells, expressing the miR-17-92 cluster at very 
high and high levels (data not shown), we evaluated transcriptional activity of this putative 
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promoter region. Indeed we showed MYC-dependent transcriptional activity emanating from 
the intronic AT-rich region (1.5 kb construct). A knockdown of MYC protein levels (K562 
cells) or a truncated reporter variant lacking the functional MYC binding site E3 (625 bp 
construct) caused substantial downregulation of luciferase activity of about 4.5-fold in K562 
and almost 20-fold in HeLa (Figure 18b). This finding supports the assumption that MYC 
binding to the E3 site plays a central role in activating transcription of miR-17-92. We further 
shortened the promoter constructs including elements with their 3’-boundary approximately 
290 bp upstream of the mature miR-17-5p coding sequence due to basal promoter activity 
obtained with the 625 bp construct. As controls we included the pGL3 control reporter vector 
lacking the SV40 promoter sequence as well as a construct with comparable AT-content 
(inverted 339 bp construct) (Figure 18a,b). In contrast to the inverted 339 bp construct all 
fragments which are shorter than ~340 bp conferred residual promoter activity indicating that 
parts of the intronic promoter region promote specific transcriptional activity (Figure 18b). 
 
 
Figure 18: MYC-dependent intronic transcriptional activity of the human C13orf25 locus. (a) Schematic 
representation of different C13orf25 segments fused to the luciferase gene. The functional MYC binding site (E3) 
is indicated in the 1.5 kb construct (white box). (b) Promoter activities of the different promoter reporter constructs 
in K562 and HeLa cells. Obtained luciferase activities were normalized to the pGL3 control vector (Promega). 
RLU values of the individual constructs were derived from 5 to 16 experiments (+/- S.E.M.). 
 
Next we considered if other factors beyond MYC may be involved in transcriptional regulation 
of the human miR-17-92 cluster. Indeed ChIP assays of the functional MYC binding site in 
the AT-rich promoter region confirmed not only association of MYC to this chromosomal 
area. Further we identified the oncogenic kinase PIM1 as well as its phosphorylation target 
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HP1G to be associated with this chromatin region (Figure 19). Additionally we were able to 
identify HP1G association along the miRNA coding region indicating that HP1G participates 
in active transcription of the miR-17-92 cluster (data not shown). 
 
 
Figure 19: ChIP analysis of 
the functional MYC binding 
site in the intronic region of 
C13orf25. In K562 cells ChIP 
analysis identified MYC, PIM1 
and HP1G association with this 
chromatin region. + AB: with 
antibody; - AB: without 
antibody; Mock: buffer without 
cell lysate; Input: supernatant of 
the - AB sample. 
 
 
To scrutinize the role of PIM1 in miR-17-92 expression, we determined cellular pri-mir-17-92 
transcription levels by qPCR after siRNA-mediated knockdown experiments of E2F3, MYC 
and PIM1 in the two different cell lines. K562 and HeLa cells were selected due to very high 
and high expression levels of the miR-17-92 cluster as well as PIM1 protein levels 
respectively. Single knockdown experiments of MYC, E2F3 or PIM1 decreased the 
pri-mir-17-92 levels to about 40, 60 and 60 % in HeLa cells and to 30, 30 and 45 % in K562 
cells respectively (Figure 20a,b). Double-knockdown experiments had additive suppression 
effects for a MYC/E2F3 knockdown in both cell lines (~20 % remaining pri-mir-17-92 levels). 
In case of MYC/PIM1 and E2F3/PIM1 double-knockdowns cooperative suppression was only 
obtained in HeLa resulting in decreased transcript levels to about 20 and 30 % (Figure 
20a,b). 
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Figure 20: Transcriptional activity of the human miR-17-92 cluster after RNAi-mediated 
knockdown of regulatory proteins. (a) Quantitative PCR of pri-mir-17-92 levels in HeLa cells 
after single- and double-knockdown experiments of MYC, E2F3 and PIM1. 2^-ΔΔpri-mir-17-92 
values were normalized against 5S rRNA and an internal control siRNA (179) and were obtained 
from at least three independent experiments (+/- S.E.M.). Statistical analyses were done using 
the software R (250). (b) Transcription levels of pri-mir-17-92 levels in K562 after single- and 
double-knockdown experiments of the respective proteins. QPCR results were normalized against 
5S rRNA and an internal control siRNA (179) and were obtained from at least three independent 
experiments (+/- S.E.M.). Statistical analysis was done using the software R (250). 
 
Discussion 
In our study the intronic AT-rich region preceding the miR-17-92 cluster was scrutinized in 
more detail than it was done in previous work (169), (248), (249) additionally regarding an 
siRNA-mediated knockdown of MYC protein on transcription. The obtained effect was similar 
to the one observed after truncation of the functional MYC binding site E3. These findings 
substantiate the conception that the E3 site plays an important role in activating transcription 
emanating from the intronic promoter region of C13orf25. However even smaller promoter 
fragments still showed substantial, but specific transcriptional activation being independent of 
the functional MYC site. This MYC-independent activation was more pronounced in K562 
cells due to the particularly high miR-17-92 cluster expression indicating cell type-specific 
differences in cluster expression. Our reporter assay data suggest multiple TSSs within this 
AT-rich region, although the predicted transcription initiation region approximately 0.2 kb 
downstream of the E3 box (169) may well be the major one.  
Colocalization of MYC, the proto-oncogene PIM1 and its phosphorylation target HP1G to the 
chromatin region harboring the functional MYC binding site was shown in ChIP analysis. 
Importantly it has been reported that PIM1-catalyzed phosphorylation of H3S10 at MYC 
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activated target genes is required for MYC-dependent oncogenic transformation (251). Three 
paralogs of HP1 proteins in mammals regulate heterochromatin formation, gene silencing or 
gene activation (252), (156). The role of HP1G has not been fully understand, but it has been 
reported that HP1G is found in association with euchromatin (253), active genes (156) and 
can further be recruited to inducible promoters where it replaces HP1B to induce a switch 
from the repressive to the active transcriptional state (254). The replacement by HP1G 
requires H3 phospho-acetylation and a transient phosphorylation of H3S10 via aurora kinase 
B (AURKB) was shown to be essential for dissociation of HP1 proteins from chromatin during 
M-phase of the cell cycle (255). Our ChIP data of HP1G provide evidence for an activating 
role of HP1G during transcription. The identification of HP1G along the miR-17-92 coding 
region is to our knowledge the first indication that HP1G is involved in the activation of 
miRNA gene transcription. Recently it has been reported that HP1G can also be localized 
within coding regions of protein genes together with elongating RNA polymerase II (POLR2) 
(254). 
Association of PIM1 with the E3 site in the intronic chromosomal region of C13orf25 gave 
rise to the assumption that PIM1 plays a crucial role in transcriptional activation of the 
miR-17-92 cluster. RNAi-mediated knockdown experiments including MYC, PIM1 and E2F3 
downregulation indicate that all three proteins are important for cluster expression. 
Transcription is affected either from the host gene promoter by E2F3 or the intronic promoter 
region regulated by MYC and PIM1. Of course, we cannot exclude indirect effects that have 
contributed as well such as effects originating from inhibition of cell proliferation (PIM1), 
changes in the kinetics of miRNA processing and global changes in transcriptional networks 
or mutual transactivation (E2F3 and MYC) (256), (257), (258). Besides it has been reported 
that miR-17-5p and miR-20a are negative regulators of E2F1-3 mRNAs (91), (166). A major 
finding of our study is the involvement of the oncogenic kinase PIM1 in the regulation of 
miR-17-92 expression. This is inferred from its MYC-dependent recruitment to the E3 site in 
the intronic promoter region and a strong negative effect of a PIM1 knockdown on 
endogenous cluster expression. Moreover double-knockdown experiments revealed a 
synergistic effect compared to individual MYC and PIM1 knockdowns in HeLa cells.  
Further investigations and extended research regarding transcriptional control of miRNA 
promoters could provide profound evidences for better understanding the complex network 
between miRNA expression and the development of cancer. 
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The proto-oncogene Pim-1 is a target of miR-33a
M Thomas1, K Lange-Gru¨nweller1, U Weirauch2, D Gutsch2, A Aigner2, A Gru¨nweller1
and RK Hartmann1
1Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps-University Marburg, Marburg, Germany and 2Institute
of Pharmacology, Faculty of Medicine, Philipps-University Marburg, Marburg, Germany
The constitutively active serine/threonine kinase Pim-1 is
upregulated in different cancer types, mainly based on the
action of several interleukines and growth factors at the
transcriptional level. So far, a regulation of oncogenic
Pim-1 by microRNAs (miRNAs) has not been reported.
Here, we newly establish miR-33a as a miRNA with
potential tumor suppressor activity, acting through
inhibition of Pim-1. A screen for miRNA expression in
K562 lymphoma, LS174T colon carcinoma and several
other cell lines revealed generally low endogenous miR-
33a levels relative to other miRNAs. Transfection of K562
and LS174T cells with a miR-33a mimic reduced Pim-1
levels substantially. In contrast, the cell-cycle regulator
cyclin-dependent kinase 6 predicted to be a conserved
miR-33a target, was not downregulated by the miR-33a
mimic. Seed mutagenesis of the Pim-1 30-untranslated
region in a luciferase reporter construct and in a Pim-1
cDNA expressed in Pim-1-deficient Skov-3 cells demon-
strated specific and direct downregulation of Pim-1 by the
miR-33a mimic. The persistence of this effect was
comparable to that of a small interfering RNA-mediated
knockdown of Pim-1, resulting in decelerated cell
proliferation. In conclusion, we demonstrate the potential
of miR-33a to act as a tumor suppressor miRNA, which
suggests miR-33a replacement therapy through delivery of
miR mimics as a novel therapeutic strategy.
Oncogene (2012) 31, 918–928; doi:10.1038/onc.2011.278;
published online 11 July 2011
Keywords: Pim-1; microRNA; miR-33a; proliferation;
RNAi; siRNA
Introduction
MicroRNAs (miRNAs) are important regulators of
gene expression, controlling developmental processes
like embryonic stem cell differentiation, several meta-
bolic pathways, cell proliferation, apoptosis and stress
responses (for reviews see Bartel, 2004; Gangaraju and
Lin, 2009). Like small interfering RNAs (siRNAs),
miRNAs are loaded into Argonaute-containing ‘RNA-
induced silencing complexes’ called miRNA ribonucleo-
protein complexes (miRNPs) (Wang et al., 2009). In
general, miRNAs have partial complementarity to their
target mRNAs leading to translational inhibition or
degradation of the respective mRNA in P-bodies (Liu
et al., 2005; Rehwinkel et al., 2005). A prerequisite for
miRNA interaction with mRNA targets is the so-called
‘seed region’ covering nucleotides (nt) 2–8 of the mature
miRNA strand. This region usually forms a continuous
duplex with the target followed by an unpaired region
and a second less stringent base-pairing interaction
(Lewis et al., 2005; Grimson et al., 2007; Bartel, 2009).
Many miRNAs have been identified to be involved
in the development of cancer or metastasis, for
example miR-21, members of the miR-17-92 cluster or
miR-155, and are therefore called oncogenic miRNAs
(Esquela-Kerscher and Slack, 2006). These miRNAs
can downregulate targets that are involved in the
regulation of apoptosis or cell-cycle progression, such
as the phosphatase and tensin homolog (Pten), the
transcription factor E2F1 or the apoptotic regulator
Bim (for review see Croce, 2009). On the other hand,
certain oncogenes like the transcription factor c-Myc
are involved in the transcriptional regulation of
miRNAs (O’Donnell et al., 2005).
Other miRNAs, for example miR-15a, miR-16-1, let-
7a and miR-145, have been reported to be able to exert
tumor suppressor activity by controlling targets that can
inhibit apoptosis or promote cell-cycle progression. The
tumor suppressor function of miRNAs is mainly directed
against classical oncogenes, including the small G-protein
Ras, the transcription factor c-Myc, Bcl-2, or cell cycle-
dependent kinases like Cdk4 and Cdk6 (Cimmino et al.,
2005; Iorio et al., 2005; Johnson et al., 2005; Croce, 2009).
Consequently, in several tumors, these miRNAs are
downregulated or not expressed at all (Garzon et al.,
2009). For example, miR-15a and miR-16-1 are encoded
in the chromosomal region 13q14.3 and loss of this region
is the most common genomic aberration in chronic
lymphocytic leukemia (Calin et al., 2002). Likewise,
downregulation or loss of expression of these two
miRNAs are frequently observed in prostata carcinomas
(Bonci et al., 2008).
Beyond Cdk4 and Cdk6, we are not aware of any
other examples of oncogenic kinases regulated by
miRNAs, despite the fact that the activities of oncogenic
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kinases are often deregulated in cancer cells (Amaravadi
and Thompson, 2005). So-called survival kinases such as
Akt, which promote anti-apoptotic responses or execute
crucial steps in cell cycle progression, have received
attention as therapeutic targets (Crowell et al., 2007;
Martelli et al., 2007). This is also true for the Pim-1
kinase that can function in a synergistic manner with c-
Myc to establish severe forms of B-cell lymphomas (van
Lohuizen et al., 1989; Verbeek et al., 1991; Zippo et al.,
2007; Zhang et al., 2008).
Pim kinases belong to the small group of constitu-
tively active kinases (Amaravadi and Thompson, 2005;
Qian et al., 2005), and thus their activity correlates with
their cellular expression levels. PIM oncogenes are
frequently overexpressed in human hematological ma-
lignancies and in several solid tumors, for example in
prostate and breast cancer. PIM kinases exert their
oncogenic potential through regulating MYC transcrip-
tional activity, cap-dependent protein translation, cell-
cycle progression as well as through suppression of
apoptosis by means of BCL2-associated agonist of cell
death (Bad) phosphorylation (for review, see Brault
et al., 2010; Nawijn et al., 2011). Isoforms of Pim
kinases include Pim-1, -2 and -3 (each B33 kDa), and
utilization of alternative start codons gives rise to
additional size variants, that is, 44 kDa (Pim-1; Xie
et al., 2006) or 37 and 40 kDa (Pim-2; Fox et al., 2003),
respectively (Amaravadi and Thompson, 2005). For
Pim-1, several phosphorylation targets have been
identified, such as Cdc25A (Mochizuki et al., 1999)
and p21 (Wang et al., 2002) among others (for review
see Bachmann and Mo¨ro¨y, 2005). So far, the expression
of Pim-1 has been found to be regulated mainly at the
transcriptional level by the action of several interleu-
kines and growth factors that activate STAT3 and/or
STAT5 via Janus kinases (Bachmann and Mo¨ro¨y, 2005).
In contrast, a regulation of Pim-1 by miRNAs, which
may well add to the differential expression in tumor
versus normal cells, has not been reported.
In this study, we establish Pim-1 as a target of miR-
33a, a miRNA that has not been implicated in tumor
progression so far. Levels of miR-33a were observed to
be low in a variety of tested cancer cell lines.
Transfection of the myeloid leukemia suspension cell
line K562 and the colon cancer adhesion cell line
LS174T with a miR-33a mimic resulted in an anti-
proliferative effect through reduced expression of Pim-1.
The potential tumor suppressor activity of miR-33a
would extend its hitherto known physiological functions
in cholesterol metabolism (Najafi-Shoushtari et al.,
2010; Rayner et al., 2010), and may offer novel options
in miRNA-based tumor therapy.
Results
For the present study, we chose the following cell lines:
(1) the suspension cell line K562 as a model for high
endogenous Pim-1 expression; (2) adherent LS174T cells
with moderate Pim-1 levels and representing solid
tumors, which can be used for the induction of colon
carcinomas in nude mice; and (3) Pim-1-negative Skov-3
cells for ectopic Pim-1 overexpression.
The 30-untranslated region of Pim-1 harbors a conserved
binding site for miR-33a
Here, we asked the question if the oncogenic kinase
Pim-1 might be a target of miRNAs. The analysis of
human Pim-1 mRNA for putative miRNA-binding sites
by TargetScan 5.1 (Whitehead Institute for Biomedical
Research, Cambridge, MA, USA) predicted conserved
binding sites for miR-124/506, miR-26a/b, miR-15a/-16-1,
miR-24, miR-33a and miR-144 (Figure 1a). Among
those, the highest context score percentile of 98 was
predicted for miR-33a. For this miRNA, the seed region
from position 2–8 nt and the anchor A (Grimson et al.,
2007) are almost completely conserved between human,
mouse, rabbit, dog and chicken. Also conserved among
all five eukaryotes is an unpaired nucleotide stretch
(positions 10–12 nt) following the seed, as well as a
second stretch (nt 13–17) complementary to the target,
thus perfectly matching the ‘Grimson rules’ (Grimson
et al., 2007; Figures 1b and c, right panels). We further
considered miR-15a/-16-1 as candidate regulators of
Pim-1 expression owing to their well-characterized
tumor suppressor activities (Cimmino et al., 2005;
Aqeilan et al., 2010). However, both miRNAs were
ranked much lower by TargetScan 5.1 (percentile of 50
for miR-15a and 67 for miR-16-1) correlating with a
lower adherence to the ‘Grimson rules’ and a lower
evolutionary conservation of the putative miR-15a/-16-1
target site in the Pim-1 30-untranslated region (30-UTR)
(Figures 1b and c, left panels). MiR-124/506, miR-26a/
b, miR-24 and miR-144 were considered less promising
(see Supplementary Information and Supplementary
Figure S1), thus prompting us to mainly focus our
studies on the potential Pim-1 targeting by miR-33a.
Profiling of selected miRNAs in K562 and LS174T cells
We next quantified the levels of miR-33a in K562 and
LS174T cells by the stem-loop primer reverse transcrip-
tase qPCR technique (Chen et al., 2005a). Our analysis
also included the closely related miR-33b, other miRNAs
predicted to target the Pim-1 30-UTR (miR-15a/-16-1,
miR-24, miR-26a, miR-144; see above), miR-17-5p/-20a
highly expressed in K562 cells (Venturini et al., 2007),
and miR-374a as a reference miRNA that shows
minimal variability in cell lines, as recommended by
Applied Biosystems (Foster City, CA, USA) for Taq-
Man MicroRNA Assays. Among the analyzed miRNAs
with seeds in the Pim-1 30-UTR, expression levels in
K562 cells decreased in the order miR-16-1>miR-26a>
miR-24>miR-15a44miR-33a44miR-14444miR-33b,
and a comparable order (miR-16-1>miR-24>miR-26a
>miR-15a44miR-33a44miR-144, miR-33b) was
observed in LS174T cells (Figures 2a and b). Notably,
miR-33a expression was comparably low in both cell
lines. Conversely, miR-16-1, to which tumor suppressor
functions have been assigned (Cimmino et al., 2005;
Aqeilan et al., 2010), showed relatively high expression
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levels in both cell lines. As expected, high levels of the
oncogenic miR-17-5p and miR-20a, encoded in the miR-
17-92 cluster, were found in K562 and LS174T cells. To
address the question if miR-33a levels also tend to be
low in other cell lines than K562 and LS174T, we further
tested HepG2 and Huh7 (liver carcinoma), Skov-3
(ovarian carcinoma) and Hek293 (embryonic kidney)
as a nontumor cell line for miR-33a expression. HepG2
and Huh7 cells were included, since miR-33 was recently
reported to contribute to the regulation of cholesterol
homeostasis in liver cells (Najafi-Shoushtari et al., 2010;
Rayner et al., 2010). Skov-3 cells were chosen because
we considered this cell line as a host for ectopic Pim-1
expression (see below). However, all the additionally
tested human cell lines had low miR-33a levels
(Figure 2c), only HepG2 cells showed substantial Pim-
1 protein expression (data not shown). Thus, at least for
the cell types analyzed so far under standard growth
conditions, a direct correlation between miR-33a and
Pim-1 levels is not evident. Our finding of similarly low
miR-33a levels in Hek293 cells relative to the tested
cancer cell lines does not support the idea that tumor
cells may further downregulate their miR-33a levels
(own observations and Willemijn Gommans, personal
communication).
Pim-1, but not Cdk6, is a target of miR-33a
The high conservation of the miR-33a-binding site in the
30-UTR of Pim-1 and the relatively low levels of miR-
33a in all tested cell lines suggested the possibility to
reduce Pim-1 overexpression in tumors by transfection
of cells with a commercially available modified miR-33a
mimic. Indeed, western blots demonstrated a substantial
downregulation of Pim-1 by the miR-33a mimic in K562
cells. Notably, no change in Pim-1 expression was
observed upon transfection with miR-15a or miR-16-1
mimics, or a nonspecific control mimic (Figure 3a).
Next, we compared an unmodified synthetic miR-33a
mimic, which represents the Dicer processing product of
pre-miR-33a (see Figure 3b and http://www.mirbase.
org) with the commercial mimic (miR-33a modified)
from Thermo Scientific (Schwerte, Germany). The
unmodified mimic was also capable of downregulating
Pim-1 in K562 cells, but less efficiently than the modified
mimic (Figure 3c). Consistent with this finding, the
unmodified miR-33a mimic led to an only moderate
reduction in Pim-1 expression in LS174T cells, while the
modified miR-33a mimic resulted in a substantial
downregulation of Pim-1 protein levels (Figure 3d).
We further asked the question if miR-33a, beyond
Pim-1, may also target another cell-cycle regulator,
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Figure 1 Predicted miRNA-binding sites in the 30-UTR of Pim-1. (a) Schematic presentation of the human Pim-1 mRNA (50-UTR in
light gray, coding sequence in gray and 30-UTR in black) based on the updated National Center for Biotechnology Information
(NCBI) Reference Sequence NM_002648.3. The coding region ranges from position 431–1372. Six conserved target sites for miRNAs
(light gray and dark gray boxes below the 30-UTR) are predicted in the 30-UTR by TargetScan 5.1. The target sites of the Pim-1-specific
siRNAs used in this study are marked by the gray-shaded boxes above exons 5 and 6, respectively. The predicted miRNA target sites
for miR-15a and miR-33a (dark gray boxes below the 30-UTR) are detailed in (b). (b) Sequence alignments of miR-15a and miR-33a
target sites in different vertebrates. MiR-33a is in a sequence context predicted to be optimal for miRNA binding (context score
percentile of 98 out of 100). The seed region (nt 2–8), the central loop region (nt 10–12) and the second pairing region are fully
conserved from human to chicken, except for two base exchanges in the mouse target sequence (indicated by lowercase letters). For
comparison, the predicted miR-15a target sequence in the Pim-1 30-UTR is less conserved. (c) Weblogos to illustrate the phylogenetic
conservation of miR-15a and miR-33a target sites in the Pim-1 30-UTR based on the sequence alignment shown in (b).
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cyclin-dependent kinase 6 (Cdk6), since Targetscan 5.1
had ranked Cdk6 position three among putative miR-
33a targets owing to the presence of two conserved
target sites in its 30-UTR (Supplementary Figure S2);
the context score percentile was 98 for target site 1
and 20 for site 2). For comparison, Pim-1 was ranked
position 56. Cdk6, as Cdk4, promotes the G1/S
transition of the cell cycle in conjunction with D-type
cyclins through phosphorylation and thus inactiva-
tion of the tumor suppressor protein Rb (Meyerson
and Harlow, 1994). Western blot analysis after transfec-
tion of K562 cells with the modified and unmodi-
fied miR-33a mimics, however, provided no evidence
for downregulation of Cdk6 by miR-33a mimics
(Figure 3c). Recently, p53 and ATP-binding cassette
transporter A1 (ABCA1) were published as targets of
miR-33a (Herrera-Merchan et al., 2010; Najafi-Shoush-
tari et al., 2010; Rayner et al., 2010). Since K562 is
a p53-deficient cell line (Zhang et al., 1993), we were
only able to test if p53 may also be downregulated
by miR-33a mimics in LS174T cells. However, transfec-
tion of miR-33a mimics in several independent experi-
ments provided no evidence for a downregulation of
p53 in LS174T cells (Figure 3d). This observation
deviates from the findings of Herrera-Merchan et al.
(2010) obtained in the mouse system, but is consistent
with the fact that, in the human system, the two
predicted target sites of miR-33a in the p53 30-UTR
(Herrera-Merchan et al., 2010) would each include two
seed mismatches when paired to miR-33a. Unfortu-
nately, the ABCA1 transporter was hardly detec
table in K562 and LS174T cells (data not shown),
which also disfavored the use of ABCA1 as a straight-
forward second model target to demonstrate inhibition
by miR-33a in K562 cells.
Pim-1 knockdown by the miR-33a mimic versus siRNA
Next, we compared the miR-33a-dependent downregu-
lation of Pim-1 with the knockdown mediated by a
Pim-1-specific siRNA (siRNA1130 directed against
exon 5, Figure 1a). While the siRNA transfection
resulted in a very efficient knockdown of Pim-1 (Figures
4a and b), the reduction in Pim-1 protein levels mediated
by the modified miR-33a mimic was less profound
(Figure 4b). However, the time dependence of Pim-1
knockdown was similar for the Pim-1-specific siRNA
and the miR-33a mimic, with decreased protein levels
already visible after 24 h, a maximum reduction being
reached after 72 h and lower Pim-1 levels still present
at 96 h posttransfection of K562 cells (Figure 4b).
A weaker knockdown by the modified miR-33a mimic
is consistent with the general trend of miRNAs to
repress expression of individual targets more moderately
than siRNAs (Selbach et al., 2008). To evaluate if the
miR-33a target site in the Pim-1 30-UTR can also be
accessed by an siRNA to possibly enhance the Pim-1
knockdown effect relative to miR-33a, we further tested
siRNA 33a fully complementary to the miR-33a target
site. Knockdown efficacy was similar to that caused
by the modified miR-33a mimic, as inferred from
western blot signal intensities (Figure 4c, cf. lanes 2
and 3). We also tested a modified miR-33b mimic but we
were unable to detect any Pim-1 downregulation (data
not shown).
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Figure 2 miRNA profiling in K562 and LS174T cells.
(a) Expression profiling of 10 human miRNAs in K562 cells using
the stem-loop primer reverse transcriptase qPCR technique. Values
are based on Cp values (see Supplementary Information) derived
from three independent experiments each performed in triplicate
(±s.e.m.). (b) Expression profiling for the same set of miRNAs in
LS174T cells. (c) Levels of miR-33a in a set of selected cell lines,
demonstrating its generally low expression.
miR-33a and cancer
M Thomas et al
921
Oncogene
Specificity of miR-33a binding to the Pim-1 30-UTR
To further analyze the repression of Pim-1 expression
by the miR-33a mimic (Figures 3 and 4), we cloned the
30-UTR of Pim-1 into a luciferase reporter vector (pGL3
control). K562 cells were cotransfected with this
construct and either the modified miR-33a mimic,
siRNA 33a targeting the same Pim-1 mRNA sequence
or the modified control mimic. A significant >50%
reduction of luciferase activity was determined for the
modified miR-33a mimic relative to the modified control
mimic (Figure 5, open bars). Compared with the western
blot analysis (Figure 4c), the siRNA 33a was more
efficient than the modified miR-33a mimic in this
reporter assay. This may suggest that either the
luciferase reporter assay is more sensitive than western
blot analysis, or the reporter assay system may some-
what differently respond to targeting by RNAi machi-
neries than the Pim-1 30-UTR in its natural context.
Figure 3 Human Pim-1 is a target for miR-33a. (a) Pim-1 is downregulated by a miR-33a mimic transfected into K562 cells, while
miR-15a and miR-16-1 mimics as well as the control mimic have no measurable effects on Pim-1 expression levels. Total cellular
protein preparations were separated on 15% sodium dodecyl sulfate-polyacrylamide gels and analyzed by western blotting with
antibodies specific to Pim-1 or b-actin used as a loading control. (b) Structure of the unmodified miR-33a mimic tested in (c) next to a
modified mimic obtained from Thermo Scientific Dharmacon; the unmodified miR-33a mimic corresponds to the natural Dicer
processing product of pre-miR-33a, but lacking the 50-phosphates; the miRNA strand is marked by gray letters; open circles indicate
G-U wobble base pairs. (c) Pim-1 knockdown efficacy of the unmodified miR-33a mimic (miR-33a unmod.) was compared with that of
a modified miR-33a mimic and the control mimic by western blotting using total protein extracts from K562 cells. After detection of b-
actin, the membrane was again stripped to detect Cdk6 in the identical samples. The miR-33a mimics had no effect on Cdk6 expression
levels although two miR-33a-binding sites are predicted in the Cdk6 30-UTR by TargetScan 5.1 (Supplementary Figure S2). For further
details, see (a). (d) Western blot analysis performed as in (c), but using LS174T cells. As another control of the miR-33a effect on Pim-
1, the same protein samples were analyzed for the level of p53 recently reported to be a target of miR-33 in mice (Herrera-Merchan
et al., 2010). However, we were unable to detect a significant repression of p53 by miR-33a in LS174T cells, as inferred from several
independent experiments.
Figure 4 Comparison of Pim-1 knockdown by the miR-33a mimic versus a Pim-1-specific siRNA in K562 cells. (a) Knockdown
efficacy of the Pim-1-specific siRNA1130 (Figure 1a) over mock-transfected (—) cells or negative control siRNA (VR1 siRNA), see
Supplementary Information. (b) Comparison of the Pim-1 knockdown persistence for the modified miR-33a mimic versus the Pim-1
siRNA, measured 24, 72 and 96 h posttransfection. (c) Comparison of Pim-1 knockdown efficacy upon transfection with the modified
miR-33a mimic (lane 2), the siRNA directed against the miR-33a target site (lane 3) or the Pim-1 siRNA1130 (lane 4). In all three
panels, western blot experiments were conducted with an antibody specific to human Pim-1, and an antibody against b-actin was used
as loading control.
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We further scrutinized the specificity of the observed
miR-33a effect on Pim-1 expression by mutating the
miR-33a seed region in the Pim-1-derived 30-UTR
of the luciferase reporter (from 50-ACAATGCA to
50-ACAGTGCG). Indeed, the repression effects obser-
ved for the modified miR-33a mimic or siRNA 33a were
essentially abrogated in the presence of a mutated seed
region (Figure 5, gray bars).
Ectopic expression of Pim-1 in Skov-3 cells
To further substantiate that miR-33a specifically and
directly represses Pim-1 expression, we transfected the
Pim-1-deficient ovarian cancer cell line Skov-3 with a
human Pim-1 full-length cDNA. Pim-1 overexpression
in Skov-3 cells resulted in Pim-1 western blot signals
comparable to those observed in K562 cells (this also
holds true for transfection of Hek293 cells with the same
cDNA; data not shown). Cotransfection of the Pim-1-
specific siRNA and the modified miR-33a mimic, but
not the control mimic, resulted in Pim-1 downregulation
(Figure 6a). However, a Pim-1 cDNA variant harboring
a mutagenized miR-33a seed (see legend to Figure 5)
remained responsive to the siRNA whose target site was
not affected by the seed mutations, but lost its
responsiveness to the miR-33a mimic (Figure 6b). Like-
wise, a deletion of the entire Pim-1 30-UTR abolished
the observed miR-33a-dependent Pim-1 downregulation
(Figure 6c). Taken together, these findings further
support our conclusion that miR-33a is able to
specifically and directly suppress Pim-1 mRNA
utilization via the identified miR-33a target site in the
Pim-1 30-UTR.
A miR-33a mimic decelerates tumor cell proliferation
To address the biological relevance of the observed miR-
33a effects on Pim-1 expression, we hypothesized that
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Figure 5 MiR-33a-specific regulation of Pim-1 expression.
Reporter assay using a plasmid-based luciferase coding region
fused to the 30-UTR of Pim-1, either containing the wild-type
miR-33a target sequence (wt seed 50-ACAAUGCA, open bars) or a
mutated miR-33a target site (mutant seed 50-ACAGUGCG, gray
bars). K562 cells were cotransfected with the control mimic,
modified miR-33a mimic or siRNA 33a fully complementary to the
mir-33a seed plus 11 nt upstream in the Pim-1 30-UTR. Data
represent mean values derived from at least three independent
experiments; RLU, relative light units (±s.e.m.), normalized to
those obtained with extracts from cells expressing the reporter
mRNA with the wt seed and cotransfected with the control mimic
(first bar on the left).
Figure 6 Effects of the miR-33a mimic and Pim-1 siRNA1491 on
ectopic Pim-1 expression in Skov-3 cells. (a) A full-length Pim-1
cDNA (25–50 ng) was transfected into Pim-1-negative Skov-3 cells
and overexpression of Pim-1 was detected by western blotting.
Cotransfection of the modified miR-33a mimic or Pim-1 siR-
NA1491 (targeting exon 6 in the 30-UTR of Pim-1; see Figure 1a)
resulted in Pim-1 downregulation; con. siRNA, VR1 siRNA;
C-mimic, modified control mimic. (b) Mutagenesis of the miR-33a
target site (mutant seed 50-ACAGUGCG) in the 30-UTR of the
full-length Pim-1 cDNA abrogated Pim-1 downregulation by the
modified miR-33a mimic, but did not interfere with suppression by
the Pim-1-specific siRNA1491; for further details, see (a); for
uniformity, the control and Pim-1 siRNA lanes were interchanged
in position relative to the original western blot, which is indica-
ted by vertical lines. (c) Deletion of the 30-UTR except for the
30-terminal B400 nt in the Pim-1 cDNA, which removes the
binding site for miR-33a, resulted in a loss of Pim-1 down-
regulation by the modified miR-33a mimic; for further details, see
(a); none, no effector siRNA or miRNA transfected. Western blot
experiments in (a–c) were conducted with an antibody specific to
human Pim-1, and an antibody against b-actin was used as loading
control. The same western blot illustrating endogenous Pim-1 levels
in K562 cells is shown in all panels for comparison on the left;
minus sign (c), no transfection with Pim-1 cDNA plasmid; plus
sign, transfected with the Pim-1 cDNA plasmid.
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miR-33a may negatively affect cell proliferation through
reduction of Pim-1, since a previous study (Zhang et al.,
2008) had suggested a direct role of Pim-1 in regulating
K562 cell proliferation. Indeed, under reduced serum
conditions (2% fetal calf serum (FCS)), but not in the
presence of 10% FCS (Supplementary Figure S3a), an
anti-proliferative effect of the miR-33a mimic was
observed in K562 cells (Figure 7a). Consistently, Pim-1
levels in untreated K562 cells were reduced under these
serum starvation conditions (2% FCS; Supplementary
Figure S3b, left two lanes). This may suggest that Pim-1
levels need to fall below a threshold concentration, and/
or that growth factors need to be lacking in the medium,
to make the cells more sensitive towards miR-33a-
mediated Pim-1 repression and thus to allow the
detection of anti-proliferative effects in this cell line. In
LS174T cells, reduced proliferation upon transfection
with the modified miR-33a mimic was already seen in
the presence of 10% FCS (Figure 7b). Again, this could
be attributed to the already lower expression levels of
Pim-1 in LS174T relative to K562 cells (Supplementary
Figure S3b). In line with the more moderate miRNA
effects observed above (see Figure 4b), analysis of K562
and LS174T cell proliferation upon transfection with
Pim-1-specific siRNAs revealed more pronounced
effects relative to those obtained with the modified
miR-33a mimic. This was indicated by strong siRNA-
mediated inhibition of cell proliferation in LS174T cells
(Figures 7d versus b) and in K562 cells already under
10% FCS conditions (Figure 7c).
Cell-cycle analysis after miR-33a- or siRNA-mediated
Pim-1 knockdown in K562 and LS174T cells provided
evidence that a downregulation of Pim-1 results in a
delay of cycle progression at the stage of the G2 to M
phase transition (data not shown), which is in line with a
previous study (Bachmann et al., 2004). This effect was
more pronounced for K562 relative to LS174T cells,
without any effects on apoptosis in both cell lines
(Supplementary Figure S4).
Discussion
In this study, we newly establish miR-33a as a miRNA
with potential tumor suppressor activity and demon-
strate by western blot analysis and reporter assays
(Figures 3–6) that the oncogenic kinase Pim-1 is an
evolutionarily highly conserved, specific and direct
target of miR-33a. Likewise, transfection of a miR-33a
mimic decelerates proliferation in colon cancer and
leukemia cells, and exerts similar effects as Pim-1-
specific siRNAs.
Notably, miR-33a had not been implicated in tumor
progression so far. In the human system, miR-33a and
the second family member miR-33b are encoded in
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Figure 7 Anti-proliferative effects of a miR-33a- or siRNA-mediated Pim-1 knockdown. (a) Proliferation of untreated K562 cells
compared with K562 cells transfected with the modified miR-33a mimic or the control mimic. Cells were cultivated in the presence of
2% FCS. Here, microscopic cell number counts are presented because in this case cell counting gave more reliable results than the
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FCS. The amount of viable cells was determined by the WST-1 assay. (c) Proliferation of K562 cells in the presence of 10% FCS after
transfection with the Pim-1-specific siRNA1130. Cell viability was determined by the WST-1 assay. (d) Proliferation of LS174T cells in
the presence of 10% FCS after transfection with the Pim-1-specific siRNA1491. Data shown in (a–d) represent mean values (±s.e.m.)
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introns of hSREBP-2 (chromosome 22) and hSREBP-1
(chromosome 17), respectively. Both are key transcrip-
tion regulators of genes involved in cholesterol biosynth-
esis and uptake. Recently, it has been reported in two
independent studies that miR-33a/b posttranscription-
ally repress ABCA1, an important positive regulator
of high-density lipoprotein synthesis and reverse
cholesterol transport (Najafi-Shoushtari et al., 2010;
Rayner et al., 2010). Tissue-specific miR-33a/b and
hSREBP RNA levels were found to be tightly corre-
lated, indicating that both intronic miRNAs are
coordinatedly expressed with the pre-mRNA they reside
in (Najafi-Shoushtari et al., 2010). In this context, anta-
gonists of endogenous miR-33 were suggested as a
potential therapeutic strategy to mitigate cardiometa-
bolic diseases.
We have demonstrated that endogenous Pim-1 levels
can be reduced in K562 and LS174T cells by a miR-33a
mimic, siRNA 33a fully complementary to the miR-33a
target site, and most efficiently, by two different siRNAs
targeting other regions of the Pim-1 mRNA. The
knockdown efficiency correlated with the strength of
the inhibitory effect on cell proliferation (‘gene dose
effect,’ see Figures 3, 4 and 7). Thus, these results
confirm previous studies, which had shown that the
reduction of endogenous Pim-1 levels by RNAi nega-
tively affects the proliferation capacity of the human
lung carcinoma cell line H1299, of the prostate cancer
cell line PC-3 and of K562 cells (Zhang et al., 2007,
2008, 2010).
Pim kinases have partially overlapping functions with
the survival kinase Akt (Amaravadi and Thompson,
2005) since (1) both kinases directly phosphorylate and
inactivate the pro-apoptotic Bad protein (Datta et al.,
1997; Aho et al., 2004), (2) both contribute to
maintaining a high rate of protein translation through
phosphorylation and inactivation of the translational
repressor 4EBP1, either directly in the case of Pim-1
(Chen et al., 2005b; Xia et al., 2009), or indirectly via
Tsc2 phosphorylation by Akt, which triggers 4EBP1
phosphorylation via the mTOR complex 1 (Huang and
Manning, 2009); (3) Akt and Pim kinases can activate
nuclear factor-kB-dependent transcription including
that of an array of anti-apoptotic genes (reviewed in
Amaravadi and Thompson, 2005). Thus, Pim kinases
may act at some points as a cellular backup system
for Akt, while supplementing Akt in other pathways
to maintain cell proliferation and survival, such as
during cardioprotection where Pim-1 acts downstream
of Akt signaling (Muraski et al., 2007). We have
demonstrated that the miR-33a target site in the Pim-1
30-UTR is evolutionary strictly conserved, and Pim-1
suppression by miR-33a is direct and specific. This is a
clear indication that Pim-1 is a genuine target of miR-
33a, although we have not yet identified the biological
constellation(s) under which endogenous miR-33a levels
increase to an extent where they effectively repress Pim-1
expression. As discussed before, expression of miR-33a
is rather low and uniform in the cancerous human
cell lines tested here (Figure 2), as it is in various human
normal and cancerous tissues (Najafi-Shoushtari et al.,
2010; Willemijn Gommans, personal communication).
This is also consistent with our finding that miR-33a
levels in human colon samples (matching pairs of
normal and tumor tissue) were very similar between
normal and tumorous tissue (data not shown). This
raises the question under which conditions miR-33a will
be substantially upregulated. Since miR-33a expression
is coupled to hSREBP-2 expression, a key transcription
regulator of genes involved in cholesterol biosynthesis
and uptake, it is not unlikely that cellular miR-33a
upregulation may link cholesterol metabolism to cell
proliferation via miR-33a-mediated repression of
Pim-1. It is conceivable that miR-33a-mediated
suppression of Pim-1 may be relevant in a specialized
biological context such as cardioprotection or embryo-
nic development.
Pim-1 is overexpressed to different extents in tumor
cell lines, for example K562 or LS174T, where cell
proliferation critically depends on the presence of Pim-1.
Furthermore, Pim kinases are overexpressed in a series
of human hematological malignancies and in several
solid tumors. In the normal cellular context, Pim-1 is
weakly or not at all expressed and appears to be
largely dispensable, as inferred from the fact that
knockout mice with a deletion of all three Pim isoforms
(Pim-1, -2, -3) showed only moderate phenotypes
(Mikkers et al., 2004). This qualifies Pim-1 as a
promising target for anti-tumor strategies, for example
through RNAi, since side effects on healthy tissues are
expected to be moderate. In contrast, single knockouts
of Akt isoforms (Akt-1, -2, -3) in mice resulted in
severe phenotypes (Yang et al., 2004). This suggests
that Pim-1 may be a more attractive target than Akt in
tumor therapy.
Beyond the inhibition of Pim-1 on the protein level by
small inhibitors or knockdown via siRNAs, we demon-
strate in this paper that a therapeutic effect may also be
achieved through miR-33a-mediated downregulation of
Pim-1. MiRNAs are estimated to have, on average, up
to 200 targets, which also opens the perspective to
exploit synergistic effects on various targets to efficiently
induce apoptosis and/or cell-cycle arrest in tumor cells.
Indeed, the concept of miRNA replacement therapy has
recently been successfully applied to the tumor suppres-
sing miR-26a in a mouse model of hepatocellular
carcinoma (Kota et al., 2009). This was the first proof-
of-concept study demonstrating that miRNAs can be
used as general anti-cancer compounds. Recently, the
Slack group demonstrated the therapeutic potential of
let-7 (Trang et al., 2009), a miRNA family whose
members map to chromosomal regions frequently
deleted in lung cancer (Calin et al., 2004), providing
another example of miRNA replacement therapy in
cancer treatment. Still, miRNA mimic or anti-miR
strategies may also result in adverse effects, arising from
the capacity of miRNAs to regulate multiple targets.
This may also be true for miR-33a mimics which,
beyond the anti-tumor effect via Pim-1 shown in this
study, may well elicit aberrations of cholesterol meta-
bolism (Najafi-Shoushtari et al., 2010; Rayner et al.,
2010) or exert additional effects on so far unknown
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targets. Thus, while we firmly establish the miR-33a/
Pim-1 axis, the suitability of miR-33a mimics as thera-
peutic molecules remains to be shown and is currently
under investigation in our laboratory. In fact, we
already have experimental data obtained in a s.c. colon
carcinoma xenograft model, showing a significant
reduction in tumor growth upon nanoparticle-mediated
delivery of miR-33a (Ibrahim et al., 2011).
Materials and methods
cDNA
The full-length human Pim-1 cDNA was purchased from
OriGene (Rockville, MD, USA).
miRNA mimics
Modified miRNA mimics (exact structure and modification
pattern not disclosed) were purchased from Thermo Scientific
and were based on the sequence of the natural mature miRNA
single strands:
miR-33a: 50-GUG CAU UGU AGU UGC AUU GCA
miR-15a: 50-UAG CAG CAC AUA AUG GUU UGU G
miR-16-1: 50-UAG CAG CAC GUA AAU AUU GGC G
negative control mimic (C-mimic) sold by Thermo Scientific for
this purpose: 50-UCA CAA CCU CCU AGA AAG AGU AGA
miR-33b: 50-GUG CAU UGC UGU UGC AUU GC
Unmodified miR-33a and miR-33b mimics were purchased
from MWG (Eurofins MWG Operon, Ebersberg, Germany).
Both represent the double-stranded Dicer processing product
of pre-miR-33a and pre-miR-33b as published in miRBase/
release14 (http://www.mirbase.org), but lacking the 50-terminal
phosphates.
siRNAs
siRNAs were purchased from Thermo Scientific:
Pim-1 siRNA1130: 50-GAU AUG GUG UGU GGA GAU
AdTdT (sense) and 50-UAU CUC CAC ACA CCA UAU
CdTdT (antisense);
Pim-1 siRNA1491: 50-GGA ACA ACA UUU ACA ACU
CdTdT (sense) and 50-GAG UUG UAA AUG UUG UUC
CdTdT (antisense);
VR1 siRNA (VsiRNA1; Gru¨nweller et al., 2003) as negative
control siRNA: 50-GCG AUC UUC UAU UCA ACdT dT
(sense) and 50-GUU GAA GUA GAA GAU GCG CdTdT
(antisense);
siRNA 33a (siRNA directed against the miR-33a target site in
the Pim-1 30-UTR): 50-AAA AUG CAC AAA CAA UGC
AdT dT (sense) and 50-UGC AUU GUU UGU GCA
UUU UdTdT (antisense).
Negative control siRNAs for transfection of LS174T cells: a)
siRNA-luc (targets luciferase mRNA): 50 -CUU ACG CUG
AGU ACU UCG AdTdT (sense) and 50-UCG AAG UAC
UCA GCG UAA GdTdT (antisense).
Antibodies
Antibodies against Pim-1 (sc-13513), b-actin (sc-47778), Cdk6
(sc-177), p53 (sc-126), ABCA1 (ab-18180) as well as the
secondary antibodies (sc-2004: goat anti-rabbit IgG HRP-
conjugated; sc-2005: goat anti-mouse IgG HRP-conjugated)
were from Santa Cruz Biotechnology (Heidelberg, Germany)
except for the ABCA1 antibody purchased from Abcam
(Cambridge, UK).
Plasmid construction, seed mutagenesis and luciferase reporter
assay
The full-length Pim-1 cDNA clone was purchased from
OriGene (Cat. No.: SC110975, Accession No.: NM_002648.2
hsa Pim-1 oncogene, vector pCMV6-XL4, vector size 4.7 kb
plus 2.6 kb Pim-1 insert DNA). To construct the plasmid
lacking two thirds of the 30-UTR (including the miR-33a target
site), 1mg of full-length Pim-1 cDNA was digested with the
HindIII fast digest enzyme (Fermentas, St Leon-Roth,
Germany) to remove the B0.9 kbp HindIII/HindIII fragment
of the 30-UTR, followed by vector religation. HindIII cleaves
B50 bp downstream of the Pim-1 stop codon (position
1424 in sequence NM_002648.3, see Figure 1a) and B400 bp
upstream of the poly(A) tail (position 2311). The Pim-1 cDNA
clone containing the mutation in the miRNA-33a target site
was derived from the existing ‘pGL3 control Pim-1 30-UTR
mut 33a plasmid’ (see below). For this purpose, the
latter plasmid was also digested with HindIII, and the B0.9
kbp HindIII/HindIII fragment containing the mutation in
the miRNA-33a site was cloned into the Pim-1 cDNA
clone (from OriGene, see above). The 30-proximal 450 nt
(including the miR-33a seed region) of all Pim-1 cDNA
constructs (full-length wild-type, Pim-1 D 30-UTR and full-
length cDNA with mutated miR-33a seed) were verified by
DNA sequencing.
The 30-UTR of human Pim-1 was cloned into the pGL3
control luciferase reporter vector (Promega, Mannheim,
Germany) via its XbaI site. The 30-UTR was initially amplified
from K562 genomic DNA with the forward primer 50-GCT
CTA GAG CTG TCA GAT GCC CGA GGG and reverse
primer 50-GCT CTA GAG CAA TAA GAT CTC TTT TAT
TCC CCT GT (XbaI sites underlined). Two G-C base pairs
were introduced beyond the XbaI sites for more efficient XbaI
digestion of the PCR product. PCR mutagenesis of the
miRNA-33a target site was carried out according to Brennecke
et al. (2005) using the following primers (sites of mutation
underlined): 50-AAA AAA TGC ACA AAC AGT GCG ATC
AAC AGA AAA GCT; 50-AGC TTT TCT GTT GAT CGC
ACT GTT TGT GCA TTT TTT. Mutations were verified by
DNA sequencing.
A total of 5mg of pGL3 derivatives were cotransfected with
1mg of miRNA mimics per 1 106 K562 cells. After 48 h,
luciferase assays were performed using the Promega Luciferase
Assay System. Briefly, cells were lysed in 100ml lysis buffer,
and 10ml of lysate was mixed with 25 ml substrate solution and
immediately measured with a Safire2 microplate reader
(Tecan, Crailsheim, Germany) in 96-well plates.
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SUPPLEMENTARY MATERIAL 
 
1. Supplementary Materials and Methods 
Cell culture and transfection  
Cell lines (K562, LS174T and Skov-3) were cultivated under standard conditions (37°C, 5% 
CO2 in a humidified atmosphere) in RPMI 1640 medium (K562) or IMDM medium (LS174T 
and Skov-3) containing 10 % FCS (PAA, Cölbe, Germany) unless stated otherwise. For 
transfection of K562 cells with miRNA mimics or siRNAs, cells were electroporated in 4 mm 
cuvettes with a single pulse at 330 V for 10 ms using a BioRad Gene Pulser XCell (Biorad, 
München, Germany). For 1 x 106 cells, 1 µg of the respective mimic or siRNA was used. 
LS174T cells were transfected with miRNA mimics using the INTERFERin siRNA 
transfection reagent (Peqlab, Erlangen, Germany) according to the manufacturer’s protocol. 
Briefly, 1 x 103, 1.5 x 105 or 2.5 x 105 cells were seeded in 96-well, 24-well or 12-well plates, 
respectively, and cultivated under standard conditions. For complexation, 0.25 to 1 µl 
INTERFERin per pmol miRNA mimic was incubated with the RNA in serum-free medium for 
10 min at room temperature. Complexes were added to the wells (5 µl INTERFERin 
complexed with 5 pmol miRNA for 24-well plates, 0.625 µl INTERFERin complexed with 2.5 
pmol miRNA for 96-well plates), followed by incubation for 72 h (time point of the 
determination of knockdown efficacy) or for the time periods indicated in Fig. 7 of the main 
manuscript (proliferation assays). For the experiment in Fig. 3 of the main manuscript, 
LS174T cells were transfected with miRNA mimics using LipofectamineTM 2000 (Life 
Technologies Invitrogen, Karlsruhe, Germany). The day before transfection 0.5 x 106 cells 
were seeded into 12-well plates. 40 pmol RNA and 2 µl LipofectamineTM 2000 were mixed in 
Opti-MEM® 1 (Invitrogen, Karlsruhe, Germany) according to the instructions of the 
manufacturer and added to the cells. After 4 to 6 h, the transfection medium was aspirated 
and IMDM + 10% FCS was added. Cells were lysed 48 h after transfection. 
For transfection of Skov-3 cells, 1 x 105 cells were seeded into 12-well plates. 2 µl 
LipofectamineTM 2000, 25 ng of Pim-1 cDNA plasmid  (full-length wild-type cDNA, full-length 
cDNA with mutagenized miR-33a seed, or a truncated cDNA with about two-thirds of the 3'-
UTR deleted) and 20 pmol siRNA or miRNA mimic were mixed in Opti-MEM® 1 (Life 
Technologies Invitrogen, Karlsruhe, Germany)  according to the instructions of the 
manufacturer and added to the cells. Cells were lysed 48 h after transfection and analyzed 
by Western blotting. 
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Quantitative RT-PCR for miRNA profiling 
Small RNAs (< 200 nt) were isolated using the mirVanaTM miRNA isolation kit from Ambion 
(Applied Biosystems, Darmstadt, Germany). For RT-PCR experiments, 100 ng of a mirVana 
RNA preparation was used. Reverse transcription was conducted using the Fermentas 
RevertAidTM H Minus First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Roth, Germany) 
with 100 ng of a mirVanaTM RNA preparation. Quantitative PCR (55 cycles) was performed 
in duplicate in a LightCycler®2.0 from Roche (Mannheim, Germany) with the AbsoluteTM 
QPCR SYBR® Green Capillary Mix (Thermo Scientific, Hamburg, Germany). All procedures 
and reactions were carried out according to the protocols provided by the manufacturers.  
For the reverse transcription step, a miRNA-specific stem-loop primer (= looped 
primer) was used (5 pmol in 20 µl reaction volume) to generate the cDNA according to Chen 
et al. (2005). Stem-loop primers carried a 3’-overhang of 6 or 7 nucleotides complementarity 
to the 3'-portion of the respective mature miRNA sequence. In the quantitative PCR (qPCR) 
following reverse transcription (see above), 1/100 of the cDNA reaction was amplified in a 
LightCycler® 2.0 (Roche Applied Biosciences, Mannheim, Germany), using the AbsoluteTM 
QPCR SYBR® Green Capillary Mix (Thermo Scientific, Hamburg, Germany) and 10 pmol of 
each primer (10 µl reaction volume). Primers, including the stem-loop primers (see above), 
were obtained from Metabion (Metabion, Martinsried, Germany) and designed with Universal 
ProbeLibrary (Roche Applied Biosciences, Mannheim, Germany) according to Chen et al. 
(2005). The qPCR forward primer was a DNA mimic of the respective miRNA sequence 
(www.mirbase.org), but lacking the 3’-terminal 6 or 7 miRNA nucleotides to avoid 
hybridization with the stem-loop primer. The forward primer’s 5’-end was extended by a 
variable number of G and C nucleotides to equalize the Tm values of PCR products to ~ 
60°C. Quantitative PCR assays were conducted as follows: Thermo-StartTM DNA polymerase 
was activated for 15 min at 95°C followed by 40 amplification cycles with a denaturation step 
for 10 s, primer annealing for 20 s at 60°C and amplification at 72°C for 12 s. Subsequently, 
a melting curve was generated for the PCR products; samples were cooled from 95°C to 
65°C (20°C per s), kept at 65°C for 15 s, followed by heating in steps of 0.1°C per second up 
to 98°C. Data were evaluated by determining the crossing point Cp value (= CT value, cycle 
of threshold). This value is defined as the PCR cycle (specified with two decimals) at which 
the fluorescent signal of the reporter dye crosses an arbitrarily placed threshold. Data are 
presented as 2-Cp according to Schmittgen and Livak (2008); to enable the reader to 
reconstruct the data shown in Fig. 2 of the main manuscript, we have added the raw data 
below (Table S1).  
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Primers used for miRNA profiling by the looped-primer technique 
 
hsa-miR-15a 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACAAAC 
qPCR forward primer: 
5'-CGCGCTAGCAGCACATAATG 
 
hsa-miR-16-1 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCCAAT 
qPCR forward primer: 
5'-CGCGCTAGCAGCACGTAAAT 
 
hsa-miR-17 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTACCTG 
qPCR forward primer: 
5'-CGCGCCAAAGTGCTTACAGTG 
 
hsa-miR-20a 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTACCTG 
qPCR forward primer: 
5'-GCCGCGCTAAAGTGCTTATAGTG 
 
hsa-miR-24 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACCTGTTC 
qPCR forward primer: 
5'-CGCGCTGGCTCAGTTCAGCAG 
 
hsa-miR-26a 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGCCTAT 
qPCR forward primer: 
5'-CGCGCTTCAAGTAATCCAGG 
 
hsa-miR-33a 
RT-qPCR stem-loop primer: 
5'-TGGATATCCACACCAGGGTCCGAGGTATTCGGTGTGGATATCCATGCAATG 
(underlined positions: base exchanges relative to the other looped primers listed)  
qPCR forward primer: 
5'-CGCGCGTGCATTGTAGTTG 
unique reverse primer qPCR: 
5'-CACCAGGGTCCGAGGT 
(underlined positions: base exchanges relative to the universal reverse primer specified at 
the end of this primer list) 
 
hsa-miR-33b 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGAATG 
qPCR forward primer: 
5'-CGCGCGTGCATTGTTCTTG 
 
 
 - 4 - 
hsa-miR-144 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGTACAT 
qPCR forward primer: 
5'-GCGCGCGCTACAGTATAGATG 
 
hsa-miR-374a 
RT-qPCR stem-loop primer: 
5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACTTAT 
qPCR forward primer: 
5'-GCCGCGCTTATAATACAACCTG 
 
universal reverse primer qPCR: 
5'-GTGCAGGGTCCGAGGT 
 
Western blotting 
Cells were resuspended in lysis buffer (125 mM Tris-HCl pH 6.8, 4 % SDS, 1.4 M 2-
mercaptoethanol, 0.05 % bromophenol blue) and heated at 95°C for 5 min. Lysed samples 
were directly loaded onto 15% SDS-polyacrylamide gels using the BioRad Mini-PROTEAN® 
3 cell mini gel system (BioRad, München, Germany) and run for 1 h at 180 V. Proteins were 
transferred to an ImmobilonTM-P PVDF membrane (Millipore, MA, USA) for 90 min at 1 mA 
per cm2 of membrane area using an EBU-4000 Semi-Dry Blotting System CE (C.B.S. 
Scientific, CA, USA). Primary and secondary antibodies were diluted in TBST (10 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20) 1:500 (Pim-1), 1:2000 (Cdk6), 1:10000 or 
1:1000 (ß-Actin), 1:1000 (p53), 1:1000 (ABCA1) and 1:5000 (secondary antibodies). After a 
final washing step, blots were incubated with Amersham ECLTM or ECLplusTM Western 
Blotting Detection Reagents according to the manufacturer’s protocol. For detection of 
chemiluminescence, Kodak® BioMaxTM light films, Kodak GBX Developer and Replenisher 
and GBX Fixer and Replenisher were used.  
Proliferation assays  
To determine the number of viable K562 cells as a measure of cell proliferation, 1 x 104 cells 
were seeded in 1.5 ml RPMI 1640 (plus 10% FCS) and cultivated under standard conditions. 
At the time points indicated, cells were pelleted and resuspended in 100 µl PBS, and 10 µl of 
the tetrazolium salt WST-1 were added to determine the activity of mitochondrial 
dehydrogenases. After incubation at 37°C for 2 h, absorbance was measured at 450 nm with 
600 nm as reference wavelength using a Safire2TM microplate reader. Alternatively, K562 
cells (0.1 –0.5 x 106 cells/ml) were counted at the indicated time points in a Neubauer 
chamber (Lauda-Königshofen, Germany). 
For the assessment of LS174T cell proliferation, 1 x 103 cells per well were seeded in 96-
well plates and transfected using INTERFERin as described above. At the time points 
indicated, the medium was aspirated and 50 µl WST-1, diluted 1:10 in serum-free medium, 
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was added to the cells. After incubation for 1 h at 37°C, absorbance at 450 nm was 
measured using a Dynex MRX microplate reader (Pegasus Scientific Inc., Rockville, MD, 
USA).  
 
Apoptosis assays 
For K562 cells, the Cell Death Detection ELISA (Roche Applied Biosciences, Mannheim, 
Germany) was utilized. Microtiter plates were pre-coated with an anti-histone antibody (clone 
H 11-4), incubated with lysed cells, followed by the addition of an anti-DNA antibody (clone 
MCA–33) and incubation for 90 min. For detection of mono- and oligonucleosomes, an 2,2'-
Azinobis-3-ethylbenzthiazolin-6-sulfonic acid (ABTS) substrate solution was applied. 
Absorbance was measured with a Safire2TM microplate reader at 405 nm. 
To determine the apoptosis in LS174T cells, the Caspase-Glo® 3/7 Assay (Promega, 
Mannheim, Germany) was used acccording to the manufacturer’s protocol. Briefly, 1 x 103 
cells per well were seeded in 96-well plates and transfected as described above. After 120 h, 
the caspase Glo® 3/7 substrate was diluted 1+1 in serum-free medium and 100 µl were 
added to the cells prior to incubating for 1 h at room temperature. For the detection of 
caspase activity, luminescence was measured using a FLUOstar OPTIMA microplate reader 
(BMG Labtech, NYC, USA). Readings from caspase 3/7 measurements were normalized to 
cell densities. 
 
2. Supplementary Results 
Other potential miRNA binding sites in the Pim-1 3’-UTR 
We excluded miR-124/506 as a serious candidate for regulation of Pim-1 mRNA translation 
in K562 and LS174T cells, because miR-124 is mainly expressed in the brain and involved in 
neurogenesis and neuronal differentiation (Cheng et al. 2009; Makeyev et al., 2007). 
Additionally, the miR-124 target site in Pim-1 is not well conserved upstream of the seed 
region between vertebrates (human to chicken) (see Fig. S1). Likewise, we disregarded miR-
26a/b because the loop adjacent to the seed pairing as well as the second pairing region 
deviate from the Grimson rules (Fig. S1), although the target site is well conserved and the 
context score percentile was relative high (88 for miR-26a relative to 98 for miR-33a); 
however, Pim-1 was ranked (total context score -0.31) by TargetScan 5.1 below the most 
favorable 200 conserved targets of miR-26a. miR-24, reported to suppress translation of the 
tumor suppressor p16 (Lal et al., 2008), was not considered either as a primary candidate for 
Pim-1 suppression based on the relatively low context score percentile (77) and an overall 
weak conservation of its target site (Fig. S1). miR-144 (percentile 93) was not further 
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considered because target site conservation included mouse, rabbit and dog, but not 
chicken.   
 
3. Supplementary Figure Legends 
Figure S1: Phylogenetic conservation of predicted miRNA binding sites in the 3‘-UTR of 
Pim-1. The phylogenetic conservation based on alignment of sequences from human, 
mouse, rabbit, dog and chicken (except for miR-144, where the chicken sequence was 
excluded because of low conservation) is illustrated by weblogos. For comparison, weblogos 
for two established conserved miRNA target sites are shown at the bottom (let-7a in the 
Lin28 3’-UTR, and miR-15/16 in the Bcl2 3’-UTR). For miR-26a/b, although showing strong 
target site conservation based on the weblogo, the sequence alignment on the right revealed 
no clearly unpaired region adjacent to the seed. 
Figure S2: miR-33a target sites in the Cdk6 3‘-UTR as predicted by TargetScan 5.1 with 
context score percentiles of 98 and 20 respectively. Both sites are only moderately 
conserved in the region immediately upstream of the seed. For details, see legend to Fig. 1 
B, C of the main manuscript. 
 
Figure S3: (A) Two independent experiments monitoring the growth of K562 cells in the 
presence of 10% FCS after transfection with the modified miR-33a mimic relative to the 
control mimic and untreated cells. No inhibitory effect of the miR-33a mimic was observed 
under these conditions. (B) Cultivation of K562 cells in the presence of 2% FCS leads to 
reduced expression levels of Pim-1 compared to cells grown under normal growth factor 
conditions (10% FCS). For comparison, Pim-1 levels in LS174T cells grown in the presence 
of 10% FCS are shown. ß-Actin was used as a loading control. For details on Western blot 
methodology, see Supplementary Materials and Methods above. 
 
Figure S4: (A) Test for changes in apoptosis (inferred from quantitation of DNA 
fragmentation) upon Pim-1 knockdown (24 h posttransfection) in K562 cells. Cells were 
transfected with the Pim-1-specific siRNA1130 (Fig 1 A), a sequence-unrelated control 
siRNA (VR1 siRNA) or without any siRNA. No substantial changes in apoptosis were 
observed up to 96 h posttransfection (data not shown). (B) Test for changes in apoptosis 
(inferred from caspase activity) upon Pim-1 knockdown (120 h posttransfection) in LS174T 
cells. Caspase activity was normalized to values measured for cells transfected with the 
control siRNA. Values in panels A and B represent the mean (± SEM) of three (panel A) or 
nine (panel B) independent experiments.  
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miRNA profilings (MV = mean value; NTC = non-template control = no RNA added; no 
RT = omission of Reverse Transcriptase) 
K562 
miRNA 
MV 1 
Cp 
MV 2 
Cp 
MV 3 
Cp 
MV 
Cp 
SEM 
Cp 
no RT NTC 
hsa-
miR-
15a 
20.25 19.59 19.55 19.80 0.227 - >35 
hsa-
miR-16-
1 
18.07 17.54 17.81 17.81 0.153 >35 33.5 
hsa-
miR-17 
15.03 15.00 15.13 15.05 0.039 24.32 28.58 
hsa-
miR-
20a 
16.11 15.14 14.44 15.23 0.484 - - 
hsa-
miR-24-
1 
18.73 19.38 20.16 19.42 0.413 26.53 27.6 
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hsa-
miR-
26a 
19.39 18.72 19.34 19.15 0.216 31.77 31.45 
hsa-
miR-
33a 
23.27 21.59 21.72 22.19 0.540 - >35 
hsa-
miR-
33b 
- - - - - - - 
hsa-
miR-
144 
25.56 24.67 23.54 24.59 0.585 - - 
hsa-
miR-
374a 
23.59 22.49 22.61 22.89 0.348 30.97 30.63 
 
 
LS 174T 
miRNA 
MV 1 
Cp 
MV 2 
Cp 
MV 3 
Cp 
MV 
Cp 
SEM 
Cp 
no RT NTC 
hsa-
miR-
15a 
20.77 19.35 21.56 20.56 0.647 - - 
hsa-
miR-16-
1 
17.51 17.18 18.81 17.83 0.498 - 34.63 
hsa-
miR-17 
17.69 17.12 18.37 17.73 0.361 27.97 27.58 
hsa-
miR-
20a 
18.68 17.96 19.63 18.76 0.484 >35 - 
hsa-
miR-24-
1 
18.04 18 19.54 18.53 0.507 28.35 27.84 
hsa-
miR-
26a 
19.91 19.1 20.73 19.91 0.471 25.69 26.33 
hsa-
miR-
33a 
23.18 21.41 22.62 22.40 0.522 - - 
hsa-
miR-
33b 
- - - - - - - 
hsa-
miR-
144 
- - - - - - - 
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hsa-
miR-
374a 
24.17 23.68 25.66 24.5 0.595 31.84 30.55 
 
data miR-33a, different cell lines 
cell 
line 
MV 1 
Cp 
MV 2 
Cp 
MV 3 
Cp 
MV 
Cp 
SEM 
Cp 
no RT NTC 
HEK 
293 
24.30 22.84 23.60 23.58 0.419 - - 
Skov-3 22.55 21.43 21.61 21.86 0.347 - - 
HUH 7 21.77 22.91 21.22 21.97 0.498 - - 
HepG2 21.34 23.61 22.78 22.58 0.663 - - 
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Abstract
MicroRNAs (miRNA) aberrantly expressed in tumors may offer novel therapeutic approaches to treatment.
miR-145 is downregulated in various cancers including colon carcinoma in which in vitro studies have
established proapoptotic and antiproliferative roles. miR-33a was connected recently to cancer through its
capacity to downregulate the oncogenic kinase Pim-1. To date, miRNA replacement therapy has been hampered
by the lack of robust nonviral delivery methods for in vivo administration. Here we report a method of miRNA
delivery by using polyethylenimine (PEI)-mediated delivery of unmodified miRNAs, using miR-145 and miR-33a
to preclinically validate the method in a mouse model of colon carcinoma. After systemic or local application of
low molecular weight PEI/miRNA complexes, intact miRNA molecules were delivered into mouse xenograft
tumors, where they caused profound antitumor effects. miR-145 delivery reduced tumor proliferation and
increased apoptosis, with concomitant repression of c-Myc and ERK5 as novel regulatory target of miR-145.
Similarly, systemic injection of PEI-complexed miR-33a was validated as a novel therapeutic targeting method
for Pim-1, with antitumor effects comparable with PEI/siRNA-mediated direct in vivo knockdown of Pim-1 in the
model. Our findings show that chemically unmodified miRNAs complexed with PEI can be used in an efficient
and biocompatible strategy of miRNA replacement therapy, as illustrated by efficacious delivery of PEI/miR-145
and PEI/miR-33a complexes in colon carcinoma. Cancer Res; 71(15); 5214–24. 2011 AACR.
Introduction
MicroRNAs (miRNA) are highly conserved, small 17 to 25
nucleotide (nt) noncoding RNA molecules which specifically
interact with target mRNAs, thus inhibiting translation or
leading to mRNA cleavage and degradation (1). It is estimated
from in silico analyses that miRNAs can control the expression
of approximately 30% of all proteins in humans (2), and it has
become clear that miRNAs regulate various cellular processes.
Many miRNAs are aberrantly expressed in pathologies such as
cancer, leading to the identification of "miRNA signatures"
characteristic of certain tumors (3). Tumor-specific miRNA
expression profiles are also functionally relevant because
many miRNAs act as tumor suppressors or, to the contrary,
as oncogenes (oncomiRs). For many miRNAs, target genes
have been identified which are relevant in tumorigenesis,
tumor growth, tumor angiogenesis, and metastasis (see ref.
4 for review). Crucial for miRNA specificity is the "seed region"
(nt 2–8); however, owing to this limited sequence, comple-
mentarity miRNAs are capable of simultaneously targeting
different genes. In fact, it is estimated that some miRNAs may
have more than 100 target genes. This translates into a
complex pattern of control of gene expression and suggests
potentially increased efficacies of miRNAs by acting through
different genes and pathways.
The observation of pathologically decreased levels of cer-
tain miRNAs acting as tumor suppressors has led to the
concept of miRNA replacement therapy. Indeed, the reintro-
duction of miR-26a in a liver cancer mouse model by using an
adeno-associated viral vector resulted in the inhibition of
cancer cell proliferation, induction of tumor-specific apopto-
sis, and protection from disease progression (5). In line with
this, the adenovirus-mediated delivery of a plasmid coding for
miRNA let-7 reduced lung tumor formation in an orthotopic
lung cancer mouse model (6). Likewise, intranasal adminis-
tration of a lentiviral let-7 miRNA construct led to reduced
tumor burden in an autochthonous non–small cell lung
carcinoma tumor mouse model (7). This study also explored
synthetic, formulated let-7 oligonucleotides which, upon
intratumoral (i.t.) injection, led to reduced tumor growth
(7). Local and/or systemic delivery in non–small lung cancer
xenografts showed antitumor effects upon application of miR-
34 formulated with a lipid-based delivery reagent (8). The
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same miRNA exhibited survivin downregulation and reduced
metastatic tumor load in the lung when delivered in a lipo-
somal nanoparticle formulation (9). In prostate tumors
initiated in the bones of mice, intravenously (i.v.) injected
atelocollagen-complexedmiR-16mimics led to reduced tumor
growth (10). Finally, in colorectal carcinoma xenografts, i.t. or
i.v. injection of miR-143 formulated in cationic liposomes
resulted in antitumor effects in the case of modified (for
increased nuclease resistance) miR-143, but not unmodified
miR-145 (11). This so far limited number of studies that are
not based on viruses indicates that applications aiming at
miRNA replacement therapy critically depend on the devel-
opment of miRNA delivery tools. Because viral delivery may
raise several issues including potential safety problems
because of the application of recombinant DNA, induction
of toxic immune responses, and possible changes in gene
expression upon random integration of DNA in the host
genome, nonviral strategies would be preferable.
Colon carcinoma is the third most common form of cancer
and the second leading cause of cancer-related death in the
Western world. Despite a favorable prognosis when detected
at early stages, it is associated with limited survival when
metastatic disease is present, which indicates the need for
novel treatment strategies. In colon carcinoma, decreased
levels of miRNA-145 are observed (see ref. 12), and previous
in vitro studies have established a proapoptotic and antipro-
liferative role of miR-145 (13). In contrast, the functional
relevance of miR-33a in cancer has only recently been estab-
lished. It was shown that miR-33a can repress the proto-
oncogene Pim-1 to act as a tumor suppressor inhibiting cell-
cycle progression (14). Thus, both miRNA-145 and miR-33a
may represent attractive candidates for miRNA replacement
therapy that have not been explored so far.
Polyethylenimines (PEI) are linear or branched polymers
which are partially protonated under physiologic conditions,
thus allowing the formation of complexes with nucleic acids
(15). PEIs have been used previously for the delivery of DNA
plasmids (15) and other DNA or RNA molecules including
ribozymes (16) and siRNAs (17). PEI-based complexes (poly-
plexes) are able to enter the cells via caveolae- or clathrin-
dependent routes and, once internalized, the high efficiency of
PEI polyplexes is governed by their facilitated release from
endosomes due to the so called "proton sponge effect" (18).
This is the first study to explore the therapeutic effects of
PEI/miRNA complexes. We introduce the low molecular
weight branched PEI F25-LMW (19, 20) as a delivery platform
for nonmodified miRNAs in miRNA replacement therapy and
show antitumor effects of PEI/miRNA complexes upon their
local or systemic application.
Materials and Methods
miRNAs, siRNAs, tissue culture, and animals
Chemically synthesized miRNAs and siRNAs without mod-
ifications were purchased from MWG (Eurofins MWG
Operon) or from Thermo Scientific. The used miRNAs repre-
sent the double-stranded Dicer processing product as pub-
lished in miRBase/release14 (21), but lacking the 50-terminal
phosphates. Additional details and sequences can be found in
the Supplementary Methods.
All cell lines were obtained from the American type culture
collection and authenticated by the vendor. Cells were culti-
vated in a humidified incubator under standard conditions
(37C, 5% CO2) in keratinocyte-SFM medium (Invitrogen
GmbH) supplemented with 20 to 30 mg/mL bovine pituitary
extract, 0.1 to 0.2 ng/mL rEGF, and 10% fetal calf serum (FCS;
PAA; 1205LU cells) or IMDM/10% FCS (all other cell lines).
Athymic nude mice (nu/nu) were purchased from Harlan
Winkelmann and kept at 23C in a humidified atmosphere
with food and water ad libitum. Animal studies were done
according to the national regulations and approved by the
Regierungspr€asidium Giessen, Germany.
PEI complexation of RNAs
PEI F25-LMW/miRNA complexes were prepared essentially
as described previously for siRNAs (20, 22). Briefly, 10 mg
miRNA was dissolved in 75 mL 10 mmol/L HEPES/150
mmol/L NaCl, pH 7.4, and incubated for 10 minutes. Ten
microliters of PEI F25-LMW (5 mg/mL) (19) was dissolved in 75
mL of the same buffer, and after 10 minutes, pipetted to the
miRNA solution. This resulted in an N/P ratio ¼ 33 which had
been determined as optimal for siRNAs (20). For in vivo
experiments, the mixture was divided into aliquots and stored
frozen (23). Prior to use, complexes were thawed and incu-
bated for 1 hour at room temperature. jetPEI complexation
was done in 1 mol/L HEPES/150 mmol/L NaCl, pH 7.4 at
N/P ¼ 5 as described previously (22).
miRNA tissue uptake in vivo
For the radioactive determination of miRNA tissue distri-
bution, 0.6 mg (0.05 nmol) miRNA were [32P] end–labeled at
both strands by using T4 polynucleotide kinase (New England
Biolabs) and g-[32P] ATP (GE Healthcare), prior to purification
by microspin columns (Bio-Rad) to remove unbound radio-
activity and complexation as described above. A total of 1.5 
106 LS174T cells in 150 mL PBS were injected s.c. into both
flanks of athymic nude mice (nu/nu) and grown until they
reached a size of approximately 8 mm in diameter. The
complexes, or noncomplexed labeled miRNAs as negative
control, were dissolved in 200 mL or 100 mL PBS for intraper-
itoneal (i.p.) or i.v. injection, respectively. After 4 hours, mice
were sacrificed, organs were removed, and subjected to RNA
preparation as described above. The total RNA was dissolved
in 200 mL DEPC-treated water, and 10-mL samples were mixed
with loading buffer, heat denatured, and subjected to agarose
gel electrophoresis before blotting and autoradiography (Bio-
max; Eastman-Kodak). Quantitation was done by phosphor-
imager analysis.
PEI F25-LMW/miRNA treatment in subcutaneous tumor
models
Athymic nudemice (Hsd:Athymic Nude-Foxn1nu, 6–8 weeks
of age) were used and kept in tight cages with standard rodent
chow and water available ad libitum, and a 12-hour light/dark
cycle. A total of 1.5  106 LS174T or HCT116 cells in 150 mL
PBS were injected s.c. into both flanks of the mice. When solid
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tumors were established, mice were randomized into specific
treatment, negative control treatment, and nontreatment
groups (n ¼ 12 tumors per group). Treatment with PEI/
miRNA or PEI/siRNA complexes was done by i.p. injection
of 0.77 nmol (10 mg) or i.t. injection of 0.3 nmol (4 mg) PEI F25-
LMW-complexed specific or nonspecific siRNA at the time
points indicated in the figures. Tumor volumes were mon-
itored every 2 to 3 days as indicated in the figures and, upon
termination of the experiment, mice were sacrificed and
tumors removed. Pieces of each s.c. tumor were immediately
fixed in 10% paraformaldehyde for paraffin embedding or
snap-frozen for RNA preparation or Western blot analysis.
Proliferation and soft agar assays
For the assessment of anchorage-dependent proliferation,
cells were seeded 24 hours prior to transfection in 96-well
plates at 1,000 (LS174T) or 300 (HCT-116) cells per well.
Transfections were done by the addition of the specific or
nonspecific PEI F25-LMW/miRNA or jetPEI/miRNA com-
plexes corresponding to 10 pmol miRNA per well. At the
time points indicated, the numbers of viable cells in 8 wells
were determined by using a colorimetric assay according to
the manufacturer's protocol (Cell Proliferation Reagent
WST-1; Roche).
Anchorage-independent proliferation was studied in soft
agar assays essentially as described previously (24). A total of
1 105 cells per well were transfected in 6-well plates with 100
nmol/L PEI-complexed miRNAs or nonspecific control siRNA
and 24 hours after transfection, trypsinized and counted. A
total of 20,000 cells in 0.35% agar (Bacto Agar; Becton Dick-
inson) were layered on top of 1 mL of a solidified 0.6% agar
layer in a 35-mm dish. Growth media with 2% FCS were
included in both layers. After 2 to 3 weeks of incubation,
colonies more than 50 mm in diameter were counted by at
least 2 independent blinded investigators.
Caspase assay and fluorescein isothiocyanate–Annexin
assay
To test for apoptosis in vitro, a commercially available
bioluminescent caspase-3/7 assay (Caspase-Glo 3/7 assay;
Promega) was applied. The Caspase-Glo 3/7 assay was con-
ducted in 96-wells with cells transfected as described above,
and luminescence was measured after 1 hour incubation at
27C in the dark by using a Fluostar Optima reader (BMG
Labtec). To normalize for differences in cell densities, a WST-1
assay was carried out in parallel on the same plate, and the
results of caspase activity were adjusted to cell numbers of the
different cell lines.
To distinguish between early and late apoptosis, a fluor-
escein isothiocyanate (FITC)–Annexin assay was done (Bec-
ton Dickinson). LS174T cells were transfected with 100 nmol/L
miRNAs in 6-well plates by using jetPEI as described above.
After 120 hours, the cells were harvested by trypsinization,
washed twice with cold PBS, and resuspended in 1 binding
buffer (0.01 mol/L HEPES (pH 7.4), 140 mmol/L NaCl, and 2.5
mmol/L CaCl2) at a concentration of 10
6 cells/mL. A total of
100 mL of the cell suspension were transferred to a new
Eppendorf tube, 5 mL FITC–Annexin and then 5 mL propidium
iodide were added, the mixture was gently vortexed and
incubated for 15 minutes at room temperature in the dark.
Directly before measurement, 400 mL 1 binding buffer was
added to the mixture and samples were measured by FACS
(FACSCalibur; Becton-Dickinson) within 1 hour.
RNA preparation and quantitative RT-PCR for mRNA
and miRNA dectection
Total RNA from tumor cells was isolated by using the Trizol
reagent (Sigma) according to the manufacturer's protocol. For
tissue homogenization prior to RNA preparation, tissues were
mixed with 200 mL Trizol reagent and homogenized. Reverse
transcription (RT) by using the RevertAid H Minus First
Strand cDNA Synthesis Kit from Fermentas and quantitative
PCR in a LightCycler from Roche by using the QuantiTect
SYBR Green PCR kit (Qiagen) were done according to the
manufacturers’ protocols and as described previously (20). To
normalize for equal cDNA amounts, PCR reactions with ERK5-
specific and with actin-specific primer sets were run in parallel
for each sample, and ERK5 levels were determined by the
formula 2CP(actin)/2CP(ERK5) with CP ¼ cycle number at the cross-
ing point (0.3).
To isolate miRNA, the mirVana miRNA isolation kit was
used according to the manufacturer's protocol (Applied Bio-
systems). Adherent cells from a 6-well plate were trypsinized
and washed in PBS, prior to adding 300 to 600 mL lysis binding
buffer and vigorous vortexing. In case of tumor tissue, the lysis
binding buffer was added as 10 volumes of the tumor weight.
For miRNA RT, specific stem-looped RT primers were used as
described previously (25). The RT product was diluted 1:10 in
nuclease-free water and used as a template for quantitative
real-time PCR (see Supplementary Methods for primer
sequences) under the following conditions: 95C for 15 min-
utes followed by 55 cycles comprising 95C for 10 seconds,
55C for 10 seconds, and 72C for 10 seconds. Levels were
determined as described above.
Western blots and immunohistochemistry
LS174T cells from 6-well plates were scraped at 96 hours
posttransfection, lysed in 200 mL denaturating lysis buffer, and
sonicated for 20 seconds, prior to incubation on ice for 30
minutes and centrifugation at 13,000 rpm for 25 minutes.
Tumor tissue was homogenized in radioimmunoprecipitation
assay buffer [25 mmol/L Tris-HCl (pH 7.6), 150 mmol/L NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS] by using a
Dounce homogenizer. After centrifugation and determination
of the protein concentration in the supernatant, samples were
analyzed byWestern blotting (see Supplementary Methods for
details).
Immunohistochemical staining of paraffin-embedded sec-
tions for proliferating cell nuclear antigen (PCNA) was done
essentially as described previously (ref. 20; see Supplemen-
tary Methods for details). For the assessment of prolifera-
tion, the PCNA staining intensity after diaminobenzidine
development was evaluated in at least 5 fields per section by
rating as 0 (no staining), 1 (weak staining), 2 (intermediate
staining), and 3 (strong staining), and expressed as PCNA
score.
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ELISA
For the quantitation of Pim-1 by sandwich ELISA, the "Pim-
1 Total Antibody Pair" and buffers (Invitrogen) were used. The
procedure was done according to manufacturer's protocol
(see Supplementary Methods), with 100 mL supernatant from a
tumor sample (homogenized in PBS and centrifuged at 13,000
rpm) being analyzed per well.
Statistics
Statistical analyses were done by Student's t test, 1-way
ANOVA/Tukey's multiple comparison posttests or 2-way
ANOVA/Bonferroni posttests by using GraphPad Prism4,
and significance levels were *, P < 0.05, **, P < 0.01, ***, P <
0.001, #, not significant.
Results
Analysis of miR-145 levels in tumor cells
Levels of miR-145 were assessed in various tumor cell lines
and compared with the nontumor fibroblast cell line NIH/3T3
(Supplementary Fig. S1). Although our data confirm previous
studies about the downregulation of miR-145 in tumors (12,
26, 27), we also show that miR-145 levels depend on the cell
line. This is particularly true for prostate carcinoma cells with
levels being very low in DU-145 cells, whereas in PC-3 cells,
almost normal levels were observed. Likewise, 1205LU mela-
noma cells showed high miR-145 expression almost in the
range of nontumor cells. Notably, all 7 colon carcinoma cell
lines tested displayed low miR-145 levels, indicating that miR-
145 downregulation is a general feature in colon carcinoma
and relevant to the pathologic state of such tumors. For
subsequent experiments, the tumorigenic colon carcinoma
cell line LS174T and the particularly aggressive cell line HCT-
116 were selected.
PEI-mediated miRNA delivery in vitro
To explore whether PEI is able to deliver miRNAs into cells,
PEI complexes based on linear jetPEI or branched PEI F25-
LMW were prepared. Transfection of LS174T cells with PEI/
miRNA complexes led to more than 10-fold increase in
intracellular miR-145 levels, indicating that the intact miRNA
is efficiently delivered into the cells (Fig. 1A). JetPEI was used
in these experiments, because in vitro, it displays higher
transfection efficacy in this cell line than the branched PEI
F25-LMW (data not shown). More importantly, PEI-mediated
miRNA transfection led to markedly more than 60% reduced
cell proliferation as compared with nontransfected or negative
control transfected cells (Fig. 1B). As negative control, a small
dsRNA molecule with length, structure, and GC content
similar to that of the miRNAs studied here and directed
against an irrelevant gene (luciferase) was employed, and
complexed with PEI under identical conditions. The specific
inhibition of cell proliferation confirms the biological rele-
vance of miR-145 in colon carcinoma cells in vitro and shows
that PEI-complexed miRNAs are functionally active. Results
were confirmed in soft agar assays which monitor anchorage-
independent cell growth. Again, a marked reduction in cell
proliferation, as indicated by fewer and smaller colonies, was
observed upon PEI-mediated miRNA delivery (Fig. 1C). The
comparison between nontransfected and negative control
transfected cells also shows the absence of nonspecific PEI
effects on proliferation (Fig. 1B and C).
The tumor cell inhibition resulting from the PEI-mediated
miR-145 delivery was studied in more detail on the cellular
and molecular level. In a fluorescence-activated cell sorting
(FACS)-based FITC–Annexin assay, a more than 2-fold
increase in early-stage and late-stage apoptotic cells was
observed upon PEI/miR-145 treatment as compared with
negative controls (Fig. 1D). The parallel increase in cas-
pase-3/-7 activation (Fig. 1E) indicated that this induction
of apoptosis relied on a caspase-3/-7–dependent pathway. In
addition, PEI/miR-145 treatment interfered with downstream
signal transduction relevant to proliferation. More specifically,
a decrease in ERK5 protein expression was observed; a parallel
reduction in ERK5 mRNA levels was less pronounced and
lacked statistical significance (Fig. 1F). Although miR-143 (see
below) has been shown previously to directly target ERK5 (28),
this establishes for the first time that ERK5 is modulated by
miR-145 as well.
miR-143 belongs to the samemiRNA family as miR-145 and
has been shown to be downregulated along with miR-145 in
tumors including colon carcinoma (29). Indeed, when mon-
itoring anchorage-independent growth in soft agar assays,
PEI-mediated delivery of miR-143 inhibited colony formation
similar tomiR-145 (Supplementary Fig. S2, right). Anchorage-
dependent proliferation, however, was not impaired by miR-
143 (Supplementary Fig. S2, left). Thus, whereas miR-143
exerts some tumor cell–inhibiting effects as well, our findings
indicate differences between both miRNAs with regard
to biological effects and targeted pathways as suggested
previously (27). Because of its more universal antitumor
effects, miR-145 was selected for subsequent in vivo
experiments.
Antitumor effects upon systemic application of
PEI/miR-145 complexes
LS174T colon carcinoma cells were s.c. injected into athy-
mic nude mice, and upon establishment of tumor xenografts,
mice were randomized into treatment and negative control
groups. In untreated controls and in mice which were i.p.
injected with PEI/nonspecific RNA complexes as negative
controls, rapid tumor growth was detected, with an approxi-
mately 15-fold increase in tumor volume over 23 days. In
contrast, i.p. injection of 10 mg PEI-complexed miR-145 three
times per week resulted in a statistically significant, almost
50% decrease in tumor growth (Fig. 2A). Upon termination of
the experiment, tumors (see representative examples in
Fig. 2A, right panel) were analyzed for ERK5, which has been
shown in vitro to be downregulated by miR-145 (see above).
Indeed, a statistically significant, that is, approximately 50%
decrease in ERK5 protein levels was detected in the tumors
(Fig. 2B, left), whereas, again comparable with the in vitro
situation, ERK5 mRNA levels remained largely unchanged
(data not shown). This indicates that PEI-delivered miR-145
exerts antitumor effects through inhibition of ERK5 transla-
tion. Strikingly, the PEI/miR-145 effects on c-Myc, another
Therapeutic PEI/miRNA Delivery
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Figure 1. In vitro effects of PEI-mediated delivery of miR-145 in LS174T colon carcinoma cells. A, miR-145 levels are markedly upregulated upon PEI/miR-145
transfection as shown by qRT-PCR. PEI/miR-145 transfection reduces anchorage-dependent growth (B) and anchorage-independent soft agar colony
formation (C). Increased apoptosis upon PEI-mediated miR-145 delivery is observed, as indicated by early-stage (D) and late-stage (E) apoptotic cells, and by
caspase-3/-7 activation (E). ERK5 is established as novel target for miR-145, being downregulated on protein (F, right), but not on mRNA levels (F, left).
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established target for miR-145 (30), were even more profound
with approximately 80% decreased c-Myc protein levels as
compared with negative controls (Fig. 2B, middle). Concomi-
tantly, an approximately 50% reduction in tumor cell prolif-
eration was observed in the specific treatment group (Fig. 2B,
right).
Radioactive biodistribution experiments confirmed that the
observed effects were indeed based on the PEI-mediated
delivery of intact miRNA molecules. Upon i.p. injection of
PEI complexes containing [32P]-labeled miRNA, total RNAs
were prepared from tissues and analyzed by gel electrophor-
esis and autoradiography. This revealed substantial uptake of
miRNA in liver and kidney, among others, and to a lesser
extent in spleen (Fig. 2C, top right panel). Particularly high
levels of intact, full-lengthmiRNAwere observed in the tumor
xenografts (Fig. 2C, top right panel). In contrast, naked
miRNAwas detectable, though, at very low levels in the tested
tissues, indicating the necessity for miRNA formulation with
PEI (Fig. 2C, top right panel). The quantitation of miRNA
bands and normalization for protein content confirmed the
PEI-mediated miRNA delivery into the xenografts (Fig. 2C,
left). To the contrary, i.v. injection resulted in strong signals in
liver and spleen, but not in s.c. tumor xenografts, andwas thus
not employed in our experiments (Fig. 2C, bottom right
Figure 2. Antitumor effects of PEI/
miR-145 treatment in s.c. LS174T
colon carcinoma xenograft mouse
models. A, systemic injection of
PEI/miR-145 complexes results in
reduced tumor growth as
compared with untreated or PEI/
RNA negative control–treated
mice. Right: representative
examples of mice after termination
of the experiment. B, tumor-
inhibitory effects of PEI/miR-145
complexes are mirrored by
reduced protein levels of ERK5
(left) and c-Myc (middle), and by
decreased cell proliferation in the
tumor tissue as determined by
immunohistochemical staining for
PCNA (right). Representative
examples of the Western blot data
and of the immunohistochemical
pictures are given. C, gel
electrophoresis and
autoradiography of [32P]
end–labeled miRNA reveals the
delivery of intact full-lengthmiRNA
molecules to various tissues
including liver (Li), kidney (Ki),
spleen (Sp), and tumors (right).
Differences in the biodistribution
are observed between i.p. (top)
and i.v. injection (bottom), with
particularly efficient miRNA
delivery into tumors upon i.p.
administration. The delivery of
intact miRNA is dependent on PEI
complexation because no signals
are observed upon injection of
naked [32P] end–labeled miRNAs.
Left: quantitation of miRNA levels,
on the basis of phosphoimaging,
after i.p. injection.
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panel). This also indicates that the mode of administration
introduces at least some tissue preference of the complexes,
even in the absence of an active ligand-mediated targeting. By
comparing the datawith nakedmiRNAs (Fig. 2C, bottom right
panel), the i.v. injection also confirmed that the detection of
intact miRNAs in a given tissue is dependent on PEI com-
plexation.
Antitumor effects upon local application of
PEI/miR-145 complexes
To further explore the therapeutic applicability of PEI/
miR-145 complexes, a local treatment regimen was tested
next. In these experiments, the particularly tumorigenic
colon carcinoma cell line HCT-116 was selected. Pre-experi-
ments in vitro confirmed that PEI-mediated delivery of miR-
145 exerts antiproliferative effects also in this cell line, as
seen by a less profound, although still statistically significant
approximately 25% to 30% decrease in colony growth in soft
agar assays (Supplementary Fig. S3). Again, the treatment 3
times per week was started after the establishment of tumor
xenografts; however, because PEI complexes were applied
locally, miRNA amounts were reduced to 4 mg. No unwanted
side effects in terms of change in mouse body weight
(Supplementary Fig. S4A, right), behavioral alterations or
other signs of discomfort were observed. Untreated tumors
showed a rapid growth with an approximately 8-fold
increase over 2.5 weeks (Fig. 3A). Reduced tumor growth
was observed in the PEI/negative control RNA group, indi-
cating some nonspecific effects of the PEI complexes upon
local injection (Fig. 3A). A control experiment confirmed the
nonspecific reduction of tumor growth also upon injection
of naked negative control RNA or PEI alone, indicating the
possibility of some local effects of the components of the PEI
complexes (Fig. 3B). Notably, however, the i.t. application of
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Figure 3. Tumor-inhibitory effects
of PEI/miR-145 complexes in s.c.
HCT-116 colon carcinoma
xenografts upon i.t. injection. A,
the local administration leads to
some nonspecific effects of PEI/
negative control RNA complexes
as compared with untreated
controls; more profound effects,
however, are observed in the PEI/
miR-145 treatment group. B,
moderate nonspecific reduction of
tumor growth upon injection of
naked negative control RNA or PEI
alone, indicating the possibility of
some local effects of the
components of the PEI
complexes. C, specific antitumor
effects are reflected by reduced
tumor cell proliferation in the
xenografts as determined by
immunohistochemical staining for
PCNA (right).
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PEI/miR-145 complexes resulted in a very profound tumor
growth inhibition, with tumor volumes in the treatment
group being reduced to approximately 40% or 60% of the
untreated or negative control–treated tumors, respectively
(Fig. 3A). After termination of the experiment, the immu-
nohistochemical analysis of the tumors revealed a marked
antiproliferative effect of the PEI/miR-145 treatment
(Fig. 3C).
Antitumor effects by systemic administration of
PEI/miR-33a complexes
To further substantiate the concept of PEI-mediated
miRNA replacement therapy, we selected a second miRNA,
miR-33a, which we showed more recently to be relevant in the
context of the oncogenic kinase Pim-1 (14). Pim-1 is upregu-
lated in various cancers including lymphoma and colon
carcinoma, is a marker of poor prognosis in prostate carci-
nomas, and has been implicated in early transformation and
tumor progression (31, 32). Importantly, Pim-1 is negatively
regulated by miR-33a. Luciferase assays based on reporter
constructs comprising the luciferase gene and the Pim-1 30-
UTR (untranslated region) revealed a direct effect of miR-33a
on the Pim-1 30-UTR, as indicated by a approximately 50%
inhibition of luciferase activity (Supplementary Fig. S5A, left
panel). This effect was abolished upon miR-33a seed muta-
genesis in the reporter construct (Supplementary Fig. S5A,
right panel), confirming the specificity of this effect. So far,
miR-33a has only been implicated with posttranscriptional
repression of the ATP-binding cassette transporter A1
(ABCA1) resulting in inhibition of cholesterol efflux from
macrophages and maintenance of cholesterol homeostasis
(33, 34). However, PEI-based in vitro transfection of miR-
33a resulted in decreased cell proliferation in colon carcinoma
cells, comparable with PEI/siRNA-mediated Pim-1 knock-
down (Supplementary Fig. S5B). Thus, this establishes an
antiproliferative role of miR-33a and makes it an attractive
candidate miRNA for replacement therapy.
To assess the therapeutic antitumor activity of miR-33a
in vivo, mice bearing s.c. LS174T tumor xenografts were
treated by i.p. injection of PEI/miR-33a complexes. The
systemic PEI/miR-33a treatment starting upon establish-
ment of the tumors at day 7 after cell injection resulted
in a statistically significant, that is, approximately 40%
reduction of tumor growth as compared with negative
control PEI/RNA-treated mice (Fig. 4A). Similar results were
obtained upon PEI-mediated delivery of a Pim-1–specific
siRNA (Fig. 4B; see Fig. 4C for representative mice). Con-
comitantly, the analysis of the tumors upon termination of
the experiment revealed an approximately 40% downregula-
tion of Pim-1 in both treatment groups (Fig. 4D). The
analysis of the mouse body weights during the whole treat-
ment period revealed no changes (Supplementary S4A, left),
and no other unwanted side effects in terms of behavioral
alterations or other signs of discomfort were observed. Upon
termination of the experiment, the determination of TNFa
serum levels showed no induction of TNFa, indicating the
absence of an immune response upon PEI/miRNA treatment
(Supplementary Fig. S4B). Likewise, no increase in the
activity of the liver enzymes aspartate aminotransferase
(AST; Supplementary Fig. S4C, left) or alanine aminotrans-
ferase (ALT; Supplementary Fig. S4C, right) were detected,
thus confirming the absence of hepatotoxicity.
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Figure 4. Antitumor effects of systemic PEI/miR-33a treatment in LS174T tumor xenografts as compared with PEI/siRNA-mediated knockdown of Pim-1.
A, systemically injected PEI/miR-33a complexes result in inhibition of tumor growth as compared with negative control–treated mice. B, similar antitumor
effects are observed upon PEI/siRNA treatment for Pim-1 knockdown. C, representative examples of mice. D, analysis of the tumor xenografts upon
termination of the experiment reveals a comparable reduction of Pim-1 levels upon PEI/miR-33a or PEI/Pim-1 siRNA treatment as compared with
negative control treatment.
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Discussion
With the discovery of RNA interference (RNAi), knockdown
strategies have gained increasing interest for the specific
inhibition of pathologically upregulated genes. More recently,
particular miRNAs were found to be aberrantly expressed in
several tumors, favoring tumor development (see ref. 3). The
functional relevance of miRNA dysregulation is supported by
the fact that the repression or reintroduction of a single
miRNA is able to substantially contribute to tumorigenesis,
tumor progression, and/or tumor metastasis, and can corre-
late with tumor differentiation, stage, and prognosis (for
review, see refs. 4, 35). Thus, in the case of upregulation,
miRNAs represent interesting target molecules for inhibition
through miRNA antagonists such as antagomiRs or antimiRs
(36, 37). However, miRNAs are more frequently downregulated
in tumors (38). Although this indicates the usefulness of
miRNA replacement therapy, only a very few studies have
explored this strategy so far. Although the literature onmiRNA
functionality suggests that miRNA effects on a given gene may
be less pronounced than siRNA-mediated knockdown through
RNAi, the major advantage may lie in the fact that a given
miRNA targets many, possibly hundreds of genes, and con-
sequently induces more widespread changes in protein
expression (39). In fact, it is the inherent mechanism of
miRNAs to repress a large number of mRNAs, also in the
case of less than 100% complementarity to the mRNA with
high specificity. Thus, the therapeutic application of a tumor
suppressor miRNA, which is downregulated in tumors, may
indeed entail multiple antitumor effects by specifically inter-
fering with several oncogenic pathways, thus making it more
difficult for tumor cells to activate escape mechanisms. One
feature of this interference is the rather modest effects on any
given single gene, whichmay actually be an advantage because
the subtle regulation of genes is the natural mechanism
and therefore particularly attractive also from a therapeutic
viewpoint.
Our results establish, for the first time, miR-33a as tumor-
relevant miRNA suited for miRNA replacement therapy.
Although miR-33a was previously shown to repress ABCA1,
an important positive regulator of high-density lipoprotein
synthesis and reverse cholesterol transport (33, 34), we have
recently shown that it is able to repress the proto-oncogene
Pim-1, thereby acting as a tumor suppressor (14). Here, we
show antitumor effects of miR-33a delivery in vivo; however, it
will have to be seen if a prolonged treatment may lead to
unwanted other effects related to the other functions of miR-
33a. Future studies with the goal to identify and verify other
miR-33a target genes will help to further scrutinize the suit-
ability of miR-33a for miRNA replacement therapy. To this
end, in silico predictions are insufficient because we found
that, for example Cdk6, although identified by TargetScan 5.1
as another high probability target, is not regulated by miR-33a
(14). Consequently, experimental confirmation is always
needed to firmly establish any regulatory mechanism of
miRNAs. This is also true for miR-145, although several target
genes have already been confirmed (see ref. 13), including c-
Myc. Notably, we newly identify ERK5, which so far had only
been reported as a target for the related miRNA miR-143 (40),
as being directly or indirectly regulated by miR-145.
Still, major limitations of siRNA-mediated therapeutic
knockdown strategies also apply to miRNAs: their protection
upon systemic injection in vivo, efficient delivery to the target
organ, cellular uptake, and intracellular release into the right
compartment. Although certain PEIs have been used pre-
viously for the delivery of other nucleic acids including small
RNA molecules in vitro and in vivo (see refs. 41, 42 for review),
this article establishes for the first time a PEI-based miRNA
replacement therapy. Notably, although several, if not all PEIs
are able to complex and protect nucleic acids, efficient PEI/
miRNA-mediated gene targeting in vivo relies on the sufficient
stability of the complexes as well as favorable pharmacoki-
netic properties and high biocompatibility. Our biodistribu-
tion data show the PEI-dependent delivery of unmodified
miRNAs into the tumors, where intact full-length miRNAs
accumulate. No chemical modifications of the miRNAs are
necessary and thus we avoid the term "miRNA mimics" to
indicate that it is in fact the naturally occurring miRNA
employed here.
The bioactivity and specificity of PEI/miRNA complexes is
shown by their antitumor effects and their inhibition of
specific targets (i.e., downregulation of c-Myc, ERK5, and
Pim-1). The previously observed biocompatibility of PEI
F25-LMW–based complexes (20), even upon repeated injec-
tion, was confirmed in this study also for PEI/miRNA com-
plexes. Notably, they can be stored frozen for a prolonged
time, thus allowing their standardized preparation and injec-
tion as efficient and stable ready-to-use formulations without
the need of processing prior to administration.
The observed antitumor effects and the fact that no
unwanted side effects were detected indicate that the clini-
cally more relevant systemic delivery rather than an only local
delivery (i.t. injection) can be pursued.
Interestingly, we observed that PEI-mediatedmiR-33a deliv-
ery versus PEI/siRNA-induced Pim-1 knockdown led to similar
antitumor effects. This was true despite the fact that onco-
genic lesions commonly result in the simultaneous repression
of many miRNAs (ref. 43), suggesting that more than one
miRNA might be needed for a successful therapeutic inter-
vention. However, previous studies indicated as well that the
delivery of just one miRNA already exerts tumor-inhibitory
effects (5–8, 10, 11). Nevertheless, it should be noted that the
nonviral delivery of miRNAs through PEI complexes easily
allows the combination of several miRNAs, which may result
in additive or synergistic effects. This may well lead to the
development of more personalized treatment strategies by
precisely analyzing miRNA expression profiles in a given
tumor prior to selectively combining miRNAs identified as
being downregulated.
Although miRNA replacement therapy seems to be rather
mild and biocompatible, yet specific and efficient as a
therapeutic strategy, it still requires the careful monitoring
of unwanted specific or nonspecific effects. On the basis of
the rather highly abundant delivery of miRNAs, any miRNA
replacement therapy will have to be tested for RISC satura-
tion, competition with other endogenous miRNAs, or
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overstimulation of a given pathway. Notably, however, the
saturation of various cellular factors, which are required for
the processing of small RNAs and whose saturation can
result in lethal effects (44), is not an issue here because
chemically synthesized mature miRNAs do not require cel-
lular processing prior to RISC incorporation. Thus, miRNAs
may provide better tools than DNA-based expression sys-
tems, as seen already in the case of small RNAs for gene
knockdown (45). Still, any off-target effects of miRNA deliv-
ery will have to be monitored in preclinical studies.
Although, in principal, nonspecific effects are rather unlikely
because the applied miRNA is identical to the physiologically
occurring one and is thus targeting the same mRNAs (as
opposed to siRNAs which do not have natural counterparts),
it has also been shown that off-target effects induced by
certain sequence motifs of synthetic RNAs can be dose
dependent (46). However, the literature on miRNA replace-
ment approaches so far (5, 6, 8, 10), as well as our results
even after prolonged treatment, do not support adverse
effects. The fact that miRNAs exert only moderate effects
on their target genes and are already present and functional
under normal physiologic conditions may account for that.
This may be particularly true for unmodified miRNAs, which
are preferable because they preclude any potentially adverse
effects resulting from chemical modification. Even more,
however, this requires the development of powerful delivery
techniques like PEI complexation which work for unmodi-
fied miRNAs.
Taken together, the PEI-based therapeutic application of
unmodified miRNAs without any chemical modifications
combines several favorable properties: (i) the miRNAs are
identical to their naturally occurring counterparts (i.e., they
are not just "biosimilars," but "bioidenticals") and, simulta-
neously, (ii) they are easy to produce via chemical synthesis.
Previous studies (iii) have established the biocompatibility of
low molecular weight PEIs, which in their linear form are
already employed in clinical studies. The fact that (iv) no DNA-
based expression constructs are employed, avoids safety
issues, for example, related to insertional mutagenesis upon
viral or nonviral delivery of DNAs or overloading of the cellular
dsRNA processing system, and (v) the ability of miRNAs to
target multiple oncogenic pathways predestines them for the
therapy of cancer as a "pathway disease" (47).
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Supplementary Materials and Methods 
 
MiRNAs, siRNAs and primers for miRNA quantitation 
Chemically synthesized miRNAs and siRNAs without modifications were purchased from MWG 
(Eurofins MWG Operon, Ebersberg, Germany) or from Thermo Scientific (Schwerte, Germany). The 
used miRNAs represent the double-stranded Dicer processing product as published in miRBase/ 
release14 (1), but lacking the 5’-terminal phosphates, and had the following sequences:  
miR-33a sense strand: 5'-CAAUGUUUCCACAGUGCAUCAC-3´ 
antisense strand: 5’-GUGCAUUGUAGUUGCAUUGCA-3';  
miR-143 sense strand: 5'-GGUGCAGUGCUGCAUCUCUGGU-3';  
antisense strand: 5'-UGAGAUGAAGCACUGUAGCUC-3' 
miR-145 sense strand: 5'-GUCCAGUUUUCCCAGGAAUCCCU-3';  
antisense strand: 5'-GGAUUCCUGGAAAUACUGUUCU-3'  
Pim-1 siRNA sense: 5’-GGAACAACAUUUACAACUCdTdT-3';  
antisense strand 5’-GAGUUGUAAAUGUUGUUCCdTdT-3´. 
An siRNA directed against an irrelevant gene (luciferase) was obtained from Thermo Scientific and 
used as negative control 
sense strand: 5'-CUUACGCUGAGUACUUCGAdTdT-3';  
antisense strand: 5’-UCGAAGUACUCAGCGUAAGdTdT-3'.  
 
For miRNA reverse transcription, specific stem-looped RT primers were used as described previously 
(2). For quantitation, specific forward and universal primers were used: 
miR-145 forward: 5'-CGCGCGTTCCAGTTTTCCCAGG-3';  
miR-143 forward: CGCGCGTGAGATGAAGCACT-3';  
universal reverse PCR primer: 5'-GTGCAGGGTCCGAGGT-3'. 
 
Western blots and immunohistochemistry 
Samples containing 100 μg protein were separated by SDS-PAGE (15% polyacrylamide gel) and 
transferred onto a nitrocellulose membrane (Protran Nitrocellulose Transfer Membrane 0.45 µm 
Schleicher&Schuell, Dassel, Germany). Membranes were blocked with 5% milk powder in Tris-
buffered saline + Tween (TBST; 20 mM Tris, pH 7.5, 150 mM NaCl, and 0.1% Tween-20) and 
incubated with rabbit polyclonal primary antibodies (anti-c-Myc, 1:500 (Santa Cruz Biotechnology, 
CA, USA), anti-ERK5, 1:1000 (Cell Signalling), or, as loading control, anti--Actin, 1:5000 (Santa 
Cruz Biotechnology)). The blots were then washed in TBST and incubated for 1 h at RT with a 
horseradish peroxidase-coupled donkey anti-rabbit IgG secondary antibody (GE Healthcare Bio-
Sciences, Uppsala, Sweden), diluted 1:2000 in TBST. After washing in TBST, bound antibodies were 
visualized by chemiluminescence (ECL SuperSignal West Pico Kit, Thermo Fisher Scientific, 
 2 
Rockford, IL, USA). Bands were scanned and quantitated using ImageJ (National Institutes of Health, 
Maryland, USA). 
 
Immunohistochemical staining of paraffin-embedded sections for PCNA was performed essentially as 
described previously (3). After deparaffinization with xylene and rehydration with graded alcohols, 
sections were boiled in 1% acetic acid in PBS for 10 min and endogenous peroxidases were 
inactivated with 0.3% hydrogen peroxide at 4°C for 30 min. After blocking with 10% normal horse 
serum in PBST/2% BSA for 1 h at RT, the slides were incubated overnight with mouse monoclonal 
anti-PCNA (proliferating cell nuclear antigen) antibodies (Dako, Hamburg, Germany), diluted 1:200 
in PBST, at RT in a wet chamber. For detection, biotinylated goat anti-(mouse-IgG) antibody (Vector 
Laboratories, Burlingame, CA, 1:500) was applied for 1 h, and immunoreactivity on the sections was 
visualized using a streptavidin-biotin-peroxidase complex (ABC kit, Vector Laboratories) and the 
peroxidase substrate diaminobenzidine (brownish colour) according to the manufacturer's instructions.  
 
ELISA 
The “Pim-1 Total Antibody Pair” and buffers (Invitrogen) were used and the procedure was performed 
according to manufacturer’s protocol. Round bottom Maxisorp 96-well microtiter plates (Nunc) where 
coated overnight at 4°C with 100 µl coating antibody, diluted 1:250 in Coating Buffer B. After 
washing with Washing Buffer and blocking for 1 h at RT with Assay Buffer, 100 µl supernatant from 
a tumor sample (homogenized in PBS and centrifuged at 13,000 rpm) was added per well, followed by 
incubation for 2 h at RT. Wells were then washed five times with Washing Buffer prior to addition of 
100 µl Pim-1 detection antibody, diluted 1:250 in Assay Buffer, followed by incubation for 1 h at RT. 
After another five times washing as above, anti-rabbit-IgG-HRP (1:1000 in Assay Buffer) was added 
and samples were incubated for 30 min at RT. After five times washing, the signal was developed with 
TMB-substrate (R&D) and after 30 min the reaction was stopped with 2N H2SO4. Absorbance was 
measured in a microplate reader at 450 nm with the reference absorbance at 630 nm.  
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 1
Suppl. Figure 1. Expression of miR-145 in various tumor cell lines. All eight tested colon carcinoma 
cell lines display low miR-145 levels as compared to non-tumorous NIH3T3 or some other tumor cell 
lines.  
 
Suppl. Figure 2. In vitro effects of PEI-mediated delivery of miR-143 in LS174T colon carcinoma 
cells. Upon PEI/miR-143 transfection no inhibition of anchorage-dependent proliferation is observed 
(A) while anchorage-independent colony formation in soft agar is reduced by ~ 50% (B).  
 
Suppl. Figure 3. Inhibition of anchorage-independent growth of HCT-116 colon carcinoma cells upon 
PEI-mediated delivery of miR-145, as determined by colony formation in soft agar.  
 
Suppl. Figure 4. Absence of non-specific effects upon PEI/miRNA treatment of mice. (A) Monitoring 
of tumor weights of mice upon repeated i.p. (left) or i.t. injection (right), referring to the experiments 
shown in Figs. 4 and 3, respectively, over the whole duration of the treatment. (B) Change in TNFα 
serum levels at 60 min after PEI/miRNA or lipopolysaccharide (LPS, positive control) treatment, as 
determined by ELISA according to the manufacturer's protocol (ELISA Development Kits from 
Preprotech, Rocky Hill, NJ). (C) Changes in the activity of liver enzymes aspartate aminotransferase 
(AST, SGOT; left) and alanine aminotransferase (ALT, SGPT; right) after four consecutive 
PEI/miRNA treatments (days 1, 3, 5, 8), as determined by enzyme assays (DiaSys Diagnostic 
Systems, Holzheim, Germany) 60 min after the last i.p. injections.  
 
Suppl. Figure 5. Tumor cell-inhibitory effects of miR-33a mediated through Pim-1 inhibition. (A) 
Direct inhibititory effect of miR-33a on the Pim-1 3'-UTR. The transfection of the cells with PEI/miR-
33a inhibits luciferase expression in the reporter construct containing the 3'-UTR of Pim-1 (left), but 
not upon miR-33a seed mutagenesis (right). Luciferase activities were determined 24 h after the co-
transfection of 200 ng reporter plasmid and 1 pmol miRNA or negative control RNA into 100,000 
LS174T cells in 24-well plates, using 1.5 µl jetPrime (Polyplus). (B) Anti-proliferative effects in 
anchorage-dependent growth of LS174T cells upon PEI/miR-33a or PEI/Pim-1 siRNA transfection.  
   Appendix
146 
 
C. Publication III 
PEI-complexed LNA antiseeds as miRNA inhibitors. 
RNA Biology (2012), 9(8), 1088-1098 
Impact Factor: 5.56* 
*RNA Biology (2011), 8(1) 
 
Author contributions: 
Research design: 40 % 
Experimental work: 60 % 
Data analysis and evaluation: 70 % 
Manuscript writing: 30 % 
©
2
0
1
2
 L
a
n
d
e
s
 B
io
s
c
ie
n
c
e
. 
D
o
 n
o
t 
d
is
tr
ib
u
te
RNA Biology 9:8, 1088-1098; August 2012; © 2012 Landes Bioscience
 ReseARch pApeR
1088 RNA Biology Volume 9 Issue 8
*Correspondence to: Roland K. Hartmann and Arnold Grünweller; Email: roland.hartmann@staff.uni-marburg.de and arnold.gruenweller@staff.uni-marburg.de
Submitted: 12/30/11; Revised: 04/24/12; Accepted: 06/19/12
http://dx.doi.org/10.4161/rna.21165
Introduction
Small non-coding RNAs (sRNA), such as miRNAs, are involved 
in the regulation of virtually all essential cellular processes, and 
their deregulation has important implications in pathogen-
esis. The impact of miRNAs on human diseases has been well 
established e.g., in the cancer field (for a review see ref. 1), where 
several miRNAs are either overexpressed in tumors (oncogenic 
miRNAs) or show reduced levels (miRNAs with tumor suppres-
sor activity). This results in the downregulation of tumor sup-
pressor genes or in the upregulation of cellular proto-oncogenes, 
respectively.2 A well characterized and important cellular tumor 
suppressor is the cell cycle regulator p21, which is post-transcrip-
tionally regulated by miRNAs of the oncogenic miR-17–92 clus-
ter.3 Oncogenic miRNAs or miRNA clusters are often found in 
chromosomal regions that are amplified in tumor cells, which 
promotes their overexpression.4,5 For example, the miR-17–92 
cluster is overexpressed in lymphoma as well as in a wide range 
of human solid tumors.6 MiRNAs of this cluster (mainly miR-
17–5p, miR-19 and miR-20a) inhibit apoptosis, promote prolif-
eration and induce tumor angiogenesis.7,8
Antisense inhibition of oncogenic or other disease-related miRNAs and miRNA families in vivo may provide novel 
therapeutic strategies. however, this approach relies on the development of potent miRNA inhibitors and their efficient 
delivery into cells. here, we introduce short seed-directed LNA oligonucleotides (12- or 14-mer antiseeds) with a 
phosphodiester backbone (pO) for efficient miRNA inhibition. We have analyzed such LNA (pO) antiseeds using a let-
7a-controlled luciferase reporter assay and identified them as active miRNA inhibitors in vitro. Moreover, LNA (pO) 14-
mer antiseeds against ongogenic miR-17–5p and miR-20a derepress endogenous p21 expression more persistently than 
corresponding miRNA hairpin inhibitors, which are often used to inhibit miRNA function. Further analysis of the antiseed-
mediated derepression of p21 in luciferase reporter constructs - containing the 3'-UTR of p21 and harboring two binding 
sites for miRNAs of the miR-106b family - provided evidence that the LNA antiseeds inhibit miRNA families while hairpin 
inhibitors act in a miRNA-specific manner. The derepression caused by LNA antiseeds is specific, as demonstrated via seed 
mutagenesis of the miR-106b target sites. Importantly, we show functional delivery of LNA (pO) 14-mer antiseeds into 
cells upon complexation with polyethylenimine (peI F25-LMW), which leads to the formation of polymeric nanoparticles. 
In contrast, attempts to deliver a functional seed-directed tiny LNA 8-mer with a phosphorothioate backbone (ps) by 
formulation with peI F25-LMW remained unsuccessful. In conclusion, LNA (pO) 14-mer antiseeds are attractive miRNA 
inhibitors, and their peI-based delivery may represent a promising new strategy for therapeutic applications.
PEI-complexed LNA antiseeds as miRNA inhibitors
Maren Thomas,1 Kerstin Lange-Grünweller,1 eyas Dayyoub,2 Udo Bakowsky,2 Ulrike Weirauch,3 Achim Aigner,3 Roland K. 
hartmann1,* and Arnold Grünweller1,*
1Institut für pharmazeutische chemie, philipps-Universität Marburg; Marburg, Germany; 2Institut für pharmazeutische Technologie und Biopharmazie, philipps-Universität 
Marburg; Marburg, Germany; 3Rudolf-Boehm-Institut für pharmakologie und Toxikologie, Universität Leipzig; Leipzig, Germany
Keywords: miRNA, miR-17-92, let-7a, antimiR, antiseed, LNA, PEI, p21, cancer
Abbreviations: PO, phosphodiester; 3'-UTR, 3'-untranslated region; LNA, locked nucleic acid; PEI, polyethylenimine; PS, 
phosphorothioate; PEI F25-LMW, polyethylenimine F25 low molecular weight; RLU, relative light units; FCS, fetal calf serum; 
WST-1, water soluble tetrazolium salt 1
Several strategies have been developed to block cellular 
miRNA function, including the use of miRNA sponges, mask-
ing of the mRNA target site or inhibition of miRNAs by anti-
sense oligonucleotides (generally termed antimiRs; for a review 
see ref. 9). For therapeutic intervention the use of antisense strat-
egies against miRNAs has been established in mice and non-
human primates.10,11 However, efficient delivery of antimiRs is 
still the main bottleneck for therapeutic applications. Several 
efforts have been made to deliver antimiRs into cells and tis-
sues, e.g., the conjugation of modified antimiRs with cholesterol, 
which were termed antagomiRs.12 Moreover, important improve-
ments with regard to antimiR efficacy, stability and delivery have 
been achieved by the incorporation of modified nucleotides (for a 
review see ref. 13). In particular, 2'-fluor (2'-F), 2'-oxymethyl (2'-
OMe), 2'-methoxyethyl (2'-MOE) and locked nucleic acid (LNA) 
modifications have been incorporated into antimiRs for in vivo 
applications. So far, the most efficient variants are 2'-F/2'-MOE 
mixmers directed against the complete miRNA guide strand,11,14 
15- or 16-mer LNA/DNA mixmers with 2'-OMe cytosines and a 
phosphorothioate (PS)10,15,16 or phosphodiester (PO) backbone,17 
and tiny LNA 8-mers with a PS backbone.18,19 All these antimiRs 
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antiseeds, and in particular the 14-mer, displayed constant activ-
ity between 5 and 20 nM (Fig. 1D). In the case of the hairpin 
inhibitor, concentrations > 20 nM even caused a further drop 
of luciferase activity to almost zero (0.026 +/- 0.011 or 0.042 
+/- 0.018 at 50 or 100 nM, respectively; data not shown). Since 
cell viability did not seem to be affected by the hairpin inhibitor 
(data not shown), we speculate that the design of hairpin inhibi-
tors23 may favor nucleic acid aggregation at higher concentrations 
when using lipofectamine as the transfection reagent, leading to 
inefficient cotransfection.
We conclude from our results that 12- and 14-mer LNA anti-
seeds containing a PO backbone are active miRNA inhibitors 
with potencies comparable to commercial miRNA hairpin inhib-
itors (Thermo Scientific Dharmacon) which are often used for 
miRNA inhibition. In addition, transfection with lipofectamine 
seems to be more robust with LNA antiseeds than hairpin 
inhibitors.
Derepression of basal p21 levels in K562 cells. The erythro-
leukemia cell line K562 expresses the tumor suppressor protein 
p21 at levels that are barely detectable in western blot analyses, 
although substantial levels of p21 mRNA are present in these 
cells as inferred from RT-qPCR analyses (data not shown). This 
indicates that p21 expression is suppressed on the post-transcrip-
tional level. Recently, it was shown that the p21 mRNA, whose 
3'-UTR harbors two conserved binding sites for miRNAs of 
the miR-106b family, is indeed a target for these miRNAs.3 Of 
note, the oncogenic miR-17–92 cluster encoding three members 
of the miR-106b family, namely miR-17–5p, miR-18a and miR-
20a, is overexpressed in K562 cells.21,25 We therefore anticipated 
that the miR-106b family members miR-17–5p and miR-20a 
repress endogenous p21 mRNA in K562 cells and tested this by 
transfecting 14-mer LNA (PO) antiseeds directed against miR-
17–5p and miR-20a into these cells by electroporation. Indeed, 
both antiseeds caused a substantial increase of p21 protein lev-
els, whereas the all-LNA control 14-mer remained without effect 
(Fig. 2).
Since it was recently shown that LNA antisense effects are 
rather persistent,26 we compared the duration of p21 derepression 
caused by the 14-mer LNA antiseeds 17–5p and 20a with that 
of the respective hairpin inhibitors. 48 h after transfection, all 
antisense molecules gave rise to substantial derepression of p21 
in K562 cells (Fig. 2). However, after 72 h the hairpin inhibitors 
had substantially lost their capacity to derepress p21, while anti-
seed 17–5p derepressed p21 for up to 96 h and antiseed 20a for 
at least 120 h. Even after 168 h a weak derepression of p21 with 
antiseed 20a was still detectable (Fig. 2). Our results on antiseeds 
are consistent with the long-term effects of LNA antisense mol-
ecules described by others.10,19
Specificity of the antiseed effect. Next, we analyzed the spec-
ificity of derepression effects observed with the 14-mer antiseeds 
against miR-17–5p and miR-20a by using luciferase reporter 
assays. For this purpose, the 3'-UTR of p21 and a mutated version 
thereof with both seeds inactivated by two point mutations (Fig. 
3A) were fused to the luciferase coding region. Cotransfection 
(with lipofectamine) of the luciferase reporter plasmid with one of 
the antiseeds, 17–5p or 20a, caused a more profound derepression 
were applied by “gymnotic delivery,”20 i.e., without any formula-
tion. In contrast, the formulated delivery of unconjugated modi-
fied antimiRs into tissues has not been explored so far.
Here we introduce 14-mer LNA (PO) antiseeds as novel 
miRNA inhibitors that are particularly potent and can inhibit 
miRNAs for up to 7 d in cell culture. We have further established 
their complexation with a cationic polymer, the low molecular 
weight polyethylenimine PEI F25-LMW, to enable delivery into 
a broader spectrum of organs and tissues. Since we have shown 
recently that PEI-complexed siRNA or miRNA can be delivered 
into tumor xenografts leading to antitumor effects in mice,21,22 
it will be promising to explore the therapeutic potential of PEI-
complexed LNA (PO) antiseeds.
Results
LNA antiseeds as miRNA inhibitors. The LNA/DNA mixmers 
used so far, as well as the tiny LNA 8-mers described recently,19 
are generally designed with a phosphorothioate (PS) backbone 
that is required for unformulated “gymnotic delivery” in vivo.20 
However, gymnotic delivery cannot be applied to all organs 
and tissues, which is a serious limitation for several therapeutic 
applications. Here, we explored short LNA antiseeds contain-
ing a phosphodiester (PO) backbone. These oligonucleotides are 
complementary to the 5'-terminal seed (nt 1–8) plus the 4–6 sub-
sequent nucleotides of the mature miRNA strand.
As a first experimental approach, we cloned a let-7a target 
sequence in the functional forward orientation into the 3'-UTR 
of a luciferase reporter gene; a luciferase reporter gene with an 
inverted let-7a target sequence placed at the same position served 
as negative control (Fig. 1A). To determine the minimum antiseed 
length for blocking miRNA function, we analyzed the effects of 
8-, 10-, 12- and 14-mer all-LNA (PO) antiseeds directed against 
let-7a (Fig. 1B and C). The luciferase reporter plasmid and LNA 
antiseeds at various concentrations (5, 20, 50 and 100 nM) were 
cotransfected into HeLa cells using lipofectamine and lucifer-
ase activity was measured as an indicator for derepression. Cells 
transfected with the luciferase reporter containing an inverted 
let-7a target site were used as the reference for maximum dere-
pression. The 8- and 10-mer antiseeds showed no or only weak 
derepression activity, whereas the 12- and the 14-mer antiseeds 
efficiently derepressed the luciferase reporter (Fig. 1C). Next, we 
compared the derepression activity of the 12- and 14-mer anti-
seeds with a commercially available miRNA hairpin inhibitor23 
against let-7a (Thermo Scientific Dharmacon). Such hairpin 
inhibitors carry a central single-stranded sequence complemen-
tary to the entire mature miRNA strand and are capped on both 
ends by hairpins consisting of 8-bp stems and apical tetraloops.23 
As negative control, we employed an unrelated all-LNA 14-mer 
directed against the RNA subunit of RNase P from E. coli.24 
When using concentrations less than 10 nM, the 12- and 14-mer 
antiseeds showed derepression activities comparable to the hair-
pin inhibitor, with RLU values reaching approx. 60% of those 
measured for the inverted control (Fig. 1D). At 10 nM or 20 
nM, however, the hairpin inhibitor partially or completely failed 
to derepress the luciferase mRNA, respectively, while the LNA 
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that the tiny LNA 8-mer (PS) was able to derepress the p21 
reporter with high efficiency (Fig. 3B). When using the lucif-
erase reporter with seed-mutagenized p21 3'-UTR, none of the 
antiseeds showed a substantial derepression effect (Fig. 3C). The 
miRNA hairpin inhibitors even somewhat reduced luciferase 
activity of the mutated reporter (Fig. 3C), suggesting unwanted 
side effects of such molecules in our experimental setup. Also, 
the LNA 8-mer (PS) slightly derepressed expression from the 
seed-mutagenized reporter (Fig. 3C), suggesting that the high 
derepression in Figure 3B includes contributions from this non-
specific stimulation.
Taken together, our results establish 14-mer LNA antiseeds 
(PO) as interesting new miRNA or miRNA family inhibitors 
with favorable properties in terms of efficacy, duration and speci-
ficity of depression effects.
Functional delivery of LNA antiseeds with PEI F25-LMW. 
A major bottleneck for the therapeutic application of any nucleic 
acid, including LNA antiseeds, is its efficient and functional 
delivery in vivo. Previously, we have established nucleic acid 
complexation with low molecular weight polyethylenimine (PEI 
of the p21 reporter than cotransfection with hairpin inhibitor 
17–5p or 20a at the same concentration (10 nM; Fig. 3B). This 
stronger derepression activity of the antiseeds as compared with 
the individual hairpin inhibitors was in line with the results from 
our western blot experiments (see Fig. 2). Next, we compared the 
derepression activity of an equimolar (each 5 nM) mixture of the 
two antiseeds with that of a mixture of both hairpin inhibitors. 
While the combination of the antiseeds did not further increase 
the derepression activity, the combined application of the two 
hairpin inhibitors resulted in an enhanced derepression activity 
that was now comparable to that of the single LNA antiseeds 
(Fig. 3B). This suggests that antiseeds are able to block miRNAs 
from the same family, while hairpin inhibitors are more specific 
for individual miRNAs.
As a further control we tested a tiny LNA 8-mer with a PS 
backbone targeting the seed region of miRNAs from the miR-
106b family. Recently, it has been shown in cotransfection 
experiments with lipofectamine that only LNA (PS) 8-mers can 
derepress a luciferase reporter efficiently, whereas shorter or lon-
ger LNA (PS) oligonucleotides are inefficient.19 Indeed, we found 
Figure 1. (A) schematic view of the let-7a forward luciferase reporter and the inverted control construct; the target sequence fully complementary 
to mature miRNA hsa-let-7a and the inverted control sequence are depicted (in the sense of the RNA transcript). The sequence of mature miRNA hsa-
let-7a is shown underneath, with upper case letters indicating the nucleotides targeted by the let-7a antiseeds. (B) sequences of the used antiseeds 
directed against the 5'-region of miRNA let-7a and sequence of the LNA control oligonucleotide directed against bacterial RNase p RNA. (c) Derepres-
sion activity of let-7a antiseeds (8- to 14-mers) at the indicated concentrations (5–100 nM) in heLa cells using lipofectamine as transfection agent. 
Luciferase activity of the control vector harboring the inverted let-7a target sequence was set to 1. Values are derived from at least three independent 
experiments (+/- s.D.). (D) comparison of LNA 12- and 14-mer antiseeds containing a pO backbone with a hairpin inhibitor (hp inhib.) targeting let-7a 
at the indicated concentrations (1 to 20 nM) in heLa cells. As control, the unrelated LNA 14-mer (LNA con.) was used. Values are derived from at least 
three independent experiments (+/- s.D.).
©
2
0
1
2
 L
a
n
d
e
s
 B
io
s
c
ie
n
c
e
. 
D
o
 n
o
t 
d
is
tr
ib
u
te
www.landesbioscience.com RNA Biology 1091
a PEI/nucleic acid mass ratio of 5:1, which had been determined 
as optimal in previous siRNA and miRNA experiments22 with 
regard to complex stability and surface charge (zeta potential). 
In our experimental setup, HeLa cells were first transfected 
with the p21 reporter plasmid using lipofectamine, followed 
by transfection of PEI/nucleic acid complexes assembled at 10 
nM of the respective nucleic acid. Similar derepression of the 
luciferase reporter carrying the p21 3'-UTR was observed with 
most antimiRs, while the hairpin inhibitor against miR-20a 
caused the highest derepression activity; no derepression at all 
was seen with the LNA (PS) 8-mer (Fig. 4A). Analysis of the 
same PEI/nucleic acid complexes in combination with the lucif-
erase reporter encoding the seed-mutagenized p21 3'-UTR ruled 
out any non-specific effects (Fig. 4B). We further analyzed PEI/
nucleic acid complexes for possible toxic side effects by using a 
WST-1 assay that senses cell viability via mitochondrial energy 
metabolism (see Supplemental Materials). We did not observe 
any significant negative effects on cell viability for up to 250 nM 
of PEI-complexed LNA antiseeds, hairpin inhibitors or the LNA 
8-mer (PS) (Fig. S1).
The absence of LNA 8-mer (PS) activity (Fig. 4A), in con-
trast to antiseeds or hairpin inhibitors, prompted us to address 
the question if complexation by PEI F25-LMW might be inef-
ficient for short single-stranded oligomers relative to siRNA 
duplexes. We thus compared PEI complexation of a double-
stranded siRNA30 with that of single-stranded RNA (14- or 
8-mer) in an agarose gel assay (Fig. 4C). Different amounts of 
PEI F25-LMW were incubated with 500 ng of the respective 
RNA to obtain PEI/RNA mass ratios of 0.1 to 10. To visualize 
PEI/RNA complexes in agarose gels, trace amounts of the respec-
tive 5'-[32P]-labeled RNA were added (~500- to 1000-fold excess 
of unlabeled RNA over labeled RNA). Notably, we observed no 
significant differences in complexation efficacies for the siRNA 
duplex or the single-stranded RNA oligomers of different length. 
In all cases, complex formation started at a PEI/RNA mass ratio 
of 0.25 (which corresponds to 125 ng PEI) and approximately 
90% complexation at a PEI/RNA mass ratio of 1:1 (Fig. 4C). 
The quantitative analysis (Fig. 4C, bottom graph) revealed only 
minor differences in complexation efficacy of siRNA duplex and 
8- or 14-meric RNA single strands. More importantly, at the 
PEI/oligonucleotide mass ratios of 2.5:1 or 5:1 used in our HeLa 
cell transfection experiments (see Fig. 4A and 5) all three types 
of RNA were fully complexed with PEI (Fig. 4C).
Visualization of PEI nanoparticles containing LNA anti-
seeds. Because 5′-[32P]-labeling by T4 polynucleotide kinase 
using standard protocols was ineffective, we could not apply the 
same agarose gel-based complexation test to LNA oligomers. 
Also, staining of PEI/LNA complexes with SYBR® Gold or sil-
ver was unsuccessful (data not shown). Thus, we analyzed PEI/
LNA complexes by atomic force microscopy (AFM). Indeed, 
upon mixing of PEI F25-LMW and LNA 14-mers (PO) at dif-
ferent mass ratios the formation of polymeric nanoparticles was 
observed (Fig. 6). At PEI/LNA mass ratios of 2.5:1 or 5:1 the 
resulting nanoparticles were quite homogeneous in size (diam-
eters of ~ 80–150 nm). Polymeric PEI nanoparticles were also 
formed with the LNA 8-mer (PS) (Fig. 6). Thus, the inability to 
F25-LMW) for the systemic administration of siRNA or miRNA 
in mice.22,27-29 While PEI F25-LMW has cell type-dependent 
transfection efficacy in vitro, it is important to note that it can 
be used for efficient delivery of nucleic acids in vivo, which is not 
possible with other liposomal transfection reagents. More spe-
cifically, PEI F25-LMW is less toxic than other PEIs, and the 
formation of PEI-based nanoparticles protects nucleic acids from 
degradation in biological fluids, mediates their cellular uptake 
and triggers their release from the endosomal/lysosomal system 
due to the “proton-sponge effect.”27,29
Here, we aimed at extending our PEI F25-LMW-based deliv-
ery platform toward LNA antimiRs for blocking the function of 
oncogenic or other disease-related miRNAs in vivo. We analyzed 
the derepression activity of PEI F25-LMW/antiseed complexes 
against miR-17–5p and miR-20a in HeLa cells and compared it 
with that of miRNA hairpin inhibitors and the tiny LNA 8-mer 
(PS) complexes in the same manner. Complexation was done at 
Figure 2. Duration of p21 derepression by LNA (pO) 14-mer antiseeds 
vs. hairpin inhibitors. expression of p21 was analyzed by western blot-
ting after transfection of LNA 14-mer antiseeds and miRNA hairpin 
inhibitors (hp inhib.) directed against miR-17–5p or miR-20a in K562 
cells. As a control, the unrelated LNA 14-mer (LNA con., see Fig. 1B) was 
used. Beta-Actin served as a loading control.
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raise derepressional effects with PEI/LNA 8-mer (PS) complexes 
(see Fig. 4A) has very likely reasons other than inefficient PEI 
nanoparticle formation.
After demonstrating the efficient formation of homogeneous 
PEI/LNA complexes at mass ratios of 2.5:1 and 5:1, we analyzed 
our PEI-based delivery strategy in the let-7a-specific luciferase 
reporter system (see Fig. 1A). The efficient repression of the let-
7a reporter in HeLa cells (Fig. 1C, cf. bars for “f” and “antiseed 
14-mer” at 50–100 nM) qualified this reporter system as optimal 
for further validating the relatively weak derepression effects of 
PEI-complexed LNA antiseeds on the p21 3'-UTR reporter sys-
tem (see Fig. 4A). We now used a PEI/nucleic acid mass ratio of 
2.5:1 and varied the 14-meric let-7a LNA antiseed concentrations 
between 10 and 250 nM. In this setup, the 14-mer LNA antiseed 
caused a specific approx. 3-fold derepression of the let-7a reporter 
at 100 nM or 250 nM (Fig. 5), which is a more robust effect than 
that observed in Figure 4A. We conclude that PEI F25-LMW 
efficiently complexes LNA antiseeds and allows for their delivery 
in vitro, thus providing the basis for future in vivo experiments.
Discussion
The inhibition of miRNAs is an important strategy to analyze 
their cellular functions and to reduce miRNA overexpression lev-
els in several disease states. This may well lead to novel therapeutic 
treatments based on reversion of the consequences of aberrantly 
high miRNA expression levels. One promising approach to block 
miRNAs is the use of LNA-based antisense strategies. LNA has 
several advantages over other nucleic acids, including the increase 
in T
m
 values of usually 2–4°C per LNA modification compared 
with DNA, its resistance against intracellular nucleases and 
nucleases in biological fluids, improved mismatch discrimination 
(for reviews see refs. 13,31 and 32) and low toxicity profiles in 
preclinical in vivo studies.10 The rate constant k
off
 of LNA/RNA 
hybrids is dramatically reduced24,33 and therefore steric block-
age of target nucleic acids is anticipated to be very efficient and 
persistent. Recently, the successful use of LNA-modified anti-
sense oligonucleotides against miRNAs has been described, for 
example tiny LNA 8-mers with a PS backbone or various LNA/
DNA mixmers (see Introduction). However, the identification of 
short-sized (~14 nt) LNA oligonucleotides that have the capacity 
to target miRNA families with common seeds, in combination 
with the development of efficient strategies for their delivery, is an 
important exercise toward in vivo applications.
In this study we have introduced 14-mer LNA antiseeds with a 
PO backbone, which displayed several context-dependent advan-
tages over other miRNA inhibitors. By using a miRNA (let-7a)-
regulated reporter gene assay in HeLa cells and lipofectamine as 
transfection agent we found 12- or 14-meric LNA antiseeds to 
be more potent than shorter variants (8- or 10-mer; Fig. 1C). 
Also, in this assay system, a commonly used miRNA hairpin 
inhibitor23 lost its otherwise similar inhibition capacity at higher 
inhibitor concentrations (≥ 20 nM), possibly due to aggregation 
effects (Fig. 1D). In our second test system, where we transfected 
K562 cells by electroporation, derepression of endogenous p21 
expression was much more persistent with LNA (PO) 14-mer 
Figure 3. (A) schematic presentation of the reporter carrying the lucifer-
ase coding sequence (cDs) followed by the p21 3'-UTR that harbours two 
miR-106b family seed regions (top). The seed regions are mutated in the 
variant reporter construct underneath, with lower case letters indicating 
the mutated nucleotides. (B) Derepression activity of the indicated miRNA 
inhibitors (hp inhib. or 14-meric LNA antiseeds) directed against miR-
17–5p and miR-20a after lipofectamine-mediated cotransfection with the 
luciferase/p21 3'-UTR reporter plasmid into heLa cells. Luciferase activity 
values obtained after cotransfection with the LNA con. 14-mer were set 
to 1. Values are derived from at least three independent experiments (+/- 
s.e.M.). (c) effects of the indicated miRNA inhibitors on luciferase expres-
sion using the seed-mutated version of the reporter (see panel A). Values 
are derived from at least three independent experiments (+/- s.e.M.).
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for individual miRNAs. This was inferred from the observation 
that hairpin inhibitors, but not antiseeds, against miR-17–5p and 
miR-20a showed synergistic effects (Fig. 3B). A seed-targeting 
tiny LNA 8-mer (PS), which has the capacity to block miRNA 
families,19 appeared to even perform best in this assay, although 
control experiments with the reporter gene that contain muta-
tions in the miR-17–5p and miR-20a target sites pointed to some 
antiseeds than with corresponding hairpin inhibitors (Fig. 2). In 
our third analysis, which was comparable to the first assay sys-
tem except for the reporter carrying the p21 3'-UTR with two 
miR-106b target sites, we found that LNA (PO) 14-mer antiseeds 
were again active (Fig. 3B). These experiments provided evidence 
that the LNA (PO) 14-mer antiseeds tend to target an entire 
miRNA family, while the hairpin inhibitors are more specific 
Figure 4. (A) Derepression of the luciferase/p21 3'-UTR reporter by peI F25-LMW-complexed LNA (pO) 14-mer antiseeds, miRNA hairpin inhibitors (hp 
inhib.) and an LNA (ps) 8-mer directed against miR-17–5p and miR-20a in heLa cells. The LNA con. 14-mer was used as a reference and the lumines-
cence measured for cell lysates harboring LNA con. was set to 1. Values are derived from four independent experiments (+/- s.e.M.). (B) effects of the 
indicated peI-complexed miRNA inhibitors on luciferase expression using the seed-mutated version of the reporter (see Fig. 3A). Values are derived 
from four independent experiments (+/- s.e.M.). (c) peI-complexation experiments using 5'-[32p]-endlabeled double-stranded siRNA or single-strand-
ed 8- or 14-meric RNA (104 cerenkov cpm per lane) as probes; peI/RNA complexes are indicated by retarded mobility of the RNA probe. To obtain peI/
RNA mass ratios of 0.1 to 10, 500 ng of either unlabeled siRNA duplex, 14-meric RNA or 8-meric RNA were combined with the corresponding labeled 
probes and incubated with different amounts of peI F25-LMW as indicated. Representative agarose gels are shown. A quantitative analysis based on at 
least three independent experiments is shown at the bottom (+/- s.e.M.).
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unspecific stimulatory effect of this type of inhibitor on reporter 
expression (Fig. 3C). From our results we conclude that hairpin 
inhibitors are suited to dissect the functions of single miRNAs 
of a miRNA family, while the broader effect of our 14-mer LNA 
(PO) antiseeds on more than one miRNA family member may 
well enhance possible therapeutic effects.
In our fourth approach (Fig. 4) we employed PEI F25-LMW 
as transfection agent instead of lipofectamine, keeping in mind 
that efficient and functional delivery in vivo remains the critical 
issue for nucleic acid-based therapeutic applications and common 
transfection reagents cannot be used here (for review, see e.g., 
ref. 34).
As shown previously, PEI complexation of nucleic acids leads 
to polymeric nanoscale particles that (1) allow the complete 
protection of the nucleic acid against degradation, (2) mediate 
the cellular uptake of the cargo, (3) trigger the release from the 
endosomal/lysosomal system due to the proton-sponge effect and 
(4) release the nucleic acid into the cytoplasm (for a review see 
ref. 35). Notably, at the amounts used for therapeutic interven-
tion, the low molecular weight PEI F25-LMW28 has been shown 
to exert no toxicity and no immunostimulatory or otherwise 
non-specific effects in vitro and in vivo.29,36 In line with these 
previous findings, we have not observed any toxic effects of PEI 
F25-LMW-complexed LNA antiseeds in the study presented here 
(Fig. S1).
Here we demonstrate that single-stranded 14-mer LNA (PO) 
antiseeds can be functionally delivered by PEI F25-LMW (Fig. 
4A and 5) with efficacies comparable to hairpin inhibitors (Fig. 
4A). In contrast, the tiny LNA 8-mer (PS) failed to show an 
inhibitory effect when using PEI F25-LMW as the delivery agent 
(Fig. 4A). This has other reasons than incomplete PEI complex-
ation of the LNA 8-mer (PS) because neither (1) its short length, 
(2) its PS backbone, (3) its single-stranded character nor (4) its 
LNA modifications had any significant negative effect on particle 
formation with PEI F25-LMW (Fig. 4C and 6). One possibility 
among several is that very short oligonucleotides such as 8-mers 
are inefficiently released from the nanoparticle within cells.
Taken together, our results establish the efficiency of LNA 
(PO) 14-mer antiseeds as new miRNA inhibitors, and demon-
strate the capability of such LNA antiseeds to build functional 
complexes with PEI that can be delivered into cancer cells in 
order to derepress tumor suppressor genes such as p21. Thus, our 
results open up an avenue toward therapeutic application of LNA 
antiseeds for miRNA inhibition.
Materials and Methods
Oligonucleotides and antibodies. Locked nucleic acids (LNA) 
antisense oligonucleotides (antiseeds) were purchased from 
RiboTask (Odense, Denmark). Antiseed sequences were as 
follows:
Antiseed against miR-17–5p (PO): 5'-CTG TAA GCA 
CT[mU]TG;
Antiseed against miR-20a (PO): 5'-CTA TAA GCA [mC]
T[mU]TA;
Antiseed against miR-17–5-p/20a (PS): 5'-GCA CT[mU]TG.
Figure 5. Derepression of the let-7a-responsive luciferase reporter by 
the peI F25-LMW-complexed LNA (pO) 14-mer antiseed against let-7a in 
heLa cells. For the control LNA 14-mer (LNA con.), see Fig. 1B. Lucifer-
ase activity of lysates derived from cells harboring the control vector 
with an inverted let-7a target sequence (Fig. 1A) was set to 1. Values are 
derived from at least three independent experiments (+/- s.e.M.).
Figure 6. Detection of peI F25-LMW/LNA nanoparticles using atomic 
force microscopy. shown are four representative images of peI/LNA 
complexes at the indicated mass ratios, containing either the LNA (ps) 
8-mer (lower panel on the right) or an LNA (pO) 14-mer (all other pan-
els). For details, see Materials and Methods.
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Specificity of p21 derepression in HeLa cells. The transfection 
of HeLa cells was performed using LipofectamineTM 2000 (Life 
Technologies Invitrogen). One day prior to transfection, 4 × 
104 cells were seeded into 24-well plates; for co-complexation, 
1 μl LipofectamineTM 2000 was combined with 10 nM LNA 
antiseed, LNA control or hairpin inhibitor and 0.5 μg of vector 
DNA (plasmid “pGL3 control” containing the p21 3'-UTR or 
the mutated p21 3'-UTR) in Opti-MEM® 1 medium according 
to the instructions of the manufacturer; the mixture was added 
to the cells, proceeding as described above (see Reporter assays 
using let-7a antimiRs in HeLa cells).
PEI complexation and delivery. Using the p21 reporter system. 
For complexation of miRNA inhibitors with PEI F25-LMW, cells 
were pre-transfected with vector DNA (“pGL3 control” plasmid 
containing the p21 3'-UTR or the mutated p21 3'-UTR) using 
LipofectamineTM 2000 as described above (see Specificity of p21 
derepression in HeLa cells). After 6 h, the medium was replaced 
with IMDM/10% FCS, and PEI complexes were added. For PEI 
F25-LMW complexation, LNA antiseeds, LNA control oligo-
nucleotide, tiny LNA 8-mer with PS backbone or hairpin inhibi-
tors were diluted in complexation buffer (150 mM NaCl, 10 mM 
HEPES pH 7.4). To gain a final concentration of 10 nM, 18 ng 
of LNA 8-mer (PS), 28.5 ng of LNA 14-mers (control, antiseed 
17–5p or antiseed 20a) and 80 ng of hairpin inhibitors 17–5p or 
20a were diluted in 50 μl complexation buffer and equilibrated 5 
min at room temperature. To obtain a PEI / oligonucleotide mass 
ratio of 5:1, 90 ng PEI was used for complexation of the LNA 
8-mer (PS), 142.5 ng PEI for complexation of the LNA antiseeds 
and LNA 14-mer control, and 390 ng PEI was required for the 
hairpin inhibitor complexes. After equilibration of PEI to room 
temperature in complexation buffer, the oligonucleotide and the 
PEI solution were mixed, briefly vortexed and incubated for 30–60 
min at room temperature to allow complex formation. PEI F25-
LMW complexes were then added to the cells (see above), and 48 h 
later cells were lysed and prepared for reporter assay measurements.
Using the let-7a reporter system. Cells were pre-transfected 
with vector DNA (“pGL3 control” plasmid containing the let-
7a forward or inverted target sequence) using LipofectamineTM 
2000 as described above (see Reporter assays using let-7a anti-
miRs in HeLa cells). After 6 h, the medium was replaced with 
IMDM/2% FCS, and PEI complexes were added. For PEI F25-
LMW complexation, the let-7a LNA 14-mer and the LNA con-
trol 14-mer were diluted in complexation buffer (150 mM NaCl, 
10 mM HEPES pH 7.4). To gain a final oligonucleotide concen-
tration of 10, 50, 100 or 250 nM, 115, 575, 1,150 or 2,875 ng of 
the LNA 14-mers were diluted in 50 μl complexation buffer and 
equilibrated to room temperature. PEI F25-LMW was used at 
a final PEI / oligonucleotide mass ratio of 2.5:1; therefore 288, 
1,440, 2,880 or 7,200 ng of PEI was diluted in 50 μl complex-
ation buffer and also equilibrated 5 min at room temperature. 
Complexation was initiated by mixing PEI and oligonucleotide 
solutions, followed by incubation at room temperature for 30 - 
60 min. PEI / LNA complexes were finally added to the cells 
and luciferase reporter measurements were performed 48 h 
posttransfection.
All residues were LNA, except for isolated 2'-oxymethyl pyrim-
idines marked as [mU] and [mC]. These changes are expected to 
reduce self-pairing without disturbing target binding.
LNA antiseeds directed against hsa-let-7a were of different 
lengths (14- to 8-mers):
Antiseed let7a-14-mer: 5'-AAC CTA CTA CCT CA;
Antiseed let7a-12-mer: 5'-CCT ACT ACC TCA;
Antiseed let7a-10-mer: 5'-TAC TAC CTC A;
Antiseed let7a-8-mer: 5'-CTA CCT CA.
Escherichia coli RNase P RNA 5'-CAA GCA GCC UAC CC24 
was used as negative control.
The sequence of the RNA 14-mer, which was used for PEI-
complexation studies, is: 5'-GUU CGG UCA AAA CU
The sequence of the RNA 8-mer, which was used for PEI-
complexation studies, is:
5'-GUU CGG UC
The sequence of the VR1 siRNA, which was used for PEI-
complexation studies, is:
5'-GCG AUC UUC UAU UCA ACdTdT (sense)
and 5'-GUU GAA GUA GAA GAU GCG CdTdT 
(antisense)30
MiRIDIAN hairpin inhibitors against hsa-let-7a, hsa-miR-
17–5-p and hsa-miR-20a were purchased from Dharmacon 
(Thermo Scientific, Langenselbold, Germany).
Antibodies against p21 (sc-6246) and β-Actin (sc-47778) as 
well as the secondary antibody (sc-2005) were purchased from 
Santa Cruz Biotechnology (Heidelberg, Germany).
Cell culture. Cells (K562 and HeLa) were cultured under 
standard conditions (37°C, 5% CO
2
 in a humidified atmo-
sphere) in RPMI 1640 (K562) or IMDM (HeLa), supplemented 
with 10% FCS (PAA, Cölbe, Germany).
Transfection procedures. Reporter assays using let-7a antimiRs 
in HeLa cells. HeLa cells were transfected with the LNA antiseeds, 
controls or the hairpin inhibitors using LipofectamineTM 2000 
(Life Technologies Invitrogen, Darmstadt, Germany) according 
to the manufacturer’s protocol. One day before transfection, 8 
× 104 cells were seeded into 24-well plates and cultivated under 
standard conditions. Twenty-four hours after seeding, cells were 
cotransfected with 0.5 μg of vector DNA (plasmid “pGL3 con-
trol” with a let-7a or an inverted let-7a target sequence) and with 
0, 10, 20, 50 or 100 nM of the LNA antiseed, LNA control or 
hairpin inhibitor, respectively, according to the manufacturer’s 
protocol. Co-complexation was performed in Opti-MEM® 1 
medium (Life Technologies Invitrogen). After 4 to 6 h, the trans-
fection medium without serum was aspirated and replaced by 
Iscove’s modified Dulbecco’s medium (IMDM) containing 10% 
FCS. Forty-eight hours after transfection, cells were lysed and 
prepared for reporter assay measurements.
p21 derepression in K562 cells. For transfection experiments, 
1 × 106 K562 cells were electroporated in 4 mm cuvettes with a 
single pulse at 330 V for 10 ms using a BioRad GenePulser XCell 
(Biorad, München, Germany). Cells were transfected with 1 μg 
LNA antiseeds, LNA controls or hairpin inhibitors. Forty-eight 
hours after transfection, cells were lysed and lysates were ana-
lyzed in western blot experiments.
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5'-GCT CTA GAG CGC TGA GCA ACT ATA CAA CCT 
ACT ACC TCA GCT CTA GAG C-3'
(XbaI and BlpI sites underlined and the hsa-let-7a sense 
sequence in italics).
To determine the effects of LNA antiseeds that are directed 
against mature miR-106 family members on the expression of 
the p21 protein, the 3'-untranslated region (3'-UTR) of p21 was 
cloned into the pGL3 control luciferase reporter vector (Promega, 
Mannheim, Germany) via its XbaI site. The 3'-UTR was initially 
amplified from K562 genomic DNA with the forward primer 
5'-TCT AGA CCT CAA AGG CCC GCT CTA-3' and the 
reverse primer 5'-TCT AGA GGA GGA GCT GTG AAA GAC 
ACA-3'; the amplicon was subcloned into a pCR 2.1-TOPO vec-
tor (TOPO TA Cloning® kit, Invitrogen, Karlsruhe, Germany) 
prior to insertion into the pGL3 vector. PCR mutagenesis of the 
two miRNA seed target sites was done according to Brennecke 
et al.40 The following primers were used for mutagenesis (sites of 
mutation underlined):
5'-target site forward: 5'-GAA GTA AAC AGA TGG GAC 
TGT GAA GGG GCC TCA CC-3',
5'- target site reverse: 5'-GGT GAG GCC CCT TCA CAG 
TCC CAT CTG TTT ACT TC-3',
3'-target site forward: 5'-CTC CCC AGT TCA TTG GAC 
TGT GAT TAG CAG CGG AA-3',
3'-target site reverse: 5'-TTC CGC TGC TAA TCA CAG 
TCC AAT GAA CTG GGG AG-3'. Mutations were verified by 
DNA sequencing.
Luciferase reporter assays. Luciferase reporter assays were 
performed using the Promega Luciferase Assay System (Promega, 
Mannheim, Germany). After aspirating the media, cells were 
washed with PBS and lysed in 100 μl reporter lysis buffer. In 
a 96-well plate, 10 μl lysate were mixed with 10 μl substrate, 
and the luminescence was measured immediately in a Safire2 TM 
microplate reader (Tecan, Crailsheim, Germany). In the case 
of the let-7a-responsive reporter assay, the measured lumines-
cence was normalized to that of lysates from cells harboring the 
inverted target vector (which was set to 1), yielding the normal-
ized “relative light units” (RLU). In the case of the reporter with 
p21 3'-UTR, RLU were normalized to the luminescence of the 
reporter in the presence of the control LNA 14-mer (set to 1) to 
illustrate the relative weak derepression effects of PEI-complexed 
oligonucleotides.
Western blotting. Cells were lysed in lysis buffer (125 mM 
Tris/HCl  pH 6.8, 4% SDS, 1.4 M 2-mercaptoethanol, 0.05% 
bromophenol blue) and heated at 95°C for 5 min. Samples were 
loaded onto 15% SDS-polyacrylamide gels (Mini-PROTEAN® 3 
cell mini gel system, BioRad) and run for 1 h at 180 V. Proteins 
were transferred onto an ImmobilonTM-P PVDF membrane for 
30 min at 10 V using a Trans-Blot® SD Semi-Dry Transfer Cell 
(BioRad), followed by blocking of the membrane with 5% milk 
powder dissolved in TBST [10 mM Tris/HCL (pH 7.6), 150 
mM NaCl, 0,1% Tween 20]. Primary and secondary antibod-
ies were diluted in TBST 1:200 (p21), 1:5000 (β-Actin) and 
1:5000 (goat anti-mouse IgG-HRP, secondary antibody). After a 
final washing step, blots were incubated with Amersham ECLTM 
or ECLplusTM Western Blotting Detection Reagents according 
Determination of PEI complexation efficacy. To determine 
the complexation efficacy of PEI F25-LMW, a radioactive assay 
was employed as described previously.37 For this purpose, 500 ng 
of single-stranded 14- or 8-meric RNA or double-stranded siRNA 
were used, mixed with trace amounts (104 Cerenkov cpm) of 
5'-[32P]-endlabeled RNA 14-mer, RNA 8-mer or siRNA, respec-
tively. Complexation was performed with the indicated amounts 
of PEI (see “PEI complexation and delivery” above and Fig. 4C). 
Samples were mixed with DNA loading buffer (10 mM Tris/HCl 
(pH 7.6), 80% glycerol, 0.03% bromophenol blue, 0.03% xylene 
cyanol blue) and analyzed by 1% agarose gel electrophoresis, run 
at 50 mA for 2 h (PEQLAB Biotechnologie). Complex formation 
was analyzed by autoradiography of the agarose gel for 3 h using 
a Fuji FLA-3000 R Phosphorimager (Fujifilm); the ratio of free 
to partially and fully complexed RNA was calculated using the 
software AIDA (Version 3.45).
Atomic force microscopy. PEI/LNA complexes were analyzed 
by atomic force microscopy (AFM). Complexes were prepared 
as described above with 500 ng of LNA 14-mer 17–5p (PO) or 
LNA 8-mer (PS) and the indicated amounts of PEI F25-LMW 
(see Fig. 6). Complexes were directly transferred onto a silicon 
chip by dipping the chip into the complex solution. AFM was 
performed on a vibration-damped NanoWizard (JPK instru-
ments, Berlin, Germany) as described in detail elsewhere.38,39 
Commercially available pyramidal Si
3
N
4
 tips (NSC16 AIBS, 
Micromasch, Estonia) mounted to a cantilever with a length of 
230 μm, a resonance frequency of about 170 kHz and a nominal 
force constant of about 40 N/m were used. To avoid damage of 
the sample surface, measurements were performed in intermitted 
contact. The scan speed was proportional to the scan size, and 
the scan frequency was between 0.5 and 1.5 Hz. Images were 
obtained by displaying the amplitude signal of the cantilever in 
the trace direction, and the height signal in the retrace direc-
tion, both signals being simultaneously recorded. The complexes 
were visualized either in height or in amplitude mode (512 × 512 
pixel).
Plasmid construction and seed mutagenesis. To introduce 
a hsa-let-7a site, two complementary DNA oligonucleotides 
encoding the let-7a target sequence (MIMAT0000062) were 
annealed, cleaved with XbaI, and cloned into the unique XbaI site 
of the reporter plasmid pGL3-Control (Promega, Mannheim, 
Germany); the XbaI cleavage site is located immediately down-
stream of the luciferase coding sequence. Insertion of the frag-
ment was identified through linearizing of recombinant plasmids 
via the unique BlpI site introduced with the insert (see below). 
Cloning of the insert resulted in two opposite orientations, which 
were identified by DNA sequencing. Clones giving rise to RNA 
transcripts with a let-7a target site were classified as “forward ori-
entation”; clones with the opposite insert orientation were clas-
sified as “inverted orientation” and were used as controls for the 
absence of a let-7a target site in the RNA transcript. The two 
annealed DNA oligonucleotides had the following sequences:
let-7a sense XbaI:
5'-GCT CTA GAG CTG AGG TAG TAG GTT GTA TAG 
TTG CTC AGC GCT CTA GAG C-3'
let-7a antisense XbaI:
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Supplementary Material 
Toxicity studies using the WST-1 assay 
WST-1 assays were performed to analyze for toxicity of the PEI/LNA 
complexes (Roche, Mannheim, Germany). HeLa cells (0.5 x 104) were seeded into a 
96-well plate and cultivated under standard conditions. 24 h after seeding, PEI F25-
LMW complexes (PEI/nucleic acid mass ratio of 5:1 at the indicated nucleic acid 
concentrations, see Fig. S1) were added to the cells. 48 h after cultivating in medium 
containing 2 % FCS, WST-1 assays were performed as described by manufacturer. 
Absorbance was measured in a Tecan Safire2 plate reader at a fixed wavelength of 
450 nm and at 600 nm as background control. Measurements were done at 0.5, 1, 2 
and 4 h to determine cell viability. 
 
Supplementary Figure 
Figure Legend 
Figure S1: WST-1 cell viability assay of HeLa cells transfected with the 14-mer LNA 
antiseed 17-5p, the hairpin inhibitor 20a and the 8-mer LNA (PS). Oligonucleotides 
were complexed with PEI F25-LMW at the indicated concentrations using a 
PEI/oligonucleotide mass ratio of 5:1. After 48 h, WST-1 activity was measured at 
450 nm with an incubation period of 2 h. Untransfected HeLa cells grown in 2% FCS 
were used as a control and their activity was set to 1 for normalization. Values are 
derived from three independent experiments (+/- S.E.M.). 
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Background: Expression of the human miR-
17-92 cluster is driven from a host gene 
promoter located within a CpG island and from 
an intronic A/T-rich region located directly 
upstream of the first miRNA 17-5p.  
Results: Substantial transcriptional activity 
from the A/T-rich region relies on c-Myc 
binding to a functional E-box element (E3 site) 
and involves a synergism between c-Myc and 
the protooncogene Pim-1.   
Conclusion: Pim-1 is part of the 
transcriptional network that regulates 
expression of the human miR-17-92 cluster. 
Significance: Little is known about promoters 
of oncogenic miRNAs or miRNA clusters. 
Understanding the regulation of oncogenic 
miRNA expression opens up new perspectives 
for the prevention of cancer. 
 
SUMMARY 
The human polycistronic miRNA cluster 
miR-17-92 is frequently overexpressed in 
hematopoietic malignancies and cancers. Its 
transcription is in part controlled by an 
E2F-regulated host gene promoter. An 
intronic A/T-rich region directly upstream 
of the miRNA coding region also contributes 
to cluster expression. Deletion analysis of 
the A/T-rich region revealed a strong 
dependence on c-Myc binding to the 
functional E3 site. Yet, constructs lacking 
the 5’-proximal ~1.3 kb or 3’-distal ~0.1 kb 
of the 1.5 kb A/T-rich region still retained 
residual specific promoter activity, 
suggesting multiple transcription start sites 
(TSS) in this region. Furthermore, the 
protooncogenic kinase Pim-1, its 
phosphorylation target HP1 and c-Myc 
colocalize to the E3 region, as inferred from 
chromatin immunoprecipitation. Analysis of 
pri-mir-17-92 expression levels in K562 and 
HeLa cells revealed that silencing of E2F3, 
c-Myc or Pim-1 negatively affects cluster 
expression, with a synergistic effect caused 
by c-Myc/Pim-1 double knockdowns in 
HeLa cells. Thus, we show for the first time, 
that Pim-1 is part of the transcriptional 
network that regulates the human miR-17-
92 cluster. 
MicroRNAs (miRNAs) are important post-
transcriptional riboregulators of gene 
expression with high relevance to cancer 
formation and metastasis (1). In general, 
miRNAs are derived from RNA polymerase II 
(RNAPII) primary transcripts (pri-miRNA) 
that are further processed to ~70 nt precursors 
(pre-miRNA) and after nuclear export to 
mature miRNAs by the activity of the two 
endonucleases DROSHA/DGCR8 and DICER 
(2-5). MiRNAs are incorporated into the 
miRNA-induced silencing complex (miRISC) 
and act as repressors of translation by 
imperfect base-pairing to their target sites in 
mRNAs (3). The majority of miRNAs is 
encoded in intronic regions, either individually 
or as “polycistronic” miRNA clusters that are 
cotranscribed (3,6). 
Several deregulated miRNAs or miRNA 
clusters are involved in tumorigenesis, 
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accounting for their designation as oncogenic 
miRNAs (7). Such miRNAs can downregulate 
targets involved in the regulation of apoptosis 
or cell cycle progression (1). One well-
characterized polycistronic cluster is the miR-
17-92 cluster, also known as OncomiR-1 or 
C13orf25. This cluster encodes six miRNAs 
belonging to four different seed families: (i) 
the miR-17 family with miR-17 and miR-20a, 
(ii) the miR-18 family with miR-18a, (iii) the 
miR-19 family with miR-19a and miR-19b-1, 
and (iv) the miR-92 family (8-11). The human 
miR-17-92 cluster is encoded in the 
chromosomal region 13q31.3 and is amplified 
in several solid tumors as well as in some 
hematopoietic malignancies (8,12). Because of 
numerous known targets of its individual 
miRNAs, the miR-17-92 locus exerts 
pleiotropic functions during development, 
proliferation, apoptosis and angiogenesis in 
different cell systems (13-15). In mice, 
deletion of the cluster prevents normal B-cell 
development as a consequence of premature 
cell death (14). In a mouse B-cell lymphoma 
model, simultaneous overexpression of c-Myc 
and the miR-17-92 cluster accelerated 
lymphomagenesis (9). This oncogenic effect 
could later be assigned primarily to miR-19a/b 
which dampens expression of the tumor 
suppressor PTEN, thereby repressing apoptosis 
(13,15).  
Analyses of transcriptional regulation of 
oncogenic miRNAs and miRNA clusters are of 
great importance for strategies aiming at 
cancer prevention. Unfortunately, most 
miRNA promoters have not been characterized 
or identified yet (16). In case of the miR-17-92 
cluster, expression is thought to be promoted 
from a host gene promoter region upstream of 
exon 1, with transcription starting at a 
consensus initiator sequence downstream of a 
non-consensus TATA box (17,18). 
Additionally, this core promoter region 
contains functional E2F transcription factor 
binding sites. E2F1-3 were shown to activate 
C13orf25 expression from this promoter and 
chromatin immunoprecipitation assays (ChIP) 
identified E2F3 to be the main E2F variant 
associated with the host gene promoter (17, 
18). No E2F binding was detected in the region 
between the host gene promoter and the miR-
17-92 cluster (18). Furthermore, nucleosome 
mapping combined with chromatin signatures 
for transcriptionally active promoters (19-21) 
indicated that transcriptional activity of the 
miR-17-92 cluster also originates from the 
intronic A/T-rich region directly upstream of 
the miRNA coding sequences (16). This is in 
line with the finding that cluster expression is 
activated by c-Myc binding to a conserved E-
box element (E3) ~1.5 kb upstream of the 
miRNA coding sequence (9,10,20). Indeed, 
luciferase reporter assays confirmed that both, 
the host gene promoter and the intronic region, 
confer transcriptional activity (16,21).  
Here, we subjected the intronic A/T-rich 
region to deletion analysis using luciferase 
reporter constructs. Transcription was found to 
strongly depend on c-Myc, but even shorter 
fragments (< 0.3 kb) of sequences directly 
preceding the miR-17-92 coding sequence still 
promoted residual, but substantial and specific 
transcriptional activity. Furthermore, we 
identified the protooncogene Pim-1 and one of 
its phosphorylation targets HP1 (22) to be 
associated with the chromatin region 
containing the E3 site, suggesting that the 
human C13orf25 locus belongs to the set of 
genes that are synergistically regulated by c-
Myc and Pim-1 (23,24). SiRNA-mediated 
Pim-1 knockdown indeed resulted in reduced 
pri-mir-17-92 levels, as did a knockdown of c-
Myc or E2F3. In Hela cells, a double 
knockdown of c-Myc/Pim-1 decreased the pri-
mir-17-92 levels more than single 
knockdowns, providing further evidence for a 
synergism of c-Myc and Pim-1 at the intronic 
C13orf25 promoter.   
 
EXPERIMENTAL PROCEDURE 
Oligonucleotides - Small interfering RNAs 
(siRNAs) were purchased from Dharmacon 
(Boulder, USA): 
VR1 siRNA (25) was used as an unrelated 
negative control, with the following sequences 
of sense and antisense strand:. 
VR1 siRNA sense 5'-GCG CAU CUU CUA 
CUU CAA CdTdT and antisense 5'-GUU 
GAA GUA GAA GAU GCG CdTdT. 
The sequences of all other siRNAs used in this 
study are: 
Pim-1 siRNA sense 5'-GAU AUG GUG UGU 
GGA GAU AdTdT and antisense 5'-UAU 
CUC CAC ACA CCA UAU CdTdT; Pim-1 
siRNA 2 sense  5'-GGA ACA ACA UUU 
ACA ACU CdTdT and antisense 5'-GAG 
UUG UAA AUG UUG UUC CdTdT; c-Myc 
siRNA sense 5'-CAG GAA CUA UGA CCU 
CGA CUA dTdT and antisense 5'-UAG UCG 
AGG UCA UAG UUC CUG dTdT; E2F3 
siRNA sense 5'- ACA GCA AUC UUC CUU 
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AAU AdTdT and antisense 5'- UAU UAA 
GGA AGA UUG CUG UdTdT. 
Antibodies - Antibodies against c-Myc (sc-
40) and Pim-1 (sc-13513) as well as the 
secondary antibody (sc-2005: goat anti-mouse 
IgG HRP conjugated) were purchased from 
Santa Cruz Biotechnology (Heidelberg, 
Germany) except for the Phospho HP1 
(Ser83) antibody (2600S), which was obtained 
from Cell Signaling Technology (Danvers, 
MA, USA).   
Plasmid construction and seed mutagenesis 
For the construction of promoter-luciferase 
fusions, the SV40 promoter of plasmid “pGL3 
control” (Promega, Mannheim, Germany) was 
removed via digestion with BglII and HindIII 
(Thermo Fisher Scientific, Schwerte, 
Germany) and replaced with fragments derived 
from the intronic A/T-rich region of C13orf25 
(reference nucleotide sequence NG_032702.1). 
Promoter fragments were amplified from 
genomic DNA of the human cell line K562 
using primers specified in Supplementary 
Material. PCR products were purified using the 
Wizard
®
 SV Gel and PCR Clean-Up System 
(Promega, Mannheim, Germany) and digested 
with BglII and HindIII for insertion into pGL3. 
All constructs were cloned in E. coli DH5 
cells and verified via DNA sequencing. The 
pGL3 vector lacking the SV40 promoter as 
well as the pGL3 construct carrying the 
C13orf25-derived 339 bp fragment in inverse 
orientation (pGL3 339 bp inv) were used as 
negative controls. 
Transfection procedures and Luciferase 
reporter assays - Assays are described in detail 
in Supplementary Material. 
Chromatin immunoprecipitation - 
Chromatin immunoprecipitation (ChIP) was 
performed according to a protocol from the Or 
Gozani lab at Stanford University 
(http://www.stanford.edu/group/gozani), with 
some modifications. For details, see 
Supplementary Material.  
 
RESULTS 
C-Myc-dependent intronic transcriptional 
activity within the human miR-17-92 locus –  
The 3.4 kb upstream genomic region of the 
miR-17-92 coding sequence can be subdivided 
into a G/C-rich and an A/T-rich part. The 
former is a CpG island (~1.9 kb, 78 % GC 
content; see http://genome.ucsc.edu, 
GRCh37/hg19 assembly) that has its 5’-
boundary ~0.4 kb upstream of the TSS of the 
host gene promoter (20) and its 3’-boundary 
~1.4 kb upstream of the miR-17-5p coding 
sequence, representing the 5’-terminal miRNA 
of the cluster. The A/T-rich region (~64 % A/T 
content) following the CpG island begins 
immediately downstream of a functional and 
highly conserved c-Myc binding site (5’-
CATGTG, E-box E3) which is localized ~1.5 
kb upstream of the miR-17-5p coding sequence 
(10) (Fig. 1A, S1).  
We have analyzed the intronic region of 
C13orf25, including the preceding functional 
c-Myc box E3 (20) and truncated segments of 
the A/T-rich region (Fig. 1B), for independent 
transcriptional activity and c-Myc dependence. 
For this purpose, luciferase reporter constructs 
were transfected into K562 and HeLa cells. We 
selected these two cell lines because they 
express the miR-17-92 cluster at very high 
(K562) and high (HeLa) levels (26, Fig. S2). 
The ~1.5 kb reporter construct, comprising 
c-Myc box E3 (Fig. 1A, S1) and the A/T-rich 
region except for the 113 bp preceding the 
mature miR-17-5p coding sequence, showed 
substantial transcriptional activity, amounting 
to 30-35 % in both cell lines relative to the 
pGL3 control plasmid harboring an SV40 
promoter (Fig. 1C). This is in line with results 
of a similar study of the mouse miR-17-92 
locus (21). Furthermore, Ozsolak et al. (16) 
predicted an intronic TSS to be localized ~0.2 
kb downstream of the E3 site. Indeed, 
truncating the 1.5 kb fragment to 625 bp, 
which deletes the E3 site, strongly reduced 
reporter activity, ~4.5-fold in K562 and almost 
20-fold in HeLa cells compared to the activity 
of the ~1.5 kb construct (Fig. 1C). To 
substantiate this finding, we tested the ~1.5 kb 
construct in K562 cells under conditions of an 
siRNA-mediated knockdown of c-Myc. This 
reduced reporter expression to a similar extent 
as the truncation to 625 bp, supporting the 
notion that c-Myc binding to the E3 site plays 
a key role in activating transcription from this  
intronic region (Fig. 1C). As the 625 bp 
fragment still conferred basal promoter 
activity, we further shortened this region to 
~340 bp, ~280 bp and ~200 bp. Additionally, 
we included short fragments with their 3’-
boundary ~290 bp upstream of the mature 
miR-17-5p coding sequence (250, 190 and 108 
bp in Fig. 1B). We also inversed the 
orientation of the ~340 bp fragment in front of 
the luciferase gene (Fig. 1C, 339 bp inv) to 
include a control fragment with comparable 
A/T content. This inversed fragment conferred 
reporter activity 5.3-fold (K562) or 2.4-fold 
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(HeLa) higher than that of the pGL3 control 
vector lacking the SV40 promoter (SV40, 
Fig. 1C).  
All the fragments ≤ 340 bp conferred 
residual promoter activity, some clearly to a 
higher extent than the inverted 339 bp 
fragment in both cell lines (see the 279 and 
197 bp fragments, Fig. 1 C).  This indicates 
that parts of the intronic A/T-rich region 
promote specific transcriptional activity, the 
extent partly differing between the two cell 
lines (Fig. 1 C). Unfortunately, we were unable 
to identify any convincing correlation between 
fragment activity and promoter elements 
predicted in this region using a variety of web-
based promoter prediction tools (see Suppl. 
Material). In K562 cells, the smaller 
fragments, including the 625 bp fragment, 
showed an overall trend towards stronger 
expression relative to HeLa cells. 
Pim-1 and HP1 are associated with the 
intronic c-Myc binding site - We next asked if 
other factors beyond c-Myc may be involved 
in human miR-17-92 cluster expression from 
the A/T-rich region. Transcriptional regulation 
by c-Myc is associated with Pim-1-dependent 
H3S10 phosphorylation in about 20 % of all 
genes regulated by c-Myc (24). Moreover, 
Pim-1 and c-Myc act synergistically in severe 
forms of B-cell lymphomas, and Pim-1 as well 
as the miR-17-92 cluster are overexpressed in 
the myeloid leukemia suspension cell line 
K562 (27). We performed ChIP assays to test 
whether c-Myc and Pim-1 localize to the 
internal promoter region of the miR-17-92 
cluster. For this analysis, we amplified a ~90 
bp DNA fragment (segment A1 in Fig. 2A) 0.1 
kb downstream of the functional c-Myc E3 
site. The same DNA segment was analyzed in 
a previous study (10). Our ChIP analysis 
revealed that not only c-Myc, as expected, but 
also Pim-1 localizes to this genomic region 
(Fig. 2B, upper and middle panels). Indeed, 
this is consistent with the finding that Pim-1-
catalyzed H3S10 phosphorylation is required 
for c-Myc-dependent transcriptional activation 
(24). We further analyzed another known 
phosphorylation target of Pim-1, the 
heterochromatin protein-1 gamma (HP1) (22), 
for its association with the E3 region. HP1 
localized to this genomic area as well (Fig. 2B, 
lower panel). Moreover, we were able to 
identify an association of HP1 along the 
miRNA coding region which is indicative of 
active transcription (see Fig. S3 and 
Discussion section).  
Transcriptional activity of the human miR-
17-92 cluster depends on c-Myc and Pim-1 - 
To further substantiate the role of Pim-1 in 
miR-17-92 cluster expression we quantified 
the cellular pri-mir-17-92 levels by qRT-PCR 
after siRNA-mediated Pim-1 knockdown 
relative to a c-Myc knockdown in K562 and 
HeLa cells. Since combined ChIP and reporter 
gene  assays suggested that transcription factor 
E2F3 is a major activator of transcription 
initiated at the host gene promoter (17,18), we 
included E2F3 in our knockdown experiments 
as a possible measure for the contribution of 
the host gene promoter to miR-17-92 
expression. We also quantified the levels of c-
Myc, E2F3 and Pim-1 mRNAs after 
knockdown by qRT-PCR to evaluate 
knockdown efficiencies (Table S1). For Pim-1, 
we have shown good correlation between 
mRNA and protein levels (27). In the study 
presented here, only experiments with a 
knockdown efficiency > 50 % were considered 
(Table S1). Single knockdowns of either c-
Myc, E2F3 or Pim-1 decreased the pri-mir-17-
92 levels in HeLa cells to ~35, 60 and 60 %, 
respectively, relative to the control siRNA 
(Fig. 3B), and to ~30, 30 and 45 %, 
respectively, in K562 cells (Fig. 3C). Double 
knockdowns had additive suppression effects 
on pri-mir-17-92 levels in the case of c-
Myc/E2F3 (HeLa and K562), c-Myc/Pim-1 
(Hela) and E2F3/Pim-1 (HeLa).  
 
DISCUSSION 
Transcription of the oncogenic miR-17-92 
cluster is thought to originate from two 
different TSSs: one is localized in close 
proximity to the host gene promoter element 
(17) (Fig. S1), and the other TSS was predicted 
to map to the region ~200 bp downstream of 
the functional c-Myc site E3 (Fig. 1A, S1). The 
latter prediction was based on nucleosome 
mapping and chromatin signatures for active 
promoters. The derived algorithm identified 
175 human promoters proximal to miRNA 
coding sequences, and was reported to 
correctly predict transcription initiation regions 
to a resolution of 150 bp with high sensitivity 
and specificity. The majority of predictions 
were also consistent with known “expressed 
sequence tag” (EST) TSSs or cDNA 5’-ends 
(16).   
Here, we investigated the intronic A/T-rich 
region preceding the human miR-17-92 cluster 
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in more detail than previously done by similar 
reporter gene assays (16,20,21). In addition, 
we analyzed the impact of an siRNA-mediated 
c-Myc knockdown (efficieny ~80 %) on 
reporter expression in K562 cells. The 
observed effect was similar to the one obtained 
by reducing the 1.5 kb fragment to 625 bp 
(Fig. 1), which deleted the c-Myc E3 site. Our 
findings substantiate the notion that this site 
plays a crucial role in activating transcription 
from the intronic promoter region (16,20,21). 
Noteworthy, the 625 bp and even some of the 
further truncated fragments (~280 and ~200 
bp) of the A/T-rich region conferred residual 
specific promoter activity in both cell types 
(Fig. 1), indicating that parts of the A/T-rich 
region, downstream and independent of the c-
Myc E3 site, contribute to cluster expression. 
This c-Myc E3 box-independent activation was 
more pronounced for K562 relative to HeLa 
cells, which correlates with the particularly 
high cluster expression in K562 cells (Fig. S2).   
ChIP assays revealed that c-Myc, the 
protooncogene Pim-1 and its phosphorylation 
target HP1 associate with the chromatin 
region harboring the c-Myc E3 site (Fig. 2B). 
Importantly, Pim-1-catalyzed phosphorylation 
of H3S10 at c-Myc target genes is necessary to 
regulate key genes required for c-Myc-
dependent oncogenic transformation (26). 
 In mammals, three paralogs of HP1 (,  
and ) regulate heterochromatin formation, 
gene silencing or gene activation (28,29). 
HP1 and  proteins are mainly recruited to 
heterochromatin regions harboring 
H3K9me2,3 modifications, whereas HP1 is 
found in association with euchromatin (30) and 
active genes (29). Furthermore, HP1c, the 
Drosophila homolog of HP1, associates with 
trancriptionally active chromatin containing 
H3K4me3 and H3K36me3 histone marks (28). 
HP1 can further be recruited to inducible 
promoters where it replaces HP1, thereby 
inducing a switch from the repressive to the 
active transcriptional state. This replacement 
with HP1 requires H3 phospho-acetylation 
(31). In this context, a transient 
phosphorylation of H3S10 (via Aurora B 
kinase) was shown to be necessary for the 
dissociation of HP1 proteins from chromatin 
during M phase of the cell cycle (32). In the 
induced state, HP1 can also be localized 
within coding regions of protein genes together 
with elongating RNA polymerase II (31).  
Our data, showing that HP1colocalizes 
with Pim-1 and c-Myc (Fig. 2), is in line with 
the aforementioned activating role of HP1 
during transcription. We extended our ChIP 
assays to the miRNA coding region of 
C13orf25 to analyze HP1 association with 
this part of the cluster. Indeed, ChIP analysis 
along the miRNA coding sequence identified 
HP1 at all four analyzed subregions (A2-A5, 
Fig. S3). This is to our knowledge the first 
indication that HP1 is involved in the 
activation of miRNA gene transcription.   
Association of Pim-1 with the intronic 
chromosomal region near the c-Myc E3 site 
gave rise to the assumption that Pim-1 plays an 
important role in the transcriptional activation 
of the miR-17-92 cluster. This was tested by 
RNAi also including E2F3 as an assumed 
indicator of host gene promoter activity. The 
strong negative effects of individual 
knockdowns of c-Myc, Pim-1 and E2F3 on pri-
mir-17-92 levels indicate that all three proteins 
are important for cluster expression and 
suggests their direct involvement in C13orf25 
expression, either affecting transcription from 
the host gene promoter (E2F3) or the intronic 
promoter region (c-Myc, Pim-1). Of course, 
we cannot exclude that indirect effects have 
contributed as well, e.g. due to effects 
originating from inhibition of cell proliferation 
(Pim-1), changes in the kinetics of pri-mir-17-
92 processing, global changes in 
transcriptional networks (E2F3, c-Myc) or 
mutual transactivation (E2F3 and c-Myc) (33-
35). Further complication may arise from the 
fact that miR-17-5p and miR-20a of the cluster 
are negative regulators of E2F1-3 mRNAs (10, 
18). 
The siRNA-mediated c-Myc knockdown, 
decreasing c-Myc mRNA levels on average by 
65 % (HeLa) or 81 % (K562; see Table S1), 
resulted in a 60-70 % reduction in pri-mir-17-
92 levels in HeLa and K562 cells (Fig. 3). This 
effect may report a rough estimate of the 
proportion of cluster transcripts normally 
initiated in the intronic promoter region in 
these two cell lines, for the following reasons. 
The C13orf25 region contains four c-Myc 
binding sites (boxes E1-4) and two additional 
ones with lower c-Myc occupancy (relative to 
E1) upstream of the host gene promoter (20). 
Box E1, immediately downstream of host gene 
promoter’s TSS, was shown by deletion 
analysis to be inhibitory, which correlates with 
c-Myc forming heterodimers with MXI or 
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MNT at this site to repress transcription (20). 
Thus, host gene promoter activity may even 
somewhat increase under conditions of a c-
Myc knockdown, although such an effect 
could in turn be neutralized by reduced c-Myc-
mediated transactivation of E2F (35). ChIP-
Seq data for K562 and HeLa-S3 cells revealed 
the by far highest c-Myc occupancy at site E3 
(little at E2 and E4), where c-Myc forms 
heterodimers with MAX to activate 
transcription (20). A straightforward 
interpretation of the additive effect of a c-
Myc/E2F3 double knockdown in Hela and 
K562 cells is that this combination negatively 
affected transcription from the host gene and 
intronic promoter regions.  
A major finding of our study is the 
involvement of the oncogenic kinase Pim-1 in 
miR-17-92 expression, as inferred from its 
recruitment to the intronic c-Myc E3 site (Fig. 
2) and the strong negative effect of a Pim-1 
knockdown on cluster expression (Fig. 3B and 
C). Moreover, double knockdown experiments 
in HeLa cells revealed a synergistic effect 
relative to individual c-Myc and Pim-1 
knockdowns (Fig. 3B). This was not seen for 
K562 cells, attributable to the extremely high 
expression of Pim-1 in this cell line (27) which 
makes it more difficult to deplete Pim-1 in 
K562 cells below a crititcal threshold. 
Furthermore, the siRNA-mediated reduction of 
c-Myc and Pim-1 mRNAs were on average 86 
% and 77 % in HeLa and 86 % and 52 %, 
respectively, in K562 cells (Table S1). The 
somewhat weaker suppression of Pim-1 in the 
c-Myc/Pim-1 double knockdown context (cf. 
with single knockdowns, Table S1) in K562 
versus HeLa cells may have contributed to the 
absence of a clear additive effect upon c-
Myc/Pim-1 double knockdown in K562 cells.  
In conclusion, we report here that miR-17-
92 cluster expression from the intronic A/T-
rich promoter region, although critically 
depending on c-Myc binding, includes a c-
Myc-independent specific contribution of 
sequences within 0.7 kb upstream of the 
mature miR-17-5p coding sequence. Our 
reporter expression data suggest multiple TSSs 
within this A/T-rich region, although the 
transcription initiation region predicted by 
Ozsolak et al. (16), 0.2 kb downstream of the 
c-Myc E3 box, may well be the major one. C-
Myc-independent transcription initiation 
within 0.7 kb upstream of the mature miR-17-
5p coding sequence was more pronounced in 
K562 versus HeLa cells (Fig. 1), indicating 
cell type-specific differences in cluster 
expression from the intronic promoter region. 
Our RNAi results are consistent with E2F3 
activating the C13orf25 host gene promoter 
and Pim-1 acting in concert with c-Myc at the 
E3 site to activate transcription from the 
intronic promoter region.  
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FIGURE LEGENDS 
 
FIGURE 1. (A) Genomic organization of C13orf25. The locus consists of four exons and three 
introns; the six miRNAs of the miR-17-92 cluster are encoded in intron 3. Sequences upstream of the 
cluster can be subdivided into a G/C-rich CpG island and an A/T-rich downstream part. The host gene 
promoter thought to be activated by E2F3 is located in the CpG island about 3.4 kb upstream of the 
miR-17-5p coding sequence. The functional c-Myc site (E3) is located 1.5 kb upstream of miR-17-
5p. Sequence numbering is based on the NCBI reference sequence NG_032702.1 and the 
GRCh37/hg19 assembly (http://genome.ucsc.edu). Note that previous related studies referred to the 
numbering system of the previous hg18 assembly (16,17,20,21). The numbering of the hg18 and hg19 
assemblies is correlated as follows: nt 92,002,872 (0 kb in Fig. 1A) of hg19 is nt 90,800,873 of hg18. 
(B) Schematic representation of the different C13orf25 portions fused to the luciferase structural gene. 
The functional E3 box for c-Myc binding is indicated in the 1.5 kb construct (white vertical line). (C) 
Promoter activities of the different luciferase reporter constructs in K562 and HeLa cells. Obtained 
luciferase activities were normalized to the pGL3 control plasmid carrying the SV40 promoter 
(Promega). A reporter construct lacking the SV40 promoter as well as a construct harboring the 339 
bp fragment of the A/T-rich intronic region in inverted orientation were used as controls. RLU values 
of the individual constructs were derived from 5 to 16 experiments (+/- S.E.M.). 
 
FIGURE 2. (A) Schematic representation of the intronic A/T-rich region preceding the miR-17-92 
coding sequence. The region A1 defines the genomic sequence 0.1 kb downstream of the functional c-
Myc binding site (E3 box) that was amplified in ChIP analyses. (B) ChIP analysis of the intronic 
region A1 in K562 cells, using antibodies specific for c-Myc, Pim-1 and HP1. + AB: with antibody; - 
AB: without antibody; Mock: buffer only without cell lysate; Input: supernatant of the - AB-sample 
after immunoprecipitation and centrifugation (for details, see Supplementary Material).  
 
FIGURE 3. (A) Illustration of the primers (arrows) used for the qRT-PCR quantification of pri-mir-
17-92 transcript levels. (B) Quantitative RT-PCR of pri-mir-17-92 transcript levels in HeLa cells after 
siRNA-mediated knockdown of c-Myc, E2F3 or Pim-1and after combined knockdown of c-
Myc/E2F3, c-Myc/Pim-1 or E2F3/Pim-1. 2^-pri-17-92 values were normalized against 5S rRNA 
and an internal control siRNA (si VR1), representing mean values from at least three independent 
experiments (+/- S.E.M.). Statistical analyses were done using the software R. (C) Same as in panel B, 
but using K562 instead of HeLa cells. 
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SUPPLEMENTARY MATERIAL 
 
Supplementary methods 
 
Cell culture - Cells (K562 and HeLa) were cultivated under standard conditions in a 
humidified atmosphere (37 °C, 5 % CO2) supplemented with RPMI 1640 (K562) or IMDM 
(HeLa) containing 10 % FCS (PAA, Cölbe, Germany). 
Chromatin immunoprecipitation (ChIP) - 2 • 107 K562 cells in 13 mL RPMI medium were 
crosslinked with 1 % formaldehyde for 10 min at 37 °C. Reactions were stopped by adjusting 
to 0.125 M glycine, and cells were collected by centrifugation at 400 g for 5 min at room 
temperature. For cell lysis, cells were resuspended in 750 µL RIPA-buffer (10 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1 % deoxycholate, 1 % NP40, 0.1 % SDS, 0.2 mM PMSF) 
supplemented with the cOmplete Mini Protease Inhibitor Mix from Roche (Mannheim, 
Germany) according to the manufacturer’s instructions. Lysed cells were sonicated in a 
Branson Sonifier 250 (duty cycle 50 %, output control 2, for 3.5 min, on ice water) 
(Heinemann, Schwäbisch Gmünd, Germany) and centrifuged at 16.000 g for 10 min at 4 °C. 
The supernatant was pre-cleared with 10 µL of blocked Staphylococcus aureus cells 
(Pansorbin
®
 Cells, Calbiochem/Merck, Darmstadt, Germany) for 15 min at 4 °C on a rotor 
wheel. After a second centrifugation step (16.000 g, 5 min, room temperature), the 
supernatant was split into two samples (each ~350 µL, representing + and – specific antibody 
(AB)), which were adjusted to buffer D (16.7 mM Tris-HCl pH 8.1, 167 mM NaCl, 1.2 mM 
EDTA, 1.1 % Triton-X 100, 0.01 % SDS) and a total volume of 500 µL. 1 µg (1 to 5 µL) of 
the respective antibody was added to “+ AB” samples, whereas the same volume buffer D 
was added to “- AB” samples. At this point, also the “Mock” control was prepared, consisting 
of 500 µL buffer D. “+ AB”, “- AB” and “Mock” samples were then incubated for at least 3 h 
at 4 °C. The following antibodies were used: monoclonal anti-c-Myc (sc-40) and anti-Pim-1 
(sc-13513) (Santa Cruz Biotechnology (Heidelberg, Germany), anti-Phospho HP1 (Ser83) 
polyclonal antibody (2600S) (Cell Signaling Technology, Danvers, MA, USA). In the case of 
mouse monoclonal antibodies (c-Myc and Pim-1), samples were additionally incubated for 1 
h with a second monoclonal goat anti-mouse IgG antibody (sc-2005, Santa Cruz 
Biotechnology, Heidelberg, Germany). Immunoprecipitation was initiated by adding 10 µL of 
Pansorbin
®
 cells (see above) to the “+ AB”, “- AB” and “Mock” samples, followed by 
incubation for 15 min at room temperature. Samples were centrifuged (16.000 g, 3 min, room 
temperature); the supernatant of the “- AB” sample was saved, later serving as the input 
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control. Pellets were washed twice with dialysis buffer (50 mM Tris-HCl pH 8.0, 2 mM 
EDTA) and four times with IP-wash buffer (100 mM Tris-HCl pH 9.0, 500 mM LiCl, 1 % 
NP40, 1 % deoxycholate). Antibody-bound material was eluted from Pansorbin
®
 cells by 
adding 150 µL elution buffer (50 mM NaHCO3, 1 % SDS), vortexing for 3 s, and 
centrifugation (16.000 g, 3 min, room temperature). The supernatant was collected and the 
procedure was repeated. Reverse crosslinking and RNA digestion was performed in 280 µL 
buffer (0.3 M NaCl, and 1 µL RNase A (10 mg/mL)) for 5 h at 67 °C. Chromatin was 
precipitated with ethanol, followed by a Proteinase K digest (Thermo Fisher Scientific). DNA 
was purified by phenol/chloroform extraction and ethanol precipitation in the presence of 0.3 
M NaOAc, pH 5.2. PCR amplification using Taq DNA polymerase and the co-
immunoprecipitated DNA as template was done under the following conditions: 2 min at 95 
°C in the absence of enzyme, followed by 35 amplification cycles of 45 s at 95 °C / 45 s at 60 
°C / 45 s at 72 °C using the following primers: 
A1 forward 5’-AAA GGC AGG CTC GTC GTT G 
A1 reverse 5’-CGG GAT AAA GAG TTG TTT CTC CAA 
A2 forward 5’-ACA TGG ACT AAA TTG CCT TTA AAT G 
A2 reverse 5’-AAT CTT CAG TTT TAC AAG GTG ATG 
A3 forward 5’-ACT GCA GTG AAG GCA CTT GT  
A3 reverse 5’-TGC CAG AAG GAG CAC TTA GG 
A4 forward 5’-CCA ATA ATT CAA GCC AAG CAA 
A4 reverse 5’-AAA TAG CAG GCC ACC ATC AG  
A5-forward 5’-GCC CAA TCA AAC TGT CCT GT 
A5-reverse 5’-CGG GAC AAG TGC AAT ACC AT 
Transfection of reporter constructs - For transfection of the suspension cell line K562, 
cells were washed in medium without serum, followed by electroporation in a BioRad Gene 
Pulser XCell (München, Germany) with a single pulse in a 4 mm cuvette, using 5 µg of the 
respective pGL3 derivative plasmid per million cells. 48 h after transfection, cells were 
washed in PBS, lysed and prepared for luciferase reporter assay measurements. 
Transfection of siRNAs - Transfection of the suspension cell line K562 was performed by 
electroporation. After a washing step in medium without serum, 106 cells were mixed with 1 
µg of siRNA (VR1 siRNA, Pim-1 siRNA, c-Myc siRNA or E2F3 siRNA). For the double 
knockdown experiments, 1 µg of each siRNA, respectively, was used. Cells were 
electroporated at 330 V with a single pulse in a BioRad Gene Pulser XCell (München, 
Germany) using a 4 mm cuvette. After electroporation, K562 cells were resuspended in 
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medium containing 10 % FCS and cultivated in a humidified atmosphere at 37 °C for 24 h. 
Cells were washed with PBS and prepared for total RNA extraction. 
Transfection of HeLa cells was done using the transfection agent Lipofectamine
TM
 2000 
(Life Technologies Invitrogen, Darmstadt, Germany). One day before transfection, 8 • 104 
cells were seeded into 24-well plates and cultivated under standard conditions. SiRNA 
complexes (VR1 siRNA, Pim-1 siRNA, c-Myc siRNA or E2F3 siRNA) were prepared 
according to the manufacturer's protocol. To perform single knockdown experiments, 40 pmol 
of the respective siRNA were used. In case of the double knockdown experiments, 20 pmol of 
each siRNA were mixed in Opti-MEM
®
 1 (Life Technologies Invitrogen, Darmstadt, 
Germany). 4 to 6 h after transfection, the medium was replaced with IMDM containing 10 % 
FCS. Cells were cultivated 48 h under standard conditions until preparation for total RNA 
extraction. 
RNA preparation and quantitative real-time PCR – For total RNA isolation, transfected 
cells (K562 or HeLa) were lysed (vortexing or mixing by pipetting up and down) in 750 µL 
lysis solution (0.8 M guanidinium-thiocyanate, 0.4 M ammonium-thiocyanate, 0.1 M sodium 
acetate pH 5.0, 5 % glycerin, 38 % phenol pH 4.5-5.0 [Roth®-Aqua-Phenol, Roth, Karlsruhe, 
Germany], 1 pellet 8-hydroxychinolin). Then, 200 µL of chloroform was added and phases 
were separated by centrifugation. The aqueous phase was mixed with 2 volumes of 
isopropanol, followed by incubation for 15 min at room temperature and centrifugation. The 
air-dried RNA pellet was dissolved in RNase-free water and incubated for 30 min at 37 °C 
with 1 U DNase I per µg RNA in 100 µL 1 x DNase I buffer (DNase I, Thermo Fisher 
Scientific, Schwerte, Germany) according to the manufacturer’s instructions. Then, another 
identical aliquot of DNase I was added, followed by incubation at 37 °C for another 30 min. 
Samples were extracted with an equal volume of Roth®-Aqua-Phenol (see above), followed 
by extraction of the aqueous phase with chloroform and isopropanol precipitation as above. 
RNA pellets were finally washed with 75 % ethanol, air-dried and redissolved in 10 µL 
RNase-free water. 0.5 to 1 µg of total RNA were reverse-transcribed with RevertAid H Minus 
RT Polymerase (Thermo Fisher Scientific) according to the manufacturer's protocol. For 
determination of KD efficiencies a random hexamer primer was used to generate cDNA 
samples. In case of calculating pri-mir-17-92 levels the gene-specific reverse primer specified 
below was used for cDNA synthesis. Quantitative RT-PCR was performed in duplicate in a 
BioRad iQ
TM
5 (BioRad, München, Germany) with the Absolute qPCR SYBR Green 
Capillary Mix (Thermo Scientific AbGene, Hamburg, Germany); cDNAs were diluted 1:5 or 
1:10 and 4 µL of the reaction mixture used for determining RNA transcription levels. 
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Quantitative PCR assays for miRNA detection were conducted as follows: Thermo-Start™ 
DNA polymerase was activated for 15 min at 95 °C followed by 55 amplification cycles of 10 
s at 95 °C / 20 s at 60 °C / 12 s at 72 °C. Subsequently, melting curves of the PCR products 
were generated: samples were cooled from 95 °C to 65 °C (20 °C per s), kept at 65 °C for 20 
s, followed by heating steps of 1 °C per cycle up to 95 °C and kept for 10 s at 95 °C.  
Quantitative RT-PCR assays for mRNA detection were changed as follows: Thermo-
Start™ DNA polymerase was activated for 15 min at 95 °C followed by 55 amplification 
cycles with a denaturation step for 10 s, primer annealing for 10 s at 55 °C and amplification 
at 72 °C for 10 s. Subsequently, a melting curve was generated for the PCR products; samples 
cooled from 95 °C to 65 °C (20 °C per s), kept at 65 °C for 20 s, followed by heating steps of 
1 °C per cycle up to 95 °C and kept for 10 s at 95 °C.   
The mRNA and pri-mir-17-92 levels were calculated from the crossing points by the 2^-
∆∆CT method (Schmittgen and Livak, 2008) using -Actin mRNA or 5S rRNA as internal 
controls. Knockdown efficiency was quantitated by qRT-PCR and only those experiments 
showing more than 65 % reduction in protein levels were used for quantification of pri-mir-
17-92 levels. All primers for qPCR measurements were purchased from Metabion 
(Martinsried, Germany) and designed using the software tool Universal ProbeLibrary (Roche 
Applied Biosystems, Mannheim, Germany). A list of all primer sequences according to the 
human sequences is shown underneath: 
Pri-mir-17-92: forward primer 5’-CAT CTA CTG CCC TAA GTG CTC CTT and reverse 
primer 5’-GCT TGG CTT GAA TTA TTG GAT GA;  
5S rRNA: 5‘- TCT CGT CTG ATC TCG GAA GC and 5‘- AGC CTA CAG CAC CCG GTA 
TT;  
c-Myc mRNA: forward primer 5‘-CCT TGC AGC TGC TTA GAC and reverse primer 5’-
GAG TCG TAG TCG AGG TCA T;  
E2F3 mRNA: forward primer 5’-GAG ACT GAA ACA CAC AGT CC and reverse primer 
5’-CCT GAG TTG GTT GAA GCC;  
Pim-1 mRNA: forward primer 5'-ATC AGG GGC CAG GTT TTC T and reverse primer 5'-
GGG CCA AGC ACC ATC TAA T;  
Actin mRNA: forward primer 5'-CCA ACC GCG AGA AGA TGA and reverse primer 5'- 
CCA GAG GCG TAC AGG GAT AG. 
Luciferase reporter assays - Luciferase reporter assays were performed using the Promega 
Luciferase Assay System (Promega, Mannheim, Germany). After aspirating the medium, cells 
were washed with PBS and lysed in 100 µL 1.2 x reporter lysis buffer. In a 96-well plate, 10 
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µL of the respective cell lysate were mixed with 10 µL of luciferase substrate. 
Chemiluminescence was measured immediately in a Safire
2 TM
 micro-plate reader (Tecan, 
Crailshaim, Germany). 
Plasmid construction and seed mutagenesis - All primers, which were used for plasmid 
construction and seed mutagenesis, are listed below (restriction sites in italics): 
pGL3 1.5 kb: 5’-ATA TAG ATC TTG CCG CCG GGA AAC GGG TT and reverse primer 
R1 5’-ATA TAA GCT TCC ATA CAA ATT CAG CAT AAT CCC TAA TGG; 
pGL3 625 bp: 5’-ATA TAG ATC TCT TTA GAC AAT GTA CCT TTT CTG and reverse 
primer R1 (see above); 
pGL3 339 bp: 5'-ATA TAG ATC TGT GGA AGC CAG AAG AGG AGG A and reverse 
primer R1 (see above); 
pGL3 279 bp: 5'-ATA TAG ATC TGG TAC ACA TGG ACT AAA TTG CC and reverse 
primer R1 (see above); 
pGL3 197 bp: 5’-ATA TAG ATC TCT CTA TGT GTC AAT CCA TTT GGG AG and reverse 
primer R1 (see above); 
pGL3 250 bp: 5‘-ATA TAG ATC TGT GGA AGC CAG AAG AGG AGG A and reverse 
primer R3 5’- ATA TAA GCT TGC CTT AAG AAT TCT TTA CAG AAG GC; 
pGL3 190 bp: 5‘-ATA TAG ATC TGG TAC ACA TGG ACT AAA TTG CC and reverse 
primer R3 (see above); 
pGL3 108 bp: 5’-ATA TAG ATC TCT CTA TGT GTC AAT CCA TTT GGG AG and reverse 
primer R3 (see above); 
pGL3 339 inv: 5’-ATA TAA GCT TGT GGA AGC CAG AAG AGG AGG A and 5’-ATA 
TAG ATC TCC ATA CAA ATT CAG CAT AAT CCC TAA TGG. 
Bioinformatical promoter analysis - For promoter analyses of the intronic A/T-rich region, 
a sequence of 1490 bp (human), beginning at the functional c-Myc site (E3) and ending at the 
5’-end of the first mature miRNA sequence, miR-17-5p (for details, see Fig. S1), was 
analyzed with several web-based promoter prediction tools. The following tools were used to 
predict promoter elements or putative TSSs:  
Neural Network promoter prediction: (Reese, 2001) 
(http://www.fruitfly.org/seq_tools/promoter.html);  
McPromoter006: (Ohler, 2006) 
(http://tools.genome.duke.edu/generegulation/McPromoter/);  
Promoter 2.0 Prediction Server: (Knudsen, 1999) (http://www.cbs.dtu.dk/services/Promoter/);  
PromPredict: (Rangannan and Bansal, 2009) 
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(http://nucleix.mbu.iisc.ernet.in/prompredict/prompredict.html).  
Putative TSSs were predicted and calculated using the software available at 
http://rulai.cshl.org/tools/genefinder/CPROMOTER/human.htm (Zhang, 1998).  
All promoter prediction tools predicted several different promoter elements in the 1.5 kb 
region upstream of miR-17-5p and only the web-based tool Promoter 2.0 failed. The 
calculated promoter predictions of the indicated tools did not match in any sequence region, 
giving the assumption that the A/T-rich 1.5 kb intronic region in front of the miR-17-92 
coding sequence has only weak promoter activity itself. Due to the fact that this intronic 
region has an overall high A/T-content, nearly all software programs were able to detect 
putative promoter regions. 
Statistical analysis - Statistical analyses were done using the software R (R Core Team, 
2012). P-values were calculated with the Welch Two Sample Test. 
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Supplementary figure legends 
 
Fig. S1: Relevant sequence region of C13orf25, including the CpG island harboring the host 
gene promoter, the A/T-rich region, and the miR-17-92 cluster; sequence and position of the 
last exon 4 of C13orf25 is indicated at the end. Shown sequences are based on the NCBI 
reference sequence NG_032702.1 and the GRCh37/hg19 assembly (http://genome.ucsc.edu). 
The boundaries of the CpG island, important previously identified regulatory elements, 
mature miRNA coding sequences and relevant primer sequences are highlighted in the 
sequence and annotated at the margins. 
 
Fig S2. Quantitative RT-PCR of the pri-mir-17-92 transcription levels in the human cell lines 
K562, HeLa and HUH7. 2^-pri-mir-17-92 values are normalized against 5S rRNA and 
obtained from at least 3 independent experiments (+/- S.E.M.). The amount of pri-mir-17-92 
transcript in K562 cells was set to 1.   
 
Fig. S3. (A) Schematic representation of the intronic A/T-rich region preceding the miR-17-
92 coding sequence. The region A1 defines the genomic sequence 0.1 kb downstream of the 
functional c-Myc binding site (E3 box) that was amplified in ChIP analyses. A2 covers a 
segment immediately upstream of the miRNA-coding region; A3-A5 are located along the 
coding sequence of the human miR-17-92 cluster. The length (bp) of each amplicon is 
indicated at the top. (B) ChIP analysis of the regions A1 to A5 in K562 cells, using an 
antibody specific for HP1or RNA polymerase II (only A2 analyzed); +AB: with antibody; -
AB: without antibody; Mock: buffer only without cell lysate; Input: supernatant of the “- AB” 
sample after immunoprecipitation and centrifugation (for details, see Supplementary 
Material). (C) ChIP analysis of the A2 region in HeLa cells using the antibody specific for 
HP1 
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Table S1: 
 
K562 c-Myc KD E2F3 KD Pim-1 KD 
 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
 0.13 77 0.21 95 1.23 72 
 0.02 87 0.16 98 0.16 69 
 0.56 59 0.60 19 1.39 55 
 0.75 74   0.76 59 
 0.33 75   0.22 49 
 0.14 99   2.38 78 
 0.20 97   1.84 87 
 0.55 80   0.80 88 
     0.27 85 
     0.40 89 
     0.52 67 
     0.69 65 
     0.37 87 
Mean 0.33 81 0.34 89 0.47 73 
SEM 0.09 5.0 0.15 8.0 0.08 5.0 
 
 
      
K562 c-Myc / E2F3 KD c-Myc / Pim-1 KD Pim-1 / E2F3 KD 
 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
 0.22 82 / 75 0.45 72 / 55 0.69 88 / 86 
 0.23 86 / 72 0.19 90 / 54 0.56 68 / 73 
 0.15 81 / 48 0.19 95 / 48 0.19 95 / 99 
 0.08 99 / 99   0.52 87 / 81 
 0.04 99 / 99   0.23 91 / 93 
       
Mean 0.15 89 / 79 0.28 86 / 52 0.44 86 / 86 
SEM 0.04 4.0 / 9.6 0.08 7.0 / 2.2 0.09 4.7 / 4.5 
 
 
HeLa c-Myc KD E2F3 KD Pim-1 KD 
 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
 0.37 70 0.72 51 0.50 47 
 0.29 82 0.66 78 0.34 72 
 0.32 61 0.40 76 0.71 63 
 0.41 99 0.53 73 0.58 80 
 0.48 55 0.64 73 0.54 87 
 0.37 64   0.78 72 
     0.70 76 
Mean 0.37 65 0.59 70 0.59 71 
SEM 0.03 6.7 0.07 6.3 0.06 4.9 
 
 
      
HeLa c-Myc / E2F3 KD c-Myc / Pim-1 KD Pim-1 / E2F3 KD 
 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
2^-∆∆CT pri-mir-
17-92 
KD 
efficiency 
 0.24 79 / 64 0.24 79 / 84 0.49 81 / 96 
 0.13 91 / 81 0.25 77 / 61 0.33 91 / 85 
 0.11 93 / 86 0.15 86 / 58 0.10 97 / 94 
 0.12 90 / 91 0.12 95 / 91 0.26 92 / 94 
 0.23 87 / 74 0.41 84 / 73   
 0.26 83 / 66 0.10 97 / 95   
Mean 0.18 87 / 77 0.21 86 /77 0.30 90 / 92 
SEM 0.03 2.2 / 4.4 0.053 3.3 / 6.0 0.08 3.3 / 2.5 
NCBI Reference Sequence: NG_032702.1  
 
Homo sapiens mir-17-92 microRNA cluster containing MIR17HG, MIR17, MIR18A, 
MIR19A, MIR19B1, MIR20A, and MIR92A1 (MIR17-MIR92); and microRNA 17 (MIR17); 
and miR-17-92 cluster host gene (non-protein coding) (MIR17HG); and microRNA 
18a (MIR18A); and microRNA 19a ... 
 
 
91,995,073 – 
 
91,999,514 AAGGGCCGGT AAAGTAATAA ACTGTGATCG CACAGCGTAC ACGTCGAGTC CCAGGGAGAG 
91,999,574  CAGGGCTCCC AGGAAGCCCC GGGAAGCGTG CGCTTCCAGG AGGGTGTGCG GCGCGCGGGG 
91,999,634 GTCTGCACGC GCGCAGAGCT TGTTAACGGA GGGCGTGCCG GAGGCGTGGC GCGAGGTGTT 
91,999,694 CGGGCGAGGC GCTCCGCGAG GCTGGCGGCG GTGGGCGGGC CACGGGGGAG CGCGGCCCGG 
91,999,754 GGAAGGCTGC GCGGCGCCGC CAGCGGCTCC CGGCTCCCGC TCTCCCGGCC GCCAAGAACG 
91,999,814 AGCCGCCGTG GGCGGGGCCT GCGGTGATTG GCGGGCGGGC GGGGAGGTCG GAAGTACTTT 
91,999,874 GTTTTTTATG CTAATGAGGG AGTGGGGCTT GTCCGTATTT ACGTTGAGGC GGGAGCCGCC 
91,999,934 GCCCTTCATT CACCCACATG GTCCTTCGAG GTGCCGCCGC CGCCGCCCGA CCTGCGCCTT 
91,999,994 CGCGCCACTT CGCGCCCTCG GGCGAGGCCG AGGGGGTGGG GACGACTACC GCAGCGCCGC 
92,000,054 CGGGGCTCGC GCTCCTCCGC GAAGCTCTCC TCGCGGGGCG GGCCGGCCGG CCGCACCCCC 
92,000,114 GGCCTGGGGC CTCCGGTCGT AGTAAAGCGC AGGCGGGCGG GGAGGCGGGA GCAGGAGCCC 
92,000,174 GCGGCCGGCC AGCCGAAGAT GGTGGCGGCT ACTCCTCCTG GTGAGTCTGC CCGCCCCTCC 
92,000,234 GGCGACGGAG GGAAACCTGT TGTGTGCGGC CCGGGTCTGG CGGGCGGGGC GGAGCGGCCC 
92,000,294 GGGGCGGACT GGCCCGGGGC AGCGTGGCGG CGGCGGCGTG GCCGGGGCGG GTCTCGGCCG 
92,000,354 TTGGCCGCCC CGGCGTGTGG CAGCCGCATC TGGCTGCCCC CTCGCTCGCC CGCGGGCCGG 
92,000,414 CGGAGGGGGG CAGGGCCGGG GCGGGAGGGT GGGAGGGGGC GGCGTGCGCG TGGCGGCCGC 
92,000,474 GCCCGGGACC CGCGCAGACC CTGCCTGGGC CGACCCGAAG GCGGGTGGGC GGACGGCGAA 
92,000,534 CACAATGGCC CCTCGGGGAG AGGACGTGCG AGGCCCGTGC CTTCTCCGGG GCCCGGGGCG 
92,000,594 CGCGCGGGGC GTGGGGTCTC TGGGTAGGAA AGTTTCTCCC GAGGGCGAGA GTTAAAGCGC 
92,000,654 CTCCAGAACA AAGCGGCGGC GGCGGCGGCA CATGGGGCAG GCCGCGGGCC GGGAGGGGGC 
92,000,714 GCGCCCACGA GGTACCTGCG CGCCAGCGGG CGGCGTGGCG TGGGCGGGAG CCCGCGGTTC 
92,000,774 CCCAAACTTT GTACGCGCGA GGGTGGGCGG AGGGGCGCCG AGATCGGCGC GGCCTGGGCG 
92,000,834 CCACCCCCGC TCCGCGTGGG CTTTGTTAGC CCGCGTGGGC AGCCTCGGGG CGGGGCCCGC 
92,000,894 AACTTCCCCG CCGTGGCCCT CGGAGGAGGC CGCAGTCGGC CTCAGCCGCG GCGTGGAGCC 
92,000,954 GCCTGCGCCC GGCCGCTTGC TGGGAGTGTG GCGCGGGAGG GCCAGCCCGG CTCGGCGGGA 
92,001,014 GCGGCGTCCC CGCCGCCATG TTCCTGCGGG GCGGGCTGCA CGGGGGTGAG GGCGGGGGAC 
92,001,074 ATGGCGGCGA CTGCGCGCCG CCGCCGATTG TTCCCGGCTT AGGCCTCGGG CCGCGTGCGA 
92,001,134 CGGGCACCGC GGCCGCGGAG CCCCCGCCCC TCTGGGCCGG GCTCGGGGGG GCTGGGGGAC 
92,001,194 ACAAAGGAGG GGCGGCGCGC CCGCGTCCCC GCCGCACTCG GGCCTCGGCG CCGCCGGTCG 
92,001,254 CCGCGCGGCT GCCGCCGGGA AACGGGTTGG GGGGGTTGCC GCGTCCGGCG GGGCCTGACT 
92,001,314 CTGACCCGCC GCCCCCTGGC GGCTACGCGG AGAATCGCAG GGCCGCGCTC CCCCTTGTGC 
92,001,374 GACATGTGCT GCCGGCCCGG GCTCCATGAG CGTGGCGGGC ACTTTGCAGT CTCGGGTGTT 
92,001,434 CCTGCCCGGT CTTCTGTTCC TAAACTGCAG CAAAGGGAAA AGGAACTGAA AAAGGCAGGC 
92,001,494 TCGTCGTTGC AATATCACCA AAAGAGAAAA TTAACGGCAT GCCATCAGGA CCACAGCAGT 
92,001,554 TGGAGAAACA ACTCTTTATC CCGGCTTGCA GCCACGAGGT CTTGATTGGG GGAGGGGTGG 
92,001,614 TGAAGAATAG TCTGTGGGCT GCTTTTTTTT TTTCCTTTTA CTGGAGCTGT ACAGTGGAGT 
92,001,674 CGGTGATTGC TGCTGATCAT AATCAAGTAT TTTAGGAGCT TATTTAGACA TGTATCTGAT 
92,001,734 AGCTAAGGAT TTTTCAACTT TATTCTCTTA CGTATTTTTC AACTGTAAAT TATTGGGCTT 
92,001,794 TTAAATCCTG CTAGTATTGC TCGACTCTTA CTCTCACAAA TGGATGGAAT TAATTGCTGT 
92,001,854 TAGGAGGTTG GAAAATAGCA AATATAGATT TGGACGGTGG TAGTAATTTT GAGCAAATAA 
92,001,914 TGTTTTATCT TTTTTTTCCT TATTTTTCCC TATTCCAGTC ATACACGTGG ACCTAACTGC 
92,001,974 ACCAGTAGCT TTTCTGAGAA TACTTGCTGA AAAGGAAGTT TTCTGGAATG GGTAAGTGTA 
92,002,034 TTCTGATTTT CTTGAACTTT TCTTAAAAAC AAATTTTTCT TGCTATTAAA GTTGAATAAA 
92,002,094 TAGGATTGGT TTCTTAGAGA GTAAAAGTAG GTGTTTCTTT CTTTAGACAA TGTACCTTTT 
92,002,154 CTGAAAAACT AACTCATTAA GTACGGATTT GCTAATTTTA AGGTAGTAAA ATTACAGTGT 
92,002,214 AAATATTCCT GTACATTTTT GGAAACTGGC TTATGCAGTT TACGAAATAT AATTTTAGAC 
92,002,274 CCTCTTTTAA GTTGGGTGAT AAAGTAGATA TAACCTGAGA TGATAGATTT AAACAGGATA 
92,002,334 TTTACGTTCT GCTACAATTG ACTGATAACA CTTGAAGTGT AGTCTGAACA GTAATTTTGT 
92,002,394 TAATCATTTC AACAAGTATT TGCTAAGTGG AAGCCAGAAG AGGAGGAAAA TGTTTTGCCA 
92,002,454 CGTGGATGTG AAGATTTCCT CTAAAAGGTA CACATGGACT AAATTGCCTT TAAATGTTCC 
92,002,514 AAAATTAGTT CTCATTTATT TGCAGTCTCA TTTTGTTTTG TTTTTTTTCT CTATGTGTCA 
92,002,574 ATCCATTTGG GAGAGGCCAG CCATTGGAAG AGCCACCACT TCCAGTGCTA GTTGGATGGT 
92,002,634 TGGTTATGAT TGCCTTCTGT AAAGAATTCT TAAGGCATAA ATACGTGTCT AAATGGACCT 
92,002,694 CATATCTTTG AGATAATTAA ACTAATTTTT TCTTCCCCAT TAGGGATTAT GCTGAATTTG 
92,002,754 TATGGTTTAT AGTTGTTAGA GTTTGAGGTG TTAATTCTAA TTATCTATTT CAAATTTAGC 
92,002,814 AGGAAAAAAG AGAACATCAC CTTGTAAAAC TGAAGATTGT GACCAGTCAG AATAATGTCA 
92,002,874 AAGTGCTTAC AGTGCAGGTA GTGATATGTG CATCTACTGC AGTGAAGGCA CTTGTAGCAT 
92,002,934 TATGGTGACA GCTGCCTCGG GAAGCCAAGT TGGGCTTTAA AGTGCAGGGC CTGCTGATGT 
92,002,994 TGAGTGCTTT TTGTTCTAAG GTGCATCTAG TGCAGATAGT GAAGTAGATT AGCATCTACT 
92,003,054 GCCCTAAGTG CTCCTTCTGG CATAAGAAGT TATGTATTCA TCCAATAATT CAAGCCAAGC 
92,003,114 AAGTATATAG GTGTTTTAAT AGTTTTTGTT TGCAGTCCTC TGTTAGTTTT GCATAGTTGC 
92,003,174 ACTACAAGAA GAATGTAGTT GTGCAAATCT ATGCAAAACT GATGGTGGCC TGCTATTTCC 
92,003,234 TTCAAATGAA TGATTTTTAC TAATTTTGTG TACTTTTATT GTGTCGATGT AGAATCTGCC 
92,003,294 TGGTCTATCT GATGTGACAG CTTCTGTAGC ACTAAAGTGC TTATAGTGCA GGTAGTGTTT 
92,003,354 AGTTATCTAC TGCATTATGA GCACTTAAAG TACTGCTAGC TGTAGAACTC CAGCTTCGGC 
92,003,414 CTGTCGCCCA ATCAAACTGT CCTGTTACTG AACACTGTTC TATGGTTAGT TTTGCAGGTT 
92,003,474 TGCATCCAGC TGTGTGATAT TCTGCTGTGC AAATCCATGC AAAACTGACT GTGGTAGTGA 
92,003,534 AAAGTCTGTA GAAAAGTAAG GGAAACTCAA ACCCCTTTCT ACACAGGTTG GGATCGGTTG 
92,003,594 CAATGCTGTG TTTCTGTATG GTATTGCACT TGTCCCGGCC TGTTGAGTTT GGTGGGGATT 
92,003,654 GTGACCAGAA GATTTTGAAA ATTAAATATT ACTGAAGATT TCGACTTCCA CTGTTAAATG 
  -      
92,006,074  CTTCATTTTA CAGGCAGACC TGTCTAACTA CAAGCCAGAC TTGGGTTTTC TCCTGTAGTT 
     TGAAGACACA CTGACTCCTG ACAAAATGCA GCCTGCAACT TCCTGGAGAA CAACTCAGTG 
     TCACATTAAA GTTTATTATG TATTTAATGA TACACTGTTT AATTGACAGT TTTGCATAGT 
     TTGTCTAACT TTAGAGAATT AAGAGCCTCT CAACTGAGCA GTAAAGGTAA GGAGAGCTCA 
     ATCTGCACAG AGCCAGTTTT TAGTGTTTGA TGGAAATAAG ATCATCATGC CCACTTGAGA 
     CTTCAGATTA TTCTTTAGCT TAGTGGTTGT ATGAGTTACA TCTTATTAAA GTCGAAATTA 
     ATGTAGTTTT CTGCCTTGAT AACATTTCAT ATGTGGTATT AGTTTTAAAG GGTCATTAGG 
     AAAATGCACA TATTCCATGA ATTTTAAGAC CCATAGAAAA GTTGAAGAAT GCTTAATTTT 
     CTTATCCAGT AATGTAAACA CAGAGACAGA ACATTGAGAT GTGCCTAGTT CTGTATTTAC 
     AGTTTGGTCT GGCTGTTTGA GTTCTAGCGC ATTTAATGTT AATAAATAAA ATACTGCATT 
92,006,774 TTAAAGCTGT TAAGAAATTG TCCAGAACGA GAATATTGAA ATAAAAACTT CAAGGTTATT 
 - 
92,008,829 
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E. Acronyms and units 
Acronyms and units 
% percentage 
[γ
32
P]-ATP gamma 
32
P-adenosine triphosphate 
°C degree Celsius 
ε molar absorptivity/ extinction coefficient 
µg microgram 
µL microliter 
µM micromolar 
µm micrometer 
2’-F 2’-fluoro 
2’-O-Me 2’-O-methyl 
2’-O-MOE 2’-O-methoxyethyl 
32
P 
32
phosphor isotope 
5S rRNA 5S ribosomal RNA 
A adenine 
A260 absorption at 260 nm 
A280 absorption at 280 nm 
AAV adenovirus-associated vector 
ABCA1 ATP-binding cassette transporter A1 
AFM atomic force microscopy 
AGO argonaute RISC catalytic component 
ALT alanine transaminase 
APS ammonium persulfate 
AST aspartate transaminase 
ATP adenosine triphosphate 
AURKB aurora kinase B 
BAD BCL-2 associated agonist of cell death 
BCL2 B-cell lymphoma 2 
BCL2L11 BCL2-like apoptosis facilitator 
B-CLL B-cell chronic lymphocytic leukemia 
BLAST Basic Local Alignment Search Tool 
bp base pair 
BPB bromophenol blue 
C cytosine 
c concentration 
C. elegans Caenorhabditis elegans 
C13orf25 chromosome 13 open reading frame 25 
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Acronyms and units 
Ca
2+
 calcium ion 
CBX3 chromobox homolog 3 
CDC25A cell division cycle 25A 
CDC25C cell division cycle 25C 
cDNA complementary DNA 
Cel Caenorhabditis elegans 
ChIP chromatin immunoprecipitation 
ChIPX cross-linked chromatin immunoprecipitation 
cm centimeter 
CMV cytomegalovirus 
cpm counts per minute 
CTGF connective tissue growth factor 
ddH2O double-distilled water 
DGCR8 DiGeorge syndrome critical region 8 
DICER1 Dcr-1 homolog (Drosohphila) 
DNA deoxyribonucleic acid 
DNaseI deoxyribonuclease I 
dNTP deoxynucleotide triphosphate 
dsDNA double-stranded DNA 
dT deoxythymidines 
DTT dithiothreitol 
E extinction 
E. coli Escherichia coli 
e.g. exempli gratia, for example 
E2F E2F transcription factor 
E-box enhancer box 
EDTA ethylenediamine tetraacedic acid 
EIF4E eukaryotic translation initiation factor 4E 
ELISA enzyme linked immunosorbent assay 
FACS fluorescence-activated cell sorting 
FastAP fast alkaline phosphatase 
FCS fetal calf serum 
FD  fast digest 
FDU fast digest unit 
fwd forward 
G guanine 
g gravitational force 
g gram 
gDNA genomic DNA 
GM-CSF granulocyte macrophage colony-stimulating factor 
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Acronyms and units 
G-phase gap phase 
GTP guanosine triphosphate 
h hour 
H3 histone 3 
H3S10 histone 3 serine 10 
HCV hepatitis C virus 
HeLa Henrietta Lacks 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HP1G heterochromatin protein 1 gamma 
HRP horse-radish peroxidase 
hsa homo sapiens 
HSP90 heat shock protein 90 
Hz hertz 
i.p. intraperitoneal 
i.t. intratumoral 
i.v. intravenous 
IgG immunoglobulin G 
IL interleukin 
IMDM Iscove’s Modified Dulbecco Medium 
kb (=kbp) kilo base pair 
kDa kilo Dalton 
kHz kilo hertz 
KRAS Kirsten rat sarcoma viral oncogene homolog 
l length 
L liter 
LAV lentivirus-associated vector 
LB lysogeny broth 
let-7a lethal-7a 
LNA locked nucleic acid 
LPS lipopolysaccharide 
luc luciferase 
M molar 
m meter 
mA milliampere 
mAB monoclonal antibody 
MAX MYC-associated factor X 
mC 2’-oxymethyl cytosine 
Mg
2+
 magnesium ion 
min minute 
miRISC miRNA-induced silencing complex 
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Acronyms and units 
miRNA microRNA 
mL milliliter 
mM millimolar 
mm millimeter 
M-MuLV RT moloney murine leukemia virus reverse transcriptase 
MOPS 3-(N-morpholino)propanesulfonic acid 
M-phase mitosis phase 
mRNA messenger RNA 
msec millisecond 
mU 2’-oxymethyl uracil 
MuLV murine leukemia virus 
MYC v-myc myelocytomatosis viral oncogene homolog 
N Newton 
N/P ratio nitrogen per nucleic acid phosphate ratio 
NCBI National Center for Biotechnology Information 
ncRNA non-coding RNA 
ng nanogram 
nm nanometer 
NP-40 nonyl phenoxypolyethoxylethanol 
nt nucleotide 
OD optical density 
OD576 optical density at 576 nm 
OH hydroxyl 
P21 cyclin-dependent kinase inhibitor 1A (CDKN1A, P21) 
P27 cyclin-dependent kinase inhibitor 1B (CDKN1B, P27) 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEI polyethylenimine 
PEI F25 LMW polyethylenimine F25 low molecular weight 
PIM proviral integration site of murine leukemia virus 
pmol picomol 
PMSF phenylmethylsulfonyl fluoride 
PO phosphodiester 
POLR2 RNA polymerase II 
PP2A protein phosphatase 2A 
pre-B-cell progenitor B-cell 
pre-miRNA precursor miRNA 
pri-miRNA primary miRNA 
pRNA product RNA 
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Acronyms and units 
PS phosphorothioate 
PTEN phosphatase and tensin homolog 
PVDF polyvinylidine fluoride 
qPCR quantitative real time PCR 
QT quantitative 
RAN Ras-related nuclear protein  
rev reverse 
RISC RNA-induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
RNase ribonuclease 
RNaseP ribonuclease P 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
RT reverse transcriptase 
RT room temperature 
S serin 
s.c. subcutaneous 
SDS sodiumdodecylsulfate 
SDS PAGE 
sodiumdodecylsulfate polyacrylamide gel 
electrophoresis 
sec second 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvate transaminase 
Si3N4 trisilicon tetranitride 
siRNA small interfering RNA 
SNP single nucleotide polymorphism 
SOCS suppressor of cytokine signaling 
S-phase synthesis phase 
ssDNA single-stranded DNA 
STAT signal transducer and activator of transcription 
SV40 simian vacuolating virus 40 
T thymine 
T4 PNK T4 polynucleotide kinase 
TBE Tris-HCl, borate, EDTA 
TBST Tris-HCl-buffered-saline-Tween 20 
TEMED tetramethylethylenediamine 
TGFB tissue growth factor beta 
TNFα tumor necrosis factor alpha 
TP53 tumor protein 53 
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Acronyms and units 
TSP1 thrombospondin-1 
TU transcription unit 
U uracil 
U unit 
UTR untranslated region 
UV ultraviolet 
V voltage 
v/v volume per volume % 
VR1 vanilloid receptor 1 
w/v mass per volume % 
WST-1 water soluble tetrazolium salt-1 
XCB xylene cyanol blue 
XPO5 Exportin-5 
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F. Gene nomenclature 
Gene nomenclature was applied according to the guidelines provided by the HUGO Gene 
Nomenclature Committee (HGNC) at http://www.genenames.org/guidelines.html (259). Gene 
symbols are italicized and all letters are in upper case. CDNA and mRNA use the gene 
symbol and formatting conventions. Protein designations are the same as the gene symbol, 
but using only upper case letters. 
 
Abbreviation gene symbol, cDNA, mRNA, protein 
ABCA1 ATP-binding cassette transporter A1 
AGO1-4 argonaute RISC catalytic component 1-4 
AURKB aurora kinase B 
BAD BCL-2 associated agonist of cell death 
BCL2 B-cell lymphoma 2 
BCL2L11 BCL2-like apoptosis facilitator 
C13orf25 chromosome 13 open reading frame 25 
CBX3 chromobox homolog 3 
CDC25A cell division cycle 25A 
CDC25C cell division cycle 25C 
CTGF connective tissue growth factor 
DGCR8 DiGeorge syndrome critical region 8 
DICER1 Dcr1-homolog (Drosophila) 
E2F 1-3 E3F transcription facto 1-3r 
EIF4E eukaryotic translation initiation factor 4E 
GM-CSF granulocyte macrophage colony-stimulating factor 
HP1G heterochromatin protein 1 gamma 
HSP90 heat shock protein 90 
KRAS Kirsten rat sarcoma viral oncogene homolog 
MAX MYC-associated factor X 
MYC v-myc myelocytomatosis viral oncogene homolog 
P21 cyclin-dependent kinase inhibitor (CDKN1A, P21) 
P27 cyclin-dependent kinase inhibitor (CDKN1B, P27) 
PIM1-3 proviral integration site of murine leukemia virus 1-3 
POLR2 RNA polymerase II 
PP2A protein phosphatase 2A 
PTEN phosphatase and tensin homolog 
RAN Ras-related nuclear protein  
SOCS suppressor of cytokine signaling 
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Abbreviation gene symbol, cDNA, mRNA, protein 
STAT 3/5 signal transducer and activator of transcription 3/5 
TGFB tissue growth factor beta 
TP53 tumor protein 53 
TSP1 thrombospondin-1 
XPO5 Exportin-5 
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J. Primers for cloning 
Plasmid Name of DNA primer Sequence 5’  3’ 
Construct 
length [bp] 
pGL3 Pim-1 3’-
UTR (*) 
Inv. hPim-1 3’-UTR F CCE GCT CTA GAG CTG TCA GAT GCC CGA GGG 
1264 
Inv. hPim-1 3’-UTR R CCE 
GCT CTA GAG CAA TAA GAT CTC TTT TAT 
TCC CCT GT 
pGL3 Pim-1 3’-
UTR miR-33a 
mut (*) 
Pim-1 miR-33a mut f1 
AAA AAA TGC ACA AAC AGT GCG ATC AAC 
AGA AAA GCT 
1264 
Pim-1 miR-33a mut r1 
AGC TTT TCT GTT GAT CGC ACT GTT TGT 
GCA TTT TTT 
pGL3 let-7a 
construct 
forward (*) 
let-7a sense XbaI 
GCT CTA GAG CTG AGG TAG TAG GTT GTA 
TAG TTG CTC AGC GCT CTA GAG C 
33 
let-7a as XbaI 
GCT CTA GAG CGC TGA GCA ACT ATA CAA 
CCT ACT ACC TCA GCT CTA GAG C 
pGL3 let-7a 
construct 
inverted (*) 
let-7a as XbaI 
GCT CTA GAG CGC TGA GCA ACT ATA CAA 
CCT ACT ACC TCA GCT CTA GAG C 
33 
let-7a sense XbaI 
GCT CTA GAG CTG AGG TAG TAG GTT GTA 
TAG TTG CTC AGC GCT CTA GAG C 
pGL3 P21 3‘-
UTR (*) 
Invitrogen P21 3‘-UTR F 
(CCE) 
GCT CTA GAG CCC TCA AAG GCC CGC TCT A 
1445 
Invitrogen P21 3‘-UTR R 
(CCE) 
GCT CTA GAG CGG AGG AGC TGT GAA AGA 
CAC A 
pGL3 P21 3’-
UTR miR-
17/20a mut (*) 
mir17/20a mut F1 
GAA GTA AAC AGA TGG GAC TGT GAA GGG 
GCC TCA CC 
1445 
mir17/20a mut R1 
GGT GAG GCC CCT TCA CAG TCC CAT CTG 
TTT ACT TC 
miR-17/20a mut F2 
CTC CCC AGT TCA TTG GAC TGT GAT TAG 
CAG CGG AA 
miR-17/20a mut R2 
TTC CGC TGC TAA TCA CAG TCC AAT GAA 
CTG GGG AG 
pGL3 1,5 kb (*) 
miR-17-92 f1 
ATA TAG ATC TTG CCG CCG GGA AAC GGG 
TT 
1496 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG CAT 
AAT CCC TAA TGG 
pGL3 625 bp (*) 
miR-17-92 f3 
ATA TAG ATC TCT TTA GAC AAT GTA CCT 
TTT CTG 
625 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG CAT 
AAT CCC TAA TGG 
pGL3 339 bp (*) 
miR-17-92 f4 
ATA TAG ATC TGT GGA AGC CAG AAG AGG 
AGG A 
339 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG CAT 
AAT CCC TAA TGG 
pGL3 279 bp (+) 
miR-17-92 f5 
ATA TAG ATC TGG TAC ACA TGG ACT AAA 
TTG CC 
279 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG CAT 
AAT CCC TAA TGG 
pGL3 197 bp (+) 
miR-17-92 f6 
ATA TAG ATC TCT CTA TGT GTC AAT CCA 
TTT GGG AG 
197 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG CAT 
AAT CCC TAA TGG 
pGL3 250 bp 
miR-17-92 f4 
ATA TAG ATC TGT GGA AGC CAG AAG AGG 
AGG A 
250 
miR-17-92 r3 
ATA TAA GCT TGC CTT AAG AAT TCT TTA 
CAG AAG GC 
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Plasmid Name of DNA primer Sequence 5’  3’ 
Construct 
length [bp] 
pGL3 190 bp 
miR-17-92 f5 
ATA TAG ATC TGG TAC ACA TGG ACT AAA 
TTG CC 
190 
miR-17-92 r3 
ATA TAA GCT TGC CTT AAG AAT TCT TTA 
CAG AAG GC 
pGL3 108 bp 
miR-17-92 f6 
ATA TAG ATC TCT CTA TGT GTC AAT CCA 
TTT GGG AG 
108 
miR-17-92 r3 
ATA TAA GCT TGC CTT AAG AAT TCT TTA 
CAG AAG GC 
pGL3 339 inv 
(+) 
miR-17-92 f4 invers 
ATA TAA GCT TGT GGA AGC CAG AAG AGG 
AGG A 
339 
miR-17-92 r1 invers 
ATA TAG ATC TCC ATA CAA ATT CAG CAT 
AAT CCC TAA TGG 
(*): (194); (+): (196) 
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K. Primers for sequencing 
Plasmid Name of DNA primer Sequence 5’  3’ 
cDNA clone variants 
OriGene 
VP 1,5 seq GGA CTT TCC AAA ATG TCG 
XL 39 seq ATT AGG ACA AGG CTG GTG GG 
Pim-1 3rd TCT CCA AAA ATC TGC CTG GGT T 
pGL3 Pim-1 3’-UTR 
variants 
Pim-1 3rd TCT CCA AAA ATC TGC CTG GGT T 
Inv. hPim-1 3’-UTR R 
CCE 
GCT CTA GAG CAA TAA GAT CTC TTT 
TAT TCC CCT GT 
pGL3 let-7a variants pGL3 ctr let7 01 TCG CCA GTC AAG TAA CAA CC 
pGL3 P21 3’-UTR 
variants 
P21 3’-UTR 3rd TCC TCT AAG GTT GGG CAG G 
Invitrogen P21 3‘-UTR 
R (CCE) 
GCT CTA GAG CGG AGG AGC TGT GAA 
AGA CAC A 
pGL3 1,5 kb variants 
miR-17-92 f1 
ATA TAG ATC TTG CCG CCG GGA AAC 
GGG TT 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG 
CAT AAT CCC TAA TGG 
RVprimer3 CTA GCA AAA TAG GCT GTC CC 
seq miR-Promo 2F TGG TGA AGA ATA GTC TGT GGG C 
pGL3 625 bp 
RVprimer3 CTA GCA AAA TAG GCT GTC CC 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG 
CAT AAT CCC TAA TGG 
pGL3 339 bp 
RVprimer3 CTA GCA AAA TAG GCT GTC CC 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG 
CAT AAT CCC TAA TGG 
pGL3 279 bp RVprimer3 CTA GCA AAA TAG GCT GTC CC 
pGL3 339 inv 
RVprimer3 CTA GCA AAA TAG GCT GTC CC 
miR-17-92 r1 
ATA TAA GCT TCC ATA CAA ATT CAG 
CAT AAT CCC TAA TGG 
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L. MiRNA sequences 
miRNA name 
miRBase Release 19.0 
accession number 
sequence 5’  3’ 
hsa-miR-15a-5p  MIMAT0000068 UAG CAG CAC AUA AUG GUU UGU G 
hsa-miR-16-5p  MIMAT0000069 UAG CAG CAC GUA AAU AUU GGC G 
hsa-miR-17-5p  MIMAT0000070 CAA AGU GCU UAC AGU GCA GGU AG 
hsa-miR-20a-5p  MIMAT0000075 UAA AGU GCU UAU AGU GCA GGU AG 
hsa-miR-24-3p  MIMAT0000080 UGG CUC AGU UCA GCA GGA ACA G 
hsa-miR-26a-5p  MIMAT0000082 UUC AAG UAA UCC AGG AUA GGC U 
hsa-miR-33a-5p  MIMAT0000091 GUG CAU UGU AGU UGC AUU GCA 
hsa-miR-33b-5p  MIMAT0003301 GUG CAU UGC UGU UGC AUU GC 
hsa-miR-144-3p  MIMAT0000436 UAC AGU AUA GAU GAU GUA CU 
hsa-miR-374a-5p  MIMAT0000727 UUA UAA UAC AAC CUG AUA AGU G 
hsa-miR-423-5p  MIMAT0004748 UGA GGG GCA GAG AGC GAG ACU UU 
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M. Equipment 
Device Manufacturer 
Agarose gel chamber PerfectBlue Gel System Mini S/M, PEQLAB Biotechnology GMBH 
Autoclave V 95, Systec 
Automatic weighing machine Sartorius 
DENVER Instruments 
Blotting equipment Trans-Blot
®
 SD Semi-Dry Transfer cell, Bio-Rad 
Cell culture dishes SARSTEDT 
Cell culture plates Cellstar
®
, greiner-bio-one 
Centrifuges Biofuge pico, Fresco 17, HERAUS 
5810R, Eppendorf 
Cryo pure tubes SARSTEDT 
Cuvettes Gene Pulser Cuvette, 4mm, Bio-Rad 
Detection films Kodak 
Electroporation system Gene Pulser Xcell, Bio-Rad 
Gel documentation Gerix 1000, Biostep 
GS-800 Calibrated Densitometer, Bio-Rad 
Hand monitor LB 1210 B, Berthold 
Heating block TB1, Biometra 
Hemocytometer Neubauer bright-line, MarienFeld 
Hybridization oven OV3, Biometra 
Imager cassettes Bas cassette 4043, Fuji Film 
Incubator BE 400, Memmert  
NuAire, Memmert 
Luminescence detector Safire
2
™ micro plate reader, Tecan 
Magnetic stirrer Heidolph Instruments GmbH and Co 
Micro plate reader Safire
2
™ micro plate reader, Tecan 
Microscope AE20, Motic 
Microwave oven 8020 E, Privileg 
Pasteur pipette SARSTEDT 
Petri dishes SARSTEDT 
pH-meter inoLab, SENTON 
Phosphorimager Fuji FLA-3000 R; Fuji Film 
Pipet boy Pipetboy acu, IBS 
Pipettes ABiMED (0.1 – 2 µL; 2 – 20 µL; 20 – 200 µL; 100 – 1000 µL) 
Polyacrylamide gel chamber custom-made, University of Lübeck 
Power supply Power N Pac 3000, Bio-Rad 
PVDF membrane Immobilon™-P, Millipore 
Quartz cuvette 104-QS, 10 mm; Hellma 
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Device Manufacturer 
Real time PCR system LightCycler
®
2.0, Roche 
MyiQ™5 Real-Time PCR Detection System, Bio-Rad 
Rotor wheel LMOM1203, Kobe 
Safety cabinet HERAsafe KS, Thermo Scientific 
Scintillation analyzer 1900 CA TRI-CARB
®
 Liquid Scintillation Analyzer, Perkin Elmer 
SDS-PAGE equipment Mini Protean
®
 3 Cell, Bio-Rad 
Serological pipettes SARSTEDT 
Shaking incubator 3033, GFL 
Sonifier Branson 250, Heinemann 
Spectral photometer Biomate 3, Thermo Scientific 
Spin columns illustra Micro-Spin G-25, GE Healthcare Life Sciences 
Thermocycler TGradient, Biometra 
Thermomixer 5436, Eppendorf 
Tips SARSTEDT 
Tubes SARSTEDT 
Vortexer 7-2020, NeoLab 
Water bath water bath with polycarbonate basin, NeoLab 
Whatman filter Thick Blot Paper, Bio-Rad 
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N. Chemicals 
Chemical Manufacturer 
2-mercaptoethanol Merck 
Acetic acid Roth 
Acrylamide/bisacrylamide (48:2) for PAA gels Roth 
Acrylamide/bisacrylamide 30 % for SDS gels Gerbu 
Agar agar Serva 
Agarose GTQ Roth 
Ammonium acetate Roth 
APS Roth 
Ammonium thiocyanate Roth 
Ampicillin Roth 
Aqua-phenol Roth 
Boric acid Roth 
Bromophenol blue Merck 
Calcium chloride Roth 
Chloroform Merck 
Crystal violet Merck 
Deoxycholate Roth 
Deoxynucleosidtriphosphates Thermo Fisher Scientific 
DTT Gerbu 
Ethanol Roth 
EDTA Gerbu 
FCS PAA 
Formaldehyde Roth 
Formamide Gerbu 
Glycerol (99,5 %) Gerbu 
Glycine Roth 
Guanidinium thiocyanate Roth 
HEPES Gerbu 
Hydrochloric acid Roth 
IMDM cell culture medium PAA 
Isopropanol Roth 
Lithium chloride Roth 
Magnesium chloride Roth, 
Thermo Fisher Scientific 
Magnesium sulfate Roth, 
Thermo Fisher Scientific 
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Chemical Manufacturer 
Methanol Roth 
Milk powder, blotting grade Roth 
MOPS Gerbu 
Nocodazole Sigma-Aldrich 
NP-40 Sigma-Aldrich 
PBS solution for cell culture PAA 
Peptone Roth 
Phenol Roth 
PMSF Sigma-Aldrich 
Potassium chloride Roth 
Potassium hydroxide Roth 
Propidium iodide Sigma-Aldrich 
RPMI cell culture medium PAA 
Rubidium chloride Roth 
SDS ultra-pure Roth 
Silver nitrate Roth 
Sodium acetate Fluka 
Sodium carbonate Roth 
Sodium chloride Roth 
Sodium hydrogen carbonate Roth 
Sodium thiosulfate Gerbu 
TEMED Roth 
Tris B Gerbu 
Tris X Roth 
Triton-X Sigma-Aldrich 
Trypsine/EDTA solution for cell culture PAA 
Tween 20 Sigma-Aldrich 
Urea Gerbu 
Water, demineralized self-made 
Water, double-distilled self-made 
XCB Merck 
Yeast extract Gerbu 
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O. Enzymes, Kits and Reagents 
Enzyme, kit, reagent Purpose Manufacturer 
Absolute qPCR SYBR Green Mix quantitative PCR Thermo Fisher Scientific 
Amersham ECL™/ECL plus™  
Western Blotting Detection Reagent 
Western Blot GE Healthcare Life Sciences 
Cell Death Detection ELISA apoptosis assay Roche Applied Biosciences 
Cell proliferation reagent WST-1 proliferation assay Roche 
cOmplete Mini Protease Inhibitor Cocktail protease inhibition Roche 
DNaseI, RNase-free DNA digestion Thermo Fisher Scientific 
DNeasy
®
 Blood & Tissue Kit genomic DNA purification Quiagen 
Ethidiumbromide for agarose gels (0.025 %) nucleic acid staining Roth 
Ethidiumbromide for PAA gels (0.5 %) nucleic acid staining Roth 
FastAP Thermosensitive Alkaline 
Phosphatase 
dephosphorylation reaction Thermo Fisher Scientific 
FastDigest enzyme BglII restriction digest Thermo Fisher Scientific 
FastDigest enzyme BlpI restriction digest Thermo Fisher Scientific 
FastDigest enzyme HindIII restriction digest Thermo Fisher Scientific 
FastDigest enzyme XbaI restriction digest Thermo Fisher Scientific 
GBX Developer and Replenisher Western Blot detection Kodak
®
 
GBX Fixer and Replenisher Western Blot detection Kodak
®
 
GeneJet™
 
Plasmid Miniprep Kit plasmid Miniprep Thermo Fisher Scientific 
Lipofectamine™ 2000 transfection of mammalian cells Invitrogen™ Life Technologies 
Luciferase Assay System luciferase assay Promega 
mirVana™ miRNA Isolation Kit miRNA isolation Ambion Life Technologies 
NucleoBond
®
 PC 500 purification kit plasmid Maxiprep Macherey-Nagel 
Optimem I transfection of mammalian cells Invitrogen™ Life Technologies 
PANSORBIN
®
 Staph A cells anti-IgG reagent for ChIP assay Calbiochem/Merck 
PEI F25 LMW transfection of mammalian cells custom-made, Sigma-Aldrich 
Pfu DNA polymerase amplification of DNA Thermo Fisher Scientific 
Proteinase K protein digestion Thermo Fisher Scientific 
RevertAid H Minus First Strand cDNA 
Synthesis Kit 
cDNA generation Thermo Fisher Scientific 
RNase A RNA digestion Thermo Fisher Scientific 
SYBR
®
 gold nucleic acid staining Invitrogen™ Life Technologies 
T4 DNA ligase ligation reaction Thermo Fisher Scientific 
T4 polynucleotide kinase phosphorylation reaction Thermo Fisher Scientific 
Taq DNA polymerase amplification of DNA Thermo Fisher Scientific 
Wizard
®
SV Gel and PCR Clean-Up System 
agarose gel extraction, PCR 
purification 
Promega 
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P. Vector sequence pCMV-XL4 (OriGene) 
Nucleotide Sequence of pCMV6-XL4  
 
GenBank Accession Number:  AF067196 
 
AACAAAATAT TAACGCTTAC AATTTCCATT CGCCATTCAG GCTGCGCAAC 
TGTTGGGAAG GGCGATCGGT GCGGGCCTCT TCGCTATTAC GCCAGCTGGC 
GAAAGGGGGA TGTGCTGCAA GGCGATTAAG TTGGGTAACG CCAGGGTTTT 
CCCAGTCACG ACGTTGTAAA ACGACGGCCA GTGCCAAGCT GATCTATACA 
TTGAATCAAT ATTGGCAATT AGCCATATTA GTCATTGGTT ATATAGCATA 
AATCAATATT GGCTATTGGC CATTGCATAC GTTGTATCTA TATCATAATA 
TGTACATTTA TATTGGCTCA TGTCCAATAT GACCGCCATG TTGACATTGA 
TTATTGACTA GTTATTAATA GTAATCAATT ACGGGGTCAT TAGTTCATAG 
CCCATATATG GAGTTCCGCG TTACATAACT TACGGTAAAT GGCCCGCCTG 
GCTGACCGCC CAACGACCCC CGCCCATTGA CGTCAATAAT GACGTATGTT 
CCCATAGTAA CGCCAATAGG GACTTTCCAT TGACGTCAAT GGGTGGAGTA 
TTTACGGTAA ACTGCCCACT TGGCAGTACA TCAAGTGTAT CATATGCCAA 
GTCCGCCCCC TATTGACGTC AATGACGGTA AATGGCCCGC CTGGCATTAT 
GCCCAGTACA TGACCTTACG GGACTTTCCT ACTTGGCAGT ACATCTACGT 
ATTAGTCATC GCTATTACCA TGGTGATGCG GTTTTGGCAG TACACCAATG 
GGCGTGGATA GCGGTTTGAC TCACGGGGAT TTCCAAGTCT CCACCCCATT 
GACGTCAATG GGAGTTTGTT TTGGCACCAA AATCAACGGG ACTTTCCAAA 
ATGTCGTAAT AACCCCGCCC CGTTGACGCA AATGGGCGGT AGGCGTGTAC 
GGTGGGAGGT CTATATAAGC AGAGCTCGTT TAGTGAACCG TCAGAATTTT 
GTAATACGAC TCACTATAGG GCGGCCGCGA ATTCAGATCT GGTACCGATA 
TCAAGCTTGT CGACTCTAGA TTGCGGCCGC GGTCATAGCT GTTTCCTGAA 
CAGATCC CGGGTGGCAT CCCTGTGACC CCTCCCCAGT GCCTCTCCTG 
GCCCTGGAAG TTGCCACTCC AGTGCCCACC AGCCTTGTCC TAATAAAATT 
AAGTTGCATC ATTTTGTCTG ACTAGGTGTC CTTCTATAAT ATTATGGGGT 
GGAGGGGGGT GGTATGGAGC AAGGGGCAAG TTGGGAAGAC AACCTGTAGG 
GCCTGCGGGG TCTATTGGGA ACCAAGCTGG AGTGCAGTGG CACAATCTTG 
GCTCACTGCA ATCTCCGCCT CCTGGGTTCA AGCGATTCTC CTGCCTCAGC 
CTCCCGAGTT GTTGGGATTC CAGGCATGCA TGACCAGGCT CAGCTAATTT 
TTGTTTTTTT GGTAGAGACG GGGTTTCACC ATATTGGCCA GGCTGGTCTC 
CAACTCCTAA TCTCAGGTGA TCTACCCACC TTGGCCTCCC AAATTGCTGG 
GATTACAGGC GTGAACCACT GCTCCCTTCC CTGTCCTTCT GATTTTAAAA 
TAACTATACC AGCAGGAGGA CGTCCAGACA CAGCATAGGC TACCTGGCCA 
TGCCCAACCG GTGGGACATT TGAGTTGCTT GCTTGGCACT GTCCTCTCAT 
GCGTTGGGTC CACTCAGTAG ATGCCTGTTG AATTGGGTAC GCGGCCAGCT 
TGGCTGTGGA ATGTGTGTCA GTTAGGGTGT GGAAAGTCCC CAGGCTCCCC 
AGCAGGCAGA AGTATGCAAA GCATGCATCT CAATTAGTCA GCAACCAGGT 
GTGGAAAGTC CCCAGGCTCC CCAGCAGGCA GAAGTATGCA AAGCATGCAT 
CTCAATTAGT CAGCAACCAT AGTCCCGCCC CTAACTCCGC CCATCCCGCC 
CCTAACTCCG CCCAGTTCCG CCCATTCTCC GCCCCATGGC TGACTAATTT 
TTTTTATTTA TGCAGAGGCC GAGGCCGCCT CGGCCTCTGA GCTATTCCAG 
AAGTAGTGAG GAGGCTTTTT TGGAGGCCTA GGCTTTTGCA AAAAGCTCCT 
CGAGGAACTG AAAAACCAGA AAGTTAATTC CCTATAGTGA GTCGTATTAA 
ATTCGTAATC ATGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA 
CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTAA AGCCTGGGGT 
GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT CACTGCCCGC 
TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC 
GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC TTCCTCGCTC 
ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA 
CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA 
AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC 
GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA 
AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT 
ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC 
CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC 
GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC 
GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC 
GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT 
ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG 
TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT 
AGAAGAACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG 
AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG 
GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT 
CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA 
AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 
CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA 
TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC 
TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCCCCG 
TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT 
GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT 
AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 
CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT 
TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT 
GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCCAAC 
GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC 
TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC 
ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 
TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA 
TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA 
TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT 
CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG 
ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC 
CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG 
GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA 
TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT 
TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC 
GAAAAGTGCC ACCTGACGCG CCCTGTAGCG GCGCATTAAG CGCGGCGGGT 
GTGGTGGTTA CGCGCAGCGT GACCGCTACA CTTGCCAGCG CCCTAGCGCC 
CGCTCCTTTC GCTTTCTTCC CTTCCTTTCT CGCCACGTTC GCCGGCTTTC 
CCCGTCAAGC TCTAAATCGG GGGCTCCCTT TAGGGTTCCG ATTTAGTGCT 
TTACGGCACC TCGACCCCAA AAAACTTGAT TAGGGTGATG GTTCACGTAG 
TGGGCCATCG CCCTGATAGA CGGTTTTTCG CCCTTTGACG TTGGAGTCCA 
CGTTCTTTAA TAGTGGACTC TTGTTCCAAA CTGGAACAAC ACTCAACCCT 
ATCTCGGTCT ATTCTTTTGA TTTATAAGGG ATTTTGCCGA TTTCGGCCTA 
TTGGTTAAAA AATGAGCTGA TTTAACAAAA ATTTAACGCG AATTTTAACA 
AAATATT 
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Q. Vector sequence pGL3 control (Promega) 
 
pGL3-Control Vector
This vector can be obtained from Promega Corporation, Madison, WI. Call 
one of the following numbers for order or technical information.
Order or Technical     1-800-356-9526
Outside U.S.             608-274-4330
pGL3-Control Vector sequence reference points:
Base pairs                                    5256
Multiple cloning region                       1-41
Promoter                                      48-250
Luciferase gene (luc+)                        280-1932
GLprimer2 binding site                        281-303
SV40 late poly (A) signal                     1964-2185
Enhancer                                      2205-2441
RVprimer4 binding site                        2518-2499
ColE1-derived plasmid replication origin      2756
Beta-lactamase gene (Ampr)                    3518-4378
F1 origin                                     4510-4965
Synthetic (upstream) poly (A) signal          5096-5249
RVprimer3 binding site                        5198-5217
..
    1  GGTACCGAGC TCTTACGCGT GCTAGCCCGG GCTCGAGATC TGCGATCTGC
   51  ATCTCAATTA GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCCG
  101  CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATC GCTGACTAAT
  151  TTTTTTTATT TATGCAGAGG CCGAGGCCGC CTCGGCCTCT GAGCTATTCC
  201  AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTT
  251  GGCATTCCGG TACTGTTGGT AAAGCCACCA TGGAAGACGC CAAAAACATA
  301  AAGAAAGGCC CGGCGCCATT CTATCCGCTG GAAGATGGAA CCGCTGGAGA
  351  GCAACTGCAT AAGGCTATGA AGAGATACGC CCTGGTTCCT GGAACAATTG
  401  CTTTTACAGA TGCACATATC GAGGTGGACA TCACTTACGC TGAGTACTTC
  451  GAAATGTCCG TTCGGTTGGC AGAAGCTATG AAACGATATG GGCTGAATAC
  501  AAATCACAGA ATCGTCGTAT GCAGTGAAAA CTCTCTTCAA TTCTTTATGC
  551  CGGTGTTGGG CGCGTTATTT ATCGGAGTTG CAGTTGCGCC CGCGAACGAC
  601  ATTTATAATG AACGTGAATT GCTCAACAGT ATGGGCATTT CGCAGCCTAC
  651  CGTGGTGTTC GTTTCCAAAA AGGGGTTGCA AAAAATTTTG AACGTGCAAA
  701  AAAAGCTCCC AATCATCCAA AAAATTATTA TCATGGATTC TAAAACGGAT
  751  TACCAGGGAT TTCAGTCGAT GTACACGTTC GTCACATCTC ATCTACCTCC
  801  CGGTTTTAAT GAATACGATT TTGTGCCAGA GTCCTTCGAT AGGGACAAGA
  851  CAATTGCACT GATCATGAAC TCCTCTGGAT CTACTGGTCT GCCTAAAGGT
  901  GTCGCTCTGC CTCATAGAAC TGCCTGCGTG AGATTCTCGC ATGCCAGAGA
  951  TCCTATTTTT GGCAATCAAA TCATTCCGGA TACTGCGATT TTAAGTGTTG
 1001  TTCCATTCCA TCACGGTTTT GGAATGTTTA CTACACTCGG ATATTTGATA
http://www.promega.com/vectors/pgl3con.txt
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 1051  TGTGGATTTC GAGTCGTCTT AATGTATAGA TTTGAAGAAG AGCTGTTTCT
 1101  GAGGAGCCTT CAGGATTACA AGATTCAAAG TGCGCTGCTG GTGCCAACCC
 1151  TATTCTCCTT CTTCGCCAAA AGCACTCTGA TTGACAAATA CGATTTATCT
 1201  AATTTACACG AAATTGCTTC TGGTGGCGCT CCCCTCTCTA AGGAAGTCGG
 1251  GGAAGCGGTT GCCAAGAGGT TCCATCTGCC AGGTATCAGG CAAGGATATG
 1301  GGCTCACTGA GACTACATCA GCTATTCTGA TTACACCCGA GGGGGATGAT
 1351  AAACCGGGCG CGGTCGGTAA AGTTGTTCCA TTTTTTGAAG CGAAGGTTGT
 1401  GGATCTGGAT ACCGGGAAAA CGCTGGGCGT TAATCAAAGA GGCGAACTGT
 1451  GTGTGAGAGG TCCTATGATT ATGTCCGGTT ATGTAAACAA TCCGGAAGCG
 1501  ACCAACGCCT TGATTGACAA GGATGGATGG CTACATTCTG GAGACATAGC
 1551  TTACTGGGAC GAAGACGAAC ACTTCTTCAT CGTTGACCGC CTGAAGTCTC
 1601  TGATTAAGTA CAAAGGCTAT CAGGTGGCTC CCGCTGAATT GGAATCCATC
 1651  TTGCTCCAAC ACCCCAACAT CTTCGACGCA GGTGTCGCAG GTCTTCCCGA
 1701  CGATGACGCC GGTGAACTTC CCGCCGCCGT TGTTGTTTTG GAGCACGGAA
 1751  AGACGATGAC GGAAAAAGAG ATCGTGGATT ACGTCGCCAG TCAAGTAACA
 1801  ACCGCGAAAA AGTTGCGCGG AGGAGTTGTG TTTGTGGACG AAGTACCGAA
 1851  AGGTCTTACC GGAAAACTCG ACGCAAGAAA AATCAGAGAG ATCCTCATAA
 1901  AGGCCAAGAA GGGCGGAAAG ATCGCCGTGT AATTCTAGAG TCGGGGCGGC
 1951  CGGCCGCTTC GAGCAGACAT GATAAGATAC ATTGATGAGT TTGGACAAAC
 2001  CACAACTAGA ATGCAGTGAA AAAAATGCTT TATTTGTGAA ATTTGTGATG
 2051  CTATTGCTTT ATTTGTAACC ATTATAAGCT GCAATAAACA AGTTAACAAC
 2101  AACAATTGCA TTCATTTTAT GTTTCAGGTT CAGGGGGAGG TGTGGGAGGT
 2151  TTTTTAAAGC AAGTAAAACC TCTACAAATG TGGTAAAATC GATAAGGATC
 2201  TGAACGATGG AGCGGAGAAT GGGCGGAACT GGGCGGAGTT AGGGGCGGGA
 2251  TGGGCGGAGT TAGGGGCGGG ACTATGGTTG CTGACTAATT GAGATGCATG
 2301  CTTTGCATAC TTCTGCCTGC TGGGGAGCCT GGGGACTTTC CACACCTGGT
 2351  TGCTGACTAA TTGAGATGCA TGCTTTGCAT ACTTCTGCCT GCTGGGGAGC
 2401  CTGGGGACTT TCCACACCCT AACTGACACA CATTCCACAG CGGATCCGTC
 2451  GACCGATGCC CTTGAGAGCC TTCAACCCAG TCAGCTCCTT CCGGTGGGCG
 2501  CGGGGCATGA CTATCGTCGC CGCACTTATG ACTGTCTTCT TTATCATGCA
 2551  ACTCGTAGGA CAGGTGCCGG CAGCGCTCTT CCGCTTCCTC GCTCACTGAC
 2601  TCGCTGCGCT CGGTCGTTCG GCTGCGGCGA GCGGTATCAG CTCACTCAAA
 2651  GGCGGTAATA CGGTTATCCA CAGAATCAGG GGATAACGCA GGAAAGAACA
 2701  TGTGAGCAAA AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA GGCCGCGTTG
http://www.promega.com/vectors/pgl3con.txt
2 von 4 09.10.2010 16:49
 2751  CTGGCGTTTT TCCATAGGCT CCGCCCCCCT GACGAGCATC ACAAAAATCG
 2801  ACGCTCAAGT CAGAGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG
 2851  CGTTTCCCCC TGGAAGCTCC CTCGTGCGCT CTCCTGTTCC GACCCTGCCG
 2901  CTTACCGGAT ACCTGTCCGC CTTTCTCCCT TCGGGAAGCG TGGCGCTTTC
 2951  TCATAGCTCA CGCTGTAGGT ATCTCAGTTC GGTGTAGGTC GTTCGCTCCA
 3001  AGCTGGGCTG TGTGCACGAA CCCCCCGTTC AGCCCGACCG CTGCGCCTTA
 3051  TCCGGTAACT ATCGTCTTGA GTCCAACCCG GTAAGACACG ACTTATCGCC
 3101  ACTGGCAGCA GCCACTGGTA ACAGGATTAG CAGAGCGAGG TATGTAGGCG
 3151  GTGCTACAGA GTTCTTGAAG TGGTGGCCTA ACTACGGCTA CACTAGAAGA
 3201  ACAGTATTTG GTATCTGCGC TCTGCTGAAG CCAGTTACCT TCGGAAAAAG
 3251  AGTTGGTAGC TCTTGATCCG GCAAACAAAC CACCGCTGGT AGCGGTGGTT
 3301  TTTTTGTTTG CAAGCAGCAG ATTACGCGCA GAAAAAAAGG ATCTCAAGAA
 3351  GATCCTTTGA TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA ACGAAAACTC
 3401  ACGTTAAGGG ATTTTGGTCA TGAGATTATC AAAAAGGATC TTCACCTAGA
 3451  TCCTTTTAAA TTAAAAATGA AGTTTTAAAT CAATCTAAAG TATATATGAG
 3501  TAAACTTGGT CTGACAGTTA CCAATGCTTA ATCAGTGAGG CACCTATCTC
 3551  AGCGATCTGT CTATTTCGTT CATCCATAGT TGCCTGACTC CCCGTCGTGT
 3601  AGATAACTAC GATACGGGAG GGCTTACCAT CTGGCCCCAG TGCTGCAATG
 3651  ATACCGCGAG ACCCACGCTC ACCGGCTCCA GATTTATCAG CAATAAACCA
 3701  GCCAGCCGGA AGGGCCGAGC GCAGAAGTGG TCCTGCAACT TTATCCGCCT
 3751  CCATCCAGTC TATTAATTGT TGCCGGGAAG CTAGAGTAAG TAGTTCGCCA
 3801  GTTAATAGTT TGCGCAACGT TGTTGCCATT GCTACAGGCA TCGTGGTGTC
 3851  ACGCTCGTCG TTTGGTATGG CTTCATTCAG CTCCGGTTCC CAACGATCAA
 3901  GGCGAGTTAC ATGATCCCCC ATGTTGTGCA AAAAAGCGGT TAGCTCCTTC
 3951  GGTCCTCCGA TCGTTGTCAG AAGTAAGTTG GCCGCAGTGT TATCACTCAT
 4001  GGTTATGGCA GCACTGCATA ATTCTCTTAC TGTCATGCCA TCCGTAAGAT
 4051  GCTTTTCTGT GACTGGTGAG TACTCAACCA AGTCATTCTG AGAATAGTGT
 4101  ATGCGGCGAC CGAGTTGCTC TTGCCCGGCG TCAATACGGG ATAATACCGC
 4151  GCCACATAGC AGAACTTTAA AAGTGCTCAT CATTGGAAAA CGTTCTTCGG
 4201  GGCGAAAACT CTCAAGGATC TTACCGCTGT TGAGATCCAG TTCGATGTAA
 4251  CCCACTCGTG CACCCAACTG ATCTTCAGCA TCTTTTACTT TCACCAGCGT
 4301  TTCTGGGTGA GCAAAAACAG GAAGGCAAAA TGCCGCAAAA AAGGGAATAA
 4351  GGGCGACACG GAAATGTTGA ATACTCATAC TCTTCCTTTT TCAATATTAT
 4401  TGAAGCATTT ATCAGGGTTA TTGTCTCATG AGCGGATACA TATTTGAATG
 4451  TATTTAGAAA AATAAACAAA TAGGGGTTCC GCGCACATTT CCCCGAAAAG
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 4501  TGCCACCTGA CGCGCCCTGT AGCGGCGCAT TAAGCGCGGC GGGTGTGGTG
 4551  GTTACGCGCA GCGTGACCGC TACACTTGCC AGCGCCCTAG CGCCCGCTCC
 4601  TTTCGCTTTC TTCCCTTCCT TTCTCGCCAC GTTCGCCGGC TTTCCCCGTC
 4651  AAGCTCTAAA TCGGGGGCTC CCTTTAGGGT TCCGATTTAG TGCTTTACGG
 4701  CACCTCGACC CCAAAAAACT TGATTAGGGT GATGGTTCAC GTAGTGGGCC
 4751  ATCGCCCTGA TAGACGGTTT TTCGCCCTTT GACGTTGGAG TCCACGTTCT
 4801  TTAATAGTGG ACTCTTGTTC CAAACTGGAA CAACACTCAA CCCTATCTCG
 4851  GTCTATTCTT TTGATTTATA AGGGATTTTG CCGATTTCGG CCTATTGGTT
 4901  AAAAAATGAG CTGATTTAAC AAAAATTTAA CGCGAATTTT AACAAAATAT
 4951  TAACGCTTAC AATTTGCCAT TCGCCATTCA GGCTGCGCAA CTGTTGGGAA
 5001  GGGCGATCGG TGCGGGCCTC TTCGCTATTA CGCCAGCCCA AGCTACCATG
 5051  ATAAGTAAGT AATATTAAGG TACGGGAGGT ACTTGGAGCG GCCGCAATAA
 5101  AATATCTTTA TTTTCATTAC ATCTGTGTGT TGGTTTTTTG TGTGAATCGA
 5151  TAGTACTAAC ATACGCTCTC CATCAAAACA AAACGAAACA AAACAAACTA
 5201  GCAAAATAGG CTGTCCCCAG TGCAAGTGCA GGTGCCAGAA CATTTCTCTA
 5251  TCGATA
Sequence revised 16-Apr-02.
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